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ABSTRACT
There has been much evidence in recent years to suggest that the k  opioid receptor 
plays a significant role in mediating a number of behavioural disorders including drug abuse 
and depression. Previous in vitro evaluation in the group of secondary and tertiary amines 
derived from 2-amino-1,1-dimethyl-1,2,3,4-tetrahydronaphthalen-7-ol showed that all 
behaved as pure opioid antagonists. These findings prompted further synthetic and 
pharmacological investigations of this scaffold, with the eventual aim of developing a short- 
acting selective opioid antagonist to further probe the k  receptor.
Using molecular modelling, a series of ligands were designed based on a previously 
prepared Af-cinnamyl analogue but incorporating a second basic nitrogen intended to mimic 
the N17’ nitrogen of norBNI and increase k  selectivity. Synthesis and pharmacological 
evaluation of the key intermediates revealed that the ortho-NH2 derivative possessed the 
greatest k  affinity and antagonist potency, although the corresponding NO2 analogue also 
exhibited high k  antagonist potency in the functional assay. Many of the synthetic steps 
were optimised and an improved protocol for the preparation of 7-methoxytetralone was 
developed.
Based on findings that aminotetralins possessing certain two-atom chains at the 3- 
position display high opioid receptor affinity, a second series of //-substituted ligands 
utilising an aminotetralin scaffold bearing a 3 -OCH3 group were synthesised which included 
an improved method for the hydride reduction of an oxime to aziridine. Preliminary 
pharmacological results indicate a considerable gain in opioid receptor binding whilst 
retaining pure antagonist activity; a novel selective k antagonist ligand was also identified.
The encouraging results of the 3-OCH3 analogues prompted investigation of a third 
series of ligands bearing 3-amino substituents, in order to evaluate the effect of an additional 
basic group in the scaffold. A synthetic route was devised which made use of a ‘nosyl’ 
group to activate the aziridine and introduce the desired ‘address’ side-chain. The 3- 
pyrrolidino analogue was successfully prepared by this method and it is anticipated that the 
route is flexible enough to allow a diverse range of analogues to be prepared in due course.
Finally, the preparation of a novel alkene intermediate utilising a cyclisation strategy 
was briefly investigated with the aim of identifying a synthetic route to future series of 
ligands which is efficient, economical and environmentally friendly.
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1.1 History of opioid research
The medicinal and recreational properties of opium, the juice extracted from 
the ripe seed capsules of the poppy papaver somniferum, have been known to 
humans for almost 6000 years.1 Early records show that the poppy was first 
cultivated by the Sumerians in the area now known as the Middle East, where it was 
used principally for its euphoric effects. Its use spread quickly throughout the 
Egyptian empire and subsequently to the Greeks, who were the first to discover its 
powerful narcotic properties.1'3 By 460BC, the Greek physician Hippocrates was 
administering opium for a whole range of complaints, from headaches and coughing 
to asthma and melancholy.3 Opium was not introduced to Britain until the 17th 
century, where its use became widespread and addiction to it acquired a certain 
social cachet.4 Towards the end of the 19th century, however, the use of the 
hypodermic syringe and needle saw the habit take on a more sinister significance.1'2
The first investigation into the constituent alkaloids of opium was carried out 
by Sertiimer in 1806 who discovered morphine (1) by dissolving opium in acid and 
neutralising with ammonia.1'5 Morphine, together with the later isolated codeine (2) 
and thebaine, comprise one of the two main classes of compound from opium: the 
opioid 4,5-epoxymethylmorphinans, that are recognised to have therapeutic 
potential.5 The other, the non-opioid isoquinolines, include the smooth muscle 
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1.2 Opioid receptors
1.2.1 The discovery o f opioid receptors
The recognition of the common structural and stereochemical requirements of 
the narcotic opioids led to the hypothesis that there was a specific “opioid” receptor
n
that mediated analgesia. The evidence to validate this theory arrived in 1975 when 
Hughes and Kosterlitz successfully isolated two pentapeptides, leu-enkephalin and
o Q
met-enkephalin ’ , which were shown to have pharmacological properties very 
closely related to those of morphine. This breakthrough directly led to the 
conclusion that the pharmacological effects of the opioids were a result of their 
ability to mimic the binding of the endogenous peptides to specific receptors in the 
body. The enkephalins became the first in a class of peptides termed the 
“endogenous opioid peptides”, characterised by the common tetrapeptide sequence 
Tyr-Gly-Gly-Phe.10 Since then many more have been isolated, including the recently 
discovered nociceptin.11
1.2.2 Opioid receptor types
The theory that opioid receptors may exist as distinct types was first proposed 
by Portoghese12 in 1965, but it was not until the work of Martin et al, 13 in 1976 that 
the first evidence to support this theory came to light. Martin proposed that the 
behavioural and neurophysiological effects of moiphine, ketazocine and N- 
allylnormetazocine could be ascribed to three distinct receptor types: the p (mu), k  
(kappa) and a  (sigma) opioid receptors respectively. It was subsequently found that 
the effects mediated by the proposed o receptor were not blocked by the universal 
opioid antagonist naloxone and were therefore non-opioid in nature.14 The 5 (delta) 
receptor was later proposed to account for the in vitro profile of the enkephalins9 and 
it has now been firmly established that there are three major types of opioid receptor
i.e. p, 5 and k .
More recent research has provided significant evidence for subdivisions 
within each of these receptor types15' 17, though the existence of their distinct genes
has not yet been proven; the possibility that these subdivisions may result from such
18phenomena as receptor dimerisation cannot be ruled out. A fourth type of opioid 
receptor, the so-called orphan opioid receptor11 (often termed ORL1), has also been 
identified and cloned but has yet to be fully characterised.
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1.2.3 The structure o f opioid receptors
Opioid receptors are part of the rhodopsin subfamily of G protein-coupled 
receptors characterised by the presence of seven transmembrane helices (Figure 1). 
The amino acid sequences of the opioid receptors are highly homologous 
(approximately 60% conserved identity), particularly in the transmembrane and 
intracellular domains.10,19 They recognise a structurally diverse array of ligands 
which includes peptide sequences, natural products and synthetic small-molecule 
ligands.
E I.-I E L -II
1 VII
Figure 1 (Structure of the kappa opioid receptor20)
1.2.4 Distribution and pharmacological profiles o f p, S and k  opioid receptors
The distribution of opioid receptors was initially investigated by radioligand
21autoradiography and later, with the development of cloning technology, by the 
detection of mRNA expression levels which correspond to cellular expression levels
IQ
of the appropriate receptor type. ’ These studies have shown that all three 
receptors are widely distributed throughout the central nervous system, but p and k  
are also widely distributed on the wall of the gastrointestinal tract (particularly in the 
stomach and proximal colon). The 5 receptor is also expressed on neurons within 
myenteric and submucous ganglia.23
As mentioned previously, the differing pharmacological effects of opioids 
are known to be mediated by the three types of receptor. The main pharmacological 
effects observed when bound by an agonist are summarised in Table 1. The table 
aptly demonstrates the striking range of actions produced by activation of opioid
3
receptors and is indicative of the great number of complex biochemical pathways 
invoked.
M u (p) Delta (5) K appa (k)
Analgesia Analgesia Analgesia




Table 1 (Pharmacological effects resulting from activation o f the three major receptor types)
1.3 The use of opioids in medicine and society
1.3.1 The mechanism o f opioid analgesia
It is a fact known to almost everyone that opioids such as morphine and 
codeine are very powerful analgesics. Indeed, a glance at any medical formulary will 
reveal that, whilst a relatively wide range of opiates and synthetic opioid ligands are 
available to the prescriber, the vast majority are used solely for the purpose of pain 
management. Prescription of opioid drugs is normally reserved for conditions where 
other drugs, with less severe side-effects, have failed; however, they remain the 
treatment of choice to manage post-operative pain and chronic pain in cancer 
patients; in the latter case the side-effect of euphoria may even be regarded as 
beneficial.
Analgesia is induced when an agonist ligand binds to an opioid receptor. 
This causes the receptor to undergo conformational change which in turn initiates a 
series of events leading to dissociation of the G protein from the receptor and 
subsequent separation of the GTP bound Ga subunit from the GpY dimer. Both the 
GTP bound Ga subunit and the Gpy dimer are then able to associate with effector 
molecules and modulate their biological functions.4,24 Analgesia is mediated by all 
three opioid receptor types, although the vast majority of opioids used in medicine 
are somewhat selective towards the p receptor. The three major mechanisms 
involved in opioid receptor-mediated analgesia are outlined below:
4
1. Inhibition of adenylate cyclase by GTP bound Ga -  inhibition of adenylate 
cyclase reduces the production of cAMP which in turn effects reduction of 
voltage-dependent current and neurotransmitter release.24
2. Inhibition of N-type Ca2+ channels by Gpy -  inhibition of Ca2+ channels in 
the presynaptic neurone directly prevents the release of neurotransmitters into 
the synaptic cleft and hence inhibits signal transmission.25
3. Activation of K+ conductance -  activation of K+ channels increases the 
outflow of K+ from the neuron. This leads to postsynaptic hyperpolarisation 
and consequent inhibition of action potential propagation.25
1.3.2 Other medicinal uses o f opioids
Although medicine has tended to focus on the use of opioids in the 
management of pain, their wide pharmacological profile has been exploited in other, 
albeit less well-documented, applications. A brief survey of the major alternative 
current clinical applications of opioids is therefore appropriate.
Probably the most well-established and commonly prescribed opioid for 
treating conditions other than pain is codeine (2). Codeine’s use as an antitussive 
(cough suppressant) has a long history and is a common ingredient in cough and cold 
remedies. The ability of morphine and codeine to produce constipation, normally an 
undesirable side-effect, is exploited as a treatment for diarrhoea although the 
peripherally-selective loperamide is normally preferred.26
Certain opioid receptor agonists also have an important role to play in the 
treatment of opioid addiction. Methadone remains the most common therapy and is 
a long-acting p receptor agonist4 which acts as a direct substitute for the opioid of 
abuse; research has shown that heroin addicts maintained on methadone are at a 
lower risk of death and are less involved in crime than when using heroin27 
Methadone is itself an addictive substance, however, and so is not regarded as an 
ideal therapy. LAAM (levo-alpha acetyl methadol) was a widely used alternative to 
methadone which possessed the advantages of requiring only thrice weekly
98administration (thus improving compliance) and not producing a subjective high ; it 
has since been discontinued due to reports of adverse cardiac events. A rather 
different agonist frequently used to treat drug abuse is buprenorphine (6), which 
belongs to the oripavine class of thebaine derivatives.29 Buprenorphine (6) is 
classified as a mixed agonist/antagonist, with partial agonist activity at the p receptor
5
and antagonist activity at the k  receptor.3031 It has an exceptional safety profile, low
?Q ^1 ^9physical dependence and minimal withdrawal symptoms ' ’ , making it a highly 
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The use of opioid antagonists in medicine is currently relatively rare, 
although this situation is changing. Naloxone (7), synthesised in 1960, was the first 
antagonist to be widely exploited in medicine.33 It effectively blocks all three 
receptor types and is used principally to reverse the effects of opioid overdosage26, 
although it is occasionally present in compound preparations of opioid agonists to 
lessen the potential for dependence (Suboxone is a combination of buprenorphine 
(6) and naloxone (7) used for the treatment of opioid addiction34). Of greater interest 
is the N-cyclopropylmethyl analogue naltrexone (8). Like naloxone, it has an affinity 
for all three types of opioid receptor but is somewhat p selective 4 At present, its 
major clinical application is in preventing relapse in addicts formerly physically 
dependent on opioids26,35 which it achieves by blocking the euphoric effect 
associated with p agonists. However, naltrexone has been shown to be successful in 
other types of addictive disorder including alcoholism36, gambling37 and
"JO
hypersexuality' (co-administered with selective serotonin reuptake inhibitors).
Overall, there is considerable incentive for the development of new opioid 
agonists and antagonists, particularly those selective for a particular receptor and 
those with interesting pharmacological profiles.
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1.3.3 Opioid tolerance and dependence
It cannot be denied that the powerful analgesic action of the opioids has 
alleviated the suffering of coundess patients with chronic pain conditions to an extent 
which is unrivalled by any other class of drug. The prescribing of strong opioid 
analgesics is, as discussed in the previous section, normally reserved only for 
patients whose pain is not sufficiently relieved by other types of analgesic such as the 
non-steroidal anti-inflammatory drugs (NSAIDs). The relegation of opioids to a ‘last 
resort’ treatment is chiefly a result of the range of unpleasant side-effects that are 
induced on activation of opioid receptors (Table 1). Perhaps the most infamous 
unwanted effect of the opioids are their ability to produce tolerance and a state of 
dependence (often referred to as addiction) in chronic users. This is a serious issue 
in contemporary society and the main focus for this project (which is funded by the 
National Institute on Drug Abuse in the USA). A discussion of the current theories 
underlying the mechanisms of tolerance and dependence is therefore of relevence.
There is often much confusion over the meanings of the terms tolerance, 
dependence and addiction which refer to somewhat different phenomena. Tolerance 
is defined as the phenomenon in which an organism is less susceptible to the effect of 
the drug as a consequence of its prior administration. Dependence may be seen as a 
two-sided phenomenon consisting of a physical component and a psychological 
component:
• ‘Physical dependence’ refers to an altered physiological state whereby 
cessation of the drug or administration of an antagonist precipitates a 
withdrawal syndrome consisting of tremors, insomnia and a variety of other 
negative symptoms.
•  ‘Psychological dependence’ is typified by a continued craving for the drug, 
manifested as compulsive, drug-seeking behaviour and an overwhelming 
involvement in drug procurement and use.
• ‘Addiction’ is less clearly defined and usually refers to a combination of 
physical and psychological dependence, with a particular emphasis on the 
latter.
7
1.3.4 The mechanism o f tolerance and physical dependence
It was originally thought that the phenomena of opioid tolerance and 
dependence could be explained simply by an upregulation or downregulation of 
opioid receptors ; however, much evidence has since been accumulated which has 
shown this hypothesis to be incorrect. It is now generally accepted that opioid 
tolerance and physical dependence (psychological dependence is discussed in a later 
section) occurs as a result of multiple processes including G protein uncoupling, 
receptor endocytosis and changes at the post-receptor level.
Agonist activation of an opioid receptor leads to its phosphorylation by G 
protein coupled receptor kinases, which subsequently leads to binding of the receptor 
to regulatory proteins known as arrestins.40 Arrestins are known to cause uncoupling 
of the receptor from its G protein and the striking work of Bohn et al.Al confirms the 
importance of arrestins in mediating opioid tolerance: knockout mice lacking (3- 
arrestin-2 failed to develop antinociceptive tolerance after chronic morphine 
treatment. Interestingly, the mice still developed physical dependence suggesting 
that the processes of tolerance and dependence are not as closely linked as was 
originally thought. An additional effect of the arrestins is to trigger the endocytosis 
of receptors. Such internalised receptors may then be dephosphorylated and recycled 
back to the plasma membrane in a fully active state, or targeted to lysosome for 
degradation.40,42 It is now widely accepted that the endocytosis and subsequent 
recycling of receptors by (3-arrestin contributes significantly to receptor 
resensitisation and the prevention of tolerance; thus arrestins appear to influence both 
desensitisation and resensitisation of opioid receptors.40 Different opioid ligands 
have been shown to produce varying degrees of receptor recycling which have been 
expressed as RAVE (relative activity vs endocytosis) values.42 Substances with low 
RAVE values, such as the endogenous opioid peptides, induce rapid endocytosis and 
recycling of receptors to their fully active state and hence resensitise the cell towards 
agonist. In contrast, substances with high RAVE values such as morphine, produce 
little endocytosis but persistently activate receptors; this leads to receptor uncoupling 
and the development of tolerance as discussed above.
Physical dependence is distinct from the phenomenon of tolerance and is 
thought to involve changes at the post-receptor level. By far the most extensively 
studied cellular mechanism in connection with physical dependence is the cAMP
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pathway.39,43 Figure 2 illustrates the change in intracellular cAMP and adenylate 
cyclase levels during chronic administration of morphine. Initiation of morphine 
produces an immediate inhibition of adenylate cyclase (and other signalling 
components) which in turn inhibits the cAMP pathway. On continued exposure, the 
level of adenylate cyclase and consequently cAMP recovers; cessation of morphine 
or administration of an antagonist results in sudden excessive cAMP production 
which is thought to be responsible for the withdrawal syndrome. The exact 
mechanisms leading to upregulation of adenylate cyclase and cAMP are at present 
unknown, though several lines of evidence indicate that cAMP-response-element- 








Figure 2 (Effect of chronic morphine administration on cAM P levels)
1.4 The development of selective opioid antagonists
It was discussed in the previous section that the use of opioid receptor 
antagonists in medicine is at present confined to a very small number of applications. 
Although new clinical uses for naltrexone (8) have been recently identified, the 
clinical (and research) use of opioid antagonists has to date been hampered by: a) the 
very limited range of clinically available compounds, and b) by the lack of available 
compounds that are greatly selective towards an individual receptor type.
9
1.4.1 The message-address concept and the development o f naltrindole
A major turning point in the development of selective opioid antagonist 
ligands came when Portoghese successfully applied the “message-address” concept 
proposed by Schwyzer44 in 1977 to the design of new selective opioid antagonist 
ligands. Schwyzer’s original concept was based on analysis of the structure-activity 
relationships of peptide hormones, from which he proposed the existence of a 
“message” and “address” sequence of amino acid residues. The message component 
was postulated as influencing signal transduction at the receptor, whilst the address 
portion provided additional binding affinity to a particular receptor type but did not 
influence efficacy. This concept was applied to the endogenous opioid peptides by 
Chavkin et al.45 who recognised a tetrapeptide message sequence (Tyr-Gly-Gly-Phe) 
and a variable address sequence which confers receptor selectivity.
The leap from peptidic agonists to non-peptidic antagonists was made by 
Portoghese and his colleagues in 1990, who envisaged that Schwyzer’s model might 
be applicable to antagonist ligands derived from opioids such as naltrexone (8), if 
such ligands also interact with both the message and address subsites of the receptor. 
This proposal led to the design and synthesis of naltrindole46 (9), a potent and 8 
selective antagonist. In this compound, the message component is a naltrexone- 
derived recognition unit joined to a benzene moiety which was thought to be the 
address component conferring 8 selectivity in the enkephalins (later proved by 
modifying the structure of 9). An additional feature not present in Schwyzer’s 
original model is a spacer which acts to restrict the benzene ring to a single 
conformation, thought to increase selectivity by preventing conformational adaption 






1.4.2 NorBNI and GNTI: Highly potent and selective kappa opioid antagonists
The message-address concept was to be later applied by Portoghese in what 
was effectively the reverse manner: rather than designing and synthesising a 
molecule combining a specified message and address moiety to give a selective 
antagonist as was the case for 9, the model was instead used to deduce the address 
moiety for a particular receptor type based on knowledge of its selectivity.
During studies into the existence of dimeric opioid receptors, a series of 
naltrexone-derived bivalent ligands (i.e. containing two pharmacophores) with 
varying interpharmacophore spacers were synthesised.10 It was found that greatest k  
antagonist potency occurred when the two pharmacophores were linked solely by a 
pyrrole ring (norBNI, 10).47 This suggested that the potency increase was due to 
bridging of neighbouring recognition sites on a single receptor rather than bridging 
of a receptor dimer. The finding that the respective meso isomer was also k  
selective48 and somewhat more potent than 10 led to the conclusion that a specific 
moiety in the second pharmacophore of 10, and not the pharmacophore itself, was 
responsible for k  selectivity. Superposition of the two structures revealed overlap of 
the N17’ basic nitrogen (circled in 10), suggesting it to be the key feature in defining 
k  selectivity. Subsequent experiments involving structural modification of 10 




Thus it was concluded that the first pharmacophore of 10, like 9, binds to a 
“message” recognition subsite on the receptor, defining the molecule as an opioid 
receptor antagonist; meanwhile the second pharmacophore acts solely as a rigid 
scaffold to direct the protonated N17’ moiety to an anionic k  recognition subsite.10'49 
Site-directed mutagenesis of the k  receptor revealed the address subsite to be the 
Glu297 residue, located at the top of transmembrane helix 6.50’51 Increasing the
11
basicity of the address nitrogen by the positioning of a guanidine moiety on the 5’ 
carbon atom of naltrindole (9) led to GNTI51,52, the most selective k  antagonist ligand 
reported to date. Figure 3 illustrates the proposed binding mode of GNTI to the k  
receptor, including the interaction of the “address” basic nitrogen with Glu297.
TM VI







Figure 3 (Proposed model of interaction of 11 with the k  opioid receptor24)
1.5 Kappa antagonists: A target for the treatm ent of addiction and depression
1.5.1 The mechanism o f psychological dependence and the role ofdynorphin
The phenomenon of psychological dependence is a major factor in the 
perpetuation of drug abuse but one which is currently poorly understood. It is now 
clear that psychological dependence is separable from physical dependence, as 
certain highly addictive drugs such as cocaine do not produce prominent physical 
dependence.53
Research into the area of psychological dependence has shown the problem to 
be a highly complex one, though certain brain regions and pathways have now been 
identified as playing important roles. Efforts have been particularly focused towards 
understanding the so-called brain-reward pathways, of which the mesolimbic 
dopamine system is now known to be the most significant.53 54 In particular, the 
neurons linking the ventral tegmental area (VTA) to the nucleus accumbens (NAc) 
appear to be particularly important. The purpose of this primal pathway is to
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produce a feeling of pleasure (by release of dopamine into the NAc) in response to 
certain stimuli such as eating or reproduction to ensure that the action is repeated in 
future.54 Administration of nearly all drugs of abuse increase dopaminergic 
transmission in the NAc53,55 (although some such as opioids can act directly on NAc 
neurons) thus activating the reward pathway and increasing the probability of 
administration recurring (i.e. positive reinforcement).
It was discussed in Section 1.3.4 that drugs of abuse such as morphine lead to
CO cc
an upregulation of the cAMP pathway and subsequent upregulation of CREB. ’ 
There is now evidence to show that upregulation of cAMP and CREB in the NAc 
may invoke a state of ‘motivational tolerance and dependance’ whereby the 
individual’s sensitivity to the rewarding effects of the drug decrease with chronic 
exposure53; cessation of the drug then leaves the individual in an amotivational, 
depressed state. One of the contributing factors to this dysphoric mood is thought to 
be the CREB-mediated induction of the endogenous k  opioid peptide dynorphin. 
Dynorphin normally acts as a negative feedback mechanism to inhibit dopamine 
release in the NAc and thus control the reward pathway57,58 (Figure 4). Upregulation 
of cAMP and CREB by chronic drug exposure leads to a concurrent upregulation of 
dynorphin.53 During drug administration, the dysphoric effects of dynorphin (caused 
by its inhibition of dopamine) are countered by the euphoric effects of the drug; 
however, an abrupt withdrawal leaves a hyperdynorphic state resulting in depressed 
mood. This may be partly responsible for the “protracted abstinence syndrome” 
observed in individuals who have already undergone detoxification59 where there is a 
high rate of relapse to drug abuse, possibly in order to escape the dysphoric mood 
state induced by dynorphin (i.e. negative reinforcement).
Dynorphin from neuron terminal 
inhibits dopam ine re lease
ORDynorphin Dopam ine
re lease DR = D opam ine receptor
VTA
dopam ine
neuron OR = Opioid receptorCREBneuron
C ocaine
Opioids
Figure 4 (Diagram illustrating the effect o f dynorphin on the reward pathway)
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New potential treatments for drug abuse are highly sought after as there are 
currently very few effective options available. The above findings have stimulated 
much interest in the potential clinical use of k  opioid antagonists in order to block the 
potent inhibition of dopamine in the NAc by dynorphin and consequently relieve the 
negative emotional symptoms of early drug withdrawal.53,59
The increased understanding of the effect of dynorphin on mood has driven 
concurrent studies to determine whether k  opioid antagonists would be effective in 
treating a wider variety of depressive states.55,60,61 The neurobiology of depression is 
not well understood and the vast majority of drug treatments to date have targeted the 
serotonergic and noradrenergic systems. There is a current need for antidepressant 
medications that act faster (most current drugs take several weeks to produce 
beneficial effects) and have fewer unpleasant side-effects. To this end, research in 
the field is beginning to shift towards seeking alternative drug targets. Recent 
findings have shown that CREB-mediated transcription is induced in the NAc in 
response to acute and chronic stress.55 Elevated expression of CREB has been found 
to increase immobility in the forced swim test , a common model used to study 
depression in rodents.63 As discussed above, elevated CREB levels lead to an 
increase in dynorphin expression which could induce a dysphoric state via inhibition 
of dopamine release. Recent successful animal studies utilising the selective k  
antagonist norBNI (10) have provided further support for the development of such 
compounds as antidepressants.60,61
Overall, there is much evidence to support the further study of selective k  
antagonists in the treatment of drug abuse and depression. Although 10 has proved a 
highly useful research tool in animal studies, certain limitations to its use have since 
been identified and progress towards a clinically available k  antagonist for use in 
humans has been slow.
7.5.2 Limitations o f current k  opioid antagonists
Selective receptor antagonists are highly important research tools in 
understanding the biochemical processes associated with specific receptors and in the 
accurate characterisation of receptor agonist ligands. The development of the highly 
selective k  antagonists norBNI (10) and GNTI (11) greatly accelerated understanding 
of the pharmacology of the k  receptor; however, in vivo studies conducted with these
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ligands revealed certain unforeseen problems which now somewhat limits their use 
as research tools.
Although a highly effective ligand in terms of its potency and selectivity, 
there is now much evidence to show that 10 possesses an extremely long duration of 
action when administered both centrally and peripherally.64 For example, a single 
dose of 10 was shown to potentiate k  antagonism for 49 days in rhesus monkeys.65 
Likewise, a study undertaken by Jewett and Woods in 1995 found that 10 continued 
to antagonise the k  agonist bremazocine even after 11 weeks.66 Experiments 
performed with GNTI (11) have also shown it to possess a long duration of action: a 
study whereby rhesus monkeys were intramuscularly administered 11 showed that its
fneffects were apparent for over 10 days in some cases. These findings clearly 
indicate that 10 and 11 are unsatisfactory for many in vivo experiments as the period 
of time between successive administrations of the compound must be in the order of 
weeks and even then may still accumulate to potentially toxic levels in the test 
animal.
Since it has been shown that the effects of 10 are surmountable and therefore 
not a consequence of irreversible binding ’ , another explanation must be sought to 
explain these observations. It was proposed by Takemori et al.69 that the long 
duration of action of 10 may be partly a consequence of slow diffusion rates into and 
out of the brain, based on findings that its peak antagonist effect occurred an 
unusually long 2 hours after subcutaneous administration; however, since the effects 
of 10 persist long after the average turnover time of receptors, it is unlikely that this 
alone is responsible for the observed duration of action. One hypothesis proposed to 
explain these observations is that 10 may somehow be sequestered in the brain, but in 
such a way that it is still free to interact with k  receptors.66 For this to occur, the 
diffusion processes into and out of the brain must not be equally effective for 10, 
though the reason for this is not clear. It is interesting to note that 10 has been shown
7 0to have a high degree of non-specific binding in experiments with tritiated ligands , 
a possible contributing factor to its very long duration of action.
The evidence given above clearly imposes limitations on the use of 10 and 11 
as both research tools and potential candidates for the clinical treatment of drug 
abuse and depression. There is thus a significant need to develop k  antagonist 
ligands with different pharmacokinetic profiles. The relative bulkiness of 10 and 11 
(particularly 10) is likely to impede their ability to cross membrane surfaces and has
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been suggested to contribute to the slow onset of antagonist activity of norBNI 
(10).69 It is also possible that this is a contributing factor to its extended duration of 
action. Therefore, by designing a molecule to include only those features which are 
necessary to obtain a selective k  opioid antagonist (with reference to the message- 
address concept), it should be possible to produce a set of ligands with superior 
diffusional properties which cross the blood-brain barrier more rapidly. The reduced 
bulk may also assist in overcoming whatever factor causes the activity of 10 and 11 
to persist for so long and therefore produce a more favourable pharmacokinetic 
profile. Such a set of ligands would be of great use in research, both as tools for 
probing the k  receptor and in the development of pharmacotherapies for opioid abuse 
and depression. Several examples of such “small molecule” series of opioid receptor 
antagonists are present in the literature, though examination of the pharmacologies or 
syntheses of these compounds has revealed particular weaknesses with each.
1.6 Literature survey of “small molecule” opioid receptor antagonists
The first (and most significant) series of opioid receptor antagonists to be 
reported which were not directly related to the epoxymorphinans (those compounds 
resembling morphine) were the rrans-3,4-dimethyl-(3-hydroxyphenyl)piperidines, 
disclosed by Zimmerman et al.11 in 1978. In the epoxymorphinan series, the 
substituent of the bridging nitrogen appears to directly determine how the compound 
behaves at the p. opioid receptor. As a general rule, an A-methyl substituent affords 
p agonist activity whereas A-allyl and A-cyclopropylmethyl groups result in 
antagonism of the p receptor.72 The frans-3,4-dimethyl-(3-hydroxyphenyl)piperidine 
ligands were unique in that they all consistently behaved as pure antagonists at 
opioid receptors, even those possessing an A-substituent normally associated with
71agonist activity in the epoxymorphinans. Thomas and his associates later expanded 
on the original series and disclosed the A-cinnamyl derivative 12 as a potent and 
selective p antagonist.73
Inspired by the success of 12, Thomas’s group undertook the synthesis of a 
combinatorial library of compounds utilising the fra«s-3,4-dimethyl-(3- 
hydroxyphenyl)piperidinyl scaffold, but avoiding those features that constituted the p. 
selective A-substituent of 12 in the hope of biasing selectivity toward the k  
receptor.74 Their efforts were rewarded when 13 was subsequently found to be a 
moderately potent and selective k  antagonist. Optimisation of the side-chain by
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replacement of the phenol with a tetrahydroisoquinoline moiety subsequently 
afforded the far more potent and selective JDTic (14).75 The increase in k  selectivity 
is thought to arise from interaction of the secondary amine group with the Glu297 
residue of the k  receptor76 in an analogous fashion to norBNI (10) and GNTI (11).
Of particular interest to the present project is that this series of compounds 
appears to obey the “message-address” concept discussed previously. The ‘message’ 
portion may be seen as the fran.s-3,4-dimethyl-(3-hydroxyphenyl)piperidinyl 
scaffold, to which may be attached various ‘address’ substituents via the basic 
nitrogen in order to bias selectivity towards a particular receptor. Unfortunately, 
although 14 exhibited greater k  antagonist potency than norBNI (10), subsequent in 




Two other closely related series of compounds were later disclosed by 
Thomas, both of which afforded selective k  antagonists. The conformationally 
constrained iV-phenylpropyl-4p-methyl-5-(3-hydroxyphenyl)morphan scaffold 
(directly derived from the 5-(3-hydroxyphenyl)morphans reported by Rogers and
*70
May ) was identified as a suitable opioid antagonist message to direct a piperidinyl 
side-chain address (15) towards the k  subsite.79 The similarly constrained c/s-4a-(3- 
hydroxyphenyl)-8a-methyloctahydroisoquinolines were also found to yield
on
antagonists , and substitution of the identical 3-(l-piperidinyl)propanamido address 
side-chain afforded similar potency at the k  receptor. However, a major drawback 
associated with both these series is their rather convoluted syntheses involving
17
certain steps which do not appear to lend themselves to larger-scale preparation e.g. 
the use of an organolithium reagent early on in both syntheses.
Small molecule opioid antagonists have also been obtained by the simple 
structural alteration of existing agonist ligands. The irreversible K-selective 
compounds UPHIT (16) and DIPPA form the most significant antagonists to arise 
from the structurally distinct arylacetamide class. 16 was derived directly from the 
highly selective k  agonist U5048881'82 (frequently used in opioid binding assays) and 
differs only in the presence of an aromatic isothiocyanate group which binds 
covalently to the receptor leading to irreversible blockade. It appears unlikely 






1.7 Aminotetralins: Novel ‘message’ scaffolds for the development of selective 
opioid receptor antagonists
As a first step in the search for a new scaffold on which to construct novel 
small-molecule opioid receptor antagonists, it was decided to examine how 
simplification of the morphine skeleton had previously led to series of active opioid 
ligands. Scheme 1 illustrates how fragmentation studies and efforts directed towards 
the total synthesis of morphine led to the identification of analgesics often many 
times more potent than morphine but with progressively simpler structures. 
Levorphanol (17) belongs to the morphinan family which notably lack the 
characteristic furan bridge of the opiates and can be considered to be the first stage in 
the simplification of morphine.24 Exclusion of the D-ring of the morphinans 
subsequently led to the benzomorphans of which the clinical analgesic pentazocine
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(18) is the most interesting, possessing a degree of k  selectivity.4 Further alteration 
of the benzomorphan structure led to the phenylpiperidines, from which JDTic (14) 
and the other Thomas compounds are derived. The drawbacks of this series 
discussed previously led to consideration of how else the benzomorphan structure 
might be simplified to provide ligands with differing pharmacological profiles and 
increased synthetic accessibility.
Scheme 1 (Structural simplification of the morphinans)
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Further survey of the literature brought attention to the aminotetralins, of 
which several previous studies have identified activity at opioid receptors. Martin et 
al.83 reported series 19 in 1969 which possessed potencies weaker than morphine but 
were remarkable in their structural simplicity. Later structural modification 
incorporating a bridging ring afforded dezocine (20)84, with an agonist potency 
similar to that of morphine. Interestingly, 20 was found to precipitate withdrawal 
symptoms in morphine-dependent monkeys85, indicating that the compound is in fact 
a partial agonist. The aminotetralins therefore appeared attractive starting points for 
the development of short-acting selective opioid ligands: studies of 19 and 20 proved 
they had significant affinity for opioid receptors; in addition they are small, 
structurally simple molecules which may translate to a favourable in vivo 
pharmacokinetic profile.
Given that the studies of 19 and 20 as opioid ligands reported significant 
agonist activity, one issue of primary importance to this project was whether it would 
be possible to derive pure antagonist ligands from an aminotetralin scaffold. It has 
been shown that substituting side-chains (particularly those possessing a three carbon 
chain and terminal aryl group) at the 14p-amino moiety of morphinone 21 
consistently results in potent opioid receptor antagonists.86 Using molecular 
modelling, a structural similarity between the 14p-amino group of 21, the basic 
nitrogen of the fra/i5-3,4-dimethyl-(3-hydroxyphenyl)piperidine series (12-14) and 
the primary amine group of 20 was clearly recognisable. This suggests that 2- 
aminotetralins such as 20 may yield selective antagonist ligands in the same way as 
12-14 if the primary amine function is furnished with a suitable ‘address’ side-chain. 
It is worthwhile to note that the original paper where 20 is disclosed also reports the 
synthesis of analogues possessing simple iV-methyl and iV-dimethyl side-chains.84 
These were found to have a significantly lower analgesic potency than the 
unsubstituted parent compound 20 and were consequently abandoned; however, only 
agonist activity was measured in this study and any antagonist properties these 
compounds may possess remain unknown.
Benzomorphan 22 was initially considered as a potential scaffold: bearing 
such strong structural resemblance to 21, it would be expected to retain antagonist 
activity. Structure-activity relationships of benzomorphans based on 18 showed the 
iV-cyclopropylmethyl group to confer potent opioid antagonist properties87, providing 
additional support for 22 as a suitable scaffold. However, examination of the
2 0
literature revealed the large majority of benzomorphan syntheses to be somewhat 








Studies of the trans-3,4-dimethyl-(3-hydroxyphenyl)piperidine series 
amongst others have clearly shown that it is possible to produce antagonist ligands 
which do not possess a bridged system and the associated synthetic complications 
seem a very reasonable basis for us to exclude such a bridge from our scaffold. 
Furthermore, if our modelling studies are correct and the primary amine moiety of 
the 2-aminotetralins directly mimics the basic nitrogen of 12-14, then an additional 
tertiary amine group on an adjacent carbon is not necessarily required for antagonist 
activity. Evidence to support this conjecture is provided by the reported mixed 
agonist-antagonist properties of 20 and by Reifenrath and Fries91 who report an N- 
cyclopropylmethyl 2-aminotetralin as being a weak opioid antagonist. After 
thorough consideration of these issues, it was decided that aminotetralin 23 may have 




The structure of 23 was envisaged as satisfying the primary criteria for the 
design of the new scaffold, namely synthetic accessibility and structural simplicity, 
whilst retaining features which should give rise to opioid receptor binding. 
Additionally, 23 bears sufficient structural distinction from the rran^-3,4-dimethyl- 
(3-hydroxyphenyl)piperidine scaffold that it may afford ligands with differing 
pharmacokinetic profiles. Aminotetralin 23 may be seen as possessing three key 
structural features, each of which was included to enhance opioid receptor binding 
and consequently the ability of 23 to act as a suitable opioid ‘message’ scaffold:
1. The phenolic group is a very common structural motif of opioid 
ligands and structure-activity relationships have established that the 
presence of a phenol in the 3-position, as is the case for naltrexone, 
is optimum for binding to opioid receptors.72,92 Mimicry of the 
tyrosine residue common to the endogenous opioid peptides may 
explain this observation.
2. A geminal dimethyl group is incorporated to mimic part of the 
bridging ring found in the epoxymorphinan and benzomorphan 
series. Such a quaternary centre was incorporated into the series of 
aminotetralins synthesised by Martin et a lP  and is thought to 
enhance binding.
3. The primary amine moiety is intended (as discussed above) to 
mimic the basic nitrogen of the trans-3,4-dimethyl-(3- 
hydroxyphenyl)piperidine scaffold and provide the means to attach 
various ‘address’ side-chains to bias selectivity towards a particular 
receptor. A correctly positioned amine group is in any case known 
to be essential for opioid receptor binding -  electrostatic interaction 
with an anionic aspartic acid residue is probably the primary 
cause24,72 (see Figure 3).
In order to further investigate the relationship between 23 and the trans-3,4- 
dimethyl-(3-hydroxyphenyl)piperidine scaffold of ligands 12-14, the two structures 
were overlayed using the molecular modelling program MOE93. Figure 5 shows the 
result obtained when the respective phenolic moeities of the two structures are 
aligned. The spacial overlap of the amine protons of the two basic nitrogen centres
2 2
(arrow A in the figure) is particularly encouraging, as this suggests that the amine 
moiety of 23 should interact with the same amino acid residues in the receptor as the 
basic nitrogen of the rra«s-3,4-dimethyl-(3-hydroxyphenyl)piperidine scaffold; hence 
a similar spectrum of antagonist activity may be obtained with 23 by the substitution 
of suitable ‘address’ side-chains.
Figure 5 -  (O verlap  o f  am inotetralin  23  [grey] and hydroxyphenylpiperid ine scaffold [orange])
The other noticeable feature of Figure 5 is the proximity of the axial 4-methyl 
group of the rra72s-3,4-dimethyl-(3-hydroxyphenyl)piperidine scaffold to one of the
on
gem-methyl groups of 23. Carroll et al. have previously elucidated that the 4- 
methyl group is important for the activity of this series at opioid receptors; the 
observed spacial overlap suggests that the gem-dimethyl group of 23 may mediate a 
similar effect in the present series of ligands.
Overall, there is clearly much scope for the investigation of aminotetralin 23 
as a potential scaffold for the development of selective, short-acting opioid receptor 
ligands.
1.8 Investigation of 2-am ino-l,l-d im ethyl-l,2 ,3 ,4-tetrahydronaphthaIen-7-ol as 
a new opioid receptor ‘message’
A series of preliminary compounds utilising the novel aminotetralin scaffold 
23 were recently synthesised and biologically evaluated within the group. In each 
case, the primary amine moiety of 23 was either mono- or di-substituted with a
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simple hydrocarbon side-chain (methyl, propyl, allyl, cyclopropylmethyl or 
cinnamyl), using a combination of either direct alkylation with the appropriate halide 
or reductive alkylation with the aldehyde. The side-chains were not specifically 
designed to confer selectivity towards a particular receptor type, rather to 
preliminarily evaluate the effectiveness of 23 (if any) as an opioid receptor 
antagonist scaffold. Intrigued as to whether a selective k  antagonist could be 
obtained by combining the isopropyl-tetrahydroisoquinoline side-chain of JDTic (14) 
with scaffold 23, it was decided that the corresponding aminotetralin analogue would 
also be synthesised. Compounds were submitted for binding and functional assays as 
their hydrochloride salts. IQ values for opioid binding were determined by 
displacement of standard tritiated agonist ligands from cloned human opioid 
receptors transfected into Chinese hamster ovary cells.94 Functional antagonist 
activity (expressed as Ke) was measured by in-vitro inhibition of [35S]GTPyS binding 
to cells transfected with cloned human opioid receptors.94 The full experimental 
details are given in Chapter 7.
The majority of the compounds showed little potency or selectivity for any of 
the three types of opioid receptor in either the binding or functional assays, though 
with some notable exceptions. Tables 2 and 3 summarise the results of the binding 




Ki ± SEM (nM)
No Ri r 2 p [3H] d a m g o 8 [3H]CI-DPDPE k  [3H]U69,593
24 nPr Me 85.0 ± 14.7 2090 ± 22.8 184 ±29.4
25 Allyl Allyl 105 ± 0.89 672 ± 127 55.8 ± 18.6
26 Cinnamyl H 10.7 ±2.73 472 ± 108 82.3 ±18.0
27 Tic* H 23.0 ±2.75 139 ±52.1 5.04 ±0.60
Table 2 (Binding assay results for selected compounds derived from scaffold 23)
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Ke ± SEM (nM)
No Ri r 2 vs DAMGO |i vs Cl-DPDPE 6 vs U69,593 k
26 Cinnamyl H 67.7 ±7.59 Not tested 42.7 ± 2.75
27 Tic* H 139 ±31.7 503 ± 120 3.04 ±0.18
Table 3 (Functional assay results for selected compounds derived from scaffold 23)
Compound 26 bearing an AT-cinnamyl substituent was revealed as the most 
interesting of the simple hydrocarbon series, possessing relatively high affinity for p 
receptors and moderate affinity for k  receptors. Although 26 is not as potent or p 
selective as the corresponding rrans-3,4-dimethyl-(3-hydroxyphenyl)piperidine 
analogue 12, the result clearly demonstrates that ligands derived from scaffold 23 
have significant affinity for opioid receptors and appear to behave exclusively as 
antagonists. An equally significant result was the finding that JDTic analogue 27 is a 
potent and selective antagonist for the k  receptor. The binding and functional assay 
results are comparable to 14, although 27 was again less potent than the 
corresponding frarcs-3,4-dimethyl-(3-hydroxyphenyl)piperidine analogue.
The above results quite clearly illustrate that 23 is indeed a suitable scaffold 
for the construction of opioid receptor antagonists. The strong correlation of 
structure-activity relationships between this series and the trans-3,4-dimethyl-(3- 
hydroxyphenyl)piperidine compounds indicate that the two basic nitrogen centres are 
equivalent and consequently ligands derived from 23 also obey the ‘message- 
address’ concept. Although 26 and 27 were less potent than the corresponding 
compounds reported by Thomas et al., the structure of 23 is unoptimised for opioid 
receptor binding and consequently there is much scope for improvement to this 
scaffold.
1.9 Research aims
The aim of this project is to expand on the previous work carried out in our 
research group using the novel aminotetralin scaffold 23, in order to further progress 
towards a series of short-acting selective k  opioid antagonists for use as research 
tools and treatments for drug abuse and depression. The specific aims of the project 
are:-
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•  To synthesise further ligands derived from scaffold 23 possessing novel side- 
chains designed to increase selectivity for the k  opioid receptor over the p  and 
8 receptors.
• To investigate structural modifications to scaffold 23 to increase the affinity 
of the ‘message’ portion of the ligand for opioid receptors - this should result 
in ligands of increased antagonist potency.
• To examine and improve the existing synthetic routes to aminotetralin 23 and 
the new ligands described above, with the aim of developing procedures 
suitable for larger scale preparation of intermediates. A particular emphasis 
will be placed on the development of routes using inexpensive, non-toxic and 
easy-to-handle reagents where possible.
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CHAPTER 2
RING-SUBSTITUTED iV-CINNAMYL DERIVATIVES OF 
2-AMINO-l,l-DIMETHYLTETRAHYDRONAPHTHALEN-7-OL
2.1 Design rationale
The preliminary investigations into the suitability of aminotetralin 23 as a 
scaffold on which to build opioid antagonist ligands revealed A-cinnamyl derivative 
26 as possessing significant affinity for the p  and k  receptor types. This was an 
encouraging result as it directly indicated that selective, small-molecule opioid 
antagonists may be derived from such a system. A high degree of selectivity for one 
receptor type is desirable for a ligand to be of value as a research tool and since 26 
does not possess any significant p  vs k  selectivity, it was decided to consider whether 
simple structural modifications to 26 might lead to a more favourable 
pharmacological profile whilst retaining synthetic accessibility. As the present 
project is particularly focused on the synthesis of K-selective antagonists, it appeared 
that application of the ‘message-address’ concept to the development of such ligands 
may be of particular value.
It was discussed in the previous chapter that the presence of a correctly 
positioned basic nitrogen moiety is thought to be the determining factor in the k  
selectivity of compounds such as norBNI (10) and JDTic (14). A rigid scaffold acts 
as a spacer between the ‘message’ pharmacophore and directs the protonated amine 
‘address’ group into a position where it is able to form an ionic interaction with the 
Glu297 residue of the k  subsite. It appeared that by attaching a guanidine or similar 
functionality to the terminal phenyl group of 26, a basic group could be orientated 
into an equivalent position where such an interaction with Glu297 could be 
established.
The double bond of the propenyl spacer and the phenyl group of 26 impart a 
degree of structural rigidity to the system; such conformational restriction can be 
advantageous in enhancing receptor selectivity and affinity as it lowers both the 
potential for interaction with other receptors (thereby increasing selectivity) and 
decreases the adverse entropy change on binding95 (increasing the free energy of 
binding and hence affinity). It was therefore decided to retain both of these features. 
In addition to providing structural rigidity to the spacer, the aromatic ring also allows
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for three differing positions of the crucial basic group. Figure 6 shows the overlay 
diagram obtained by aligning the phenolic moieties of GNTI (11, orange) and the 
cinnamyl derivative of the new aminotetralin scaffold (26, grey); the proximity of the 
basic guanidine moiety of 11 to the ortho, meta and para  positions on the terminal 
aromatic ring of 26 are indicated by arrows. Thus the ability to vary the position of 
the basic group in this manner increases the likelihood of obtaining the desired k  
selectivity.
meta
F igure 6 (O verlay illustrating  the p roxim ity  o f  the guanidine group o f  11 to the o, m and p  positions
on the term inal arom atic ring  o f  26)
Whilst guanidine-substituted analogues of 26 were the eventual intended 
targets of this project due to the high basicity of this functional group, it was decided 
to initially focus on the synthesis of the intermediate primary amines 28-30 from 
which the corresponding guanidine ligands would later be prepared. In addition to 
being synthetically more accessible than the guanidines, the pharmacological 
evaluation of 28-30 would increase the very limited structure-activity information on 
this series and may provide an insight into which position on the terminal aromatic 








The work of Portoghese showed that k  selectivity correlated directly with the 
basicity of the ‘address’ nitrogen -  the guanidine derivative GNTI (11) possessing 
the greatest selectivity of all.1052 On this basis, the primary amine group of 28-30 
(pKa of aniline = 4.63) would not be expected to exhibit particularly high k  
selectivity compared to the guanidine analogues (pKa of guanidine = 12.5) due to 
delocalisation of the nitrogen’s lone pair of electrons around the aromatic ring. 
Conversely, it may also be argued that a guanidine group could enhance interaction 
of the ligand with the receptor to a point where the pharmacokinetic profile becomes 
undesirable and the ligand possesses a long duration of action in vivo (as reported for 
11 -  see Section 1.5.2). It therefore appeared logical to begin with an ‘address’ 
amine of relatively low basicity (i.e. the primary amine in 28-30); if the degree of k  
selectivity is found to significantly increase relative to 26 then the investigation of 
other amine ‘address’ moieties of intermediate basicity (i.e. pKa 5-12) may be 
justified before progressing to the highly basic guanidines.
2.2 Literature methods of 2-aminotetralin synthesis
The synthesis of basic 2-aminotetralin skeletons is well established in the 
literature and numerous examples have been previously reported as the starting 
points for ligands acting at opioid, dopamine and adrenergic receptors amongst 
others. The actual synthetic route employed does not in general vary significantly
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between literature reports, and the pathway followed by Ye et al. is typical 
(Scheme 3). In this example, the commercially available 2-tetralone 
(tetrahydronapthalenone) 31 is first converted to its corresponding oxime 32 by 
standard reaction with hydroxylamine hydrochloride under mildly basic conditions. 
The oxime is subsequently reduced by catalytic hydrogenation to afford primary 












Schem e 3 (Typical literature synthesis of 2-aminotetralins96)
A particular advantage of using the route illustrated in Scheme 3 as the basis 
for the synthesis of aminotetralin 23 is that the ketone moiety of the starting material 
31 considerably enhances the acidity of protons at the 1-position due to conjugation 
of the resulting enolate. Thus deprotonation of 31 with a relatively strong base and 
subsequent alkylation with halide would appear to be a favourable method for the 
introduction of the geminal dimethyl group of 23 into the structure; the ketone may 
then be converted to the oxime as before, followed by subsequent reduction and O- 
demethylation. Indeed, this was the route previously adopted within the group for 
the synthesis of scaffold 23 (Scheme 4). The actual transformations remained 
virtually identical to those of Scheme 3, though the oxime reduction was performed 
using refluxing lithium aluminium hydride as this was considered to be more 
convenient than high pressure catalytic hydrogenation.
One significant drawback of this route is the relatively high price (~£30/g) of 
the starting material, 7-methoxy-2-tetralone (35). In addition, the compound is 
somewhat unstable (3,4-dehydrogenation to the thermodynamically favourable 
conjugated ketone being the most likely pathway) and must be stored at subzero 
temperatures.
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Scheme 4 (Route previously employed for synthesis of 23 and derivatives)
There are very few reports in the literature of 1,1-disubstituted 2- 
aminotetralin syntheses; however, a rather different approach based on the route 
applied by Reifenrath et a l 9] begins with the significantly less expensive 7-methoxy-
1-tetralone (40) (Scheme 5). The key intermediate is a-ketoamine 43, which may be 
formed by nitrosation of 40 with potassium fm-butoxide and isoamyl nitrite to yield 
the oxime 42 after tautomerisation, followed by selective catalytic hydrogenation. 
An alternative synthesis of 43 would be formation of the O-tosyloxime 41, followed 
by Neber rearrangement with potassium ethoxide). Intermediate 43 is then rapidly 
acylated with the desired side-chain (which prevents self-polymerisation), leaving 
the ketone group free to undergo addition with Grignard reagents. In the series of 
Reifenrath et al.91 1,1-disubstitution was introduced by addition of phenylmagnesium 
bromide, followed by alkylation of the resulting tertiary alcohol to form ethers. To 
introduce a geminal dimethyl group, the most direct approach from 43 would appear 
to be addition of methylmagnesium iodide to afford 44. Conversion of the alcohol
moiety to a more labile methanesulfonate or triflate group, followed by further 
reaction with methylmagnesium iodide should yield the 1,1 -dimethylated 45. 
Reduction of the amide group and subsequent O-demethylation would then afford the 
desired ligands.
Although the alternative route to 2-aminotetralins (Scheme 5) may prove to 
be somewhat more economical than the previously employed route (Scheme 4), it 
was decided after consideration to concentrate on the optimisation of the prior route; 
one particular advantage being that diversification occurs at a much later stage in the 
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Scheme 5 (Alternative approach to 1, 1 -disubstituted 2-aminotetralins)
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In view of the high price of the starting ketone (35), it appeared appropriate to 
examine whether laboratory synthesis from less expensive materials might be 
feasible. Examination of the literature revealed that 35 may indeed be prepared in a 
two step route from 2,7-dihydroxynaphthalene, a commercially available and 
inexpensive material (~£0.20/g).
2.3 Synthetic studies
It quickly became apparent after the preliminary in vitro results that large 
quantities of aminotetralin 23 (and the intermediate oxime 37 which is the starting 
point of a later synthesis) would be required and consequently much time was 
invested into improving and optimising the experimental procedures. Additionally, 
the availability of multigram quantities of 23 would increase the feasibility of optical 
isomer separation by fractional crystallisation - this would allow the active isomer of 
pharmacologically significant ligands to be identified.
2.3.1 Synthesis of7-methoxy-l,2,3,4-tetrahydronaphthalen-2-one
Investigation of the laboratory preparation of tetralone 35 was considered 
important due to the vast difference in cost compared with its precursor, 2,7- 
dihydroxynaphthalene (46). The two-step synthesis begins with the dimethylation of 
46 to afford diether 47. The reaction was initially attempted by deprotonation of diol 
46 with the aggressive base sodium hydride in DMF in order to promote complete 
conversion to its dipotassium salt. Iodomethane was employed as the alkylating 
agent and an 87% yield of pure 2,7-dimethoxynaphthalene (47) was obtained after 
quenching and filtering. It quickly became apparent, however, that this method was 
not suitable for preparing larger quantities of 47 due to the hazardous nature of 
sodium hydride.
The weaker but considerably less hazardous base potassium carbonate is 
commonly used for the formation of ethers from phenolic compounds97 and appeared 
an attractive alternative to sodium hydride for large scale preparations. A solution of 
46 was therefore treated with 3 equivalents of potassium carbonate and iodomethane, 
the resulting mixture being heated to reflux overnight. Although acetone is the 
standard solvent for such reactions, ethanol is occasionally used98 but in this case 
resulted in a lower yield of 47 (see Table 4); a significant quantity of unreacted 
starting diol remained in both cases and it was thought that this could be partly due to
33
iodomethane escaping from the system (bpt. of iodomethane is only 42°C). When 
iodomethane was replaced with dimethyl sulfate (bpt. 188°C), consistently high 
yields (>80%) were obtained after only 4 hours at reflux (Scheme 6).
Electrophile/Base Solvent Conditions Yield
Mel / NaH DMF RT, 18 hrs 87%
Mel / K2C 0 3 EtOH Reflux, 18 hrs 62%
M eI/K 2C 0 3 Acetone Reflux, 18 hrs 70%
Me2S 04 / K2C 0 3 Acetone Reflux, 4 hrs 81%
Table 4 (Reaction conditions used to attempt dimethylation of 46)
A cetone 
Reflux, 4  h 
81%
Scheme 6 (Optimum dimethylation method of 46)
An alternative improved work-up procedure which avoids partitioning and 
extraction of the crude product was also devised. Previously, the product 47 had 
been obtained in the ‘classical’ manner by partitioning the reaction mixture between 
diethyl ether and aqueous sodium hydroxide solution followed by sequential 
extractions with diethyl ether. Further investigation found that by simply adding a 
4M aqueous solution of potassium hydroxide to the cooled reaction mixture (which 
dissolves both unreacted 46 and potassium carbonate) followed by evaporation of the 
acetone in vacuo, the pure ether 47 precipitates and can be easily collected by suction 
filtration, dried and used without further purification in the next step.
Transformation of diether 47 to tetralone 35 may be considered to be a two 
step process, involving reduction of 47 to the 2,3-enol ether 48 which is subsequently 
hydrolysed to afford ketone 35 (Scheme 7); isolation of the intermediate 48 is not 




Scheme 7 (Conversion of diether 47 to tetralone 35)
Consultation of the literature shows that reduction of 47 to 48 has been 
achieved using two mechanistically identical but experimentally distinct approaches. 
The Birch reduction, involving the transfer of single electrons from alkali metals to 
substrates, is a widely applicable technique for the reduction of aromatic rings97 and 
reliably results in a characteristic 1,4-dihydro pattern of reduction. The classical 
conditions of the Birch reaction involve introducing a solution of the substrate in an 
alcohol (commonly ethanol) to a deep blue solution of the alkali metal (typically 
sodium) in liquid ammonia at -78°C. Application of this technique to diether 47 
constitutes one of the two main approaches to 48, and tetralone 35 may be readily 
obtained after acid hydrolysis.99
A somewhat different technique to effect reduction of mono- and 
dimethoxynaphthalenes was developed earlier by Comforth et al.m  in 1942. This 
method also uses sodium metal as a source of electrons and may be considered as 
mechanistically identical to the Birch reduction. The two techniques diverge, 
however, in their choice of reaction solvent and conditions. Unlike the Birch 
reduction, the procedure of Comforth stipulates refluxing ethanol as the solvent of 
choice. Although the quoted yields are generally inferior to those of the Na/NH^ 
Birch reduction, the practical disadvantages of liquid ammonia make the Comforth 
method more convenient for repeated large scale preparations of 35. With this in 
mind, it was decided to pursue the Comforth method of reduction and investigate 
whether alterations to the literature procedures could be made to increase the yield of 
tetralone.
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The process of reducing 47 to enol ether 48 was initially carried out in 
essentially the same manner as described by Comforth for 2-methoxynaphthalene. 
This involves adding an excess (approximately 10 equivalents) of freshly cut sodium 
metal in small pieces to a refluxing solution of 47 in ethanol. Higher yields of 35 
were generally obtained when the addition of sodium was carried out as quickly as 
possible. Commencing the addition below reflux temperature resulted in a 
considerably diminished yield of tetralone, with no reaction occurring at all at room 
temperature.
The resulting enol ether 48 was subsequently hydrolysed to the tetralone by
the rapid addition of 5M hydrochloric acid at 0°C (which also serves to protonate the
sodium ethoxide formed). A deep blue colour is observed during the addition,
i noreferred to as ‘tetralone blue’ in the literature Presumably, this colouration 
originates from deprotonation of 35 by residual sodium ethoxide forming a 
conjugated enolate (49). Care must be taken at this stage to avoid polymerisation 
and the hydrolysis was conducted rapidly to facilitate reprotonation of the enolate.
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Purification of the crude tetralone was achieved via formation of the addition 
compound (50). Such compounds are readily formed from unhindered ketones and 
aldehydes by stirring the crude product with a saturated aqueous solution of sodium 
bisulfite.101 The solid bisulfite adduct may then be separation by suction filtration 
and decomposed to the parent carbonyl compound by reaction with sodium carbonate 
solution. This proved to be an excellent method for purifying 35 and efficient 
washing at the filtration stage was found to afford a product of high purity by ]H 
NMR after basic decomposition; further purification by reduced-pressure distillation 
was not considered to be necessary.
The highest yield of 35 obtained with the above procedure was 63%, 
consistent with literature values. This appears to suggest that only moderate yields 
of tetralone are possible with the present method. Additionally, the experimental 
procedure is somewhat tedious and time-consuming: the initial reduction stage where
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pieces of sodium are dropped into refluxing ethanol via the condenser frequently 
takes in excess of an hour to perform and has obvious safety implications. It was 
therefore decided to investigate whether a more convenient, high-yielding procedure 
could be developed.
109In a short paper published in 2003, Menzek et al. reported a novel high- 
yielding procedure for the reduction of naphthalene (51) to 1,4-dihydronaphthalene 
(52), a reaction previously achieved using Na/EtOH at high temperatures. In this 
modified version, sodium is allowed to react with a solution of 51 in THF to form the 
corresponding radical anion which is subsequently quenched with terr-butanol to 
afford 52. This “pre-formation” of the radical anion is an interesting contrast to the 
Na/EtOH technique where the anion is both formed and quenched simultaneously. 
The mild conditions and high yield (97%) also make it an attractive and convenient 
procedure. As the transformation of 51 to 52 can be considered to be analogous to 
47 to 48, it was decided to investigate whether the present synthetic method of 35 





RT, 3 h  
97%
Schem e 8 (Novel reduction of naphthalene to 1,4-dihydronaphthalene102)
One of the most significant features of the Menzek procedure is that 
reduction is successfully effected at room temperature, being in direct contrast to the 
high (>80°C) temperatures required for the Comforth technique. It was therefore 
decided to attempt reduction of diether 47 under similar conditions. Accordingly, 10 
equivalents of sodium were added in small pieces to a solution of 47 in anhydrous 
THF at room temperature followed by an excess of tert-butanol. The mixture was 
stirred for 4 hours (until the sodium had completely reacted) and 5M HC1 
subsequently added. TLC analysis indicated that no reaction had occurred. An 
identical result was obtained when ethanol (which has a lower pKa) was substituted
109as the proton source. It is interesting to note that Menzek et al. report a distinct 
blue colouration when the sodium is added to the naphthalene solution. No such
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colour was observed with 47 as the substrate, suggesting that formation of the 
corresponding radical anion does not occur at room temperature. One way to 
rationalise this observation is that 47 is a more ‘electron-rich’ substrate than 51 due 
to the donating ether groups and therefore addition of an electron to 47 would be 
expected to have a higher energy barrier.
In order to further investigate this hypothesis, the reaction was repeated but 
the system heated to 60°C prior to addition of the alcohol. No colouration was 
observed, likewise suggesting the absence of a radical anion; however, TLC analysis 
after treatment with ethanol and subsequent hydrolysis with HC1 showed that 
complete conversion to 35 had indeed occurred. It was consequently decided to 
repeat the process on a larger scale in order to compare the yield and quality of 
product with that obtained using the original method, l l g  of 47 were carefully 
reacted under these conditions and subjected to the standard work-up procedure. 
This was found to result in a surprisingly high yield of 35 after purification through 
the bisulfite adduct (50). Analysis by *H NMR showed the product to be of high 
purity and several successive attempts consistently afforded improved yields (>80%) 
over the Comforth method. The following additional advantages of the new 
experimental protocol were also noted:-
• As sodium does not react with THF or 47, the required quantity of sodium 
may be added rapidly over a few minutes when the system is still at room 
temperature; the ethanol may then be added via a dropping funnel, leaving the 
user free to complete other tasks (however, care must be taken to maintain 
efficient stirring as the THF has a tendency to froth). Previously, addition of 
the sodium took nearly 1 hour and the reaction was considerably more 
vigorous.
• A significantly lower volume of ethanol is used which greatly facilitates the 
partitioning stage of the work-up (inseperable emulsions were common with 
the Comforth method and the ethanol frequently had to be evaporated in 
vacuo before re-partitioning).
•  Viscous brown material was often formed after the sodium addition stage 
with the previous method. This does not seem to occur with the modified 
procedure and the product possesses a cleaner overall appearance.
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Menzek et al.]02 employ terf-butanol as the proton source due to its lower 
reactivity with sodium; this produces a slower, more controlled reduction process. 
The decision to replace terf-butanol with ethanol was a result of the findings of
Comforth who reported the yield of 2-tetralone to be inferior when propan- l-ol was
100used as solvent. A possible explanation is that the initial 1,4-reduction product 53 
rearranges to conjugated 54 in the presence of refluxing sodium propoxide solution. 
Further reduction can then occur to give 55 (Birch-type reactions do not normally 
reduce isolated double bonds), which is unable to hydrolyse to 56 (Scheme 9).
N aO P r
Na, PrOH
Scheme 9 (Rearrangement and further reduction of 53 in the presence of NaOPr)
Evidence for the above hypothesis is provided by Menzek et al.102, who 
report that naphthalene (51) reduces to 1,2,3,4-tetrahydronaphthalene with 
Na/BuOH under reflux via NaOlBu-induced rearrangement of 1,4- 
dihydronaphthalene (52). From this it can be postulated that sodium ethoxide does 
not possess a sufficiently high pKa to effect rearrangement (even at elevated 
temperatures) as the 1,4-reduction product is the sole one obtained.
MeO OMe
1) Na, EtOH/THF 
Reflux, 2 h
2) 5M HC(aq) 
Reflux, 1 h
95%  overall yield
MeO
Schem e 10 (Improved procedure for reduction of 47 to tetralone 35)
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In summary, a convenient and high-yielding procedure for the reduction of 
diether 47 to tetralone 35 (Scheme 10) has been developed. The yields obtained 
appear to be consistent and considerably greater than previously reported for this 
type of reduction. Further experiments to determine whether the new procedure is 
applicable to other mono- and dimethoxynaphthalene systems are planned.
During the optimisation of the above reaction, it was decided to concurrently 
investigate the work of Ostashevskaya et al.m  who report an interesting one-step 
synthesis of 7-hydroxytetralone 57 from diol 46 (Scheme 11). This remarkable 
reaction is thought to proceed via an ionic hydrogenation mechanism involving 




RT, 24  h 
84%
Scheme 11 (Reported ionic hydrogenation of 2,7-dihydroxynaphthalene103)
The reaction appeared easy to perform: the reagents are simply dissolved in 
dibromomethane and the system allowed to stir for 24 hours at room temperature; 
however, repeated attempts to effect transformation of 46 using the reported 
procedure afford only a trace of product upon TLC of the quenched reaction mixture. 
The use of a different manufacturer’s reagents, increasing the reaction temperature to 
reflux and even assistance from the author of the procedure still yielded no success. 
As a result of this and the relatively high cost of aluminium bromide, this method 
was abandoned and efforts focused on the Na/EtOH reduction procedure.
2.3.2 Synthesis o f 2-amino-], 1 -dimethyl-1,2,3,4-tetrahydronaphthalen-7-ol
Now that a suitable high-yielding route to precursor 35 had been identified, 
the remaining synthetic steps leading to aminotetralin 23 (see Scheme 4) could be 
investigated. Initially, introduction of a geminal dimethyl group at the 1-position of 
tetralone 35 was achieved by treating a solution of 35 in THF with sodium hydride, 
followed by iodomethane as alkylating agent. Subsequent reflux and aqueous work­
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up gave a viscous brown oil which was purified by reduced-pressure distillation to 
afford low to moderate yields (<60%) of 36 as a light yellow liquid.
The method of Dailey et al.m  reports that very high yields (91%) of the 
corresponding 6-methoxy analogue of 36 may be obtained using sodium hydride in 
benzene at room temperature; this latter condition is specifically stipulated as being 
necessary for a high yield. Application of this procedure to 35 (substituting toluene 
for benzene) afforded consistently greater yields (60-65%) of 36 after distillation, 
although the excellent yields reported by Dailey were not obtained. A viscous brown 
tar was observed to remain in the distillation vessel after collection of the product 
was complete; this was thought to be composed of aldol-like self-condensation 
products of 35 and probably contributed significantly to the diminished yield.
The existing procedures for the dimethylation of 35 appeared to be rather 
unsatisfactory: moderate yields were obtained but required tedious reduced-pressure 
distillation to separate the product from the residual tar (36 cannot be purified by 
column chromatography due to its tendency to decompose on silica gel). In addition, 
analysis of the crude reaction mixtures by TLC indicated the presence of multiple 
alkylation products, suggesting that sodium hydride may not be the optimal base for 
this transformation. It was therefore decided to attempt the dimethylation of 35 
under a range of alternative conditions (Table 5).
The primary aims of the investigation were to develop a robust procedure 
which selectively afforded the 1,1-dimethylation product 36 (i.e. did not lead to over- 
alkylation) in a suitably pure form such that further purification was not required 
(due to the aforementioned difficulties in purifying 36). Consequendy, the success 
of the reaction was determined using a combination of TLC and *H NMR analysis, 
and by visual inspection of the product obtained after work-up.
Hart et al.m  report the successful dimethylation of 35 using sodium
2-propoxide as base. This result is somewhat contradictory to the studies of the
106methylation of phenylacetone by Suter et al. , who state that the use of sodium
2-propoxide leads to exclusive monomethylation. Nonetheless, it was decided to 
attempt the preparation of 36 using the original conditions described by Hart105 and a 
slightly modified procedure (entries 3 and 4 respectively in Table 5). TLC analysis 
of the quenched reaction mixture showed a moderately clean reaction, although some 
starting material was clearly evident. The decision not to pursue this procedure 
further was a result of the commercial unavailability of sodium 2-propoxide,
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necessitating its time-consuming (and somewhat hazardous) laboratory preparation 
by the reaction of sodium (or sodium hydride) with propan-2-ol.
In the same paper, Suter et a l 106 report that dimethylation of phenylacetone 
readily occurs in the presence of potassium tert-butoxide. As this base is 
inexpensive and readily available in its powdered form, it was decided to investigate 
its suitability as a replacement for sodium isopropoxide. A variety of conditions and 
solvents were tested and it was found that portionwise addition of 3 equivalents of 
KOlBu to a solution of 35 and 2.5 equivalents of iodomethane in THF afforded a 
product of clean appearance (no viscous brown material observed) and high purity by 
*H NMR (entry 8 in Table 5 and Scheme 12).
No Reagents Solvent O rder of addition Conditions
1
NaH (4 eq) 
Mel (3.5 eq)
THF
NaH added to solution of 35 in 
THF followed by Mel
0°C to RT 
3 h
2
NaH (3 eq) 
Mel (3 eq)
Toluene
35 added to suspension of NaH 
in toluene followed by Mel
0°C to RT 
18 h
3
NaCVPr (10 eq) 
Mel (3 eq)
Propan-2-ol
35 added to solution of NaC^Pr 
in propan-2-ol followed by Mel
0°C to rflx 
2 h
4
NaCyPr (3 eq) 
Mel (3 eq)
Propan-2-ol
35 added to solution of NaO'Pr 
in propan-2-ol followed by Mel
0°C to rflx 
3 h
5
KOlBu (3 eq) 
Mel (3 eq)
DME
35 added to mixture of KOlBu 




KO'Bu (3 eq) 
Mel (3 eq)
Toluene
KOlBu added to solution of 35 
in toluene followed by Mel
0°C to rflx 
18 h
7
KO'Bu (2.3 eq) 
Mel (2.5 eq)
DME
KOlBu added to solution of 35 
and Mel in DME
0°C to RT 
17 h
8
KO'Bu (3 eq) 
Mel (2.5 eq)
THF
KOlBu added to solution of 35 
and Mel in DME
0°C to RT 
17 h
T able 5 (Conditions used to attempt dimethylation o f tetralone 35)
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O  0°C to  RT, 18 h
o
35 36
Scheme 12 (Dimethylation of tetralone 35)
The decision to switch the order of addition of KOlBu and iodomethane was 
taken out of the need to minimise polymerisation of the enolate of 35, a factor 
thought to be largely responsible for the presence of brown tar in the product. This 
technique effectively reduces the ‘lifetime’ of the enolate in the reaction mixture as it 
can rapidly react with the electrophile. One specific concern with this immediate 
alkylation method was whether rearrangement of the kinetic enolate would be able to 
occur rapidly enough to avert methylation at the 3-position; this applies particularly 
to the introduction of the second methyl group where deprotonation at the 3-position 
might be expected to be favoured due to the sterically-hindered nature of the tert- 
butoxide anion (Scheme 13). 'H  NMR studies of the product showed no indication 
of 1,3-dimethylation and TLC analysis revealed only trace amounts of the starting 
material and the 1-monomethylated product. Evidently, either rearrangement to the 
thermodynamic enolate occurs very rapidly due to the lower energy state afforded by 
conjugation with the aromatic ring, or the protons at the 1-position are so 
overwhelmingly more acidic that deprotonation at the 3-position does not occur to 
any significant extent with KOlBu. The fact that no products corresponding to tri- or 
tetraalkylation of 35 were detected suggests that a combination of both these two 
factors may be responsible.
KINETIC THERMODYNAMIC
Schem e 13 (Rearrangement of kinetic and thermodynamic enolates)
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The quality of the product obtained using the new procedure was such that it 
could be used in the next stage of the synthesis without purification (in practice, 36 
was always converted immediately to oxime 37 to avoid darkening of the material). 
The use of KO'Bu instead of sodium hydride as base improves the safety and 
convenience of the process, allowing multigram quantities of 36 to be rapidly 
synthesised.
Conversion to the oxime 37 (Scheme 4) was readily achieved by treating 36 
with hydroxylamine hydrochloride and sodium acetate according to the procedure 
previously used within the group. As 37 is insoluble in the Me0H/H20 solvent 
system, it may be easily collected by suction filtration and dried for immediate use in 
the next stage. Additionally, trace impurities from the previous dialkylation step 
were not found to be present in the product oxime, affording 37 in an excellent state 
of purity. An improved yield was obtained if the reaction was first heated to reflux 
before stirring at room temperature (previously no heating was applied), and a 15g 
batch of 37 was successfully prepared in 81% yield from tetralone 35 using this 
method (Scheme 14). Unlike ketone 36, oxime 37 was found to be highly stable and 




M e O H /H p  
RT to  reflux, 21 h 
81%  from 35
Scheme 14 (Conversion of ketone 36 to oxime 37)
An interesting effect of the geminal dimethyl group is that it appears to exert 
complete steric control over the configuration of the oxime group of 37. The 
presence of both syn and anti isomers in a given sample are clearly revealed by *H 
and 13C NMR spectroscopy as the oxime OH group causes a change in chemical shift 
of spatially proximal protons leading to ‘doubling-up’ of the signals in the NMR 
spectrum.107 Examination of the 13C NMR spectrum of 37 clearly indicates that only 
one isomer is present as 12 separate signals (corresponding to 12 chemical 
environments of 37) appear in the spectrum. Given the steric crowding of the syn
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isomer (Figure 7) and the efficient reduction of 37 to the corresponding aziridine (see 
Chapter 3), it is highly probable that the oxime exists in the anti form.
S Y N  ANTI
U nfavourable steric  crowding 
b e tw een  oxim e an d  gem inal 
dim ethyl g roups
Figure 7 (Isomeric syn and anti forms of oxime 37)
The reduction of oxime 37 to the primary amine 38 (Scheme 4) was initially 
carried out using 4 equivalents of lithium aluminium hydride in refluxing THF 
according to the method previously used within the group. TLC analysis of the crude 
reaction mixture after 24 hours at reflux revealed complete consumption of 37 and 
the presence of 3 product spots by UV (Rf values 0.34-0.60). Subsequent 
purification by column chromatography afforded the desired amine 38 in rather low 
43-54% yields.
It is well established in the literature that the reduction of oxime groups to 
amines by LiAlR* is complicated by the formation of aziridines as side-products. 97  
For this to occur, the molecule must possess a methylene or methyl group a to the 
oxime ; indeed, in cases where the methylene or methyl group is adjacent to an 
aromatic ring, the corresponding aziridine replaces the amine as the major reduction 
product. The low yields of 38 were primarily a result of such a side-reaction 
occurring (a phenomenon which was later exploited in Chapter 3). Additional 
drawbacks associated with the use of LiAlHi are its tendency to spontaneously ignite 
when first combined with the solvent and the inconsistent levels of activity between 
different batches of the reagent (on one occasion, a newly purchased batch was found 
to react slowly even with water!). Investigation of alternative reduction methods of 
37 was therefore justified.
MeO
L ess sterically  crow ded and  
oxim e oxygen ideally positioned 
for reduction to  aziridine
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Attempts to effect reduction using ‘non-hydride’ reducing agents such as
i no  inn
sodium in refluxing ethanol and zinc in acetic acid were unsuccessful. The 
combination of certain Lewis acids and sodium borohydride afford powerful 
reducing reagents and several examples have been reported in the literature as 
successfully reducing oxime functionalities to amines9 7 ,1 1 0 ,1 1 1  These systems 
appeared particularly attractive as the reducing species is generated in situ, thus 
avoiding the ignition hazards encountered with LiAlfL*. Additionally, the reported 
yields of amine are high and aziridines are not generated as side-products.
The TiCU/NaBLU system was initially chosen due to the ready availability of 
the reagents. Kano et al.u0 state that oximes may be readily reduced at room 
temperature with this system; however, no conversion of 37 was detectable by TLC 
analysis after 24 hours under these conditions. As discussed previously, the steric 
bulk of the gem-dimethyl group of 37 significantly attenuates reactions occurring at 
the 2 -position and it appeared that this was the most probable reason for the lack of 
activity. Repetition of the reaction at reflux and subsequent TLC analysis indicated 
complete conversion to the amine 38, though only a modest yield (57%) of product 
was obtained after acid extraction of the reaction mixture. The formation of 
emulsions arising from the presence of titanium salts significantly hampered the 
work-up process and was thought to be a major factor contributing to the low yield.
In view of developing a more convenient, higher-yielding procedure, the 
ZrCl4/NaBH4  system of Itsuno et al.]U was also investigated. One particular 
disadvantage of TiCL is its high degree of air sensitivity, which makes manipulation 
of the reagent somewhat troublesome; ZrCU, however, is a relatively stable solid and 
may be conveniently weighed on the bench. As with the previous system, 37 did not 
undergo reduction at room temperature with ZrCL/NaBEU in DME, but repeating the 
reaction at reflux afforded complete conversion.
DME




Scheme 15 (Reduction of oxime 37 with ZrCl4/NaBH4)
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An improved procedure for quenching the reducing agent was also devised, 
whereby the reaction mixture was treated with excess solid NaSO4 . 1 0 H 2O (based on 
a similar procedure for the quenching of UAIH 4 112); this produced a granular 
precipitate of metal salts which were easily removed by suction filtration. Pure 38 
was obtained as its HC1 salt in improved 6 8 % yield by subsequently treating the 
filtrate with propanolic HC1, evaporating the solvents and recrystallising the residue. 
This procedure represents a substantial improvement on the previous methods 
employed for this reaction as it is relatively free from hazards, uses inexpensive 
reagents, is easy to perform and requires no column chromatography.
The change in hybridisation of the 2-carbon has a significant effect on the ’H 
NMR spectra of 37 and 38. The presence of three sp carbon centres in the B-ring of 
37 forces it to adopt a rather strained conformation (Figure 8  —» A) where four of the 
six C -C  bonds are virtually planar. The geminal dimethyl protons are fixed in 
identical chemical environments (as shown by the accompanying Newman 
projection) and appear in the *H NMR spectrum as a single peak at approximately 
1.20ppm integrating to 6  protons. Reduction of the oxime group causes a concurrent 
sp2 —» sp3 change in the hybridisation of the 2 -carbon; the ring adapts by shifting to 
the energetically favourable ‘half-chair’ conformation9 1 ,1 1 3  characteristic of the 
cyclohexenes (Figure 8  —> B).
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Examination of the corresponding Newman projection reveals that the methyl 
groups are now clearly in differing chemical environments - the consequence for the 
'H NMR spectrum is a change from one single peak to two peaks each integrating to 
3 protons. This feature was observed in all subsequent spectra of compounds 
possessing the aminotetralin scaffold, although the separation of the two signals 
varied somewhat according to the Af-substituent as the ring adapted to the lowest 
energy conformation.
The next step in the synthesis required the O-demethylation of the 7-methoxy 
group. A variety of methods for the cleavage of phenolic methyl ethers have been 
reported, of which the most established are concentrated hydrobromic acid116, boron 
tribromide117 and sodium propanethiolate. 118 Hydrobromic acid was initially 
selected for the O-demethylation of 38, being the most convenient and economic 
method of the three. Methyl ether 38 was subsequently heated with 48% 
hydrobromic acid at 100°C for 3 hours; basification and standard work-up followed 
by column chromatography of the residue afforded the desired aminotetralin scaffold 
23 in 40-60% yield. TLC analysis of the crude product often revealed a non-polar 
spot with a significantly higher Rf than the expected 23. It is possible that a small 
proportion of HBr becomes oxidised to elemental bromine during the reaction 
(darkening of the reaction was observed to occur), which then reacts readily with the 
aromatic ring of 38 (or 23) to form brominated side-products (flushing the system 
with nitrogen did not eradicate the problem, however).
A greater consistency of yield was achieved when O-demethylation was 
performed instead using 2 equivalents of boron tribromide in CH2CI2 at -78°C .117 
Cautious quenching of the system with methanol followed by work-up as for HBr 
afforded consistent yields of 23 in excess of 65% after chromatography.
c h ,c i2




Scheme 16 (Methyl ether cleavage of 38 to afford aminotetralin scaffold 23)
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The use of boron tribromide as a reagent for the cleavage of methyl ethers has 
one distinct advantage over the other methods in that the reaction is performed under 
extremely mild conditions, considerably limiting the number of potential side- 
reactions. It is, however, a comparatively expensive and air-sensitive reagent which 
makes it rather inconvenient for multigram preparation of 23. There is consequently 
still room for improvement in this synthetic step; recent experiments in the group 
utilising 10 mol% of tetra-n-butylammonium bromide in 48% HBr as a system for O- 
demethylation119 have afforded promising results.
2.3.3 Synthesis o f ring-substituted amines
The establishment of improved experimental procedures for the synthesis of 
intermediates leading to the aminotetralin scaffold 23 meant that sufficient material 
could now be prepared for the attachment of appropriate ‘address’ side-chains. It 
was discussed at the beginning of this chapter that the suitable positioning of an 
amine functionality via attachment to the terminal aromatic group of 26 may provide 
a means to enhance k  receptor selectivity. Primary amines 28-30 were proposed as 
the three key intermediates which, after obtaining preliminary pharmacological data, 
may be subsequently modified to afford ligands with ‘address’ amines of higher 
basicity (e.g. guanidines). During the preliminary work in the group on aminotetralin 
23, diversification at the primary amine group was achieved using a combination of 
direct alkylation and reductive alkylation methods. The particular choice of method 
depended primarily on the commercial availability and stability of the corresponding 
electrophiles. Direct ^-substitution in this manner is clearly inappropriate for the 
preparation of 28-30, as the exposed primary amine moiety is liable to react with the 
bromide/aldehyde group. It was therefore decided to use the corresponding nitro 
derivatives as masked amines for the initial coupling to scaffold 23; reduction would 





The synthesis of secondary amines by reaction with halides is generally 
difficult to achieve in satisfactory yield as the product readily undergoes further 
alkylation to afford tertiary (and often quaternary) amines. 97 This normally 
undesirable result was exploited in the preliminary work on 23 as it enabled mono- 
and disubstituted analogues to be readily prepared in one reaction. Since only 
monosubstituted ligands are required for the present investigation (the di-cinnamyl 
derivative of 23 displayed little activity in the binding assay), it appeared unwise to 
pursue this method of alkylation.
The reaction of a compound possessing an aldehyde or ketone group with a 
primary or secondary amine under dry conditions results in the elimination of water 
and formation of an imine (in the case of primary amines) or enamine (in the case of 
secondary amines). In reductive alkylation, the imine or enamine is subsequently 
reduced by catalytic hydrogenation or hydride reducing agents to furnish a secondary 
or tertiary amine respectively. Figure 9 illustrates this process.
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■^0 \  Reduction \  H:o +  r 'n h 2 -  w N --------- -- ; — n
H +H2° H FT H XR'
Aldehyde 1° amine ,mine fam ine
Figure 9 (Synthesis of secondary amines by reductive alkylation)
Modified reducing agents such as sodium cyanoborohydride and sodium 
triacetoxyborohydride selectively reduce imines in the presence of ketones or 
aldehydes, thus enabling imine formation and reduction to be achieved in a one-pot 
process.9 7 ’ 120 As the resulting secondary amines are significantly more nucleophilic 
than the parent primary amines, further reaction generally occurs and tertiary amines 
are normally the major products. This technique was previously used in the group as 
an alternative to direct alkylation for the preparation of mono- and disubstituted 
derivatives of 23 in one reaction; it is not suitable, however, for the selective 
formation of monosubstituted ligands such as 28-30.
The use of a two-stage reductive alkylation process for the synthesis of
191secondary amines has been reported in the literature. “ The first stage involves 
reaction of the primary amine-containing compound with a slight excess of the
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aldehyde or ketone to form the corresponding imine intermediate. Upon completion 
of the reaction, the crude mixture is treated with sodium borohydride which reduces 
both the imine and unreacted carbonyl, thus preventing further reaction and 
formation of tertiary amines. An alternative procedure for the synthesis of secondary 
amines has been reported by Mattson et a l}22 whereby the amine and carbonyl 
compound are combined in titanium(IV) isopropoxide and the resulting intermediate 
reduced with sodium cyanoborohydride; this method appeared to be somewhat more 
hazardous and inconvenient, however, and it was therefore decided to adopt the 
former procedure.
With the exception of 3-nitrocinnamaldehyde, the other aldehydes were 
conveniently available commercially in the trans form. 3-Nitrocinnamaldehyde (58) 
was obtained by direct condensation of 3-nitrobenzaldehyde with acetaldehyde in
190
31 % yield according to a known procedure (Scheme 17).




Reflux, 45  min
31 %  overall yield 
Scheme 17 (Synthesis o f 3-nitrocinnamaldehyde123)
Reaction of the nitrocinnamaldehydes with 23 to form the corresponding 
imines was carried out in CH2CI2 at room temperature. This was followed by 
evaporation of the solvent and treatment of the crude mixture with 4 equivalents of 
NaBRi in methanol; aqueous work-up and purification by column chromatography 
afforded excellent yields of the secondary amines 59-61 (Table 6 ). Curiously, the 
imines derived from meta- and p<2 ra-nitrocinnamaldehydes precipitated out of the 
reaction as they formed and were found to be only sparingly soluble in methanol 
leading to very poor yields after reduction. This problem was solved by the addition 
of a small quantity of DMF (see Table 6 ) which efficiently solvated the imines, 





H (1.2-1.5 eq) 
CH,CI2, RT, 18 h
2) NaBH4 (4 eq)
MeOH, 0°C to  RT, 16 h
No Position Reduction solvent Yield
59 ortho MeOH 83%
60 meta 4:1 MeOH/DMF 8 6 %
61 para 4:1 MeOH/DMF 81%
Scheme 18 and Table 6 (Reductive alkylation of 23 with nitrocinnamaldehydes)
2J  = 14.4 Hz 4J  = 1.2 Hz
3J  = 5.6 Hz
Figure 10 (Diastereotopism of the methylene protons in 61)
The partial structural rigidity of the nitrocinnamyl side-chain is amply 
demonstrated by the !H NMR spectra of 59-61. The lack of free rotation about the 
alkene bond causes the allylic methylene protons to become diastereotopic and 
appear on the spectrum of as two distinct ‘doublet of doublet of doublets’ at 3.44 and
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3.69 ppm (for 61). The three observed coupling constants for the methylene protons 
of 61 are rationalised in Figure 10; one noticeable feature is the presence of long- 
range ( J) coupling characteristic of such allylic systems.
Completion of the synthesis of 28-30 required unmasking of the aromatic 
nitro group to afford the primary amine. A vast array of methods are available for 
the reduction of aromatic nitro groups utilising a wide range of both elemental metals 
and their salts. 9 7  The Raney nickel/hydrazine hydrate reduction system had been 
previously applied within the group for such transformations and has the additional 
advantage of being effective under mild conditions. Treatment of the ortho 
derivative 59 according to the method of Brown and Nelson124 at room temperature 
afforded a clean reaction with only one product apparent by TLC. Purification by 
column chromatography and subsequent NMR analysis, however, showed that over­
reduction to the saturated compound 62 had occurred (Scheme 19). It was decided to 
submit this compound for biological testing in order to investigate how a greater 
degree of conformational freedom in the address side-chain would affect the 
pharmacological profile.
H .N N H j.H .p
R aney  Ni 
59  --------------------
EtOH 
RT, 15 h 
79%
62
Scheme 19 (Raney Ni/hydrazine hydrate results in over-reduction of 59)
Attempted reduction of 59 using iron powder in acetic acid at reflux afforded 
a mixture of products including a significant proportion of 62 which proved difficult 
to remove during purification. Cuerva et al} 25 report that iron(II) sulfate 
heptahydrate in aqueous ammonia reduces aromatic nitro groups at reflux. 
Treatment of 59 using this method was found to successfully afford the desired 
unsaturated amine 28 in satisfactory 6 6 % yield after purification. The remaining 
amines were obtained in a similar manner, although a degree of over-reduction was 
observed for the para derivative resulting in a diminished yield of 28%.
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F e S 0 4.7H20  
7M NH4OH(aq)
59-61 ---------------------
M eO H /H .0 
Reflux, 2 h 
28-66%
2 8 -3 0
Scheme 20 (Successful iron(II) sulfate/ammonia reduction o f 59-61)
The purified ligands 28-30 were converted to their respective HC1 salts (as 
described in Chapter 7) and submitted for pharmacological evaluation. A sample of 
ortho-NO2 derivative 59 was also submitted as excess material was available 
(unfortunately, sufficient quantities of the meta and para analogues 60 and 61 for 
testing were unavailable and would have required complete re-synthesis).
At this point in the project, increasing focus was being placed on the 
investigation of 3-methoxy-substituted ligands (see Chapter 3) and it was therefore 
decided to delay synthesis of analogues of higher basicity {e.g. guanidines) until the 
in vitro pharmacological data on compounds 28-30 had been received. These results 
became available close to submission of this thesis and there was unfortunately 
insufficient time to further expand on the series. However, the improved procedures 
leading to key intermediates 28-30 should enable larger quantities of these 
compounds to be rapidly synthesised and consequently provide a robust starting 
point for further investigations.
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CHAPTER 3
INVESTIGATION OF 3-METHOXY ANALOGUES OF 
2-AMINO-l,l-DIMETHYLTETRAHYDRONAPHTHALEN-7-OL
3.1 Design rationale
Whilst conducting the initial stages of the work directed towards the synthesis 
of aromatic primary amine derivatives 28-30 (see p. 49), a novel series of 
aminotetralin ligands for opioid receptors were independently disclosed in a letter by 
Caroline Roy and her associates. 126 The design of the ligands was again inspired by 
dezocine (2 0 ), but a different approach was taken in the structural simplification 
which is of significant interest to the present project.
In an effort to obtain opioid analgesics with superior potency to 20, the 
corresponding thioether derivative 63 was synthesised. Subsequent binding and 
antinociceptive assays showed that 63 possessed a high degree of p receptor binding 
and significant analgesic ability. Presumably recognising that exclusion of the 
bridging ring could provide a series of ligands with a somewhat simpler synthesis but 
retaining affinity for opioid receptors (in a similar manner to the design rationale of 









Scheme 21 (A series of structurally simplified analgesics based on dezocine126)
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A series of analogues of 64 possessing different substituents at the 3-position 
were synthesised and tested for opioid binding. Table 7 shows the data obtained for 
a selection of the more active compounds. It should be noted that the compounds 
were prepared and submitted as their racemic cis and trans forms - the 




R 1 R 2 5 K
H s c h 3 286 Not tested Not tested
s c h 3 H 1 . 1 349 6 6
H CH2CH3 135 Not tested Not tested
CH2CH3 H 2 1 4507 345
OCH3 H 1 . 8 5216 184
Table 7 (Binding assay results for selected compounds reported by Roy et al.'26)
One particularly striking feature of this series is the considerable difference in 
p binding affinity between corresponding cis and trans isomers of compounds 
bearing the same 3-substituent: comparison of the p affinities for the two isomers of
9 1the 3-thiomethyl derivative (Table 7: cis R“ = SCH3 , trans R = SCH3 ) indicates a 
260-fold increase in p receptor binding when the 3-thiomethyl substituent is trans 
relative to the primary amine moiety. From these results it appears that an additional 
residue on the receptor may be enhancing ligand binding under certain conditions - a 
trans relationship between the amine and 3-substituent may facilitate the greatest 
degree of interaction between each of the two groups and its corresponding binding 
site on the receptor; a cis arrangement, on the other hand, may allow one group to 
interact but place the other at too far a distance from its target site on the receptor. 
The enhanced analgesic potency of the trans isomer compared to the cis form is 
somewhat unexpected given that dezocine (2 0 ) possesses a cis relationship between 
the bridging ring and the primary amine at the 2 -position.
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Of the three substituents tested, thiomethyl (SCH3) confers greatest affinity at 
p, 8  and k  opioid receptors. The methoxy (OCH3) derivative exhibits an almost 
equal degree of binding at the p receptor, though with a substantial loss of affinity at 
the 8  and k  receptors. The ethyl (CH2CH3) substituted analogue is the 
pharmacologically least significant of the three, exhibiting only moderate affinity for 
the p receptor (but significantly lower than SCH3 and OCH3) and poor affinities for 
the 8  and k  receptors. No explanation for the high p affinity of the SCH3 and OCH3 
analogues is provided by the authors of the paper and the results do not appear to 
correlate with any clear trend in electronegativity, hydrogen-bonding ability or other 
factor which might enhance ligand-receptor interaction.
In summary, the above results indicate that an SCH3 or OCH3 group at the 3- 
position in general affords superior opioid receptor binding affinity for 
aminotetralins of structure 64, though only when the substituent is orientated trans to 
the primary amine moiety. These findings are of great interest to the present project, 
as one of the major aims was the investigation of possible structural alterations to the 
‘message’ scaffold 23 in view of obtaining ligands with superior affinities for opioid 
receptors. One particularly attractive feature is that inclusion of an SCH3 or OCH3 
substituent to the scaffold would not significantly increase the overall size of the 
ligand, thus retaining the desired ‘small molecule’ criterion which is pivotal to the 
current project.
The use of 3-substituted aminotetralin 64 as a scaffold on which to construct 
opioid antagonist ligands was not established in the report of Roy et a l , as the 
primary focus of the work was on the development of potent p agonists for use as 
analgesics. The preliminary work on scaffold 23 in the group has already shown that 
simple secondary and tertiary amine derivatives behave purely as opioid antagonists, 
despite the structure of 23 being directly derived from the agonist dezocine (20). 
This evidence, together with the potential pharmacological ramifications already 
discussed, gives strong support to the synthesis and biological assay of an equivalent 
3-substituted series of compounds.
Whilst Table 7 indicates that the SCH3 -substituted analogue possesses the 
highest affinity for all three receptor types, it was decided after consideration to 
instead utilise the OCH3 -substituted aminotetralin as the starting point for the present 
investigation. The major factor in this decision was the synthetic route to this
176particular analogue reported by Roy and co-workers is two steps shorter than the
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corresponding SCH3 derivative. As the OCH3 analogue exhibited an almost equally 
high affinity for the p receptor as the SCH3 compound and moderate affinity for the k  
receptor, it was concluded that the use of an OCH3 3-substituent would be more than 
sufficient to enable the pharmacological ramifications of including such a group at 
the 3-position to be evaluated whilst necessitating a shorter and hence more attractive 
synthesis than the corresponding 3 -SCH3 aminotetralin.
In order to investigate how a 3 -OCH3 substituent in aminotetralin 23 would 
affect the ability of A-substituted derivatives to function as pure opioid antagonists, it 
was decided to synthesise a series of compounds based on modified scaffold 65 
possessing simple alkyl A-substituents. This would allow direct comparison to the 
series previously synthesised in the group derived from original scaffold 23, enabling 










It was discussed in Chapter 1 that the combination of the 
tetrahydroisoquinoline side-chain utilised in JDTic (14) and novel aminotetralin 
scaffold 23 was found to afford a potent and selective k  antagonist (27, p. 24), 
though less potent than 14 itself. Given that inclusion of a 3 -OCH3 group has the 
potential to increase receptor affinity in derivatives of 23, it was decided that 
synthesis of the corresponding 3 -OCH3 analogue of 27 would be an interesting 
addition to the studies of the alkyl derivatives of 65. If successful, 6 6  may prove to 
be a useful research tool as an alternative to norBNI (10) and JDTic (14) for studies 
of the k  opioid receptor. Separation of the two diastereomers of 6 6  (since the valine 
and tetrahydroisoquinoline units are chirally pure) was also of interest in order to 
compare the effects of the two aminotetralin trans isomers on the pharmacological 









3.2 Overview of literature synthetic route
126Roy et al. report that the preliminary test compounds (in Table 7) were 
prepared as mixtures of cis and trans isomers by direct alkylation of l,l-dimethyl-7- 
methoxy-2-tetralone (36, p. 31) with the appropriate electrophile (the exception to 
this was the OCH3 analogue which was prepared exclusively by the new method 
described below) followed by conversion to the primary amine via the oxime; 
column chromatography was then used to separate the mixtures into cis and trans 
forms. As it became apparent that the trans isomers had greater opioid receptor 
affinity, a new synthetic route was devised utilising an aziridine ring-opening 
reaction which selectively afforded the desired trans forms. Scheme 22 illustrates 
the synthetic route used to obtain rraws-3-methoxyaminotetralin 65 (Scheme 22), 
though unfortunately the actual experimental procedures were not disclosed in the 
original paper.
The synthesis of 3-methoxyaminotetralin 65 begins with the commercially 
available 7-methoxy-2-tetralone (35) which is subsequently dimethylated and 
converted to oxime 37 (Scheme 4) in a similar manner to that described for 
aminotetralin 23. Usefully, the two synthetic routes share the common intermediate 
37 whose synthesis has already been optimised as described in Chapter 2. Aziridine 
67 represents the most important intermediate in the synthesis of 65, as it is the 
means by which the crucial trans relationship between the 3-methoxy group and the 
primary amine moiety is established. The conditions used to transform oxime 37 to 
aziridine 67 are rather interesting as the system which is employed, UAIH4 in 
refluxing THF, is one of the standard methods to reduce oximes to primary amines 
(up to 55% yields of 38 were previously obtained from 37 using this method). It was 
discussed in Chapter 2 that aziridines are frequently observed side-products of 
LiAlFL* reductions; in this case the presence of diethylamine in the reaction mixture 
appears to reverse the outcome of the reaction so that 67 is the major product (in 
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Schem e 22 (Literature synthesis o f 3-methoxyaminotetralin 65126)
Aziridine 67 is subsequently O-demethylated using boron tribromide to 
afford phenol 6 8  in 66-80% yield. This is followed by acylation of the aziridine 
nitrogen and phenol with B0 C2O affording the activated aziridine species 69. Acid- 
catalysed ring-opening with methanol under mild conditions introduces the required 
trans stereochemistry to yield 70 as a mixture of the two enantiomers. Finally, facile 
Boc deprotection with trifluoroacetic acid affords a quantitative yield of the 3- 
methoxyaminotetralin 65.
As the majority of the steps in the synthesis of 65 given by Roy et al. 
appeared relatively straightforward, it was decided to pursue this route for the 
preparation of the proposed ligands. The availability of alternative routes to 65 is 
somewhat hampered by the requirement of the 2,3-trans stereochemistry; aziridine 
ring-opening therefore appears the only feasible option in this case. It should be 
noted that Boc protection of the phenolic moiety was originally undertaken to
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10fiprovide a common intermediate (69) for the synthesis of other analogues (notably 
SCH3) but is superfluous in the preparation of 65; however, it was decided to adhere 
to the original scheme so as to compare and improve the yields of all steps.
3.3 Synthetic studies
3.3.1 Synthesis o f 3-methoxyaminotetralin scajfol
Until recently, the use of aziridines as intermediates in organic synthesis has 
been largely neglected due to the lack of convenient preparative methods for this 
functional group. This situation is rapidly changing, however, and is primarily a 
result of the considerable progress being made in nitrene-transfer methods of 
aziridine synthesis which allow direct preparation from alkenes. 127 Much effort has 
also been applied to the development of asymmetric catalysts for these reactions128' 
13°, and it appears likely that in the near future the aziridine group will rival the 
epoxide in terms of synthetic accessibility and applications in organic synthesis.
The preparation of aziridines by the hydride reduction of oximes in the 
literature is largely confined to a small number of papers submitted by Kotera et 
0 / . 107’131' 133 in the 1960’s and a brief investigation by Landor and colleagues134 in 
1974. Aside from these reports, the method appears to have been almost completely
177abandoned and in a recent review of aziridine chemistry , it was noticeably absent 
from the list of viable synthetic methods. Although it cannot be denied that the 
nitrene-transfer preparation of aziridines from alkenes offers greater potential in 
terms of superior yields and stereoselectivity, there will be occasions in organic 
synthesis where introduction of an alkene moiety is not feasible and it is desirable to 
have an alternative means by which to introduce the aziridine functional group. 
Further exploration of this reaction with the specific aim of improving the 60% yield 
of intermediate 67 reported by Roy et al.126 was therefore conducted.
Due to the inconsistent and somewhat hazardous nature of LiAlEU, it was 
decided to investigate the use of the related reducing agent sodium 
bis(2-methoxyethoxy)aluminium hydride (SMEAH or Red-Al®), shown previously 
by Landor et a l 134 to lead to superior yields in this type of reaction. SMEAH is a 
derivative of LiAlHL* with similar reactivity but is non-pyrophoric135 and therefore 
considerably safer than LiAlH*; this is a particular concern when designing a suitable 
procedure to obtain multigram quantities of the aziridine. Whereas the experimental
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procedure of Landor et al. 134 advocates the use of THF as solvent, it was initially 
decided to attempt the conversion of oxime 37 to aziridine 67 in solvents of higher 
boiling point. This decision was based on the finding that elevated temperatures 
were required to effect reduction of 37 to primary amine 38 with the ZrCLj/NaBH* 
system (see p. 46), despite the literature examples specifying room temperature as 
being sufficient. 111 This was taken as an indication of the considerable steric 
obstruction of the 1,1-dimethyl group of 37 on the carbon atom of the neighbouring 
oxime, inhibiting the approach of nucleophiles to the 2 -position.
As SMEAH is supplied as a solution in toluene, it appeared logical to attempt
the reaction in this solvent as it is of relatively high boiling point and immiscible
with water which facilitates aqueous work-up. Treatment of a solution of 37 in
toluene with 5 equivalents of SMEAH and 10 mol% diethylamine (see below)
followed by 18 hours at reflux afforded a 35% yield of aziridine 67 after acid/base
work-up and column chromatography. The product was easily characterised as an
aziridine by the two peaks at 2.12 and 2.47 ppm in the NMR spectrum - each
integrated to 1 proton and exhibited a vicinal coupling constant of 6.2 Hz, indicating 
1 ^ 6a cis relationship between the protons at the 2 and 3 positions. TLC analysis 
showed that a significant amount of starting material and primary amine was present 
in the crude product. It was thought that poor solubility of oxime 37 could be 
contributing to the low yield of 67 and the reaction was therefore repeated using 
varying mixtures of toluene and the more polar solvent DME (Table 8 ).
Solvent Auxiliary amine Eq. Red-Al Yield
Toluene Diethylamine 5 30%
Toluene A-Methylbutyl amine 5 35%
1:1 DME:Toluene A-Methylbutylamine 4 45%
1:1 DME:Toluene 4-Dimethylaminopyridine 4 47%
2:1 DME:Toluene A-Methylbutylamine 4 55%
Table 8 (Effect o f  solvent and auxiliary amine on yield o f aziridine 67)
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The results obtained show that increasing solvent polarity increases the yield 
of aziridine. This may be a result of either improved solubility of 37 or increasing 
solubility of the intermediate aluminium complex according to the reaction 
mechanism presented by Landor et a l 134 (Figure 11). They proposed that formation 
of the aziridine 67 over the primary amine 38 depends on elimination of the AIR2HO' 
fragment in the initial transition state to form an unsaturated nitrene species; 
effective solvation of the aluminium complex aids its elimination and consequently 
favours the pathway of aziridine formation. Kotera et a l m  also found yields of 
aziridine to be considerably greater when the reduction was conducted in THF and 
DME rather than diethyl ether, providing support for this theory.
The addition of a catalytic quantity of a secondary amine to the reaction 
mixture has been briefly reported by Kotera et a l to more than double the yields 
of aziridine when LiAlH* is used as the reducing agent. The reason for this is not 
clear and no subsequent studies are reported in the literature, though it has been 
established that the effect of auxiliary amine substitution on yield of aziridine is of 
the order: secondary > primary > tertiary. These results strongly suggest that a 
nucleophilic mechanism is involved. Interestingly, there is no mention of the use of 
a catalytic amine in the later work of Landor et al. 134 on SMEAH reduction of 
oximes; however, it was decided to incorporate an auxiliary amine into the present 
experimental investigation as there was no apparent reason that it should not exert a 
similarly beneficial effect on the yield of aziridine 67. The use of
1^ 1
A-methylbutylamine instead of diethylamine gave rise to a slightly increased yield 
of 67; this may be a consequence of the higher boiling point of A-methylbutylamine 
(90°C) over diethylamine (56°C) resulting in proportionally less existing in the 
vapour phase at any one time. The hypemucleophilic catalyst 4- 
dimethylaminopyridine (DMAP) was not found to significantly improve the yield of 
67 compared to A-methylbutylamine, though whether increasing nucleophilicity 
exerts an effect on the overall rate of reaction remains to be elucidated. This, 
together with the testing of further secondary amines with the aim of discovering a 
superior catalyst, was to be the subject of further study although unfortunately this 
could not be accomplished within the time restraints.
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Figure 11 (Proposed mechanisms for formation of primary amine 38 and aziridine 67 by hydride 
reduction of oxime 37 adapted from Landor et a / .134)
The effect of solvent on yield of 67 (Table 8 ) indicated that solubility of 
oxime 37 and/or the intermediate aluminium complex (Figure 11) was of greater 
importance than the gain in reaction temperature afforded by the use of toluene. It 
was therefore decided to attempt reduction of 37 in 100% THF. In an effort to make 
the procedure more convenient, the addition was carried out in reverse: a solution of 
the oxime in THF was introduced to the reaction vessel containing SMEAH via a 
dropping funnel; this replaced the rather tedious dropwise addition of viscous 
SMEAH solution via syringe. This was found to result in consistently high (>70%) 
yields of 67 exceeding the 60% conversion quoted by Roy et al.ne (Scheme 23); in 
addition this method was easier to perform, less hazardous (no LiAlH4 ) and the 
reaction was very clean requiring only facile purification to remove the small 
quantity of primary amine side-product (67 can be obtained in an excellent state of
119purity by a “dry-column chromatography” technique " which requires only minimal 
amounts of silica gel).
MeO NOH
37
SMEAH (4 eq) 
MeNHBu (0.1 eq)
THF 
Reflux, 18 h 
74%
Scheme 23 (Improved reduction of oxime 37 to aziridine 67)
One final investigation was carried out in an attempt to further improve the 
yield of aziridine 67. Inspired by the theory of Landor et al.134 regarding the 
dependence of aziridine yield on the ability of the complex transition state to be 
effectively solvated (see Figure 11), it was thought that solubility of the aluminium 
complex might be further increased by addition of a crown ether to the reaction 
mixture. Crown ethers are effective phase-transfer catalysts which have a wide 
application in organic synthesis. Their catalytic effect arises from their ability to 
surround certain cations (particularly Na+ and K+) resulting in a diffuse positive 
charge which markedly increases the solubility of both the cation and accompanying 
anion in organic solvents. 9 7 It was thought that chelation of Na+ ions in the reduction 
of 37 might lead to a concomitant increase in the solubility of the negatively charged 
transition state. To test this hypothesis, reduction of 37 was conducted with the
65
addition of 10 mol% of 15-crown-5 to the reaction mixture. A 77% yield of 67 was 
obtained after purification - this was not considered to be a significant gain on the 
74% yield afforded without 15-crown-5 and consequently no further investigations 
were carried out.
A rather interesting variation on the hydride reduction of oximes to aziridines 
has been described by Girault et a / . 1 3 7 ,1 3 8 They reported that N,N,N- 
trimethylhydrazonium salts such as 71 could be reduced with SMEAH under mild 
conditions to the aziridine 72 (Scheme 24) in greater yields than that obtained from 
reduction of the corresponding oxime. It was therefore considered worthwhile to 
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72
Scheme 24 (Alternative preparation of aziridines from /V,/V,/V-trirnethylhydrazoniurn salts137)
Although no explanation is given for the increased preference shown for the 
aziridine over the primary amine, one possible reaction pathway might be 
“deprotonation” of the methylene group adjacent to the hydrazone by intermolecular 
attack of aluminium hydride resulting in formation of an unsaturated nitrene 
intermediate which subsequently cyclises to aziridine 72 via the azirene. Approach 
of aluminium hydride to the hydrazone carbon and formation of primary amine via 
the saturated nitrene is disfavoured as a result of the steric hindrance imparted by the 
quaternary ammonium centre.
Preparation of jV-trimethylhydrazonium salts has been achieved in the 
literature by the condensation of a carbonyl compound with N,7V-dimethylhydrazine, 
followed by treatment with iodomethane to give the quaternary salt. 139 Using this 
methodology, a solution of ketone 36 in benzene was treated with excess N,N- 
dimethylhydrazine and the system heated at reflux with azeotropic collection of 
water. Unfortunately, conversion to hydrazone 73 could not be achieved after 2 days 
at reflux (Scheme 25) and TLC analysis showed only starting material. It is highly
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likely that this is again a result of the steric hindrance imparted on the 2 -carbon by 
the proximal dimethyl group. Utilising a sealed tube system or conducting the 
reaction under solvent-free conditions may afford better results, but the success of 
the improved SMEAH oxime reduction method and the highly toxic nature of N,N- 






Scheme 25 (Failed conversion of ketone 36 to N,N-d\ methyl hydrazone 73)
After formation of aziridine 67, the next stage in the synthesis of 
aminotetralin 65 was O-demethylation to give the corresponding phenol 6 8  (Scheme 
22). The number of available methods to effect this transformation is severely 
restricted by the presence of the aziridine moiety. As discussed in Chapter 2, strong 
protic acids such as HBr are a facile way to cleave aromatic methyl ethers; exposure 
of aziridines to such acids, however, leads to protonation of the nitrogen and 
subsequent ring-opening by the halide (Figure 12). The use of highly nucleophilic 
thiolates at elevated temperatures also affords ring-cleavage products.
NH
MeO MeO ’NFL (a s  HBr salt)
Figure 12 (Exposure of aziridines to strong protic acids leads to ring-opening)
It appeared that boron tribromide was the only feasible option and therefore 
67 was treated according to the procedure applied to O-demethylation of 38 using 
this reagent. The yields obtained were rather inconsistent (40-70%) and TLC 
analysis indicated the presence of numerous side-products on most attempts. As the 
residue obtained after quenching with methanol was distinctly acidic, it appeared that
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acid-induced cleavage of the aziridine may be a possible cause of side-product 
formation. In an attempt to prevent this, the reaction was instead quenched by 
pouring over a mixture of concentrated ammonia and ice though this gave similarly 
disappointing yields. Far superior results were obtained by the dropwise addition of 
a 1:4 mixture of the stronger base triethylamine and methanol at -78°C. This 
consistently afforded high (>75% yields) of phenol 6 8  and minimal side-products by 
TLC.
Efficient Boc-acylation of the phenolic and aziridine moieties of 6 8  was 
achieved using catalytic DMAP to afford 69 (Scheme 22) in high yield. The major 
role of the Boc group here is not one of protection from electrophiles but activation 
of the heterocycle towards ring-opening. The diminished electronegativity of 
nitrogen compared to oxygen means that aziridines are less susceptible to ring- 
cleavage than epoxides. 127 Direct nucleophilic ring-opening of //-unsubstituted 
aziridines requires high temperatures and the products are liable to participate in 
polymerisation reactions unless the attacking species is of high nucleophilicity. At 
elevated temperatures there is also likely to be an accompanying loss of 
regioselectivity. These difficulties can be largely averted by the use of a suitable 
aziridine activating group, of which the most widely utilised are carbonyl (esp. Boc) 
and sulfonyl (esp. Ts) types . 127 Ring cleavage may then be effected under very mild 
conditions using a wide range of nucleophiles140 including alcohols141, water142, 
amines143 and halides144; high regioselectivity is normally observed for these 
reactions and the primary amine moiety resulting from cleavage remains masked and 
consequently cannot participate in further nucleophilic reactions.
The remarkable way in which aziridine activating groups transform the 
conditions required for ring-opening has been attributed to two factors . 127 Crucially, 
the electron-withdrawing nature of these groups provide a kinetic activation by 
enhancing the polarisation of the C-N bond; this in turn increases the partial positive 
charge on the aziridine carbon atoms, thus making the ring considerably more 
susceptible to nucleophilic attack. Of secondary importance but significant in the 
case of carbonyl activating groups is a thermodynamic effect resulting from 
delocalisation of the amide-like anion produced after ring-cleavage. These effects 
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Figure 13 (/V-substituents activate aziridines by kinetic and thermodynamic mechanisms)
Cleavage of activated aziridines is normally conducted in the presence of a 
catalyst in order to eradicate the need for heating and maximise regioselectivity. An 
enormous range of such catalysts have been investigated to effect ring-opening 
including protic acids140, Lewis acids1 4 1 ,14 3 and cyclodextrins. 145 Different catalysts 
appear to favour different classes of nucleophile and there is consequently no 
‘universal catalyst’ for aziridine ring-opening available. For conversion to 70 
(Scheme 22), Roy and co-workers126 utilised the weak acid pyridinium para- 
toluenesulfonate (PPTS) which presumably acts simply via protonation of the 
aziridine nitrogen (it should be noted that delocalisation of the nitrogen’s lone pair 
does not occur to any significant extent in 69 due to the additional ring-strain which 
would result from the resonance isomer); thus the aziridine is now sufficiently 
activated to enable attack even by the weak nucleophile methanol. This appeared to 
be an inexpensive and very convenient method for ring cleavage and consistently 
afforded high (80%) yields of 70. The 1,1-dimethyl group plays a crucial role in the 
high yield by inhibiting approach of methanol to the 2 -carbon, resulting in a 
completely regioselective reaction with no trace of the other isomer apparent by 
TLC. One puzzling aspect of this reaction was that between 10-20% starting 
material was consistently recovered during purification. Complete consumption of 
69 could not be achieved even after stirring for several days, heating at reflux or 
adding excess catalyst; the reason for this is unclear. An alternative method using 
boron trifluoride diethyl etherate as catalyst141 gave inferior yields of 70 and the 
formation of side-products was evident by TLC.
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The synthesis of 3-methoxyaminotetralin 65 was completed by Boc 
deprotection of the phenolic and amine moieties of 70. This was readily achieved in 
quantitative yield using an excess of trifluoroacetic acid which afforded 65 in a state 
of sufficient quality by NMR that purification was deemed to be unnecessary. The 
*H NMR spectrum of 65 clearly confirms the required trans relationship between the 
3-methoxy group and the primary amine moiety by the presence of a vicinal coupling 
constant of -10 Hz136 between the 2-CH and 3-CH protons.
3.3.2 Synthesis o f alkyl N-substituted analogues
The attachment of A-substituents to the aminotetralin scaffold 65 to afford the 
desired ligands was achieved using a variety of synthetic methods (Table 9).
,OMe
HO NHR
No R Electrophile Method Yield
74 Cinnamyl PhCH=CHCHO A 82%
75 Cyclopropylmethyl (CH2)2CHCHO B 23%
76 Allyl (mono) CH2=CHCH2Br C* 50%
77 Allyl (di) CH2=CHCH2Br C* 35%
78 n-Propyl CH3 (CH2)2Br c 43%
79 n-Propylphenyl Ph(CH2)3Br c 54%
obtained in same reaction
Reagents and conditions: (A) i) RCHO, CH2C12, RT ii) NaBFL,, MeOH, 0°C to RT; (B) RCHO, 
NaB(OAc)3H, DCE, RT; (C) RBr, Na2C 0 3, cat. TBAI, THF, Reflux
Table 9 (Alkylation methods used to synthesise ligands 74-79)
The stepwise reductive alkylation method of secondary amine synthesis 
which was successfully used to obtain aminotetralin derivatives 28-30 (p. 49) 
initially appeared an attractive route to the desired alkyl analogues of 65 due to the 
mild conditions employed and the absence of side-products resulting from over-
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alkylation. As expected, treatment of 65 with trans-cinnamaldehyde readily gave the 
corresponding imine which was reduced with NaBFL* to cleanly afford 74 in high 
yield. During the preliminary work on alkyl derivatives of aminotetralin 23, the 
CPM derivative was obtained in 69% yield over two steps by acylation of 23 with 
cyclopropanecarbonyl chloride followed by LiAlHU reduction. As CPM-aldehyde is 
also commercially available, it appeared worthwhile to investigate whether reductive 
alkylation might provide an alternative and slightly more convenient route to this 
analogue. Unfortunately, treatment of 65 with cyclopropanecarboxaldehyde did not 
produce a clean reaction and several decomposition products were visible by TLC. 
The poor results were most likely caused by a lack of stabilising groups on the 
aldehyde: in situations where the aldehyde group is conjugated to an aromatic ring, 
as is the case for cinnamaldehyde, the resulting imine is normally highly stable and 
may often be isolated97 (such compounds are known as Schiff bases). For simple 
saturated aldehydes no such stabilisation is present and decomposition and/or 
polymerisation often rapidly occurs.97 Better results were obtained when 1.5 
equivalents of CPM-aldehyde and the selective reducing agent sodium 
triacetoxyborohydride120 were introduced in rapid succession at the start of the 
reaction in order to immediately ‘capture’ the imine and prevent decomposition. 
This afforded 75 in 23% yield after chromatography, although a significant quantity 
of starting material (65) and other side-products were evident by TLC.
In view of the disappointing yields obtained by reductive alkylation, it was 
decided to search for a suitable alternative method for the synthesis of the remaining 
analogues. This was particularly necessary for the allyl derivative as competing 
Michael reactions between acrolein (the corresponding aldehyde) and the primary 
amine group of 65 would further reduce the yield. The allyl analogue of 23 was 
previously prepared in the group by direct alkylation with allyl bromide in DMF 
which gave the mono- and dialkylated forms in 41% and 15% yield respectively. 
The formation of quaternary ammonium compounds was prevented by using a base 
of sufficient weakness (NaHCOa) so as to discourage over-alkylation; it is also 
probable that steric hindrance imparted on the amine moiety by the 1,1-dimethyl 
group disfavours alkylation beyond the tertiary stage.
A different protocol for direct A-alkylation has been proposed by de Sousa et 
al.u 6 for the selective A-dialkylation of amino alcohols. Tertiary amines were 
obtained in high yield by refluxing the amino alcohol with the relevant bromide,
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sodium carbonate and catalytic tetra-/i-buty 1 ammonium iodide in THF. It was 
reported that longer reaction times and several equivalents of base were required to 
afford tertiary amines using unreactive alkyl bromides; this suggested that good 
yields of the corresponding secondary amines might be obtained by careful 
monitoring of the reaction and quenching before significant over-alkylation to the 
tertiary amine occurred. The choice of solvent also made this method somewhat 
more appealing than the one previously employed as THF is significantly less 
harmful and easier to remove than DMF.
Alkylation of 65 with allyl bromide was performed according to the original 
procedure of de Sousa et a l 146 although the reagent proportions were altered to bias 
the outcome of the reaction in favour of the secondary amine product (Table 10). 
Complete consumption of the starting material was apparent by TLC after 24 hours, 
at which point the reaction was terminated. Subsequent column chromatography 
afforded the mono- (76) and dialkylated (77) products in 50% and 35% yields 
respectively. A significant proportion of 77 was expected on the basis of the high 
reactivity of allyl bromide, although the yield of both products remained superior to 
those obtained using the NaHCC>3/DMF procedure. As expected, the less reactive n- 
propyl and n-propylphenyl bromides required prolonged reflux and additional 
portions of halide and base were added to reduce reaction times. Satisfactory yields 
of 78 and 79 were obtained, although it should be noted that starting material was 
still apparent by TLC in both cases when the reactions were terminated; it is 
therefore highly likely that the yields quoted could be improved. In summary, this 
alkylation method has proved to be a convenient route for the one-step preparation of 
alkyl analogues of 65. It is also notable that no dialkylated products or those 
resulting from phenolic alkylation were isolated in the case of 78 and 79.
No R Eq. bromide Eq. Na2 CC>3 Eq. TBAI Time
76 + 77 Allyl 1.6 2.5 0.2 24 h
78 n-Propyl 2.2 3.5 0.5 68 h
79 n-Propylphenyl 2.5 4.0 0.5 60 h
Table 10 (Proportions o f reagents required for RBr/Na2C03/TBAI alkylation o f 65)
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3.3.3 Synthesis o f tetrahydroisoquinoline ‘JDTic ’ compound 66
The synthetic route initially utilised to prepare ligand 66 possessing the 
identical ‘address’ side-chain to JDTic (14, p. 17) was adapted from the 
combinatorial approach to trans-3,4-dimethyl-(3-hydroxyphenyl)piperidinyl 
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Schem e 26 (Initial route to 66 adapted from the combinatorial approach o f Thomas et a /.74'76)
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Construction of the side-chain was achieved by sequential coupling and Boc 
deprotection of two amino acid residues, with an intermediate reduction step to 
preserve the basic nature of the aminotetralin amine group.
The synthesis of amides is frequently achieved by conversion of a carboxylic 
acid to an acyl chloride, followed by direct reaction with an amine under mildly basic 
conditions. Whilst successful for relatively simple alkyl achiral carboxylic acids, this 
method is largely unsuitable for sensitive acids or those possessing chiral centres, 
and a range of peptide coupling reagents have been developed to facilitate direct 
amide synthesis from the amine and carboxylic acid under mild conditions. 147 The 
underlying mechanism of all such coupling reagents is initial formation of an active 
ester from the carboxylic acid and coupling reagent. This is followed by attack of 
the amine on the ester which is promoted by displacement of the activating group to 
give a stable side-product and the desired amide. The DCC/HOBt combination 
remains the most widely used system for peptide coupling, although phosphonium 
salts (e.g. BOP148, 84) and other carbodiimide reagents (e.g. EDCI149, 85) are also 
popular.
The active esters derived from phosphonium salts are more reactive than the 
corresponding ones derived from DCC and consequently attack by the amine 
nucleophile occurs before any significant degree of racemisation can take place. 
This makes reagents such as 84 particularly suitable for amide formation using chiral
JDTic (14). Coupling of aminotetralin 65 to Boc-L-Valine using this procedure 
afforded moderate (54%) but consistent yields of amide 80; some degree of ester 
formation resulting from reaction of the phenolic group of 65 was also apparent by 





Figure 14 (Peptide coupling reagents)
carboxylic acids and as such was employed by Thomas et for the synthesis of
74
though no separation could be achieved by either TLC or column chromatography. 
80 was then treated with trifluoroacetic acid under the standard conditions for Boc 
cleavage to afford the corresponding amine 81.
It was discussed above that reduction of the amide moiety of 81 was required 
in order to restore the basic nature of the aminotetralin nitrogen atom. In keeping 
with the procedure described by Thomas et al.14, 81 was treated with borane.DMS 
complex which was expected to smoothly afford the diamine 82. Unfortunately, 
inconsistent yields were obtained (35-87%) and the crude reaction mixture was 
frequently found to contain numerous side-products with similar Rf’s to the desired 
product 82. The reason for this was not clear, and the use of fresh borane and strict 
adherence to the literature procedure failed to give a more consistent outcome. 
Attempted reduction of 81 using LiAlIL afforded similarly poor results, as did 
ZrCU/NaBIL.
Introduction of the tetrahydroisoquinoline (Tic) ‘address’ moiety was again 
achieved using peptide coupling chemistry. Treatment of 82 with commercially 
availabile Boc-D-Tic(OH)-OH and BOP (84) afforded the required amide, though 
due to the polar nature of 83 separation of the tris(dimethylamino)phosphine oxide 
by-product of BOP (84) by column chromatography proved to be rather troublesome. 
Repetition of the reaction employing the related coupling reagent PyBOP also 
resulted in a significantly contaminated product. It was at this point that attention 
turned to the carbodiimide EDCI (85) as a potential solution to this problem. A 
particularly attractive feature of this reagent is that both the parent carbodiimide and 
its by-product are soluble in water149, allowing easy removal by aqueous washing. 
Thus 82 was coupled to Boc-D-Tic(OH)-OH using EDCI.HC1 and HOBt (required in 
this case to accelerate the reaction and so minimise racemisation of the chiral amino 
acid). TLC analysis indicated a significantly cleaner reaction and the desired 83 was 
obtained after chromatography. A very minor trace of side-product was evident by 
NMR, though it was decided to delay further purification until the final stage of 
the synthesis in order to minimise loss of material. Treatment of 83 under standard 
Boc cleavage conditions afforded the desired ligand 6 6  (Scheme 26) which was 
obtained free of contamination in 72% yield (over two steps) after facile column 
chromatography. Unfortunately, diastereomeric separation could not be achieved at 
any point in the synthesis and the intermediate compounds were always isolated as 
1:1 mixtures. As a consequence of this, the !H and 13C NMR spectra are complex
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and difficult to interpret with the majority of signals appearing twice (except those 
atoms distant from the diastereomeric centres). The use of different chromatographic 
solvent systems similarly failed to produce any observable degree of separation and 
it was therefore decided to submit 6 6  for pharmacological evaluation as a mixture of 
diastereomers. Studies are currently being conducted elsewhere in the group to 
evaluate the use of chiral derivatising agents in the enantiomeric separation of 
aminotetralins 23 and 65.
The synthetic route adopted for the preliminary synthesis of ligand 6 6  
(Scheme 26) is purely linear in its approach and involves a total of 14 steps from 2,7- 
dihydroxynaphthalene (46). Such linear syntheses suffer from considerable overall 
loss of material and are less time-efficient than convergent routes as each synthetic 
step must be carried out sequentially. One additional concern with the former route 
was the unreliable borane reduction of the intermediate amide 81. With this in mind, 
it was decided to examine whether a convergent approach to 6 6  might be feasible.
A highly desirable improvement to the existing procedure would be to 
construct the tetrahydroisoquinoline side-chain as a separate unit to the scaffold 65; 
coupling of the two fragments and subsequent Boc-deprotection would then afford 
the completed ligand 6 6 . This route would appear to be more efficient as 
aminotetralin 65 and the side-chain could be synthesised in parallel, which decreases 
both the time required and the total number of linear steps. The proposed synthetic 
route is given in Scheme 27. In view of the difficulties encountered during reduction 
of amide 81, it was decided to forgo the use of peptide coupling chemistry for this 
reaction in favour of a reductive alkylation approach which would directly afford 
secondary amine 83 and eliminate the need for amide reduction. It was envisaged 
that the required aldehyde 8 8  would be synthesised by coupling of Boc-D-Tic(OH)- 
OH (8 6 ) to L-valinol to give alcohol 87; mild oxidation would then afford 8 8 .
Amino acid 8 6  successfully underwent peptide coupling with commercially 
available L-valinol in the presence of PyBOP to cleanly afford 87 in 96% yield. 
However, it was found that the product was virtually insoluble in most organic 
solvents and a poor NMR spectrum was obtained even in DM SO-^. This caused 
severe difficulties in the next stage and attempted oxidation of 87 under the Swem 
conditions (oxalyl chloride in DMSO) resulted in a mixture of many products. It was 
thought that interaction of the phenolic group of 87 with the oxidising agent may also 
have contributed to the poor outcome of the reaction.
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L-Valino! 
















Schem e 27 (Proposed convergent synthesis of ligand 66)
It appeared that the difficulties encountered with the oxidation of 87 might be 
at least partially overcome by suitable protection of the phenolic group. A protecting 
group of high lipophilicity would confer greater solubility in organic solvents in 
addition to preventing interaction of the phenolic group with oxidising agents. The 
trityl (triphenylmethyl) protecting group appeared ideal for this purpose as it 
possesses a very high degree of lipophilicity and may be removed under acidic 
conditions (thus enabling it to be cleaved concurrently with the Boc group). 
Reaction of 8 6  with triphenylmethyl chloride and DMAP afforded a satisfactory 
(63%) yield of the trityl-protected amino acid; however, subsequent coupling with L- 
valinol gave poor results and TLC of the crude product suggested that decomposition 
had occurred. A possible explanation for this is that the carboxylic acid moiety 
promoted a form of ‘self-deprotection’ of the trityl group in the solution phase. It is 
possible this problem may be overcome by the use of a more acid-stable protecting
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group such as triisopropylsilyl (TIPS), but in view of the difficulties already 
encountered with this reaction pathway it was decided to investigate other 
alternatives.
Although it appeared that an unconvoluted synthesis of aldehyde 8 8  may not 
be possible, the use of reductive alkylation to introduce the valine unit still appeared 
an attractive solution to the problematic amide reduction. An alternative approach 
was therefore proposed (Scheme 28) whereby the valine fragment would be 
introduced in its A-protected form by reductive alkylation; this would be followed by 

















48  h, 81%  (from 89)
Schem e 28 (Improved synthetic route to ligand 66)
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The initial step involved oxidation of the commercially available Boc-L- 
valinol (89) to the corresponding aldehyde 90. The reagent selected to perform this 
transformation was the Dess-Martin periodinane150, a hypervalent iodine compound 
which has found wide application in organic synthesis for the selective oxidation of 
alcohols to aldehydes. It possesses the advantages of high yields of aldehyde, simple 
experimental protocols and mild reaction conditions; the latter making it particularly 
suitable for the oxidation of highly functionalised and sensitive substrates. 
Treatment of 89 with 1.5 equivalents of Dess-Martin periodinane at room 
temperature was found to rapidly afford the required aldehyde 90 after 1.5 hours 
(monitored by TLC). Due to the often sensitive nature of aldehydes, it was decided 
to react 90 immediately with aminotetralin 65 without purification. Accordingly, a 
slight excess of 90 was combined with 65 in 4:1 DCE/DMF (65 was found to be 
poorly soluble in pure DCE) and the mixture immediately treated with excess sodium 
triacetoxyborohydride. TLC analysis of the crude product after aqueous work-up 
indicated a very clean reaction, and a pleasing yield (83%) of pure 91 was obtained 
after passing through a short column of silica gel. The formation of tertiary amine 
products which normally limits the use of one-step reductive alkylation methods was 
absent in the aforementioned case as the isopropyl moiety of the valine group 
prevents the reaction of the secondary amine with a further molecule of aldehyde 90.
The remaining steps of the synthesis were carried out as described previously: 
Boc-deprotection of 91 readily afforded diamine 82 which was coupled with Boc-D- 
Tic(OH)-OH (8 6 ) to give 83. Finally, treatment with trifluoroacetic acid afforded the 
required ligand 6 6 . Overall, the new synthetic route was found to be both faster to 
perform and experimentally more convenient than the purely linear approach. This 




INVESTIGATION OF 3-AMINO ANALOGUES OF 
2-AMINO-l,l-DIMETHYLTETRAHYDRONAPHTHALEN-7-OL
4.1 Design rationale
The investigations of Roy et al. into the binding affinity and analgesic 
activity of 3-substituted aminotetralins constituted a range of analogues utilising 
various alkyl, oxygenated and sulfonated 3-substituents. As discussed in Chapter 3, 
it transpired that the more potent members of this series were terminal methyl 
derivatives resembling structure 64; of particularly high p. affinity were the 
heteroatomic SCH3 and OCH3 analogues which possessed a trans orientation relative 
to the primary amine group.
The specific rationale which led to the introduction of heteroatomic 3- 
substituents in the Roy series of aminotetralins is not entirely clear, as the design of 
the ligands was apparently inspired by dezocine (2 0 , p. 19) which possesses a purely 
alkyl 3-substituent. By comparing the structure of 64 with that of morphine (1), one 
might speculate that the 3-substituent is intended to mimic the bridging ring of the 
epoxymorphinans. The highlighted bonds of morphine (1) in Figure 15 illustrate the 
structural features common to both 1 and aminotetralin 64; it can be clearly seen that 





Figure 15 (Common structural features of 1 and 64; equivalence o f the tertiary nitrogen centre to the 
heteroatomic 3-substituent o f 64 is apparent)
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If mimicry of the bridging ring of 1 by the XCH3 group of 64 is indeed 
occurring, it would be of interest to synthesise and biologically evaluate a series of 
analogues of 64 bearing nitrogenated 3-substituents. Given that a nitrogen centre in 
this position is common to all analgesic epoxymorphinans, it is somewhat surprising
10f\that the series of Roy et a l had not been extended to include such derivatives (in 
view of the findings discussed in this chapter, it is possible that synthetic difficulties 
may have precluded prior investigation of these compounds).
It has been established that the tertiary nitrogen centre of the 
epoxymorphinans increases opioid receptor affinity by interacting electrostatically 
with the Aspl38 residue common to all three opioid receptor types24 (see Figure 3). 
Since the primary amine moieties of 2-aminotetralins 23 (p. 21) and 65 (p. 58) 
occupy a similar position (differing by only one carbon atom) with respect to the 
phenolic group, an equivalent electrostatic interaction would be expected to partially 
account for the observed opioid receptor affinity of these ligands. As illustrated in 
Figure 15, an amine moiety in the 3-position would closely mimic the bridging 
nitrogen group of morphine (1 ), perhaps placing it in a superior position for 
interaction with Asp 138; the amine group at the 2-position would then act solely as a 
means to direct the ‘address’ side-chain towards its subsite on the receptor. The 
close proximity of the amine groups in such a series also suggests an alternative 
binding mode where both are suitably positioned for interaction with the Aspl38 
residue leading to the establishment of two electrostatic bonds; this too may have 
interesting repercussions for the pharmacological profile of the ligand.
As discussed in the previous chapter, the trend in binding affinity of the 
CH2CH3 , OCH3 and SCH3 analogues of Roy et al.126 implies that an electrostatic 
interaction is not responsible for the differences in IQ observed in this series. An 
analogous series of ligands bearing nitrogenated basic 3-substituents would not be 
expected to adopt a similar mode of binding to the existing compounds of structure 
64 as the 3-substituent would be positively charged at physiological pH and able to 
interact with the receptor in the electrostatic manner described above. This makes 
such a series unique from the other 3-substituted analogues previously reported.
A rather different approach was taken to the design of the present series of 
nitrogenated 3-substituted ligands from that used in the oxygenated analogues 
described in Chapter 2. In the previous series, the 3-substituent universally 
employed was OCH3 due to its previous reported success at enhancing opioid
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receptor affinity. Diversity was then introduced by variation of the A-substituent in 
order to investigate the effect of different side-chains on receptor binding and 
selectivity. It was thought that an interesting alternative approach would be to retain 
the identical A-substituent at the 2 -position throughout the series, but to vary instead 
the nitrogenated 3-substituent. Despite the high potency obtained by the use of 
OCH 3 and SCH 3 groups at the 3-position, it is somewhat surprising that Roy et al, 126  
did not expand on these results by the investigation of other related 3-substituents 
(such as OCH 2CH 3 ) in order to determine whether such changes might lead to even 
greater receptor affinity. In view of this, it was decided to adopt such a ‘reverse’ 
approach to the design of the present series of nitrogenated 3-substituted ligands (92- 
94). The results will provide additional insight into the effect of the 3-substituent on 
opioid receptor binding and assist in determining whether other ‘non-methyl’ 
oxygenated/sulfonated 3-substituents would also be worthy of investigation (though 
due to the possible differences in binding mode of the nitrogenated analogues 92-94, 
equivalent pharmacological profiles may not be obtained in the 
oxygenated/sulfonated series).
It was disclosed in Chapter 1 that the analogue which exhibited highest 
opioid receptor binding in the preliminary series derived from scaffold 23 was the A- 
cinnamyl derivative (26, p. 24). Such cinnamyl substituents are readily introduced 
by facile reductive alkylation and it was thus decided to retain this A-substituent 
throughout the present series and observe the effect of varying the 3-substituent on 
receptor binding.
The pyrrolidine analogue (92) was selected for investigation for three 
reasons: i) a pyrrolidine moiety is present in many of the arylacetamide series of k  
selective agonists from which the k  selective antagonists UPHIT (16, p. 18) and 
DIPPA are directly derived and is the sole basic nitrogen centre in both, strongly 
suggesting that interaction with the Aspl38 residue occurs as described above (this
94: R =  HNMe
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mode of interaction has indeed been proposed for the arylacetamide U50488 k  
agonist24); ii) the evaluation of ligands containing strongly basic tertiary nitrogen 
centres at the 3-position will assist in determining whether interaction with an 
anionic residue in the receptor is occurring; iii) tertiary amine centres are less 
susceptible to electrophilic attack than secondary amines and therefore would not 
require protecting during the synthesis -  this makes pyrrolidine a better choice of 3- 
substituent for initial testing of the chemistry than, for example, NCH3 . The N- 
cyclopropylmethyl analogue (93) was proposed on the basis of this group being 
associated with antagonist behaviour in the epoxymorphinan series, e.g. naltrexone 
(8 ); the frequent appearance of this group in opioid ligands made it a logical choice 
for investigation. Finally, the A-methyl derivative (94) would enable direct 
comparison to the OCH3 derivative (74, p. 70) whose synthesis was described in 
Chapter 3.
4.2 Literature methods of trans vicinal diamine synthesis
Although there is no specific literature precedent for the synthesis of trans 
vicinal diamines of an aminotetralin-like structure, two general approaches to this 
functional group have been developed. The ring-opening of aziridines with amine 
nucleophiles constitutes the first and most widely investigated method for trans 
vicinal diamine synthesis. A whole plethora of catalysts have been developed in 
recent years specifically to promote ring-cleavage of activated aziridines with 
primary and secondary amines, including bismuth trichloride151, lithium 
bistrifluoromethanesulfonimidate143 and ytterbium (III) triflate152. High yields of the 
corresponding protected diamines are obtained under mild conditions (Scheme 29), 







Scheme 29 (Synthesis o f trans vicinal diamines by catalysed ring-opening of aziridines)
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A rather interesting alternative approach to the synthesis of vicinal diamines 
uses an aziridinium ion to introduce the required trans stereochemistry153 154 (Scheme 
30). Tertiary amino-alcohols (obtained from the corresponding epoxides) are treated 
with methanesulfonyl chloride in the presence of excess triethylamine to give the 
highly reactive mesylate species; subsequent intramolecular nucleophilic attack by 
the tertiary nitrogen results in ring-closure and formation of an aziridinium ion. The 
desired primary or secondary amine nucleophile is then introduced which attacks the 
strained intermediate at the least hindered carbon resulting in ring-opening in an 
analogous manner to aziridines: trans stereochemistry is likewise always observed. 
This method appeared attractive as it uses inexpensive and relatively 
environmentally-friendly reagents; one noticeable disadvantage, however, is that the 
reacting amine centre must be tertiary which in turn may necessitate additional 
synthetic steps. Given that aziridine ring-opening chemistry had previously been 
employed successfully for the synthesis of the 3-methoxy analogues and that a 
reliable route to intermediate aziridine 68 (Scheme 22) had previously been 
established, it was decided to initially adopt the former approach (i.e. Scheme 29) to 
the synthesis of ligands 92-94.
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Schem e 30 (Synthesis of trans vicinal diamines using an aziridinium interm ediate153)
4.3 Preliminary synthetic studies
4.3.1 Ring-opening o f aziridines bearing carbamate activating groups
Di-Boc protected aziridine 69 was the universal intermediate for all 3-
1
substituted analogues reported by Roy et al. and appeared a logical starting point 
for the synthesis of the present trans vicinal diamines. It was initially envisaged that 
a two-step route (Scheme 31) involving ring-opening of 69 with pyrrolidine in the 
presence of an appropriate catalyst would afford protected diamine 95; subsequent 
Boc-deprotection would afford the aminotetralin 96 which could be furnished with a
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cinnamyl N-substituent using the stepwise reductive alkylation protocol previously 
described.
Of the many available catalysts which have been developed to effect aziridine 
ring-cleavage with amine nucleophiles, the lanthanide Lewis acid ytterbium (III) 
trifluoromethanesulfonate appeared particularly appropriate for this purpose. 
Meguro and Yamamoto152 report that ring-opening of aziridines proceeds with high 
yield and regioselectivity with this compound to give masked trans vicinal diamines 
under mild conditions. One of the major deciding factors for the use of this catalyst 
in the present investigation is its reported compatibility with Boc as the aziridine 
activating group. Additional advantages of Yb(OTf) 3  include low catalyst loadings 
(typically 10 mol% is required), insensitivity to moisture and low cost. Activated 
aziridine 69 was therefore treated with 10 mol% Yb(OTf) 3  and pyrrolidine in THF at 
room temperature, affording a 64% yield of protected diamine 95 after column 














Schem e 31 (Attempted synthesis o f diamine 96 by cleavage of Boc-activated aziridine 69)
It was expected that Boc-deprotection of 95 would proceed smoothly to 
afford the free base 96 which could be subsequently converted to ligand 92 by 
reductive alkylation. However, treatment of 95 with trifluoroacetic acid in the 
standard manner was found to result in complete decomposition when the crude
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reaction mixture was examined by TLC; repetition of the reaction using fresh 
trifluoroacetic acid gave an identical outcome. Although difficulties in the cleavage 
of Boc groups are relatively uncommon except in cases where the substrate is 
particularly acid sensitive, such decompositions of Boc-protected diamines have 
been reported . 155 It is possible the problem was caused by highly reactive tert-butyl 
trifluoroacetate liberated during the Boc-deprotection process which subsequently 
undergoes further reaction with the substrate; the phenolic moiety of tyrosine 
analogues has been reported to undergo undesirible reactions of this nature. 156
The carbobenzoxy (Cbz) amine protecting group is a carbamic acid derivative 
closely related to Boc which undergoes a similar mechanism of deprotection in the 
presence of strong protic acids. Although the conditions required to cleave the Cbz 
group are harsher than for Boc, it possesses a distinct advantage for the present 
investigation in that deprotection liberates the somewhat less reactive benzyl 
bromide; the difficulties thought to arise from the presence of tert-butyl 
trifluoroacetate during Boc cleavage may thus be avoided. It was therefore decided 
to re-attempt the synthesis of 96 using Cbz as the activating group (Scheme 32).
Preparation of the activated aziridine 97 was achieved by treating previous 
intermediate 6 8  with benzyl chloroformate in the presence of excess triethylamine 
and the acylation catalyst DMAP. The reaction proceeded smoothly and a high yield 
of 97 was obtained after simple column chromatography. Although Meguro and 
Yamamoto152 do not report the use of Yb(OTf) 3  with Cbz as the activating group, the 
great similarity between the latter and Boc suggested that compatibility issues were 
unlikely. Hence di-Cbz protected aziridine 97 was reacted with pyrrolidine under 
analogous conditions to that used for 69, resulting in a high (89%) yield of 98 after 
purification.
There are two major methods in the literature for the cleavage of Cbz groups: 
catalytic hydrogenation (typically Pd/C) and concentrated HBr in acetic acid. 156 The 
latter appeared to be the more convenient and averted possible complications 
resulting from chelation of palladium by the vicinal diamine group. Therefore, 98 
was treated with a 1:1 mixture of 48% aq. HBr and glacial acetic acid at room 
temperature. TLC of the crude reaction mixture indicated the presence of several 
products, though one appeared to be present in greater quantity than the others. 
Evaporation of the solvent afforded a quantitative yield of the di-HBr salt, but
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attempted isolation of the free base via treatment with excess concentrated ammonia 
and extraction resulted in a very low (<2 0 %) recovery.
The isolated free base of 96 was subsequently found to be virtually insoluble 
in CH2CI2 and CHCI3 , probably accounting for the poor recovery of crude product. 
The 'H NMR spectrum suggested the major product was the desired 96 but the 
sample contained significant impurities; recrystallisation from propan-1 -ol/diethyl 
ether afforded a degree of improvement but with an approximately 40% loss of 
material.
CICOgCHgPh 


















Schem e 32 (M odified synthesis of diamine 96 and attempted conversion to ligand 92)
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Due to the aforementioned difficulties with obtaining sufficient quantities of 
the free base of 96, it was decided to attempt reductive alkylation with trans- 
cinnamaldehyde by forming the free base in situ; this method has been reported by 
Abdel-Magid and co-workers120 using triethylamine as the base. The di-HBr salt of 
96 was therefore reacted with 1.5 equivalents of frarcs-cinnamaldehyde and 4 
equivalents of triethylamine in MeOH. After stirring for 24 hours at room 
temperature, the mixture was treated with excess sodium borohydride. 
Unfortunately, the TLC of the resulting crude product revealed the presence of 
several products, none of which were conclusively identified as the desired 92 after 
column chromatography.
A final attempt at producing diamine intermediate 96 was made which 
involved the direct ring-cleavage of 6 8  (Scheme 33). Although it was stated in 
Chapter 3 that the products of A-unsubstituted aziridine ring-opening readily undergo 
oligomerisation, the successful cleavage of a simple iV-unsubstituted cyclohexyl- 
aziridine with pyrrolidine has been reported by Cheng et a / . 157 utilising ammonium 
chloride as catalyst. The reaction was carried out in dioxane/water with prolonged 
heating at 100°C; the necessity of such harsh conditions serves to illustrate the 
powerful effect on reactivity exerted by activating JV-substituents. Treatment of 
aziridine 6 8  under identical conditions afforded only decomposition, however, and 
this route was consequently abandoned.
(CH>)4NH 
n h 4c i
- x -
Dioxane/HjO 
100PC, 48  h
Schem e 33 (Attempted direct ring-cleavage of 68)
To summarise, it appeared that the simple ring-opening/deprotection strategy 
which was successfully applied to the synthesis of 3-methoxyaminotetralin 65 would 
not be a viable approach for the present diamine series. The difficulties associated 
with the isolation of the free base of 96 and its lack of organic solubility made 
purification and subsequent introduction of the side-chain somewhat troublesome.
88
After consideration of these issues, it was decided to investigate the use of alternative 
synthetic routes which did not incorporate 96 as an intermediate.
4.3.2 Ring-opening o f aziridines bearing unactivated N-substituents
i co
In 2003, Watson and Yudin disclosed a study which reported the efficacy 
of tris(pentafluorophenyl)borane as a catalyst specifically for the ring-opening of 
nonactivated aziridines with amine nucleophiles. This study was unique in its focus 
on nonactivated aziridine N-substituents -  previous studies of catalytic aziridine ring- 
cleavage almost invariably focused on strongly activating A-substituents which effect 
ring-opening under far milder conditions. It therefore appeared that a possible 
approach to the required vicinal diamine ligands might be alkylation of the aziridine 
nitrogen with the A-substituent required to be at the 2-position (cinnamyl in the case 
of 92-94), followed by B(C6Fs)3-assisted ring-opening with the primary or secondary 
amine required to be at the 3-position (Scheme 34). Unlike the synthetic approaches 
to 92-94 discussed in Section 4.3.1, this route does not incorporate the problematic 
intermediate diamine 96 or rely on reductive alkylation to introduce the side-chain 






R = d esired  su b s titu en t 
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Schem e 34 (Proposed ring-opening of unactivated /V-alkyl aziridines)
One of the major priorities in the development of a synthetic route to the 
present series of ligands was the ability to introduce a variety of primary and 
secondary amines to the 3-position; the option to use side-chains other than cinnamyl 
is also highly desirable (and will be a necessity if the pharmacological results of this 
preliminary series appear promising). Whilst Watson and Yudin comprehensively 
investigated the mechanism and conditions of B(C6F5)3-assisted ring-cleavage158, 
the actual range of TV-substituents and amine nucleophiles tested was rather limited.
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Not wishing to waste valuable material, it was decided to further investigate the
scope of the reaction by initially utilising a simplified and rapidly accessible model
1compound. Watson and Yudin * thoroughly investigated the ring-opening of N- 
benzyl substituted aziridines with B(C6Fs) 3  and report universally high yields (84- 
99%); non-benzylic unactivating N-substituents, however, afforded mixed results 
and the range of examples is very limited. For this reason, it was decided to 
incorporate a 3-phenylpropyl TV-substituent into the model compound (102) rather 
than a cinnamyl substituent, as it was thought that the latter would resemble benzyl 
in reactivity; the results obtained using a 3-propylphenyl N-substituent are therefore 
likely to be a better reflection of the true scope of the reaction.
Scheme 35 illustrates the synthetic route used to obtain the cyclohexane- 
based model compound, 102. The intermediate aziridine 101 was prepared 
according to a literature procedure.157 Thus, cyclohexene oxide (99) was reacted 
with sodium azide under reflux conditions to afford rrarcs-azidoalcohol 100. Ring- 
closure in the presence of triphenylphosphine in a variation of the Staudinger 
reaction gave 101 in 35% overall yield; a low recovery of product after vacuum 
distillation of the crude aziridine most likely accounts for the poor yield.
THF 
Reflux, 24  h 







Schem e 35 (Synthetic route used to prepare model compound 102)
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Alkylation of 101 with 1 -bromo-3-phenylpropane was initially attempted 
using sodium hydride in refluxing THF, although only a 25% yield of A-substituted 
aziridine 102 was obtained after column chromatography. An alternative protocol 
developed specifically for the A-alkylation of aziridines has been described by 
Ahman et al,159 utilising potassium carbonate and catalytic 18-crown-6 in THF. 
These milder conditions are reported to afford yields of the A-alkylated products 
which are far superior than those obtained using sodium hydride. Treatment of 101 
with 1.2 equivalents of 1-bromo-3-phenylpropane according to the literature protocol 
resulted in only a trace of product being visible by TLC after 15 hours at room 
temperature. Heating the system to reflux for 18 hours afforded a 38% yield of the 
required compound 102 after purification, but the recovery of a significant quantity 
of the bromide indicated that complete conversion had not occurred (reflecting the 
low reactivity of the electrophile). Aside from this, the TLC showed the reaction to 
be very clean and doubtless the yield could be much improved upon after prolonged 
reflux.
Ring-opening of 102 was then attempted using a range of amine nucleophiles
1 SRaccording to the protocol of Watson and Yudin. Thus, 1 equivalent of aziridine 
102 was treated with 1.2 or 4.0 equivalents of the nucleophile (according to its 
expected reactivity) and 10-20 mol% of B(C6Fs) 3  in non-anhydrous acetonitrile (see 
below). The system was heated at 75°C for 40 hours without any precautions to 
exclude moisture, after which time the crude product was stirred with Amberlyst 
A-21 ion exchange resin to remove the catalyst. Purification was achieved by 
column chromatography affording the yields quoted in Table 11. All amine 
nucleophiles were obtained commercially, with the exception of 109 which was 
synthesised in 88% yield by the stepwise reductive alkylation of 
aminomethylcyclopropane with benzaldehyde.
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No N ucleophile E q. o f Nuc.
M ol%
B (C 6F 5)3
Yield
1 0 3 nh* 1.2 10 100%





1 0 6 A ^ Nh2 4.0 20 0%
1 0 7 O U ^ A  (109) 4.0 20 0%
1 0 8 1.2 10 65%
T able 11 (Attempted ring-opening of aziridine 102 with amines in the presence of B(C6F5)3)
Aziridine 102 was found to undergo efficient ring-cleavage in the presence of 
aniline to afford 103 in quantitative yield - this is consistent with the high yields 
obtained with this nucleophile by Watson and Yudin. A-Methylbenzyl amine also 
afforded a satisfactory yield of the corresponding diamine 104. The use of a masked 
methylamine derivative was considered to be more appropriate than methylamine 
itself in this case, as the prolonged heating required to effect ring-opening would 
inevitably result in substantial loss of the nucleophile from the reaction mixture. For 
this approach to be viable for the synthesis of 3-aminomethyl substituted ligands, a 
satisfactory cleavage method for the tertiary A-benzyl group was required. Although 
catalytic hydrogenation is normally the preferred technique for TV-debenzylation97, 
this method would preclude the use of unsaturated side-chains (such as cinnamyl) at 
the 2-position and therefore restrict the range of ligands which could be prepared 
using this synthetic route. An alternative method which utilises eerie ammonium 
nitrate (CAN) to selectively cleave tertiary A-benzyl groups has been reported by 
Bull and co-workers.160 The reaction proceeds via an oxidative cleavage mechanism 
and high yields of the corresponding secondary amines are reported for many 
substrates under mild conditions. This technique appeared attractive for the present
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investigation as functionalities normally sensitive to catalytic hydrogenation are 
reported to remain unaffected in the presence of CAN; however, treatment of 104 
under the conditions specified resulted only in decomposition of the substrate 
(Scheme 36) and it was consequently decided not to pursue this method further 
although the B^FsX^-catalysed approach to 3-aminomethyl derivatives may yet 
prove to be of use where a saturated side-chain is desired at the 2-position (i.e. one 




RT, 4  h
Scheme 36 (Failed cleavage of tertiary /V-benzyl group with eerie ammonium nitrate)
Ring-cleavage using pyrrolidine, aminomethylcyclopropane or nucleophile 
109 was not previously reported by Watson and Yudin.158 Unfortunately, none of 
these amines were found to afford any degree of reaction with aziridine 102 even 
when large excesses of the nucleophile were used. A possible explanation may lie 
with the mechanism of B(C6F5 )3 -activated ring-opening. Through substantial NMR 
investigations, the original authors of the method have concluded that the in situ 
formed [(C6F5)3B(0 H2 )].H2 0  is the species which most likely catalyses aziridine 
ring-opening. The complex has been shown to exert its effects via a Brpnsted acid 
mechanism involving protonation of the aziridine nitrogen to form an activated 
aziridinium ion which subsequently undergoes attack by amine nucleophiles. The 
probable intermediate species formed between the [(C6Fs)3 B(0 H2 )].H2 0  complex 
and 102 is illustrated in Figure 16.
The Brpnsted acid mechanism described above implies that the ability of the 
catalyst to activate the aziridine depends on the attacking amine nucleophile being of 
lower pKa than the aziridine nitrogen. If this is not the case and the amine is of 
significantly higher basicity than the substrate, then the expected pathway of the 
reaction would be protonation of the amine and consequent inhibition of ring-
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opening. Table 12 lists the pKa values for amine nucleophiles tested for use with 
B(C6F5 )3 . A noticeable decrease in ring-opening efficacy is apparent when the pKa 
of the attacking amine increases beyond that of benzylamine. Sweeney127 gives the 
pKa of unsubtituted aziridine (i.e. C2H4NH) as being 7.98, though it is likely that the 
value will be higher in the case of substituted 102. It is possible then that 
benzylamine represents the uppermost limit of pKa for B(C6F5)3 -mediated ring- 
cleavage of 102, with more basic amines such as n-butylamine (and 
aminomethylcyclopropane) completely inhibiting protonation of the aziridine 
nitrogen.
"b (C6F5)3\
F igure 16 (Activated aziridinium complex formed between [(C6F5)3B(OH2)].H20  and 102)
Amine pK a161 Outcome of reaction*
Aniline 4.63 High (>95%) yields
Benzylamine 9.33 High (>95%) yields
/-Butylamine 10.68 Did not go to completion with excess NuH
n-Butylamine 10.77 Long rxn times and large excess of NuH needed
Pyrrolidine 11.27 No reaction
T able 12 (pKa values of amine nucleophiles and corresponding reactivity)
Additional evidence for the above hypothesis is provided by Watson and 
Yudin , who report that addition of Proton Sponge (pKa 12.1) to the reaction 
mixture severely retards ring-cleavage. In the case of f-butylamine and nucleophile 
109, steric hindrance would also be expected to contribute significantly to the 
observed lack of reactivity. Due to the poor results obtained from attempted ring-
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opening of model compound 102, it was decided not to further investigate the use of 
an unactivated aziridine pathway to synthesise ligands 92-94.
i co
On a final note, Watson and Yudin report that benzenethiol is superior to 
amine nucleophiles in effecting ring-opening with B(C6 F5 )3 . This is to be expected, 
as thiols possess both higher nucleophilicity and lower basicity than amines. As 
benzenethiol was the only sulfonated nucleophile tested, it was of interest to see if 
the reaction could be applied to alkyl thiols as well as aromatic thiols. Reaction of 1 - 
propanethiol with 102 afforded a 65% yield of the corresponding ring-opened 
product after only 2 hours at room temperature. Aziridine ring-opening with thiols 
using this protocol might therefore provide a considerably shorter synthetic route to 
ligands bearing sulfonated 3-substituents than the approach used by Roy et a /.126 as 






R = d es ired  substituen t 
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Schem e 37 (Application of B(C6F5)3 to the synthesis of sulfonated 3-substituted aminotetralins)
4.4 Synthetic studies using the nosyl protecting group
4.4.1 Overview and rationale
Of the two approaches to trans vicinal diamines investigated in Section 4.3, it 
appeared that ring-opening of activated aziridines was the more promising of the two 
routes; however, significant difficulties were associated with the isolation and 
purification of the polar 2-unsubstituted diamine intermediate 96 (Scheme 31) which 
prevented the final reductive alkylation step in the synthesis. A synthetic strategy 
was therefore required which did not incorporate such an intermediate. It was 
thought that if the desired side-chain could be installed whilst the amine moiety at 
the 2-position was masked as an amide, carbamate or sulfonamide then the molecule 
would be less polar, more soluble in organic solvents and therefore easier to purify 
than 96. Deprotection to afford the vicinal diamine would preferably be the last step
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of the synthesis, allowing the final ligand to be purified by recrystallisation of the salt 
if solubility problems were apparent (though the lipophilicity of the side-chain 
should increase organic solubility).
An extensive search of the literature revealed a protecting group which
appeared to satisfy the above criteria. The nitrobenzenesulfonyl (nosyl) group was
162used by Fukuyama et al. as a facile means of preparing and protecting secondary 
amines. Reaction of a primary amine with 2- or 4-nitrobenzenesulfonyl chloride in 
the presence of triethylamine gives the corresponding secondary sulfonamide. Due 
to the electron-withdrawing effect of the nitro group, the sulfonamide proton is 
significantly acidic and may be removed with relatively weak bases such as 
potassium carbonate. This enables alkylation to be performed under mild conditions 
(far milder than carbamate derivatives, for instance, which require sodium hydride to 
deprotonate them). The nosyl group may then be selectively cleaved using thiolates 
(typically benzenethiol/K2 C0 3  or mercaptoacetic acid/LiOH) to afford the required 
secondary amine. The non-acidic conditions of the deprotection stage make this 
group particular attractive as it averts possible complications in the reaction work-up 
arising from protonation of the diamine. A proposed general synthetic strategy 
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Schem e 38 (The nosyl group as applied to the synthesis o f trans vicinal diamines)
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The nosyl group has also been reported to be a highly activating //-substituent 
for aziridines163, being 50-60 times more activating than the tosyl group and is 
compatible with a wide range of nucleophiles. Overall, the nosyl group appeared to 
be the ideal activating group for the present project and it was decided to further 
investigate its potential application in the synthesis of the desired series of diamine 
ligands.
4.4.2 Synthesis o f model compounds
In order to test the feasibility of the proposed nosyl approach to diamines 
(Scheme 38), it was decided to prepare a model compound analogous to aziridine 
102 (p. 90) on which to first test the synthetic route (Scheme 39). One particular 
motivation for such an approach was to gain an understanding of the stability and 
solubility of the final diamines, in particular to determine whether purification may 
be carried out by the preferred method of column chromatography rather than by 
recrystallisation of the HC1 salt. This knowledge would be invaluable when applying 
the chemistry to the synthesis of the corresponding aminotetralin ligands as loss of 
material at the final stage of the synthesis could be prevented.
It appeared logical to retain the simple cyclohexyl-aziridine structure 
incorporated into 102 due to the synthetic accessibility of such compounds. It was 
initially envisaged that the equivalent nosyl aziridine would be most easily prepared 
by sulfonation of aziridine 1 0 1  (prepared in two steps from cyclohexene oxide) with 
nitrobenzenesulfonyl chloride. However, review of the literature revealed that nosyl 
aziridines may be prepared directly from alkenes by the catalytic addition of a 
suitable nitrene species. 127 ,130 ,164 ,165
The increasing realisation of the number of potential applications for 
aziridines in organic synthesis has generated considerable interest in the development 
of efficient methods for the one-step aziridination of alkenes. The mechanism of
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aziridination is invariably nitrene addition to the double bond , and a variety of 
nitrene precursors have been investigated for their ability to undergo addition in an 
efficient manner. The use of alkoxycarbonylnitrenes and azides for this purpose is 
well established in the literature, but generation of the active nitrene species 
generally requires photolysis or heating . 166 More recent research has focused on the 
use of metal-stabilised nitrenes as aziridinating agents, of which N- 
tosyliminophenyliodinane and its derivatives have attracted particular attention in
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this regard. The first successful reported aziridination using this nitrene precursor 
was reported in 1984 by Mansuy et al.]61 who utilised Fe(III) and Mn(III) porphyrins 
as catalysts. Since then, interest has shifted towards Cu(I) and Cu(II)-based catalysts 
which are more accessible and often afford very high yields of the corresponding 
aziridines.130,164
The preparation of model compound 111 from cyclohexene has been reported 
to proceed in 92% yield in the presence of catalytic [Cu(CH3CN)4 ]C1 0 4  and the nitro 
analogue (110) of Af-tosyliminophenyliodinane164 (conveniently for the present 
investigation, nitrene precursor 110 has been consistently reported to undergo 
addition to alkenes in higher yields than the parent Af-tosyliminophenyliodinane). 
However, this particular copper catalyst did not appear to be readily commercially 
available and attention turned instead to the use of copper (II) 
trifluoromethanesulfonate. This catalyst has been studied in great detail by Taylor et 
al.uo in conjunction with the aziridination of styrene by the aforementioned nitrene 
precursors and is relatively inexpensive. As the synthesis of the corresponding tosyl 
analogue of 111 using Cu(OTf) 2  had been previously reported in 68% yield168, it 
therefore appeared extremely likely that nitrene precursor 110 would react with 
similar (or greater) efficacy given its established superior ability as an aziridinating 
agent. The preparation of 110 was carried out according to the very convenient one- 
step procedure of Taylor et a/.130 (Scheme 39). Thus, equimolar quantities of 
hypervalent iodobenzene diacetate and p-nitrobenzenesulfonamide were combined in 
methanolic potassium hydroxide solution. After stirring for 3 hours, the required 110 
was isolated in 60% yield (consistent with the literature value) by simple suction 
filtration of the reaction mixture.
MeOH 
0°C to RT, 3  h 
60%
Schem e 39 (Preparation of nitrene precursor 110)
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Cyclohexene was hence treated with 1.5 equivalents of nitrene precursor 110 
and a catalytic amount of Cu(OTf)2 in acetonitrile at room temperature (Scheme 40). 
The addition of 110 was carried out portionwise as Sodergren et al.m  report that 
slow addition of the nitrene precursor results in a superior yield. Column 
chromatography of the crude product obtained after 4 hours of stirring afforded a 
77% yield of 111, noticeably greater than the 68% yield reported with N- 
tosyliminophenyliodinane. It therefore appeared that direct nitrene transfer with 110 
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Schem e 40 (Synthesis of model compound 111 and subsequent conversion to diamine 114)
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Due to the success of Yb(OTf) 3  in effecting aziridine ring-opening with 
amine nucleophiles observed in Section 4.3.1, it was decided to retain this catalyst 
for the present investigation. Treatment of 111 with pyrrolidine in the presence of 
Yb(OTf)3 resulted in an 8 8 % yield of masked trans-diamine 112 after passing the 
crude product through a short column of silica gel. Since nosyl TV-substituted 
aziridines are reported to be very highly activated towards ring-opening, it was not 
known whether Yb(OTf)3 actually improved the efficiency of the reaction by any 
measurable degree in this instance; however, it has since been shown that not all 
nosyl TV-substituted aziridines are nearly so activated (see Section 4.4.3).
Alkylation of the secondary sulfonamide moiety of 112 was carried out
1 fS)according to the general literature procedure employing 1 . 2  equivalents of 1 - 
bromo-3-phenylpropane and excess potassium carbonate in DMF. A rather low yield 
(45%) of the tertiary sulfonamide 113 was obtained after 20 hours at room 
temperature; the isolation of a significant mass of unreacted l-bromo-3- 
phenylpropane was indicative of the bromide’s low reactivity (unreacted 1 1 2  was 
present as its potassium salt and therefore was not isolated during column 
chromatography). Higher yields would probably be obtained after prolonged stirring 
or heating of the system.
Of the two deprotection methods specified by Fukuyama et a i r \  the 
benzenethiol/K2C0 3  system was selected due to the ready availability of the 
reagents. The addition of benzenethiol to excess potassium carbonate in DMF 
generates the benzenethiolate anion which efficiently cleaves nosyl groups via 
formation of a Meisenheimer complex with the substrate. Treatment of 113 with this 
reagent immediately resulted in a dark brown reaction mixture which was allowed to 
stir overnight. TLC analysis indicated the presence of 4 substances, of which one 
may be attributed to the by-product derived from reaction of the thiolate anion with 
the nosyl group. Separation by column chromatography and subsequent *H NMR 
analysis revealed that the most polar component corresponded to the desired trans 
vicinal diamine 114 which was obtained in 74% yield. A particularly pleasing 
finding was that no evidence of decomposition of 114 was apparent during 
chromatography which greatly simplified the purification.
The successful synthesis of diamine 114 using the nosyl strategy described 
above was highly encouraging and it appeared likely that this synthetic approach
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would be applicable to ligands 92-94 (p. 82). The geminal dimethyl group of the 
previously synthesised aminotetralins has been shown on numerous occasions to 
impart steric hindrance to the 2-position. A remaining concern was whether the 
presence of the geminal dimethyl group would significantly attenuate alkylation of 
the secondary sulfonamide moiety and consequently render this synthetic route 
unusable for the preparation of 92-94.
It was therefore decided to prepare a second model compound analogous to 
111 with the addition of a geminal dimethyl group adjacent to the aziridine in order 
to further gauge the applicability of this synthetic strategy (119, Scheme 41). Such a 
gem-dimethylcyclohexane structure could also be considered as the ‘next stage’ in 
simplification of the aminotetralin scaffold, perhaps providing scope for a future 
series of ligands - this would enable the effect of the phenolic group on opioid 
receptor binding to be determined and hence discover to what extent the scaffold can 
be simplified before significant loss of opioid receptor affinity occurred.
1 1 5
i) NaNH,, E t20  
RT to  reflux, 18 h
ii) Mel, E t ,0  
Reflux, 3  h
TsNHNH,
EtOH 
6 0 ° C ,1.5 h 
43%  from
116
N 0 2(C6H4) S 0 2N=l Ph 
Cu(OTf^, 4A s ie v es
CHgCN 
RT, 20  h 
57%
MeLi
E t p  
-78°C to RT, 3 h 
84%
118
Schem e 41 (Synthetic route used for synthesis of model compound 119)
It appeared that introduction of the geminal dimethyl group by alkylation 
would be most appropriately carried out at an early stage of the synthesis, as such 
reactions often lead to substantial loss of material via alkylation of other positions in 
the molecule. Analysis of the literature showed that 2-methylcyclohexanone (115) 
may be methylated under suitable conditions to furnish 2,2- 
dimethylcyclohexanone169 (116) (it should be noted that 116 is available
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commercially but is extremely expensive). It was discussed in Chapter 2 that 
alkylation at the 1-position is strongly favoured in 2-tetralone 35 due to conjugation 
of the corresponding enolate with the neighbouring aromatic ring. Unfortunately, no 
such stabilisation occurs when 115 is deprotonated and consequently even more care 
must be taken over the reaction conditions to ensure that the desired gem-dimethyl 
product (116) is the major one. The enolate derived from 115 is a classic example of 
‘thermodynamic vs kinetic’ reaction pathways. Deprotonation can occur at either the 
2- or 6-positions of 115 leading to products 116 and 120 respectively (Scheme 42). 
Generation of the kinetic enolate is favoured by sterically hindered bases (attenuating 
deprotonation at the more hindered 2-position) and low temperatures (preventing 
isomerisation to the thermodynamic enolate). Accordingly, formation of the 





120 1 1 5 116
Schem e 42 (Products of kinetic and thermodynamic enolates of 115)
The base selected for use in the methylation of 115 was sodium amide (the 
compact nature of the anion should render hindrance from the 2-methyl group 
negligible) and the procedure adopted was a modified version of that described by 
Gartner.169 The thermodynamic enolate of 115 was generated by slow addition of 
the ketone to a suspension of sodium amide in diethyl ether, followed by prolonged 
stirring at room temperature and a subsequent period at reflux. Introduction of the 
electrophile and further reflux completed the reaction. Analysis of the methyl peaks 
in the !H NMR spectrum of the crude reaction mixture indicated that approximately 
50% of the material was the desired compound 116, with the remaining 50% 
accountable to over-alkylation products and starting material. Repeated attempts did 
not improve on this result by any significant degree, and the use of sodium hydride 
as base afforded an inferior yield of 116. Purification also proved to be 
troublesome, as the various methylated products possessed very similar Rf values by
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TLC. In addition, 116 is rather volatile which led to substantial losses of product 
when concentrating the chromatography fractions in vacuo.
The conversion of 116 to alkene 118 has previously been reported in the 
literature170 in a two-step methodology utilising the Shapiro reaction . 171 In this 
method, the ketone-derived hydrazone is converted to a dianion using an alkyllithium 
base which is decomposed directly to the vinyl anion; aqueous quenching then 
affords the corresponding alkene. It was envisaged that a more convenient 
separation of the various products of the alkylation step could be achieved by 
converting the crude 116 directly to the crystalline tosylhydrazone. Hence the 
residue obtained from methylation of 115 was heated with 1 equivalent of 
toluenesulfonylhydrazide in ethanol for 3 hours. TLC of the reaction mixture 
indicated that a greater difference in polarity ( - 0 . 2  between the mono- and di- 
methylated compounds) now existed between the various products of alkylation, 
greatly facilitating their separation by column chromatography; however, further 
experimentation found that the desired 117 could be made to crystallise direcdy from 
the crude oil by storing at low temperature (-10 to -20°C) for several days. 
Separation of the crystals by facile suction filtration and washing with ethanol 
afforded satisfactory 40-50% yields of 117 after thorough drying.
Decomposition of hydrazone 117 to the corresponding alkene 118 was 
achieved by the Shapiro reaction as stated above. The procedure of Hassner et a l 170 
relating specifically to the preparation of 118 was employed, although it was decided 
to conduct the addition of methyllithium at -78°C rather than 0°C as recommended 
by Tormakangas172 and co-workers in their detailed investigation of the Shapiro 
reaction. Upon removal of the cooling bath, it was observed that formation of the 
dianion (indicated by a deep red colour) and subsequent decomposition (indicated by 
the vigorous evolution of nitrogen) occurred at temperatures far below 0°C - it was 
therefore somewhat surprising that addition of the alkyllithium reagent at this 
temperature was stipulated by the original authors. 170 A modified work-up procedure 
was devised which eliminated the need for distillation and afforded 118 in a high 
state of purity by NMR: after extraction of the crude product into pentane, the 
combined organic layers were concentrated in vacuo to ensure complete removal of 
the diethyl ether; further pentane was then added, which dissolved hydrocarbon 118 
but left residual hydrazone 117 as insoluble white particles; suction filtration through
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Celite® followed by rinsing of the filter pad with pentane afforded a clear filtrate 
which was cautiously concentrated in vacuo (using relatively high pressure to avoid 
co-evaporation of 118) to leave alkene 118 which was used directly in the next stage 
without further purification.
Now that a viable route to 118 had been established, it remained to convert 
the alkene to its corresponding nosyl-aziridine to give the target model compound 
119. The successful aziridination of cyclohexene with nitrene precursor 110 and 
Cu(OTf) 2  gave support to the preparation of dimethyl-analogue 119 using this 
protocol. Thus 118 was reacted with freshly prepared 110 to afford a 57% yield of 
119 after purification. It is possible that the lower yield of aziridine obtained from 
118 may be caused by the gem-dimethyl group impeding approach of the metal - 
nitrene complex to the double bond, thus resulting in a slower reaction and 
competing decomposition of 110 (Taylor et a / . 130 report that the addition of Cu(OTf) 2  
to a suspension of nitrene precursor 110 causes it to decompose rapidly in the 
absence of an alkene substrate).
Model compound 119 was converted to the corresponding pyrrolidine trans 
diamine using an identical synthetic strategy to that outlined for 114 (Scheme 43). 
Reaction of 119 with pyrrolidine and Yb(OTf) 3  afforded an excellent yield (92%) of 
the ring-cleavage product 120, with complete regioselectivity being observed. It was 
discussed above that the primary rationale for synthesising a dimethyl analogue of 
model compound 1 1 1  was to investigate possible steric hindrance of this group on 
alkylation of the secondary sulfonamide moiety. In the case of 120, it was thought 
that deprotonation of the sulfonamide might be somewhat retarded by the presence of 
the dimethyl group. This would subsequently increase the lifetime of unreacted 
halide in the reaction mixture, which in turn may lead to decomposition in the case of 
light or temperature-sensitive halides (e.g. cinnamyl bromide), or competing 
substitution reactions involving nucleophilic attack of the base on the halide. In an 
effort to minimise such occurrences, potassium carbonate was replaced with the 
more powerful base cesium carbonate. Thus, 120 was reacted with 2 equivalents of 
CS2CO3 and 1.5 equivalents of cinnamyl bromide; purification afforded a very high 
(94%) yield of tertiary sulfonamide 121, indicating that the alkylation process was 
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Schem e 43 (Synthesis of model compound 119 and subsequent conversion to diamine 122)
Deprotection of 121 was this time attempted using the second of the two 
methods given by Fukuyama et al. employing LiOH and HSCH2CO2H. This 
method possesses an advantage over the PhSH/K^CO.^ system in that the carboxylic 
acid group of mercaptoacetic acid allows the by-product of nosyl cleavage to be 
removed by simple base extraction of the crude reaction mixture. Treatment of 121 
using this protocol resulted in a rather slower reaction than had been observed during 
deprotection of 113; TLC analysis indicated an approximately 70% consumption of 
121 after 24 hours at room temperature. Increasing the temperature to 50°C did not 
appear to greatly accelerate the reaction; completion was eventually achieved by 
addition of a further 2 equivalents of HSCH2CO2H and 3 equivalents of LiOH with 
heating at 60°C for 16 hours. Basic extraction of the by-product as discussed above 
was performed, although column chromatography was still required to remove other 
minor side-products. A satisfactory (53%) yield of diamine 122 was subsequently 
obtained using this deprotection procedure, though rather inferior to that afforded
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using the previous PI1 SH/K2CO3 method of cleavage; however, chromatographic 
purification of 1 2 2  was found to be more facile as the majority of thiol-containing 
by-products were removed during the work-up stage.
4.4.3 Synthesis o f aminotetralin-based diamines bearing tertiary 3-substituents
The successful application of the nosyl protecting group to the synthesis of 
structurally-simplified trans-diamines 114 and 122 gave strong support to the 
application of this strategy to the synthesis of the desired aminotetralin diamines 
92-94 (p. 82). Whilst the model nosyl-protected aziridines 101 (p. 90) and 119 (p. 
1 0 1 ) were prepared directly from alkenes by copper-catalysed nitrene transfer, it 
appeared that synthesis of the corresponding aminotetralin nosyl aziridine would be 
most easily achieved by sulfonation of N-unsubstituted aziridines 67 or 6 8  (Scheme 
22). It was initially envisaged that an analogous synthetic strategy to the attempted 
Boc and Cbz activation routes described in Section 4.3.1 would provide a convenient 
pathway to the 3-pyrrolidine ligand 92 (Scheme 44) - such a route is not appropriate 
for the preparation of 93 or 94 as the secondary amine group would undergo 
alkylation concurrently with the sulfonamide moiety.
Sulfonation of the aziridine and phenolic moieties of 6 8  with 2-
nitrobenzenesulfonyl chloride (somewhat less expensive than 4-NsCl and reported by
1 (\)Fukuyama et al. to be equally effective) proceeded relatively cleanly to afford a 
high yield of 123 as a solid. The acquisition of satisfactory NMR spectra of 123 was 
severely hampered by its lack of solubility in organic solvents - CH2CI2 , CHCI3 , 
THF, MeOH, DMF and DMSO all proving unsuccessful. It is highly likely that this 
is a result of strong intermolecular forces arising from the presence of numerous 
polar bonds in the structure of 123.
Ring-opening of 123 with pyrrolidine in the presence of Yb(OTf) 3  was 
initially attempted in THF according to the previously described protocol; however, 
it was found that little consumption of 123 occurred even after prolonged reflux. 
Repetition of the reaction in CH2CI2 afforded a similar result, most likely explained 
by the lack of solubility of 123 in these solvents. With continued experimentation, it 
was eventually found that 123 was soluble in a large excess of the highly polar 
aprotic solvent DMSO (dipole moment = 3.96), and a high yield (95%) of the ring- 























Scheme 44 (Synthetic route initially envisaged for ligand 92)
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Although alkylation of the sulfonamide group of 120 with cinnamyl bromide 
proceeded with high efficacy, analogous alkylation of 124 proved rather less 
straightforward. Indeed, no evidence of alkylation was apparent at room temperature 
even when utilising the powerful base sodium hydride; heating the reaction system to 
60°C appeared to result in degradation of the components. The reason for this lack of 
reactivity is not clear, but owing to the additional difficulties encountered due to lack 
of solubility of di-nosylated aziridine 123, it was decided that this synthetic pathway 
would not provide a convenient general route for the preparation of the desired 
ligands. Investigation of an alternative pathway was therefore undertaken.
In order to overcome the aforementioned solubility problems, it was decided 
to restrict the role of the nosyl group to purely that of an aziridine activating 
substituent and to utilise a different protecting group for the phenolic moiety. 
Aminotetralin aziridine 67 (p. 60) appeared an ideal starting point for such an 
investigation, as the methyl ether protecting group would enhance solubility of the 
synthetic intermediates in organic solvents rather than inhibit it as appeared to be the 
case for the nosyl group. Scheme 45 illustrates the proposed synthetic pathway.
Nosylation of aziridine 67 was achieved using 4-NsCl to afford TV-substituted 
126 in 6 8 % yield after purification. It was decided to revert to the 4- 
nitrobenzenesulfonyl activating group as used in the successful synthesis of model 
diamines 114 and 122 in order to exclude any ‘hidden’ attenuating effects that the 2- 
nitrobenzenesulfonyl group may have exerted on reactivity of the sulfonamide 
moiety in compound 124. Treatment of 126 with pyrrolidine and Yb(OTf)3  at room 
temperature was expected to readily afford masked diamine 127 as had consistently 
been observed with the previous nosyl-protected aziridines investigated. TLC 
analysis of the reaction mixture, however, revealed that only slight consumption of 
126 had occurred after 18 hours. Heating the system at reflux appeared to accelerate 
the reaction, although 42 hours were required to achieve total conversion to 127. 
The initial attempt to alkylate secondary sulfonamide 127 with cinnamyl bromide 
was made using cesium carbonate in DMF. Encouragingly, a 53% yield of the 
desired 128 was obtained after 18 hours at room temperature, a striking improvement 
to the lack of reactivity observed when attempting to alkylate di-nosylated 124. In an 
effort to improve the convenience of the reaction work-up, it was decided to evaluate 
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Scheme 45 (Alternative synthetic route used to prepare ligand 92)
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The K2 CC>3/ 1 8 -crown- 6  method was originally reported by Ahman et a l}59 in 
conjunction with the //-alkylation of aziridines (see Section 4.3.2). It was envisaged 
that the crown ether would increase the solubility of the carbonate anion in 
acetonitrile, eliminating the need for DMF which is markedly more time-consuming 
to evaporate. Reaction of 127 under these conditions was found to result in a slower 
reaction, although an approximately 55% yield of 128 was obtained after stirring for 
30 hours. The facile work-up of this latter method made it somewhat more attractive 
than the original method of Fukuyama et a l  and would be of particular value when 
performing such a reaction on a multigram scale.
Cleavage of the nosyl group from the model compounds was found to occur 
more readily using the reagent system PhSH/K2C0 3  rather than HSCIUCChH/LiOH 
and it was therefore decided to attempt deprotection of 128 using the former method. 
The reaction proceeded without complication and was complete after 48 hours at 
room temperature. Analysis by TLC revealed a certain amount of streaking of the 
product diamine, suggesting that slight decomposition was occurring on the silica 
gel. As it appeared unlikely that 129 could be readily purified by other means, it was 
decided to subject the residue to column chromatography using 1 % triethylamine in 
CH2CI2 as the eluant. The use of the stronger base triethylamine instead of ammonia 
was to ensure that the acidicity of the silica gel was sufficiently regulated to 
minimise decomposition of the diamine during purification. This technique was 
found to be successful, and a pleasing 94% yield of 129 was obtained.
From analysis of the *11 NMR spectra of intermediates 127-129 (Figure 17), it 
was apparent that the presence of the nosyl group at the 2-position in 127 and 128 
was influencing the chemical shift of the two methylene groups adjacent to the 
pyrrolidine nitrogen. In secondary sulfonamide 127, the aforementioned groups 
appear as two multiplets, each integrating to two protons and separated by 0 . 1 0  ppm. 
Upon alkylation of the sulfonamide moiety with cinnamyl bromide, the separation 
between the two multiplets increases in 128 to 0.26 ppm. It would appear from these 
observations that steric crowding in the region of the vicinal diamine moiety 
somewhat impedes the rotation of the pyrrolidine group about the nitrogen/tetralin 
ring bond resulting in two distinct chemical environments for the methylene protons. 
The high degree of hindrance arising from the nosyl and cinnamyl group in 128 
attenuates rotation to a greater extent than 127, leading to an increase in separation of 
the two peaks in the !H NMR spectrum.
110
0.26 ppm Merged into
| | one multiplet
0.10 ppm
N— S NO, M eOM eO
129128
M eO NO.N—
F igure  17 (Partial 'H NMR spectra of 127-129 showing the effect of the nosyl group on the chemical equivalence of the pyrrolidine protons [shown circled])
It is interesting to note that coalescence of the peaks in 128 did not occur 
even when the spectrum was acquired at 50°C, indicative of the high barrier to 
rotation. Cleavage of the nosyl protecting group to afford 129 releases the 
pyrrolidine group from its rotational restriction, causing the methylene protons to 
merge into the typical 4-proton multiplet characteristic of this heterocycle.
The final step in the synthesis of ligand 92 (Scheme 45) was cleavage of the 
aromatic methyl ether. A major concern was that acidic O-demethylation methods 
might lead to similar difficulties in the partitioning of the crude product as was 
observed for 96. With this in mind, it was decided to initially employ sodium 1- 
propanethiolate (prepared from sodium hydride and 1-propanethiol in DMF) to effect 
this reaction, being neither a significantly acidic nor basic reagent. Heating methyl 
ether 129 with 9 equivalents of NaSPr at 120°C for 24 hours, however, resulted only 
in a trace of product being apparent by TLC. A far more successful result was 
obtained by treating 129 with 3 equivalents of boron tribromide and quenching using 
the triethylamine/MeOH protocol designed for the acid sensitive aziridine 6 8 . By 
this method, a 49% yield of the desired ligand 92 was successfully obtained after 
purification.
To summarise, the chemistry developed with the aid of model compounds 
utilising the nitrobenzenesulfonyl group was found to be a convenient pathway for 
the synthesis of aminotetralin trans-diamine ligands where the 3-substituent is a 
tertiary nitrogen (as in 92). It now remained to ascertain whether this chemistry 
could be extended to the preparation of diamine ligands bearing secondary amine 
groups at the 3-position.
4.4.4 Synthesis o f aminotetralin-based diamines bearing secondary 3-substituents
In a previous discussion, it was established that the original synthetic route 
involving a tertiary pyrrolidine 3-substituent would not directly transfer to the 
preparation of vicinal diamines bearing secondary 3-substituents such as 93 and 94 
(p. 82) as alkylation of the sulfonamide moiety would lead to concurrent alkylation 
of the amine group. The development of a modified synthetic pathway incorporating 
an additional protection step for the secondary amine group appeared the most 
logical solution to this problem.
112
The penultimate step in the synthesis of ligand 92 (Scheme 45) is cleavage of 
the nosyl protecting group to afford the free diamine. As this reaction has been 
shown to proceed with high facility, it appeared that the nosyl group would also be 
most suitable for protection of the secondary amine functionality at the 3-position 
which results from attack of the primary amine nucleophile on the aziridine ring - 
removal of both protecting groups could then be effected in one step. The pathway 
envisaged for secondary 3-substituted diamines is depicted in Scheme 46.
Ring-opening of aziridine 126 with iV-cyclopropylmethylamine (AT-CPM) 
proceeded at an equally slow rate to the corresponding reaction with pyrrolidine, 
requiring a total of 5 days at reflux to achieve an 83% yield of 130. To investigate 
whether a different catalyst might increase the rate of conversion, the reaction was 
repeated using 10 mol% B(C6Fs) 3  in acetonitrile (see Section 4.3.2). Monitoring of 
the reaction by TLC indicated that the rate of consumption with B(C6Fs) 3  was equally 
slow as with Yb(OTf)3 ; a 74% yield of 130 was obtained after 3.5 days at reflux.
Ring-cleavage of 126 was also attempted using methylamine (solution in 
THF) as the nucleophile, although loss of the amine resulted in an even slower rate 
of reaction than A-CPM. In an effort to compensate for this, additional portions of 
methylamine solution were added periodically although only a 37% yield of the ring- 
opened product 131 was obtained after 4 days at reflux. It is likely that a superior 
yield could be obtained by the use of a sealed-tube system to prevent loss of 
methylamine. Due to time restrictions, however, it was decided to develop the 
synthetic route using the N-CPM product 130 which was more rapidly accessible.
It is interesting to consider at this stage the conditions required to effect ring- 
opening of the activated aziridines synthesised during this project. When the 
observations are compiled together (Table 13), a particular pattern is apparent. It 
appears that those aziridines possessing an electron-withdrawing phenolic group 
(Boc, Cbz, Ns) readily undergo ring-cleavage at room temperature, whereas 126 
which possesses an electron-donating methyl ether group requires high temperatures 
and long reaction times to effect the same transformation. The lack of reactivity of 
126 is very unusual for a nosyl aziridine as such activating groups are consistently 
reported as being extremely efficient promotors of aziridine ring-opening.127,140,163 A 
possible explanation for these observations is apparent, however, if one considers the 
electron density of the carbon p-orbitals of the aromatic ring. In aziridine 126, the 
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Scheme 46 (Initial synthetic pathway envisaged for secondary 3-substituted diamines)
lone pairs. It is proposed that this could promote intermolecular stacking of the 
aromatic groups (through interaction of carbon p-orbitals) making the aziridine 
carbon less accessible for nucleophilic attack. As electron-donating groups 
particularly enhance the electron density of those carbon atoms at the ortho and para 
positions, it may also be hypothesised that the p-orbital of the para aromatic carbon 
atom might attenuate the reaction by donating electron density towards the aziridine 
carbon at the 3-position thus decreasing its electropositivity and therefore 
susceptibility to attack. The electron-withdrawing groups of aziridines 69, 97 and 
123 decrease aromatic electron density and consequently have the reverse effects.
NR,
Aziridine Ri r 2 Nucleophile Conditions required to cleave
69 Boc Boc Pyrrolidine Room temperature for 18  h
97 Cbz Cbz Pyrrolidine Room temperature for 18  h
123 Ns Ns Pyrrolidine Room temperature for 16  h
126 Me Ns Pyrrolidine Reflux for 42 h
126 Me Ns A-CPM Reflux for 120 h
126 Me Ns Methylamine Reflux for 96 h (incomplete)
Table 13 (Conditions required to effect aziridine ring-opening)
The next stage of the synthesis required protection of the exposed secondary 
amine moiety at the 3-position. Reaction of 130 using 4-nitrobenzenesulfonyl 
chloride proceeded in excellent (92%) yield, theoretically allowing the secondary 
sulfonamide group to react selectively with the desired halide. Attempted alkylation 
of 132 with cinnamyl bromide and cesium carbonate in DMF, however, proved 
unsuccessful: no reaction was evident by TLC after 16 hours at room temperature nor 
after a further 4 hours at 60°C. Examination of the 3D structures of 130 and 132 
(Figure 18 -  structures generated using the “3D Structure Optimization” facility on 
ChemSketch114 and exported to RasMol115) reveals a significant change in
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conformation of the cyclohexene ring when the N-CPM  moiety is protected with 4- 
nitrobenzenesulfonyl chloride. This is indicative of the steric requirements of the 
two bulky nosyl groups in 132, and directly leads to the suggestion that the 
subsequent introduction of a cinnamyl group may place too many steric demands on
11 ' Xthe system. Kas’yan et al. , however, report the successful alkylation of hindered 
norbomene sulfonamides under phase transfer conditions. Using this protocol, a 
solution of 132 and cinnamyl bromide in toluene was vigorously stirred with aq. 
12.5M NaOH at 60°C for 15 hours. TLC of the organic layer indicated that a 
reaction had occurred, but not cleanly. Unfortunately, column chromatography of 
the residue after work-up afforded no material that could be convincingly assigned to 
the required product 133 by *H NMR. It thus appeared unlikely that 132 would 
undergo alkylation efficiently, and it was consequently decided to seek an alternative 
route to ligand 93.
F ig u re  18 (O ptim ised structures o f  130 (top) and 132 (bottom ) illustrating  the steric dem ands
im parted by the second nosyl group)
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It was thought that the aforementioned alkylation difficulties could be 
overcome by ensuring that introduction of the cinnamyl group was performed on a 
less sterically-hindered system than 132. By analysis of Scheme 46, it appeared that 
one way to achieve this would be to cleave the secondary nosyl group at the 2- 
position immediately after protection of the N-CPM moiety. This would unmask the 
primary amine group which could be reductively alkylated with trans- 
cinnamaldehyde and sodium borohydride to introduce the desired side-chain. In 
order to accomplish this, an alternative protecting group unreactive towards thiolates 
would be required for the N-CPM moiety. With these concepts in mind, Scheme 47 
was developed.
The Boc group was selected for protection of the N-CPM moiety due to its 
facile protection/deprotection methods and unreactivity towards most nucleophiles. 
Ring-opened compound 130 was therefore reacted with B0 C2O and catalytic DMAP 
to afford a moderate yield (61%) of protected 134 after purification. The presence of 
a closely-running product by TLC suggested that acylation of the secondary 
sulfonamide group may have been a competing reaction.
The reagents utilised for cleavage of the nosyl group were selected after 
much deliberation. Although PhSH/K2C0 3 -assisted deprotection had previously 
resulted in high yields of the unmasked amine, it was necessary to remove excess 
benzenethiol and the by-product derived from reaction of the thiolate anion with the 
nosyl group (via the Meisenheimer complex). This factor was relatively insignificant 
in the previous applications of this reaction, as the diamine product was considerably 
more polar than either of these two undesired substances and therefore separation 
was generally unproblematic. For the present case, however, the presence of a Boc 
group would decrease the polarity of the product which could result in purification 
difficulties if the Rf coincided with a by-product of the reaction. It therefore 
appeared prudent to use the alternative, HSCFkCC^H/LiOH deprotection system 
where the by-product and excess reagent is removable by extraction with aqueous 
base. Reaction of 134 under these conditions afforded a rather low (48%) recovery 
of product after column chromatography, which unfortunately remained impure due 
to co-elution with a slightly more polar contaminant. Rather than attempting further 
purification at this stage with possible loss of valuable material, it was decided to 
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Scheme 47 (Alternative synthetic pathway to secondary 3-substituted diamines)
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which may afford better results has been reported by Farr and co-workers174 who 
were prompted by disappointing results with the HSCH2C0 2 H/Li0 H method to 
develop a novel nosyl-cleavage procedure using dodecanethiol and LiOH under 
phase-transfer conditions. This system is apparently highly effective and the 
lipophilicity of the dodecyl chain (far greater than PhSH) allows for facile removal of 
the by-products; in addition dodecanethiol is inexpensive and virtually odourless.
The primary amine resulting from denosylation of 134 underwent efficient 
reductive alkylation with frans’-cinnamaldehyde using the two-step methodology 
discussed previously to smoothly afford a 71% yield of 135 (34% over the two 
steps). As expected, the contaminant from the previous step was now easily removed 
by column chromatography. Deprotection of the Boc group to yield 136 was 
achieved using TFA, although the process appeared to be somewhat slow and 
required 30 equivalents of acid to drive it to completion. ^  NMR analysis indicated 
the reaction to be extremely clean, and no purification was required after basification 
of the residue and extraction according to the standard protocol.
The previously synthesised diamines 92, 114 and 122 were all found to be 
stable at room temperature for several weeks, but unfortunately this was not so for 
136. Due to unforeseen circumstances, it was necessary to delay cleavage of the 
methyl ether to afford 93 by one week after which time it was apparent by TLC that 
the compound had undergone substantial decomposition. This was unexpected given 
the stability of the other diamines and there was regrettably insufficient time to 
repeat the synthesis. In light of the instability of 136, a revised protocol whereby O- 
demethylation is carried out immediately after cleavage of the Boc group would 
probably afford superior results; storage of 93 as its di-HCl salt under anhydrous 
conditions may assist in preventing similar degradation.
To summarise, this synthetic pathway shows considerable promise for the 
preparation of secondary 3-substituted diamines. Improvement of the nosyl 
deprotection procedure (perhaps by utilising the dodecanethiol method described) 
and subsequent measures to prevent decomposition of the unmasked diamines should 
result in a synthetic route enabling flexible variation of both the 2- and 3- 
substituents, thus giving access to a wide range of rra/is-diamine ligands.
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4.4.5 Investigation o f an alternative approach to vicinal diamines utilising an 
aziridinium ion intermediate
In Section 4.2, the possibility of using an aziridinium ion as a means of 
synthesising fraws-diamines was discussed. The method involves reacting a trans 
amino alcohol (where the nitrogen must be tertiary) with methanesulfonyl chloride 
and mild base to transform the alcohol moiety to an efficient leaving group. Rapid 
intramolecular attack by the tertiary amine then occurs to afford an aziridinium ion, 
at which point a primary or secondary amine may be introduced which readily 
undergoes Sn2 attack with the ring to afford a trans-diamine.
A particular difficulty with applying such chemistry to the preparation of 
diamines 92-94 (p. 82) highlighted in Section 4.2 was the requirement of a tertiary 
amine centre. This appeared to limit the applicability of this approach to 92-94 as 
the amine at the 2-position is always required to be secondary. It appeared that a 
relatively simple way to overcome this problem would be to protect the secondary 
amine with a benzyl derivative, thus transforming the nitrogen to a tertiary centre 
whilst retaining its nucleophilicity. The 4-methoxybenzyl protecting group appeared 
ideal for this purpose, being more labile than the simple benzyl group and easily 
removed using 2,3-dichloro-5,6-dicyano-l,4-benzoquinone (DDQ)156; this oxidative 
cleavage method also allows for the inclusion of unsaturation in the side-chain.
As the synthesis of a tertiary amino alcohol precursor based on the 
aminotetralin scaffold would require the planning of a new synthetic route, it was 
decided to again utilise a cyclohexyl-type model compound to evaluate whether such 
chemistry would provide a viable route to the required ligands. Scheme 48 depicts 
the initial one-step strategy envisaged for model compound 138.
Secondary amine 137 was prepared in 49% yield from stepwise 
reductive alkylation of 4-methoxybenzylamine with trans-cinnamaldehyde and 
sodium borohydride. It was initially envisaged that 137 would undergo nucleophilic 
attack on cyclohexene oxide (99) in the presence of a suitable catalyst. The 
inexpensive weak Lewis acid lithium bistrifluoromethanesulfonimidate (LiNTf2) has 
been reported as an efficient promoter of ring-opening reactions of epoxides with
17Samines and appeared a logical choice for the present investigation. Hence 99 was 
treated with 1.2 equivalents of 137 and 0.5 equivalents of LiNTf2 in CH2CI2 
according to the literature protocol. However, only a trace of product was detectable 
by TLC after 24 hours at room temperature and heating the system at reflux for the
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same length of time did not significantly drive the reaction forward. It therefore 
appeared that the bulkiness of 137 was severely attenuating its ability to effect ring- 
cleavage of 99 and an alternative approach to 138 would be required.
CHjCI,,, Reflux /  \
Schem e 48 (Initial synthetic route planned for model compound 138)
It was invisaged that 138 could instead be constructed in a two-stage 
synthesis utilising 4-methoxybenzylamine rather than 137 as the ring-cleaving 
nucleophile (Scheme 49); such an approach would irradicate any difficulties arising 
from steric hindrance of the amine. Hence equimolar quantities of 99 and 4- 
methoxybenzylamine were stirred at room temperature with 0 . 2  equivalents of 
LiNTf2 in the absence of solvent for 3 days. Conversion to the HC1 salt and 
subsequent recrystallisation from propan-l-ol afforded a satisfactory (6 6 %) yield of 
the trans secondary amino alcohol. Attempts to effect ring-cleavage in the presence 
of catalytic zirconium(IV) chloride176 gave decidedly inferior results.
It appeared that the most facile way to introduce the required cinnamyl group 
selectively to the amine moiety would be by reductive alkylation. Indeed, treatment 
of 139 free base with rrans-cinnamaldehyde and excess sodium
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triacetoxyborohydride resulted in a very clean reaction; conversion to the HC1 salt 
and recrystallisation gave tertiary 140.HC1 in excellent (90%) yield.
Previous literature examples of diamine preparation via aziridinium ion 
intermediates have always employed simple, ‘symmetrical’ N-substituents in the 
tertiary amino alcohol precursor e.g. dibenzyl (see Scheme 30), diethyl and 
piperidinyl. 1 4 6 ,1 5 3 ,1 5 4  Therefore, it was not known at this point whether more bulky, 























Scheme 49 (Alternative synthetic route to 138 and attempted conversion to diamine 141)
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The protocol of de Sousa et al.146 was utilised as it specifically focuses on the 
use of methylamine as the attacking nucleophile and was therefore of particular 
relevance to the present project. Accordingly, a suspension of 138.HC1 (as excess 
triethylamine was used in the procedure, it was decided that prior conversion to the 
free base was not necessary) in diethyl ether at 0°C was treated with 3 equivalents of 
triethylamine followed by 1.2 equivalents of methanesulfonyl chloride. After stirring 
for 30 minutes to allow the aziridinium ion to form, a large excess of aqueous 
methylamine solution was added. TLC of the crude reaction mixture after stirring 
overnight indicated the presence of mainly starting material, although a significant 
quantity of a less polar substance was evident as were traces of highly polar products 
near the baseline. Repetition of the reaction using the free base of 138 afforded 
similarly poor results. In the latter case it was observed that precipitation of 
triethylamine.HCl occurred upon addition of methanesulfonyl chloride to the system 
(consistent with the observations of de Sousa and co-workers146), suggesting that the 
spot of greater Rf in the crude TLC is the methanesulfonyl derivative of 138.
A somewhat different result was obtained when the reaction was conducted at 
low temperature (below -20°C). TLC monitoring of the system indicated complete 
consumption of starting material 20 minutes after the addition of methanesulfonyl 
chloride. Two prominent spots on the plate were apparent: a product of lower 
polarity with Rf equal to that observed previously and a substance which remained on 
the baseline. This latter spot appeared to suggest the presence of the aziridinium 
intermediate 140, although subsequent treatment with methylamine did not result in 
the formation of any prominent polar product by TLC. Interestingly, heating of the 
system instead of addition of methylamine was found to lead to conversion of the 
baseline product back to starting material 138.
The above results appear rather ambiguous but suggest that formation of 
aziridinium ion 140 did occur to some extent, although its failure to then react with 
methylamine in the efficient manner reported for the literature examples suggests 
that the intermediate species was not stable. As the nosyl route of trans-diamine 
synthesis was proving to be considerably more successful, it was decided to 




INVESTIGATION OF A NEW COMMON INTERMEDIATE FOR 
LIGAND SYNTHESIS USING A CYCLISATION APPROACH
5.1 Design rationale
The alkene functional group is a highly versatile tool in organic synthesis, 
readily undergoing reaction with a vast range of electrophiles. Alkenes may thus be 
rapidly transformed to a variety of other functionalities including epoxides, aziridines 
and diols amongst others. It was thus envisaged that such an unsaturated moiety 
could be incorporated into the essential 1 ,1 -dimethyltetralin structure to provide a 
new common intermediate, 142, which would enable access to a far greater range of 
ligands than could be provided by oxime 37 (p. 31). Scheme 50 illustrates a few of 











Scheme 50 (Possible synthetic transformations of alkene 142)
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5.2 Synthetic studies
Perhaps the most obvious synthetic approach to alkene 142 is Shapiro 
reaction of the tosylhydrazone derived from 1,1-dimethyltetralone 36 (p. 31). In an 
analogous manner to 2,2-dimethylcyclohexanone (116) in Scheme 41, ketone 36 
would be converted to its corresponding tosylhydrazone by heating with 
tosylhydrazide. This intermediate would then be expected to undergo decomposition 
in the presence of methyl or butyllithium to afford the desired alkene 141. Such an 
approach has been previously applied successfully by Miller and co-workers177 for 
the preparation of a similar 1,1-dibenzyltetralin compound.
The many possible series of ligands which could be readily accessed from 
141 require that the experimental procedures used to prepare alkene need to be 
robust, convenient and applicable enough to enable multigram quantities to be 
prepared. The synthesis of 141 via the Shapiro reaction as described above uses 
ketone 36 as its starting point, which in turn is prepared in three steps from 2,7- 
dihydroxynaphthalene (46). Consideration of the individual experimental procedures 
reveals several unsatisfactory aspects of this synthetic route:
1. The use of several highly hazardous reagents: dimethyl sulfate, iodomethane, 
metallic sodium and methyllithium.
2. Three out of the five steps require external heating and one must be 
conducted at low temperature (-78°C) -  somewhat inconvenient for larger 
scale preparations (and refluxing solvents are a potential fire hazard).
3. The intermediate tetralone 35 is expensive when obtained commercially and 
its synthesis (though now improved) is rather time-consuming.
The above limitations of the initially envisaged synthetic route gave sufficient 
motivation for the investigation of alternative pathways. The presence of the 1,1- 
dimethyl group adjacent to the aromatic ring in 141 immediately suggests that 
formation of the cyclohexyl ring might be feasible via nucleophilic attack of the 
aromatic ring on a tertiary cation centre. The synthesis of tetralins by the acid- 
catalysed cyclodehydration of alcohols is a long established method for the 
preparation of such compounds178 and is particularly successful when dehydration 
leads to a tertiary cation (as is the case where 1,1-disubstituted tetralins are the 
products) due to the stabilising effect of the alkyl groups. The convenience,
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economy and low toxicity of such an approach made it seemingly ideal for the 
multigram scale of ligand precursor 141.
One important factor which needed to be addressed was how the alkene 
moiety would be introduced in the required 2,3-position. The most straightforward, 
economical and reliable way to achieve this appeared to be the classical method of 
base-induced elimination. For this to occur, a suitably positioned leaving-group such 
as a Cl, Br, I, OMs, or OTs must be present in the molecule. In order to introduce 
the double bond in the 2,3-position required for 141, the leaving-group must be 
vicinal to the tertiary alcohol moiety otherwise the conjugated 3,4-alkene would be 
the predominant elimination product. It is well know that halohydrins (1,2- 
haloalcohols) may be readily prepared from the corresponding alkene and it was 
therefore decided to use a halide as the leaving group in the elimination reaction. 
Retrosynthetic Grignard disconnection of the hydrocarbon chain of the parent alkene 
resulted in two commercially available and inexpensive halides as the starting 





Schem e 51 (Retrosynthetic analysis of 141)
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Formation of the Grignard reagent from 4-methoxybenzyl chloride (142) was 
achieved by iodine-initiated reaction with pulverised magnesium turnings in 
anhydrous THF at room temperature. The formation of homodimers of 142 was 
evident in early attempts, but it was found that this could be entirely suppressed by 
efficient grinding of the magnesium turnings prior to reaction with the halide. Once 
a cooled solution of the Grignard reagent had been obtained, 1 -bromo-3-methylbut- 
2 -ene was cautiously added and the product subsequently isolated by standard 
aqueous work-up. If the reaction was performed carefully enough, it was found that 
purification was not required and the near quantitative yield of 143 obtained could be 
used directly in the next step.
MeO
142
i) Mg, L, THF, RT
ii) (CH3)2C=CHCH,Br 
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Schem e 52 (Attempted synthesis of ligand precursor 141)
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Of the 4 stages of this synthetic pathway (Scheme 52), this initial step may be 
regarded as the most hazardous and least convenient due to the sensitive nature of the 
Grignard reagent; however, the fact that the reagent is prepared and immediately 
reacted with the bromide in the same flask greatly minimises any hazards resulting 
from the flammable/corrosive nature of the material. This should be compared 
directly with the Shapiro reaction which requires the user to transfer large quantities 
of methyllithium solution via syringe or cannula -  undoubtedly a far more hazardous 
and inconvenient procedure.
Conversion of 143 to the halohydrin was initially attempted using the 
‘classical’ method of A-bromosuccinimide in THF/water. This method generates 
hyperbromous acid (HOBr) in situ which may then undergo reaction with alkenes to 
afford bromohydrins. In the case of 143, reaction did not occur at all smoothly and 
many products were visible by TLC. This was not entirely suprising, as aromatic 
rings bearing activating substituents are highly susceptible to halogenation by a wide 
range of reagents including A-bromosuccinimide. A more selective method was 
therefore required.
Analysis of the literature revealed that the majority of systems used to 
transform alkenes to halohydrins were also reported to halogenate activated aromatic 
rings. Further investigation brought to attention the studies of M endoza et al.179 
into the use of trichloroisocyanuric acid (TCIA) as an efficient reagent for the 
preparation of chlorohydrins. Although chloride ion is a less effective leaving-group 
than bromide, this method appeared very attractive as the reagent is extremely 
inexpensive and non-toxic; only 0.34 equivalents of the reagent are required (due to 
the presence of 3 chlorine atoms in the molecule); it is not reported to halogenate 
aromatic rings; and the reaction proceeds under mild conditions. Hence 143 was 
treated with 0.34 equivalents of trichloroisocyanuric acid in acetone/water at room 
temperature according to the literature protocol. TLC of the reaction mixture after 
20 hours indicated a major product of higher polarity than 143 accompanied by a 
trace of a side-product of similar Rf. These were assigned as the desired 144 
(Markovnikov addition) and other regioisomer (anti-Markovnikov addition) 
respectively. A small amount of starting material was also apparent (perplexingly, 
complete consumption of 143 could never be achieved even with excess reagent or 
prolonged reaction times) but the absence of other reaction products indicated that 
chlorination of the aromatic ring had not occurred. Column chromatography of the
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crude product proved rather troublesome and resulted in partial decomposition of 144 
(although the decomposition product was later identified as cyclised 145). 
Attempted cyclisation of unpurified chlorohydrin, however, afforded very poor 
results indeed and it was therefore decided to conduct rough chromatographic 
purification in the presence of 1% triethylamine to inhibit tertiary cation formation. 
Removal of the unwanted regioisomer was not deemed to be necessary at this point 
as only the tertiary alcohol 144 was expected to undergo acid-catalysed cyclisation - 
it was thought that separation would be more facile after the next step of the 
synthesis and no further purification of the crude mixture was attempted.
Cyclodehydration reactions are most commonly carried out by treating a
178solution of the alcohol with a neat acid, typically sulfuric or polyphosphoric acid. ; 
heating is often required to obtain good yields of the tetralin. Kropp and co- 
workers180, however, report that greater yields of tetralins may be obtained by 
utilising acid pre-absorbed onto the surface of activated silica gel. In this method, a 
suspension of silica gel in CH2CI2 is treated with neat acid (phosphoric acid is 
reported as being particularly efficient for this purpose) and the mixture stirred to 
allow absorption to occur. A solution of the alcohol is then introduced and stirring 
continued at room temperature until cyclodehydration is complete (completion of the 
reaction generally occurs within 2 hours). This protocol appeared highly convenient, 
economical and reasonably environmentally friendly, fulfilling the requirements of 
the current project.
Treatment of crude chlorohydrin 144 with 1 equivalent of phosphoric acid 
according to the conditions of Kropp et a l m  failed to effect cyclisation to the 
desired 145. Further experimentation, however, revealed that cyclodehydration was 
extremely efficient when a solution of 144 in CH2CI2 was slowly added to 2 
equivalents of neat sulfuric acid absorbed onto silica gel. The reaction was 
consistently complete within 2 hours and required only facile column 
chromatography to afford a high (77%) yield of 2-chloro-l,l-dimethyltetralin 145. 
As expected, the corresponding regioisomer of 144 remained unchanged after 
exposure to acid and was very easily removed during purification.
A vast number of reagents are reported in the literature for the elimination of 
alkyl halides, particularly common systems being alcoholic potassium hydroxide, 
l,8-diazabicyclo[5.4.0]undec-7-ene (DBU) and potassium tert-butoxide in DMSO. 
Since there was no literature precedent for the dehydrochlorination of a tetralin-like
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compound, it was decided to initially utilise KOlBu in DMSO as this system was
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successfully applied to the dehydrochlorination of chlorocyclodecane. Whereas 
the authors report that room temperature is sufficient to effect elimination, treatment 
of 145 under these conditions resulted in no reaction. Heating the system to 40°C 
similarly afforded no reaction, although at 60°C elimination was found to occur. 
Analysis of the ]H NMR spectrum after aqueous work-up confirmed that 
dehydrochlorination had indeed occurred, but it was apparent that the desired 2,3- 
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F igure  19 (Rearrangement of alkene 141 in the presence of potassium tert-butoxide)
This type of rearrangement has been reported previously by Miller et al.]77 
for a similar 2,3-unsaturated tetralin system at elevated temperatures. It was 
expected that dehydrochlorination of 145 would proceed without the need for heating 
thus avoiding potential migration of the double-bond. Since this was evidently not 
the case, it was decided to substitute KOlBu for other bases to investigate whether 
elimination could be made to occur without subsequent deprotonation at the 
4-position. Attempted dehydrochlorination of 145 using DBU or triethylamine in 
toluene at 90°C failed and only starting material was recovered in both cases. Due to 
time restrictions, investigation of further elimination systems unfortunately could not
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be conducted although it was apparent from the above observations that a more labile 
leaving group would be required (allowing the use of a milder base) if elimination to 
141 was to be achieved without subsequent rearrangement to 146.
Based on the above findings, a modified synthetic pathway which may afford 
greater success was envisaged as the subject of a future study (Scheme 53). The 
route begins as before with alkene 143, constructed by reaction of 4- 
methoxybenzylmagnesium chloride with 1 -bromo-3-methylbut-2-ene. Whereas 
previously 143 had been treated with trichloroisocyanuric acid in the presence of 
water to furnish chlorohydrin 144, it was proposed instead to subject the alkene 
moiety of 143 to dihydroxylation to afford intermediate 147. A large number of 
methods are available to effect this transformation and since a cis orientation of the 
hydroxyl groups is not required, the need for highly toxic and expensive osmium 
reagents is eliminated. The use of potassium permanganate under basic conditions 
often affords high yields of the corresponding diol , although the method of Usui et 
al.m  utilising Nafion NR50 beads with hydrogen peroxide is considerably more 
environmentally friendly and excellent results are reported for a range of substrates. 
One difficulty with the use of Nafion beads in the latter case is that the acidic groups 
may promote immediate cyclisation to 148 in the manner observed during silica gel 
chromatography of chlorohydrin 144; it is possible, however, that a one-pot 
procedure could be easily devised to directly transform alkene 143 to tetralol 148.
HjCX/Nafion NR50
or KM nO./NaOH
R S 0 2C I/B ase
Schem e 53 (Alternative synthetic route to alkene 141)
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The single hydroxyl group of cyclised 148, obtained either directly from 143 
or by the silica gel-mediated cyclodehydration method applied previously, may then 
be reacted with an appropriate aromatic sulfonyl chloride to enhance its ability as a 
leaving group. As tosylated alcohols still require relatively strong bases (KOlBu etc.)
97to eliminate them to their respective alkenes , it was envisaged that a more efficient 
leaving group such as a nosylate or triflate would be required to enable elimination to 
be achieved under milder conditions so as to avert rearrangement of 141 to the 
conjugated alkene 146. Since a reasonably large number of such activating sulfonyl 
reagents are available commercially, this step would require some investigation to 
determine which leaving group affords the optimum balance between elimination 
efficacy, economy of the reagent and experimental convenience (i.e. air-sensitivity, 
toxicity, etc.). In an optimum procedure, activation and elimination of the hydroxyl 
group of 148 would be performed in a one-pot manner in the presence of excess base 
to yield 141.
Although the desired alkene 141 has yet to be successfully prepared, the 
rapidity, convenience and relative safety of the routes discussed provides much 






The purified ligands synthesised in Chapters 2, 3 and 4 were submitted for 
binding and functional assays (as the corresponding HC1 salts) in order to assess 
affinity and agonist/antagonist activity at j i , 6  and k  opioid receptors. The 
pharmacological evaluation of all ligands was performed by NIDA-OTDP through a 
contract to SRI according to the protocols described in Chapter 7. At the time of 
submission of this thesis, only pharmacological data relating to 9 of the 15 
compounds submitted for assay was available.
In the early years of opioid research, pharmacological characterisation of 
compounds was normally limited to in vivo antinociceptive methods. This typically 
involved subjecting an animal to thermal, mechanical or electrical stimuli in the 
presence and absence of the test compound in order to determine its antinociceptive 
potency relative to existing narcotic drugs such as morphine184. Further development 
led to in vitro methods of evaluation which, when used in conjunction with tissue 
containing a homogenous population of a particular receptor type, provide a far more 
convenient and informative approach to initial ligand characterisation.
6.2 Methods of in vitro pharmacological evaluation
6.2.1 Radioligand binding assays
The affinity of a given ligand for |i, 8  and K opioid receptors may be assessed 
by the use of tritiated versions of the selective agonists DAMGO (p), Cl-DPDPE (8 ) 
and U69,593 (k) . 9 4  The usual approach is to incubate samples of the membrane (in 
this case prepared from cloned human opioid receptors transfected into Chinese 
hamster ovary cells) bearing a population of the desired receptor with the tritiated 
agonist and various concentrations of the test ligand until equilibrium is reached. 
The membrane is then separated and its radioactive content measured by 
scintillation, enabling the IC5 0  value (concentration of unlabelled test ligand required 
to displace 50% of the tritiated selective agonist from the receptor) and dissociation 
constant (KO to be calculated.
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6.2.2 [35S]GTP)S-binding functional assays
The binding of the GTP analogue guanosine-5’-0-(3-[3 5 S]thio)triphosphate 
([3 5 S]GTPyS) to cloned human opioid receptors stimulated by a given ligand 
provides a means by which agonist activity may be measured. 9 4 Membrane samples 
are incubated with [3 5 S]GTPyS, GDP and the test compound. The resulting 
radioactivity of the separated membrane is determined as for the binding assay, 
enabling a dose-response curve for the test ligand to be created. A dose-response 
curve utilising a prototypical full agonist (DAMGO, Cl-DPDPE and U69,593 for p., 
6  and k  respectively) is also obtained in order to measure % maximal stimulation and 
identify partial agonists.
High affinity ligands (with Kj < 200 nM) exhibiting no agonist activity were 
subsequently tested as antagonists. In this assay, dose-response curves are obtained 
in the presence of a prototypical full agonist and at least three concentrations of the 
test ligand. A statistical analysis is conducted and the equilibrium dissociation 
constant (Ke) calculated which represents the antagonist potency of the test ligand in 
question.
6.3 Results of pharmacological assays
6.3.1 Ring-substituted N-cinnamyl derivatives
A jiSEM  (nM) Selectivity
No R
6 K
p /K 6 / k[3H] DAMGO [3H] Cl-DPDPE [3H] U69,593
28 o-NH2 14.810.35 17101399 35.9 19.93 0.4 48
29 m-NH2 48.7 ± 2.65 8741 120 339 1 14.5 0 . 1 2 . 6
30 p -n h 2 13.813.41 880177.6 78.0112.2 0 . 2 1 1
59 o-N 0 2 41.015.68 608 1  145 36.1 15.87 1 . 1 17
62 0 -n h 2* 26.1 10.19 34801652 64.0112.0 0.4 54
26 H 10.712.73 4721 108 82.3118.0 0 . 1 5.7
with double-bond hydrogenated
T ab le  14 (Binding assay results for aromatic substituted derivatives of 26)
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Ke ± SEM (nM) Selectivity
No R
§ K
vs DAMGO vs Cl-DPDPE vs U69,593 p/K
28 <?-NH2 5.24 ±0.61 NT 9.03 ±0.25 0 . 6
29 m-NH2 72.9 ± 12.6 NT NT -
30 p-NH2 35.6 ± 2.08 NT 89.7 ±4.35 0 . 6
59 0 -NO2 255 ± 49.9 NT 15.5 ±0.47 16
62 0 -NH2 ’ 16.5 ±1.03 NT 29.7 ±1.05 0 . 6
26 H 67.7 ± 7.59 NT 42.7 ± 2.75 1 . 6
with double-bond hydrogenated; NT = not tested 
Table 15 (Functional assay results for aromatic substituted derivatives o f 26)
Tables 14 and 15 show the binding and functional assay results obtained for 
the aromatic substituted derivatives of 3-unsubstituted cinnamyl ligand 26 described 
in Chapter 2. Analysis of the binding assay results reveals that whilst none of the 
ligands exhibit markedly superior j j / k  selectivity to 26, both the ortho-NH2 
compound 28 and the ortho-NO2  compound 59 both show an approximately two-fold 
improvement in k  receptor affinity. It was discussed in Chapter 2 that the design of 
this series of ligands was based on the findings of Portoghese et a l 10,48,51 who 
elucidated that a correctly positioned basic nitrogen centre was crucial in conferring 
K-selectivity to norBNI (10) and GNTI (11). Whilst the increase in k  affinity for 
ortho-NH2 derivative 28 may be explained using this concept, the observed k  affinity 
of ortho-NO2 ligand 59 is entirely unexpected. Hydrogenation of the alkene moiety 
of 28 to afford 62 appeared to result in a loss in k  affinity, though the relatively high 
8/ k  selectivity is retained. The meta-NH2 compound 29 was notable due to its low 
affinity for all but the jn receptor.
The functional assay results in Table 15 confirm the previous finding that N- 
substituted derivatives of the aminotetralin scaffold behave as pure opioid 
antagonists. The ortho-NH2 ligand 28 was found to be a moderately potent p. and k  
antagonist, displaying increased potency relative to unsubstituted 26. Although 
saturated derivative 62 exhibited almost identical k  affinity to 28 in the binding 
assay, it was subsequently found to be a 3-fold less potent k  antagonist in the 
functional assay. The ortho-NO2 ligand 59 again afforded the most surprising 
results: although 59 displayed unexpected k  affinity in the binding assay, its p /K  
selectivity was only marginally superior to the other ligands and certainly of no 
pharmacological significance. When subjected to the functional assay, however, 59
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was found to be not only a moderately potent k  antagonist but possessed a 16-fold 
greater |o/ k  selectivity than was apparent in the binding assay. It is at present unclear 
why the ortho-NO2 ligand 59 should possess such significant k  affinity and 
selectivity, though the complete absence of basicity in the nitro group suggests a 
rather different mode of receptor interaction than the basic nitrogen/Glu297 model 
proposed by Portoghese. 10 52 It would be of interest to determine whether it is the 
highly polar nature of the nitro group or its electron withdrawing ability that 






K, ± SEM (nM) Selectivity
No R
P 6 K
\jJ k 5/k[3H] DAMGO [3H] Cl-DPDPE [3H] U69,593
65 H 17.5 ±5.90 2430 ± 422 149 ±2.15 0 . 1 16
74 Cinnamyl 1.63 ±0.58 22.4 ±6.70 7.50 ± 0.84 0 . 2 8 . 0
76 Allyl 2.3 ±0.15 1000 ±89.8 17.2 ± 2.18 0 . 1 58
66 Tic* 365 ±4.04 1970 ±241 3.77 ±0.02 97 520
26 10.7 ±2.73 472± 108 82.3 ± 18.0 0 . 1 5.7
R = Tic* (27) 23.0 ±2.75 139 ±52.1 5.04 ±0.60 4.6 28
T able 16 (Binding assay results for 3-methoxy ligands)
Ke ± SEM (nM) Selectivity
5 K
No R vs DAMGO vs Cl-DPDPE vs U69,593 \iJk S/k
65 H
**
Agonist NT 49.3 ± 4.3 - -
74 Cinnamyl 2.62 ± 0.40 26.3 ± 3.90 2 . 1 2  ± 0 . 1 1 1 . 2 1 2
76 Allyl 1.69 ±0.13 NT 2.91 ±0.29 0 . 6 -
66 Tic* NT NT 15.6 ± 1.28 - -
26 67.7 ±7.59 NT 42.7 ± 2.75 1 . 6 -
R = Tic* (27) 139 ±31.7 503± 120 3.04 ±0.18 46 165
EC50 = 234 ± 55, 31.6% stimulation relative to DAMGO 
T able  17 (Functional assay results for 3-methoxy ligands)
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The binding profile for the p-selective A-unsubstituted aminotetralin 65 
(Table 16) is in general agreement with that previously reported for this compound 
by Roy et al. , although in the present assay 65 displayed an approximately 10-fold 
lower affinity for the p receptor (it is notable that the details of the assay used by the 
original authors were not disclosed). Comparison of the results obtained for the N- 
cinnamyl ligand 74 to 3-unsubstituted analogue 26 reveals that the 3-methoxy group 
exerts a considerable effect on the receptor affinity of this ligand: addition of a 3- 
methoxy moiety orientated trans to the A-cinnamyl group significantly increases 
affinity for all three receptors. Receptor selectivity remains relatively unchanged 
between the two compounds, with a slight increase in 5/ k  selectivity. The ability of 
the 3-methoxy group to increase affinity is further illustrated by A-allyl derivative 
76. In the preliminary 3-unsubstituted series, the A-allyl compound displayed only 
weak affinity for p receptors (IQ = 202 ± 0.92 nM) and moderate affinity for k  
receptors (IQ = 63.7 ± 6.60 nM). Addition of the 3-methoxy moiety has increased p 
binding 8 8 -fold and k  binding almost 4-fold, with 76 displaying a preference for the 
p receptor. The most considerable gain in selectivity was observed in the JDTic- 
analogue 6 6 . Although the ligand did not exhibit increased affinity for receptors 
other than k , the loss in affinity at p and 8  has translated into a far more desirable 
increase in k  receptor selectivity. The new 3-methoxy ligand 6 6  displays a 97- and 
520-fold preference for the k  receptor over the p and 8  receptors respectively.
The functional assay results (Table 17) confirm the findings of Roy et al.126 
that 65 behaves as an agonist at the p receptor, although of lower potency than 
suggested in the original publication; interestingly, the ligand was also found to 
moderately antagonise k  receptors. As predicted by the binding results, A-cinnamyl 
ligand 74 was found to be a potent p and k  antagonist with only moderate affinity for 
the 8  receptor. Of equal significance is the finding that A-allyl compound 76 is also 
a potent p and k  antagonist, placing this side-chain alongside cinnamyl in its ability 
to confer antagonist potency. It will be of interest to compare the results of 76 with 
those of A-CPM analogue 75 when available, as the A-allyl and A-CPM groups 
mediate similar antagonist activity in the morphinan and related series.
In marked contrast to the binding assay, JDTic-like ligand 6 6  exhibited a 
somewhat disappointing k  antagonist activity in the functional assay, being 5-fold 
less potent than the analogous ligand 27 lacking a 3-methoxy group. Nonetheless,
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the high selectivity of 27 for the k  receptor justifies further pharmacological 
investigation of this interesting ligand and it is intended that in vivo studies will be 
conducted in the near future.
6.4 Concluding remarks
The above pharmacological results confirm the ability of suitable 
aminotetralin structures to function as ‘message’ scaffolds in the development of 
short-acting pure opioid antagonist ligands and provide much scope for further 
investigation. The unexpected finding that the ortho-NO2 analogue 59 is a 
moderately potent and selective k  antagonist justifies the further exploration of this 
side-chain as a k  ‘address’ and the synthesis of other non-basic ortho analogues of 
26. The considerable pharmacological effects exerted by the presence of a 3- 
methoxy group also warrant further investigation of this structural feature: one 
particularly interesting possibility would be to synthesise the corresponding 3- 
methoxy substituted analogue of 59 to observe the effect on k  affinity and selectivity. 
The exploration of other 3-substituted aminotetralin scaffolds is currently underway 
(including the vicinal diamines discussed in Chapter 4) which will provide further 
information on the structure-activity relationships in this series and may yet yield 
ligands with superior pharmacological profiles to those already disclosed.
At the time of submission, the binding and functional assay results for 9 of 
the 15 ligands synthesised were available. The pharmacological evaluation of the 
remaining 6  compounds (Table 18) is expected to be completed in the near future.
No Ri r 2 R3 R4
75 H OMe H CPM
77 H OMe Allyl Allyl
78 H OMe H n-Propyl
79 H OMe H n-Propylphenyl
92 H N(CH2)4 H Cinnamyl
129 Me N(CH2)4 H Cinnamyl





Binding and functional in vitro assays were carried out by the National 
Institute on Drug Abuse (NIDA) at Stanford Research Institute, California, USA94. 
The procedures described below were those used to obtain all pharmacological 
results quoted in this thesis. Compounds selected for in vitro testing were converted 
to their corresponding HC1 salts by dissolving the free base in a 5 to 6 N solution of 
HC1 in propan-2-ol, followed by carefully evaporation of the solvent in vacuo. The 
resulting salt was thoroughly dried in a vacuum desiccator prior to submission to 
NIDA.
7.1.1 Radioligand binding assays
Receptor binding studies were conducted on human opioid receptors 
transfected into Chinese hamster ovary (CHO) cells. The p cell line was maintained 
in Ham’s F-12 medium supplemented with 10% foetal bovine serum and 400 pg/ml 
Geneticin (G418). The 8  and k  cell lines were maintained in Dulbecco’s minimal 
essential medium (DMEM) supplemented with 10% foetal bovine serum, 400 pg/ml 
G418 and 0.1% penicillin/streptomycin. All cell lines were grown to full confluence, 
then harvested for membrane preparation. The membrane used for binding assays 
was prepared in 50 mM Tris buffer, pH 7.7. Cells were harvested by scraping the 
plates with a rubber policeman and centrifuged at 500 x g for 10 minutes. The cell 
pellet was subsequently homogenised in buffer with a polytron, centrifuged at 2 0 , 0 0 0  
x g for 20 minutes, washed and recentrifuged before resuspending at 3 mg 
protein/mL in buffer to determine protein content. The homogenate was stored at - 
70°C in 1 mL aliquots.
Routine binding assays were conducted using the prototypical agonist ligands 
[3H]DAMGO, [3H]C1-DPDPE and [3H]U69,593 for p, 8  and k  receptors respectively. 
The assay was performed in triplicate in a 96-well plate. Non-specific binding was 
measured using 1.0 pM of the unlabelled counterpart of each radioligand. Cell 
membranes were incubated with the appropriate radioligand and unlabelled test 
compound for 1 hour at 25°C. For routine experiments, membranes were incubated
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with the test compounds at concentrations ranging from 10' 5 to 10' 10 M, after which 
the samples were filtered through glass fibre filters using a Tomtec cell harvester. 
Filters were dried overnight and bagged with 10 ml scintillation cocktail before 
counting for 2 minutes on a Wallac Betaplate 1205 liquid scintillation counter
Full characterisation of compounds includes analysis of the data for IC50  
values and Hill coefficients using the program PRISM. Kj values were calculated 
using the Cheng-Prusoff transformation:
g  _  I C 5 0  
' 1 + { L / K d)
where L  is the radioligand concentration and IQ the binding affinity of the 
radioligand as determined previously by saturation analysis.
7.1.2 [35S]GTP')S-binding functional assays
Compounds having IQ values of 200 nM or better in the binding assay were 
evaluated for agonist/antagonist activity. The membrane was prepared as described 
for the radioligand binding assay above with the exception that buffer A (20 mM 
HEPES, 10 mM MgCh and 100 mM NaCl at pH 7.4) was used instead of 50 mM 
Tris buffer. The membrane was incubated with [3 5 S]GTPyS (50 pM), GDP (usually 
lOpM) and the test compound in a total volume of 200 pL for 60 minutes at 25°C. 
Samples were subsequently filtered through glass fibre filters and counted as before. 
A dose-response curve with a prototypical full agonist (DAMGO, Cl-DPDPE and 
U69,593 for p, 5 and k  receptors respectively) was conducted in each experiment to 
identify full and partial agonist compounds.
High affinity compounds (Kj < 200 nM) that demonstrated no agonist 
activity were tested as antagonists. For each test compound, a Schild analysis was 
conducted utilising a full agonist dose-response curve in the presence of at least three 
concentrations of the antagonist. pA2 values and Schild slopes were determined 
using a statistical program designed for these experiments. The equilibrium 
dissociation constant, IQ, was calculated as follows:
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a
K e = ----------D R - I
where a is the nanomolar concentration of the antagonist and DR the shift of 
the agonist concentration-response curve in the presence of a given concentration of 
antagonist.
7.2 Analytical specifications
All chemicals were purchased from Aldrich, Acros, Fluka, Avocado or 
Lancaster chemical companies. The majority of solvents were GPR grade obtained 
from Fisher Scientific and were used without further purification. Where 
“anhydrous” is specified in the experimental text, this refers to the “absolute” form 
of the solvent over molecular sieves available from Fluka.
Column chromatography was performed under gravity using silica gel 60 
(35-70 pm) purchased from Merck. Thin layer chromatography for analytical 
purposes was carried out using aluminium-backed plates coated with silica gel 60 
F254 purchased from Merck. The chromatograms were visualised using UV light, 
iodine, ninhydrin, phosphomolybdic acid, 2,4-dinitrophenylhydrazine and potassium 
permanganate stains.
!H and 13C NMR spectra were recorded using either a JEOL GX 270 
(operating at 270 MHz for *H and 70 MHz for 13C) or a JEOL EX 400 (operating at 
400 MHz for *H and 100 MHz for 13C) spectrometer. Chemical shifts are expressed 
in ppm and spectra were referenced using tetramethylsilane or residual solvent. 
Coupling constants (7) are reported in Hz and the multiplicities abbreviated as 
follows: s (singlet), d (doublet), t (triplet), q (quadruplet), quint (quintet), m 
(multiplet) and br (broad). The abbreviations Ar-CH and Ar-C appearing in the 13C 
data refer to either aromatic carbon atoms or alkene carbon atoms conjugated with an 
aromatic group. All mass spectrometry was carried out by the University of Bath 
Mass Spectrometry Service. High and low resolution fast atom bombardment (FAB) 
mass spectra were recorded on a Fisons VG AutoSpec Q instrument with a matrix of 
m-nitrobenzylalcohol. High and low resolution electron impact (El) mass spectra 
were obtained using El ionisation at 70 eV on a VG AutoSpec Q instrument 
equipped with a Fisons autosampler. Microanalyses were performed with a Perkin- 
Elmer 240C analysis by the Microanalysis Laboratory, Department of Chemistry,
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University of Bath. Melting points were obtained using a Gallenkamp MFB-595 
melting point apparatus or a Reichert-Jung hot stage microscope apparatus and are 
uncorrected.
7.3 Synthetic procedures
2-Amino-l,l-dimethyl-l,2,3,4-tetrahydronaphthalen-7-ol (23) - Method A
Methyl ether 38 (1.04 g, 5.04 mmol) was dissolved in aq. 48% hydrobromic 
acid (10 ml) and the reaction heated to reflux for 3 hours. The mixture was allowed 
to cool to RT and the solvent cautiously evaporated in vacuo to leave the crude 
phenol hydrobromide. Water (15 ml) was added and the solution basified to pH 10 
with conc. NH4OH. The resulting emulsion was extracted with CHCI3 (3 x 40 ml) 
and the combined organic layers were dried (MgSC>4 ), filtered and concentrated in 
vacuo. Column chromatography (1-5% MeOH: CH2CI2 : 1% NH4 OH) afforded the 
title product as a brown oil (0.47 g, 49%); Rf (10% MeOH: 89% CH2CI2 : 1% 
NH4 OH) 0.31; 8 h (270 MHz, CDC13): 1.21 (3H, s, gem-CH3), 1.30 (3H, s, gem- 
CH3), 1.68-1.82 (1H, m, 3-CH), 1.95 (1H, dtd, 7 =  12.9, 6.4, 3.0, 3-CH), 2.80 (2H, 
m, 2-CH + 4-CH), 2.87 (1H, m, 4-CH), 6.57 (1H, dd, J  = 8.4, 2.7, 6 -ArH), 6.80 (1H, 
d ,J =  2.7, 8 -ArH), 6.91 (1H, d, J  = 8.4, 5-ArH); 8 C (7 0 MHz; CDC13): 25.68, 27.08, 
27.68, 30.08, 39.27, 56.76, 113.93 (Ar-CH), 114.06 (Ar-CH), 126.35 (Ar-C), 130.21 
(Ar-CH), 146.05 (Ar-C), 155.00 (Ar-C); E l MS m/z 191 (M+, 40%)
2-Amino-l,l-dimethyl-l,2,3,4-tetrahydronaphthalen-7-ol (23) - Method B
To a stirred solution of methyl ether 38 (0.52 g, 2.52 mmol) in CH2CI2 (15 
ml) at -78°C under an atmosphere of nitrogen was added boron tribromide (5.0 ml, 
1.0M solution in CH2CI2 , 5.00 mmol) dropwise over 30 minutes via a syringe. When 
the addition was complete, the cooling bath was removed and the reaction was stirred 
for 15 hours. After this time the reaction was quenched by the dropwise addition of 
MeOH (15 ml). The solvent was evaporated in vacuo and the residue redissolved in 
MeOH (30 ml). After stirring for 15 minutes, the solvent was again evaporated and 
the residue basified to pH 10 with conc. NH4 OH. Water (10 ml) was added and the 
emulsion extracted with 3:1 CHCI3 : EtOH (3 x 15 ml). The combined organic 
extracts were washed with water (40 ml), dried (MgS0 4 ), filtered and concentrated in
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vacuo. Column chromatography (8 % MeOH: 91% CH2CI2 : 1% NH4OH) afforded 
the title product as a brown oil (0.31 g, 64%). See Method A for data.
2-{[(£')-3-(2-Aminophenyl)prop-2-enyl]amino}-l,l-dimethyl-l,2,3,4-tetrahydro 
naphthalen-7-ol (28)
To a stirred solution of 39 (0.32 g, 0.91 mmol) in MeOH (20 ml) at RT was 
added aq. 7M NH4 OH (18 ml) and iron (II) sulfate heptahydrate (2.27 g, 8.17 mmol). 
The reaction was heated to reflux for 2 hours after which time the mixture was 
cooled and suction filtered. The filter pad was washed with CHCI3 (30 ml) and the 
filtrate adjusted to pH 7 with aq. sat. NH4 CI. The resulting two-phase system was 
separated and the aqueous layer extracted with CHCI3 (3 x 40 ml). The combined 
organic extracts were washed with water ( 2  x  1 0 0  ml), dried (MgS0 4 ), filtered and 
concentrated in vacuo to give a red oil. Column chromatography (3% MeOH: 96% 
CH2CI2 : 1% NH4OH) afforded the title product as a yellow foam (0.19g, 6 6 %); Rf 
(10% MeOH: 89% CH2C12: 1% NH4 OH): 0.20; vmax (film) 3220 (br, O-H), 1613 (N- 
H) cm '1; 6 h (400 MHz, CDC13): 1.24 (3H, s, gem-CH3), 1.36 (3H, s, gem-CH3), 1.71-
1.80 (1H, m, 3-CH), 2.05-2.11 (1H, m, 3-CH), 2.65 (1H, dd, J  = 9.6, 2.4, 2-CH), 
2.72 (1H, ddd, J  = 16.4, 9.2, 5 .6 ,4-CH), 2.83 (1H, dt, J=  16.4, 5.6, 4-CH), 3.41 (1H, 
ddd, J  = 14.4, 7.2, 1.6, NHCH 2CH), 3.66 (1H, ddd, J  = 14.4, 6.0, 1.6, NHCH2CH),
6.18 (1H, dt, J  = 15.6, 6 .8 , CH2CH=CH), 6.56 (1H, dd, J  = 8.4, 2.8, 6 -ArH), 6.59 
(1H, d, J  = 15.2, CH2CH=CH), 6 . 6 8  (1H, dd, J  = 8.4, 1.2, Ar-H[o-NH2]), 6.72 (1H, 
dd, /  = 7.6, 0.8, Ar-H[p-NH2]), 6.77 (1H, d, J  = 2.8, 8 -ArH), 6.89 (1H, d, J  = 8.4, 5- 
ArH), 7.06 (1H, td, J  = 7.6, 1.6, Ar-H[p-CH=CH]), 7.23 (1H, dd, J  = 7.6, 1.6, Ar- 
H[o-CH=CH]); 8 C (100 MHz; CDC13): 24.06, 26.10, 27.92, 29.77, 39.10, 50.93, 
62.56, 113.50 (Ar-CH), 113.73 (Ar-CH), 116.35 (Ar-CH), 119.30 (Ar-CH), 123.79 
(Ar-C), 127.33 (Ar-CH), 127.69 (Ar-CH), 128.59 (Ar-CH), 129.96 (Ar-CH), 130.62 
(Ar-CH), 143.58 (Ar-C), 146.95 (2 x Ar-C), 154.09 (Ar-C); El MS m/z 324 (MH+, 
70%); El MS m/z 322 (M \ 45%); HRMS calc, for C2 iH26N20  322.2045, found 





The procedure used for the preparation of 28 was employed. Nitro compound
40 (0.12 g, 0.35 mmol) was treated with iron (II) sulfate heptahydrate (0.87 g, 3.12 
mmol) in the presence of NH4 OH according to the protocol described. Column 
chromatography (3% MeOH: 96% CH2CI2 : 1% NH4 OH) afforded the title compound 
as a colourless oil (74 mg, 6 6 %); Rf (10% MeOH: 89% CH2C12: 1% NH4OH): 0.15; 
vmax (film) 3370 (O-H), 1614 (N-H) cm '1; 5H (400 MHz, CDC13): 1.23 (3H, s, gem- 
CH3), 1.34 (3H, s, gem-CH3), 1.72-1.83 (1H, m, 3-CH), 2.04-2.22 (1H, m, 3-CH), 
2.67 (1H, dd, J  = 9.6, 2.8, 2-CH), 2.70-2.78 (1H, m, 4-CH), 2.83 (1H, dt, J  = 16.8,
5.6, 4-CH), 3.40 (1H, ddd, J  = 14.0, 7.2, 0.8, NHCH2CH), 3.66 (1H, ddd, J  = 14.0,
5.6, 1.2, NHCH2CH), 3.70-4.20 (4H, br-s, O-H + N-H + NH2), 2.90 (1H, ddd, J  =
15.6, 7.2, 6.0, CH2CH=CH), 6.49 (1H, d, J  = 15.6, CH2CH=CH), 6.60 (2H, dd, J  =
8.0, 2.4, 6 -ArH + Ar-H[p-CH=CH]), 6.71 (1H, pseudo-1, J  = 2.0, Ar-H[o-CH=CH, 
0 -NH2]), 6.78-6.82 (2H, m, 8 -ArH + Ar-H[p-NH2]), 6.91 (1H, d, J  = 8.0, 5-ArH), 
7.13 (1H, t, /  = 8.0, Ar-H[m-NH2]); 8 C (100 MHz; CDC13): 23.57, 25.67, 27.53, 
29.29, 38.66, 50.27, 62.28, 113.06 (Ar-CH), 113.59 (Ar-CH), 113.73 (Ar-CH),
114.76 (Ar-CH), 117.41 (Ar-CH), 126.63 (Ar-C), 128.26 (Ar-CH), 129.55 (Ar-CH),
129.79 (Ar-CH), 131.97 (Ar-CH), 138.15 (Ar-C), 146.28 (Ar-C), 146.65 (Ar-C), 
154.38 (Ar-C); FAB MS m/z 323 (M lT, 100%); HRMS calc, for C21H27N 2O 
323.2123, found 323.2125; CHN calc, for C21H26N2O.2 HCI.CH3OH.O.5 H2O: C 60.5, 
H 7.62, N 6.42, found: C 60.1, H 7.40, N 6.02
2-{[(E)-3-(4-Aminophenyl)prop-2-enyl]amino}-l,l-dimethyl-l,2,3,4-tetrahydro 
naphthalen-7-ol (30)
The procedure used for the preparation of 28 was employed. Nitro compound
41 (0.097 g, 0.28 mmol) was treated with iron (II) sulfate heptahydrate (0.69 g, 2.48 
mmol) in the presence of NH4OH according to the protocol described. Column 
chromatography (3% MeOH: 96% CH2CI2 : 1% NH4OH) afforded a mixture of the 
saturated and unsaturated product. Therefore, column chromatography was repeated 
(1% MeOH: 98% CH2CI2 : 1% NH4OH) to give the pure title compound as a yellow 
oil (25 mg, 28%); Rf (10% MeOH: 89% CH2C12: 1% NH4OH): 0.24; vmax (film) 
3368 (O-H), 1609 (N-H) cm '1; 8 H (400 MHz, CDC13): 1.22 (3H, s, gem-CH3), 1.35
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(3H, s, gem-CH3), 1.68-1.78 (1H, m, 3-CH), 2.02-2.10 (1H, m, 3-CH), 2.63 (1H, dd, 
/  = 9.2, 2.4, 2-CH), 2.71 (1H, ddd, / =  16.4, 10.0, 6.0, 4-CH), 2.81 (1H, dt, / =  16.4,
5.2, 4-CH), 3.34 (1H, ddd, J  = 13.6, 7.2, 0.8, CH2CH=CH), 3.60 (1H, ddd, J  = 13.6,
6.0, 1.2, CH2CH=CH), 6.12 (1H, dt, J  = 15.6, 6.4, CH2CH=CH), 6.43 (1H, d, J  =
15.6, CH2CH=CH), 6.56 (1H, dd, J  = 8.0, 2.8, 6-ArH), 6.62 (2H, d-pseudo-t, J  = 8.4,
2.0, 2 x Ar-H[o-NH2]), 6.77 (1H, d, J  = 2.8, 8-ArH), 6.88 (1H, d, J  = 8.0, 5-ArH),
7.17 (2H, d-pseudo-U J  = 8.4, 2.0, 2 x Ar-H[o-CH=CH]); 8C (100 MHz; CDC13):
24.06, 26.07, 27.97, 29.68, 39.09, 50.87, 62.39, 113.38 (Ar-CH), 113.70 (Ar-CH), 
115.43 (Ar-CH), 125.27 (Ar-CH), 127.30 (Ar-C), 127.60 (Ar-CH), 128.14 (Ar-C), 
129.94 (Ar-CH), 131.52 (Ar-CH), 145.83 (Ar-C), 147.11 (Ar-C), 154.00 (Ar-C); 
FAB MS m/z 323 (MH+, 35%); HRMS calc, for C2iH27N20  323.2123, found 
323.2112; CHN calc, for C2iH26N20.2HC1.1.5H20 : C 59.7, H 7.40, N 6.63, found: C
60.0, H 7.46, N 6.23
7-Methoxy-3,4-dihydronaphthalen-2(l//)-one (35) - Method A
To a stirred refluxing solution of 47 (11.0 g, 59.1 mmol) in EtOH (150 ml) 
was carefully added freshly cut sodium (13.6 g, 591 mmol) in small pieces at such a 
rate as to maintain vigorous reflux (30 min). When all the sodium had dissolved, the 
mixture was cooled to 0°C and 5M HC1 (150 ml) was carefully added, causing the 
colour of the solution to change from colourless to blue to yellow. The reaction was 
heated to reflux for a further 30 min before allowing to cool to RT. The mixture was 
then extracted with Et20  (3 x 120 ml) and the combined organic layers washed with 
sat. aq. NaHCC>3 (100 ml) before removal of the solvent in vacuo. The crude ketone 
was then added to a vigorously stirred mixture of sat. aq. sodium bisulfite (100 ml) 
and EtOH (70 ml). After 30 min, stirring was stopped and the mixture allowed to 
stand for a futher 15 min. The white solid which formed was filtered off and washed 
with Et20  (3 x 50 ml), before redissolving in H20  (150 ml). An excess of solid 
Na2C0 3  was added with vigorous shaking and the mixture re-extracted with Et20  (3 
x 100 ml). The combined extracts were washed with H20  (3 x 150 ml), brine (100 
ml), dried (MgS0 4 ), filtered and concentrated in vacuo to afford the title product as a 
yellow liquid (6.56 g, 63%); Rf (50% EtOAc : 50% Hexanes): 0.60; vmax (film) 1713 
(C=0) c m 1; 8h (270 MHz; CDC13) 2.54 (2H, t, /  = 7.0, 3-CH2), 3.00 (2H, t, J  = 7.0, 
4 -CH2 ), 3.56 (2H, s, I-CH 2 ), 3.79 (3H, s, 7-OCH3), 6.68 (1H, d, J  = 2.6, 8-ArH),
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6.76 (1H, dd, J  = 8.4, 2.6, 6 -ArH), 7.14 (1H, d, J  = 8.4, 5-ArH); 6 C (67.8 MHz; 
CDC13) 27.18, 38.28, 44.90, 55.01, 112.02 (Ar-CH), 113.23 (Ar-CH), 128.25 (Ar- 
CH), 128.48 (Ar-C), 134.27 (Ar-C), 158.27 (Ar-C), 210.29 (C=0); El MS m/z 176 
(M+, 50%)
7-M ethoxy-3,4-dihydronaphthalen-2(l//)-one (35) - Method B
Freshly cut sodium (13.0 g, 565 mmol) in small pieces was added to a 
solution of 47 (13.3 g, 70.7 mmol) in anhydrous THF (180 ml) contained in a 1L 
round-bottomed flask at RT - moderate stirring was maintained throughout the 
addition to avoid clumping. The flask was then fitted with a pressure-equalising 
dropping funnel charged with EtOH (200 ml) and the system purged with nitrogen. 
The mixture was cautiously heated to 60°C and the ethanol added with vigorous 
stirring at such a rate as to maintain reflux (the rate of addition was slow at first as 
frothing tended to occur but as this subsided the rate was gradually increased -  total 
addition time 45 minutes). When the addition was complete, the reaction was 
maintained at reflux temperature until all the sodium had reacted. The system was 
then cooled to 0°C and aq. 5M HC1 (150 ml) was added as rapidly as possible 
(causing a colour change of colourless —> blue —> yellow), after which the mixture 
was heated to reflux for a further hour. The reaction was allowed to cool to RT and 
diethyl ether (400 ml) added. The resulting two-phase system was separated and the 
aqueous layer extracted with diethyl ether (2 x 200 ml). The combined organic 
layers were washed with water (2 x 200 ml) and concentrated in vacuo. The 
resulting orange oil was added to a vigorously stirred mixture of aq. sat. sodium 
metabisulfite (100 ml) and EtOH (70 ml) at 0°C. The mixture was stirred vigorously 
for 30 minutes then allowed to stand for a further 30 minutes. The bisulfite adduct 
was subsequently collected by suction filtration and repeatedly washed with diethyl 
ether until a clean white solid was obtained. The adduct was then dissolved in water 
(300 ml) and excess sodium carbonate added with vigorous stirring. The mixture 
was allowed to stir at RT for 30 minutes after which time a yellow oil had separated. 
The system was extracted with diethyl ether (3 x 150 ml) and the combined organic 
layers washed with water (3 x  200 ml), then dried (MgS0 4 ), filtered and 
concentrated in vacuo to afford the title product as a yellow liquid (11.8 g, 95%); See 
Method A for data.
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7-Methoxy-l,l-dimethyl-3,4-dihydronaphthalen-2(l//)-one (36) - Method A
To a stirred slurry of sodium hydride (2.61 g, 60 % dispersion in oil, 68.4 
mmol) in toluene (100 ml) at 0°C under an atmosphere of nitrogen was added a 
solution of 36 (4.02 g, 22.7 mmol) in toluene (15 ml) dropwise over 15 minutes via a 
syringe. Iodomethane (4.26 ml, 68.4 mmol) was then added dropwise and the 
mixture allowed to stir for 15 hours at RT. After this time the reaction was quenched 
by the cautious addition of sat. aq. NH4 CI (50 ml). Water (50 ml) was added and the 
layers separated. The aqueous layer was extracted with Et2 0  (2 x 70 ml) and the 
combined organic layers were washed with 1 0 % sodium bisulfite solution ( 2  x  80 
ml), brine (70 ml) and dried (MgSC>4 ). Filtration and evaporation of the solvent in 
vacuo gave a brown oil which was distilled under reduced pressure (b.p. 145-148 °C 
at 5 mmHg) to afford the title product as a colourless liquid (2.87 g, 62%); Rf (50% 
EtOAc : 50% Hexanes): 0.73; 6 H (270 MHz; CDC13): 1.43 (6 H, s, 2 x gem-CH3), 
2.66 (2H, t, J  = 6.4, 3-CH2), 3.04 (2H, t, /  = 6 .4 ,4-CH2), 3.82 (3H, s, 7-OCH3), 6.75 
(1H, dd, J  = 8.2, 2.7, 6 -ArH), 6 . 8 8  (1H, d, J  = 2.7, 8 -ArH), 7.10 (1H, d, /  = 8.2, 5- 
ArH); 6 C (70 MHz; CDCI3): 26.55, 27.49, 37.24, 47.63, 55.01, 111.14 (Ar-CH),
111.96 (Ar-CH), 127.15 (Ar-C), 128.83 (Ar-CH), 144.63 (Ar-C), 158.56 (Ar-C), 
214.47 (Ar-C); FAB MS m/z 204 (1VT, 100%)
7-Methoxy-l,l-dimethyl-3,4-dihydronaphthalen-2(l//)-one (36). Method B
To a stirred solution of ketone 35 (15.0 g, 85.1 mmol) and iodomethane (13.2 
ml, 213 mmol) in anhydrous THF (300 ml) at 0°C was added potassium tert- 
butoxide (26.8 g, 255 mmol) in small portions over 40 minutes. When the addition 
was complete, the system was purged with nitrogen and stirred at 0°C for 1 hour. 
The reaction was then allowed to warm to RT and stirred for a further 18 hours. Aq. 
2M HC1 (100 ml) was added cautiously to quench the reaction and the mixture 
stirred for 15 minutes. The THF was evaporated in vacuo and the resulting emulsion 
extracted with diethyl ether (3 x 150 ml). The combined organic layers were washed 
with aq. 2M sodium metabisulfite (200 ml) and water (200 ml), then dried (MgS0 4 ), 
filtered and concentrated in vacuo to afford the crude dimethylated ketone as a 
yellow liquid (21.4 g). See Method A for data. The ketone was immediately 
converted to oxime 37 without further purification.
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7-Methoxy-l,l-dimethyl-3,4-dihydronaphthalen-2(l//)-one oxime (37)
To a vigorously stirred solution of hydroxylamine hydrochloride (21.8 g, 314 
mmol) and sodium acetate (21.5 g, 262 mmol) in water (80 ml) at RT was added a 
solution of unpurified dimethylated ketone 36 (21.4 g, 105 mmol) in MeOH (80 ml). 
The reaction was heated at reflux for 3 hours then cooled to RT and stirred for a 
further 18 hours. The solid oxime which formed was collected by suction filtration, 
washed with ice-cold MeOH (2 x 20 ml) and dried in a vacuum desiccator to afford 
the title product as a white solid (15.0 g, 81% from 35); Rf (50% EtOAc: 50% 
Hexanes): 0.59; m.p. 140-142 °C; vmax (KBr) 1628 (C=N), 1386 (gem-(CH3)2) cm '1; 
8 h (270 MHz; CDC13): 1.50 (6 H, s, 2 x  gem-Od3), 2.79-2.92 (4H, m, 3-CH2 + 4- 
CH2), 3.81 (3H, s, 7 -OCH3 ), 6.71 (1 H, dd, J  = 8.4, 2.6, 6 -ArH), 6.94 (1H, d, /  = 2.6,
8 -ArH), 7.06 (1H, d, J  = 8.4, 5-ArH), 7.39 (1H, br-s, O-H); 8 C (70 MHz; CDC13): 
22.23, 27.05, 27.99, 41.20, 55.41, 111.13 (Ar-CH), 111.51 (Ar-CH), 128.62 (Ar-C), 
129.22 (Ar-CH), 145.07 (Ar-C), 158.61 (Ar-C), 165.10 (C=NOH); El MS m/z 219 
(M+, 65%)
7-Methoxy-l,l-dimethyl-l,2,3,4-tetrahydronaphthaIen-2-amine (38) -  Method A
To a stirred solution of 37 (1.30 g, 5.93 mmol) in 1,2-dimethoxyethane (20 
ml) at 0°C was added sodium borohydride (0.90 g, 23.7 mmol). The mixture was 
stirred at 0°C for 10 minutes under an atmosphere of nitrogen before the dropwise 
addition of 100% titanium (IV) chloride (1.3 ml, 11.9 mmol) via a syringe. The 
reaction was then heated to reflux for 15 hours after which time the mixture was 
cooled to 0°C and quenched by the cautious dropwise addition of H20  (20 ml). The 
solution was acidifed to pH 4 with aq. 2M HC1 and subsequently washed with CHCI3 
(3 x 50 ml). The aqueous layer was then basified to pH 10 with conc. NH4OH and 
extracted with CHCI3 (3 x 50 ml). The combined extracts were washed with water 
(2 x  80 ml), brine (70 ml), dried (MgS0 4 ), filtered and concentrated in vacuo to 
afford the title product as a colourless oil (0.70 g, 57%); Rf (10% MeOH: 89% 
CH2C12: 1% NH4 OH): 0.38; vmax (film) 1610 (N-H) cm '1; 8 H (270 MHz, CDC13):
1.23 (3H, s, gem-CH3), 1.33 (3H, s, gem-CH3), 1.68-1.82 (1H, m, 3-CH), 1.94 (1H, 
dtd, J  = 13.2, 7.3, 3.3, 3-CH), 2.76-2.85 (2H, m, 2-CH + 4-CH), 2.88 (1H, m, 4-CH),
3.79 (3H, s, 7-OCH3), 6 . 6 8  (1H, dd, J  = 8.4, 2.6, 6 -ArH), 6.89 (1H, d, J  = 2.6, 8 -
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ArH), 6.99 (1H, d, 7 =  8.4, 5-ArH); 8 C (70 MHz; CDC13): 24.85, 26.65, 27.57, 29.17, 
38.74, 55.03, 56.04, 111.00 (Ar-CH), 112.34 (Ar-CH), 126.89 (Ar-C), 129.52 (Ar- 
CH), 146.00 (Ar-C), 157.71 (Ar-C); El MS m/z (M*. 100%)
7-Methoxy-l,l-dimethyl-l,2,3,4-tetrahydronaphthaIen-2-amine (38) -  Method B 
To a stirred solution of zirconium (IV) chloride (0.72 g, 3.09 mmol) in 
anhydrous 1,2-dimethoxyethane (20 ml) at RT was added sodium borohydride (0.37 
g, 9.86 mmol) in small portions over 5 minutes. The flask was fitted with a pressure- 
equalising dropping funnel containing a solution of oxime 37 (0.54 g, 2.46 mmol) in 
anhydrous 1,2-dimethoxyethane (10 ml) and the system purged with nitrogen. The 
mixture was stirred for 1 0  minutes until the effervescence had subsided, after which 
the oxime solution was added in a dropwise fashion over 15 minutes. When the 
addition was complete, the reaction was heated to gentle reflux for 24 hours then 
allowed to cool to RT. An excess of sodium sulfate decahydrate was added (until a 
granular precipitate was obtained) to quench the reaction and the inorganic salts 
separated by suction filtration. The filter pad was washed with 1,2-dimethoxyethane 
(2 x 1 5  ml) and the filtrate concentrated in vacuo. The residue was redissolved in 5M 
HC1 in propan-2-ol (20 ml) and the solvent subsequently removed in vacuo to afford 
the amine hydrochloride as white crystals which were washed with EtOAc (2 x 15 
ml) and dried in a vacuum desiccator (0.41 g, 6 8 %). The free base was obtained by 
treating the hydrochloride with conc. NH4 OH and extracting with CHCI3 . See 
Method A for data.
2,7-Dimethoxynaphthalene (47) - Method A
To a stirred suspension of sodium hydride (15.0 g, 60% dispersion in mineral 
oil, 375 mmol) in anhydrous DMF (200 ml) at 0°C under an atmosphere of nitrogen 
was added a solution of 2,7-dihydroxynaphthalene (15.0 g, 93.7 mmol) in anhydrous 
DMF (60 ml) dropwise via syringe. The mixture was stirred at 0°C for 10 minutes 
before the dropwise addition of iodomethane (17.5 ml, 281 mmol), after which the 
reaction was allowed to warm to RT and stirred for 18 hours. The mixture was 
quenched by the very cautious (HIGHLY EXOTHERMIC!) addition of water (150 
ml) to the reaction mixture at 0°C. The resulting precipitate of 2,7- 
dimethoxynaphthalene was collected by suction filtration, washed with water (2 x  50
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ml) and dried overnight in a vacuum desiccator to give the title product as light pink 
crystals (15.1 g, 87%); Rf (50% EtOAc: 50% hexane): 0.71; m.p. 136-138 °C (Lit. 
138 °C); (KBr) 3058 (aromatic C-H), 2834 (OC-H) cm '1; 5H (270 MHz, CDC13): 
3.91 (6 H, s, 7-OCH3), 7.00 (2H, dd, J  = 8 .8 , 2.6, 3-ArH + 6 -ArH), 7.06 (2H, d, J  =
2.6, 1-ArH + 8 -ArH), 7.66 (2H, d, J  = 8 .8 , 4-ArH + 5-ArH); 6 C (70 MHz; CDC13): 
55.24 (2 x OCH3), 105.22 (Ar-C), 115.99 (Ar-CH), 124.23 (Ar-C), 129.12 (Ar-CH), 
135.89 (Ar-C), 158.04 (Ar-C); El MS m/z 188 (MH*,100%)
2,7-Dimethoxynaphthalene (47) - Method B
To a vigorously stirred solution of 2,7-dihydroxynaphthalene (23.1 g, 144 
mmol) in acetone (350 ml) at RT was added powdered potassium carbonate (59.8 g, 
433 mmol). The mixture was stirred for 5 minutes before dimethyl sulfate (41.0 ml, 
433 mmol) was added rapidly. The reaction was subsequently heated to reflux for 4 
hours then allowed to cool to RT. Aq. 4M KOH (300 ml) was cautiously added and 
the mixture stirred at RT for 30 minutes, after which time the acetone was evaporated 
in vacuo causing 2,7-dimethoxynaphthalene to precipitate out. The product was 
collected by suction filtration, washed with water (3 x  50 ml) and dried over 
phosphorus pentoxide to afford the title product as light brown crystals (2 2 . 0  g, 
81 %). See Method A for data.
3-(3-Nitrophenyl)acryIaldehyde (58)
To a stirred suspension of 3-nitrobenzaldehyde (5.00 g, 33.1 mmol) in 
acetaldehyde (15 ml) at 0°C was added a 25% solution of potassium hydroxide in 
MeOH dropwise until the solid dissolved. Acetic anhydride (25 ml) was added and 
the mixture heated at reflux for 1 hour. The reaction was then allowed to cool to RT 
before pouring into water (50 ml). The mixture was acidified by the addition of aq. 
5M HC1 (20 ml) and heated to reflux for a further 45 minutes, after which the flask 
was cooled in ice. The crystals which formed were collected by suction filtration and 
subsequently recrystallised from EtOH to afford the title product as fine yellow- 
brown crystals (1.81 g, 31%); Rf (40% CH2CI2 : 60% Hexanes): 0.34; vmax (KBr) 
1678 (unsat. C=0), 1524 and 1354 (N=0) cm '1, 5H (270 MHz, CDC13): 6.81 (1H, dd, 
J  = 16.1, 7.4, CH=CHCOH), 7.53 (1H, d, /  = 16.1, ArCH=CHCOH), 7.64 (1H, t, J  = 
7.9, Ar-H[<?-N02]), 7.88 ( 1 H, d, /  = 7.9, Ar-H[p-N02]), 8.28 ( 1 H, ddd, J  = 8.2, 2 .2 ,
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1.0, Ar-H[p-CH=CH]), 8.41 (IH, pseudo-l, J  = 1.8, Ar-H[o-N02 + o-CH=CH]), 9.76 
(lH ,d , 7 = 7.4, COH); 6 C (70 MHz; CDC13): 123.11, 125.37, 130.93, 133.64, 148.80, 
149.13, 192.93; FAB MS m/z 178 (MH+, 65%)
l,l-Dimethyl-2-{[(£')-3-(2-nitrophenyl)allyl]amino}-l^,3,4-tetrahydro 
naphthaIen-7-oI (59)
To a stirred solution of 23 (0.21 g, 1.09 mmol) in anhydrous CH2CI2 (10 ml) 
at RT was added 2-nitrocinnamaldehyde (0.29 g, 1.64 mmol). The reaction was 
stirred for 15 hours at RT after which time the solvent was removed in vacuo. The 
residue was redissolved in anhydrous MeOH (20 ml) and the solution cooled to 0°C. 
Sodium borohydride (0.17 g, 4.37 mmol) was added portionwise over 1 hour and the 
resulting mixture stirred for a further 15 hours at RT. The reaction was quenched by 
the dropwise addition of aq. 1M HC1 (15 ml) and the solution adjusted to pH 7 with 
aq. sat. NaHC03. The mixture was extracted with CH2CI2 (3 x 25 ml) and the 
combined extracts were washed with brine (40 ml), dried (MgS0 4 ), filtered and 
concentrated in vacuo. Column chromatography (30% EtOAc: 70% Hexanes) 
afforded the title product as a yellow foam (0.32 g, 83%); Rf (10% MeOH: 89% 
CH2C12: 1% NH4 OH): 0.40; vmax (film) 3324 (br, O-H), 1523 and 1345 (N=0) c m 1; 
8 h (270 MHz, CDC13): 1.22 (3H, s, gem-CH3), 1.35 (3H, s, gem-CH3), 1.62-1.78 
(1H, m, 3-CH), 2.02-2.12 (1H, m, 3-CH), 2.61 (1H, dd, J  = 9.6, 2.7, 2-CH), 2.72-
2.81 (2H, m, 4 -CH2 ), 3.44 (1H, ddd, J  = 14.2, 6.9, 1.2, NHCH2CH), 3.67 (1H, ddd, J  
= 14.2, 5.8, 1.7, NHCH 2CH), 6.29 (1H, dt, J  = 15.6, 5.7, CH2CH=CH), 6.56 (1H, dd, 
J  = 8.4, 2.6, 6 -CH), 6.79 (1H, d, /  = 2.6, 8 -CH), 6.90 (1H, d, J  = 8.4, 5-CH), 7.02 
(1H, d, J  = 15.6, CH2CH=CH), 7.35 (1H, ddd, J  = 8.2, 6.9, 2.0, Ar-H[p-CH=CH]), 
7.50-7.58 (2H, m, Ar-H|>CH=CH] + Ar-H[p-N02]), 7.89 (1H, dd, J  = 8.2, 1.2, Ar- 
H[0 -NO2]); 8 c (70 MHz; CDC13): 23.53, 25.64, 27.45, 29.41, 38.82, 50.08, 62.01, 
113.14 (Ar-CH), 113.40 (Ar-CH), 124.48 (Ar-CH), 126.34 (Ar-CH), 127.22 (Ar-C),
127.82 (Ar-CH), 128.62 (Ar-CH), 129.79 (Ar-CH), 132.21 (Ar-C), 133.00 (Ar-CH), 





To a stirred solution of 23 (82 mg, 0.43 mmol) in anhydrous CH2CI2 (2 ml) at 
RT was added aldehyde 58 (91 mg, 0.51 mmol). The reaction was stirred for 17 
hours under an atmosphere of nitrogen, during which time a cream precipitate of the 
imine formed. The solvent was evaporated in vacuo and the residue redissolved in 
4:1 MeOH: DMF (7 ml) and the solution cooled to 0°C. Sodium borohydride (65 
mg, 1.72 mmol) was added portionwise over 1 hour and the resulting mixture stirred 
for a further 15 hours at RT. The reaction was quenched by the dropwise addition of 
aq. 1M HC1 (15 ml) and the solution adjusted to pH 7 with aq. sat. NaHC0 3 . The 
mixture was extracted with CH2CI2 (3 x  15 ml) and the combined extracts were dried 
(MgS0 4 ), filtered and concentrated in vacuo. Column chromatography (30% 
EtOAc: 70% Hexanes) afforded the title product as a yellow oil (130 mg, 8 6 %); Rf 
(10% MeOH: 89% CH2C12: 1% NH4 OH): 0.34; 8 H (270 MHz, CDC13): 1.22 (3H, s, 
gem-CRi), 1.35 (3H, s, gem-CH3), 1.64-1.80 (1H, m, 3-CH), 2.00-2.12 (1H, m, 3- 
CH), 2.61 (1H, dd, J  = 9.7, 2.7, 2-CH), 2.66-2.88 (2H, m, 4-CH2), 3.26 (2H, br-s, N- 
H + O-H), 3.41 (1H, dd, J  = 14.6, 6.4, NHCH2CH), 3.66 (1H, ddd, J  = 14.6, 5.4, 1.0, 
NHCH 2CH), 6.45 (1H, dt, J  = 15.8, 5.9, CH2CH=CH), 6.56 (1H, dd, J  = 8.2, 2.7, 6 - 
CH), 6.61 (1H, d, J  = 15.8, CH2CH=CH), 6.78 (1H, d, /  = 2.5, 8 -CH), 6.89 (1H, d, J  
= 8.2, 5-CH), 7.44 (1H, t, J  = 7.9, Ar-H[m-N02]), 7.62 (1H, d, J  = 7.9, Ar-H[p- 
N 0 2]), 8.04 (1H, ddd, J  = 7.9, 2.0, 1.0, Ar-H[p-CH=CH]), 8.17 (1H, t, J  = 2.0); FAB 
MS m/z 353 (MH+, 100%); HRMS calc, for C21H25N2O3 353.1865, found 353.1875
1.1-Dimethyl-2-{[(£')-3-(4-nitrophenyl)allyl]amino}-l,2,3,4-tetrahydro 
naphthalen-7-ol (61)
The procedure used for the preparation of meta-NO2  analogue 60 was 
employed. Aminotetralin 23 (0.14 g, 0.73 mmol) was reacted with 4- 
nitrocinnamaldehyde (0.16 g, 0 . 8 8  mmol) and the resulting imine subsequently 
treated with sodium borohydride (0.11 g, 2.93 mmol). Column chromatography (1% 
MeOH: 98% CH2CI2 : 1% NH4OH) afforded the title product as a yellow oil (0.21 g, 
81%); Rf (10% MeOH: 89% CH2C12: 1% NH4 OH): 0.44; vmax (film) 3369 (br, O-H), 
1514 and 1343 (N=0) c m 1; 8 H (400 MHz, CDC13): 1.25 (3H, s, gem-CH3), 1.38 (3H,
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s, gem-CH3), 1.68-1.79 (1H, m, 3-CH), 2.03-2.11 (1H, m, 3-CH), 2.61 (1H, dd, 7  =
9.6, 2.8, 2-CH), 2.73 (1H, ddd, 7 =  15.6, 9.2, 5.6, 4-CH), 2.83 (1H, dt, 7 =  15.6, 5.6, 
4-CH), 3.44 (1H, ddd, 7 = 14.4, 6.4, 1.2, NHCH2CH), 3.69 (1H, ddd, 7 = 14.4, 5.6,
1.2, NHCH2CH), 6.52 (1H, dt, 7 = 16.0, 6.4, CH2CH=CH), 6.58 (1H, dd, 7  = 8.4,
2.8, 6 -CH), 6.63 (1H, d, 7 = 16.0, CH2CH=CH), 6.80 (1H, d, 7  = 2.0, 8 -CH), 6.90 
(1H, d, 7 = 8.4, 5-CH), 7.47 (2H, d-pseudo-t, J  = 8 .8 , 1.6, 2 x  Ar-H[o-CH=CH]),
8.15 (2H, d-pseudo-t, J  = 8 .8 , 1 .6 , 2 x  Ar-H[o-N02]); 5C (100 MHz; CDC13): 24.06,
26.08, 27.84, 29.83, 39.19, 50.44, 62.67, 113.35 (Ar-CH), 113.60 (Ar-CH), 124.21 
(Ar-CH), 126.90 (Ar-CH), 127.27 (Ar-C), 129.12 (Ar-CH), 129.99 (Ar-CH), 134.71 
(Ar-CH), 143.87 (Ar-C), 146.85 (Ar-C), 147.01 (Ar-C), 153.91 (Ar-C); FAB MS m/z 
353 (MIT, 45%); HRMS calc, for C2 iH25N20 3 353.1865, found 353.1883
2-{[3-(2-Aminophenyl)propyl]amino}-l,l-dimethyl-l,2,3,4-tetrahydro 
naphthalen-7-ol (62)
To a vigorously stirred solution of 59 (0.20 g, 0.57 mmol) in EtOH (25 ml) at 
RT was added Raney nickel (1 spatula). The mixture was stirred for 5 minutes 
before the dropwise addition of hydrazine hydrate (0.18 ml, 5.67 mmol). Stirring 
was continued for 15 hours at RT after which time the reaction mixture was filtered 
carefully through Celite® (ensuring that the catalyst remained moist at all times). 
The filter pad was washed with EtOH (50 ml) and the filtrate evaporated in vacuo. 
Column chromatography (6 % MeOH: 93 %DCM: 1% NH4 OH) afforded the title 
product as a colourless oil (0.15 g, 79%); Rf (10 % MeOH: 89 % DCM: 1 % 
NH4 OH) 0.26; (film) 1614 (N-H) c m 1; 6 H (270 MHz, CDC13): 1.19 (3H, s, gem- 
CH3), 1.30 (3H, s, gem-CH3), 1.62-1.75 (1H, m, 3-CH), 1.84 (2H, quint., 7 = 6.4, 
NHCH2CH2), 1.97-2.09 (1H, m, 3-CH), 2.53-2.67 (5H, m, 2-CH + NHCH2CH2 + 
CH2CH2Ar), 2.68-2.78 (1H, m, 4-CH), 2.80-2.93 (1H, m, 4-CH), 4.07 (4H, br s, N- 
H + O-H + NH2), 6.55 (1H, dd, 7 = 8.4, 2.5, 6 -ArH), 6.67 (1H, d, 7 = 7.9, A r-H |>  
NH2]), 6.73 (1H, d, 7 = 2.5, 8 -ArH), 6.76 (1H, d, 7 = 7.4, Ar-H[o-CH=CH]), 6.87 
(1H, d, 7 = 8.4, 5-ArH), 7.00-7.08 (2H, m, Ar-H[p-CH=CH] + Ar-H[p-NH2]); 8 C (70 
MHz; CDCI3): 23.11, 25.61, 27.10, 28.23, 29.53, 29.66, 38.51, 46.53, 62.88, 113.37 
(Ar-CH), 113.50 (Ar-CH), 115.83 (Ar-CH), 118.90 (Ar-CH), 126.51 (Ar-C), 126.64 
(Ar-C), 126.93 (Ar-CH), 129.56 (Ar-CH), 129.70 (Ar-CH), 144.35 (Ar-C), 146.37 
(Ar-C), 154.22 (Ar-C); FAB MS m/z 325 (MH+, 100 %); HRMS calc, for C2 iH2 9N20
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325.2280, found 325.2269; CHN calc. for C2 1 H23N2O.2 HCLl.5 H2O: C 59.4, H 7.84, 
N 6.60, found: C 59.3, H 7.53, N 6.53
lra/is-2-Am ino-3-m ethoxy-l,l-dim ethyl-l,2,3,4-tetrahydronaphthalen-7-ol (65)
To a stirred solution of 70 (1.11 g, 2.63 mmol) in CH2CI2 (20 ml) at RT was 
added trifluoroacetic acid (2.92 ml, 39.5 mmol) dropwise. The reaction was stirred 
for 18 hours then quenched by the dropwise addition of aq. sat. NaHC0 3  ( 2 0  ml). 
The aqueous layer was adjusted to pH 10 with conc. NH4 OH and the layers were 
separated. The aqueous layer was extracted with 3:1 CHCI3 : EtOH (2 x 25 ml) and 
the combined organic layers were dried (MgS0 4 ), filtered and concentrated in vacuo 
to afford the title product as an off-white solid (0.58 g, 100%); Rf (10% MeOH: 89% 
CH2C12: 1% NH4OH): 0.15; vmax (film) 3294 (O-H), 1582 (N-H) cm '1; 8 H (270 MHz, 
CDCI3 ): 1.15 (3H, s, gem-CH3), 1.38 (3H, s, gem-CH3), 2.56 (1H, dd, 7 =  15.6, 9.9, 
4-CH), 2.84 (1H, d, J  = 10.1, 2-CH), 3.22 (1H, dd, J  = 15.6, 5.4, 4-CH), 3.37 (1H, 
td, J  = 9.9, 5.4, 3-CH), 3.46 (3H, s, 3-OCH3), 6.61 (1H, dd, J  = 8.2, 2.5, 6 -ArH), 
6.78 (1H, d, J  = 2.5, 8 -ArH), 6 . 8 8  (1H, d, J  = 8.2, 5-ArH); 8 c (70 MHz, CDC13): 
25.22, 27.49, 33.56, 40.00, 56.13, 60.25, 77.00, 112.79 (Ar-CH), 113.58 (Ar-CH),
122.82 (Ar-C), 129.61 (Ar-CH), 145.16 (Ar-C), 154.56 (Ar-C); FAB MS m/z 222 
(MH+, 100%); HRMS calc, for C 13H20NO2 222.1494, found 222.1506; CHN calc, for 
C 13H 19NO2 .HCLl.5 H2O: C 54.8, H 8.14, N 4.92, found: C 55.0, H 7.75, N 4.90
(3R)-7-Hydroxy-iV-[(lS)-l-({[/ra/is-7-hydroxy-3-methoxy-l,l-dimethyl-l,2,3,4- 
tetrahydronaphthalen-2-yl]amino}methyl)-2-methyIpropyI]-l,2,3,4-tetrahydro 
isoquinoline-3-carboxamide (6 6 )
To a stirred solution of 82 (0.22 g, 0.38 mmol), Boc-D-Tic(OH)-OH (0.23 g, 
0.42 mmol), 1 -hydroxybenzotriazole hydrate (0.11 g, 0.42 mmol) and triethylamine 
(0.21 ml, 1.51 mmol) in 30:1 CH2CI2 : DMF (15 ml) at 0°C was added l-(3- 
dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.17 g, 0.45 mmol) 
portion wise over 10 minutes. The reaction was stirred at 0°C for 1 hour then at RT 
for 15 hours. Water (10 ml) and CHCI3 (15 ml) were added and the layers separated. 
The aqueous layer was extracted with CHCI3 (2 x 20 ml), and the combined organic 
layers were dried (Na2S0 4 ), filtered and concentrated in vacuo. Column 
chromatography (1-3% MeOH: CH2CI2 : 1% NH4 OH) afforded the amide as a
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colourless foam (0.30 g). *H NMR showed the presence of a small amount of side 
product, therefore Boc-deprotection was carried out without further purification. The 
amide was redissolved in CH2CI2 (20 ml) and trifluoroacetic acid (0.38 ml, 5.16 
mmol) was added dropwise at RT. The reaction was stirred at RT for 18 hours, then 
quenched by the cautious addition of aq. sat. NaHCC>3 (15 ml). The aqueous layer 
was further basified (to pH 9) with conc. NH4 OH, then the layers were separated. 
The aqueous layer was extracted with 4:1 CHCI3 : EtOH (2 x 30 ml), and the 
combined organic layers were washed with brine (15 ml), dried (MgS0 4 ), filtered 
and evaporated to afford the title product as a colourless oil (0.25 g, 72% over two 
steps); Rf (10% MeOH: 89% CH2C12: 1% NH4 OH): 0.13; 5H (400 MHz, CD3 OD): 
0.90 (3H, d, J  = 7.2, Val-CH3 CHCH3), 0.92 (3H, d, J  = 6.4, Val-CH3 CHCH3), 1.06 +
1.09 (3H, s, diast. gem-CH3), 1.28 + 1.29 (3H, s, diast. g£m-CH3), 1.81 + 1.88 (1H, 
oct., J  = 6 .8 , diast. Val-CH3CHCH3), 2.37 + 2.40 ( 1 H, d, J  = 9.6, diast. 2-CH), 2.56 
(1H, m, Tic-CHCH2Ar), 2.64-2.76 (2H, m, 4-CH + Val-NHCH2CH), 3.00-3.11 (2H, 
m, Val-NHCH2CH + Tic-CHCH2Ar), 3.18 + 3.19 (1H, d-pseudo-t,, J  = 15.6, 6.0, 4- 
CH), 3.40 (4H, m, diast. 3-OCH3  + 3-CH), 3.47 (1H, ddd, J  = 10.8, 4.8, 1.6, Val- 
CH2CHNH), 3.65-3.82 (1H, m, Tic-NHCOCHCH2), 3.89 (2H, s, Tic-NHCH2Ar), 
6.48 (1H, d, /  = 2.4, Tic-ArH), 6.57 + 6.58 (1H, dd, J  = 8.4, 2.4, diast. 6 -ArH), 6.62 
(1H, dt, J  = 8.4, 2.4, Tic-ArH), 6.71 + 6.73 (1H, d, J  = 2.4, diast. 8 -ArH), 6.82 + 
6.84 (1H, d, J  = 8.4, diast. 5-ArH), 6.93 (1H, d, /  = 8.4, Tic-ArH); 6 c (100 MHz, 
CDCI3): 18.12, 18.76, 19.15 + 19.34 (diast), 26.13 -1- 26.19 (diast), 27.99, 30.11 + 
30.36 (diast), 30.45 + 30.56 (diast), 34.72 + 34.78 (diast.), 41.12 + 41.21 (diast),
47.23 + 47.32 (diast), 53.36 + 53.60 (diast), 54.62 + 55.08 (diast.), 56.60 + 56.76 
(diast), 68.18 + 68.43 (diast.), 78.45 + 78.68 (diast.), 112.06 + 112.09 (diast Ar- 
CH), 112.92 + 112.95 (diast. Ar-CH), 113.63 (Ar-CH), 113.93 (Ar-CH), 123.08 +
123.18 (diast Ar-C), 124.75 + 124.80 (diast. Ar-C), 129.81 (Ar-CH), 129.93 +
129.97 (diast Ar-CH), 136.42 + 136.50 (diast. Ar-C), 146.15 + 146.21 (diast Ar-C),
154.98 + 155.06 (diast Ar-C), 173.71 + 173.91 (diast C=0); FAB MS: submitted; 
CHN: submitted
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7-M ethoxy-l,l-dim ethyl-l,2,3,4-tetrahydronaphtho[2,3]azirene (67)
To a stirred solution of sodium bis(2-methoxyethoxy)aluminium hydride 
(14.1 ml, 3.5M solution in toluene, 49.3 mmol) in anhydrous THF (60 ml) at RT was 
added Af-methylbutylamine (0.15 ml, 1.23 mmol). The flask was fitted with a 
pressure-equalising dropping funnel containing a solution of oxime 37 (2.70 g, 12.3 
mmol) in anhydrous THF (30 ml) and the system purged with nitrogen. The oxime 
solution was subsequently added dropwise to the flask at RT over 30 minutes, after 
which the reaction was allowed to stir for 15 minutes until the evolution of hydrogen 
had ceased. The mixture was heated to reflux for 18 hours then allowed to return to 
RT. Sodium sulfate decahydrate was added (initially in small portions) until a 
granular precipitate of metal salts was obtained. The salts were separated by suction 
filtration and washed with THF (2 x 20 ml). The filtrate was then concentrated in 
vacuo to yield a brown oil. Column chromatography (1-2% MeOH: CH2 CI2 : 1% 
NH4 OH) afforded the title product as a yellow oil (1.93 g, 74%); Rf (10% MeOH: 
89% DCM: 1% NH4 OH) 0.51; vmax (film) 3236 (O-H) cm '1; 8 H (270 MHz, CDC13):
1.23 (3H, s, gem-CH3), 1.51 (3H, s, gem-CH3), 2.12 (1H, d, J  = 6.2, 2-CH), 2.47 
(1H, d, J  = 6.2, 3-CH), 3.14 (2H, s, 4-CH2), 3.78 (3H, s, 7-OCH3), 6.69 (1H, dd, /  =
8.2, 2.5, 6 -CH), 6.85 (1H, d, J  = 2.5, 8 -CH), 6.96 (1H, d, /  = 8.2, 5-CH); 5C (67.8 
MHz; CDCI3) 26.90, 29.36, 29.49, 29.54, 35.94, 41.31, 55.09, 111.38 (Ar-CH),
111.81 (Ar-CH), 122.58 (Ar-C), 130.43 (Ar-CH), 142.83 (Ar-C), 158.64 (Ar-C); El 
MS m/z 203 (M+, 60%)
1,1 -Dimethyl-1,2,3,4-tetrahydronaphtho[2,3]aziren-7-ol (6 8 )
To a stirred solution of methyl ether 67 (2.94 g, 14.5 mmol) in CH2CI2 (70 
ml) at -78°C under an atmosphere of nitrogen was added boron tribromide (28.9 ml, 
1.0M solution in CH2CI2 , 28.9 mmol) dropwise via a syringe. When the addition 
was complete, the cooling bath was removed and the reaction was stirred for 18 
hours. After this time the system was cooled to -78°C and quenched by the dropwise 
addition of a solution of triethylamine (10 ml) in MeOH (40 ml) via syringe, 
maintaining an atmosphere of nitrogen throughout. The system was allowed to 
return to RT and the solvent evaporated in vacuo. The resulting residue was 
partitioned between water (40 ml) and 3:1 CHCI3 : EtOH (80), and the layers were 
separated. The aqueous layer was extracted with 3:1 CHCI3 : EtOH (2 x 80 ml) and
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the combined organic extracts were washed with water (70 ml), dried (MgSC>4 ), 
filtered and concentrated in vacuo. Column chromatography (2-5% MeOH: CH2CI2 : 
1% NH4 OH) afforded the title product as a brown foam (2.16 g, 79%); Rf (10% 
MeOH: 89% DCM: 1% NH4 OH) 0.39; vmax (film) 3284 (br, O-H) cm '1; 8 H (270 
MHz, CDCI3): 1.21 (3H, s, gem-CH3), 1.45 (3H, s, gem-CH3), 2.16 (1H, d, J  = 6.2, 
2-CH), 2.51 (1H, d , /  = 6.2, 3-CH), 3.07 (1H, d d , /=  15.3, 1.7,4-CH), 3.15 (1H, dd, 
J  = 15.3, 1.7, 4-CH), 6.55 (1H, dd, J  = 8.2, 2.5, 6 -CH), 6.71 (1H, d, J  = 2.5, 8 -CH),
6.82 (1H, d, J  = 8.2, 5-CH); 8 c (70 MHz; CDC13): 27.18, 28.87, 29.59, 30.63, 35.84,
42.09, 113.14 (Ar-CH), 114.68 (Ar-CH), 119.93 (Ar-C), 130.90 (Ar-CH), 141.82 
(Ar-C), 156.92 (Ar-C); El MS m/z 189 (M+, 20%)
terf-Butyl-7-[(terf-butoxycarbonyl)oxy]-l,l-dimethyl-l,2,3,4-tetrahydronaphtho 
[2,3]azirene-l-carboxylate (69)
To a stirred solution of 6 8  (0.70 g, 3.70 mmol), 4,4-dimethylaminopyridine 
(60 mg, 0.37 mmol) and triethylamine (1.04 ml, 7.40 mmol) in CH2CI2 (20 ml) at RT 
was added di-terf-butyl dicarbonate (2.42 g, 11.1 mmol) in one portion. The reaction 
was stirred at RT for 5 hours, after which time water (15 ml) was added and the 
layers separated. The aqueous layer was extracted with CH2CI2 (2 x 30 ml) and the 
combined organic layers were washed successively with aq. 1M HC1 (40 ml) and aq. 
sat. NaHCC>3 (40 ml), then dried (MgS0 4 ), filtered and concentrated in vacuo. 
Column chromatography (10% EtOAc: 90% Hexanes) afforded the title product as a 
colourless platelets (0.51 g, 65%); Rf (50% EtOAc: 50% Hexanes): 0.70; m.p. 183- 
184 °C; vmax (film) 1757 (ester C=0), 1716 (carb. C=0) cm '1; 8 H (270 MHz, CDC13):
1.18 (3H, s, gem-CH3), 1.38 (9H, s, NBoc-(CH3)3), 1.44 (3H, s, gem-CH3), 1.52 (9H, 
s, OBoc-(C H 3)3), 2.52 (1H, d, /  = 6.7, 2-CH), 2.94 (1H, m, 3-CH), 3.02 (1H, dd, J  =
15.6, 1.5, 4-CH), 3.27 (1H, d, J=  15.6, 2 .2 ,4-CH), 6.92 (1H, dd, J  = 8.2, 2.5, 6 -CH),
6.98 (1H, d, J  = 8.2, 5-CH), 7.05 (1H, d, J  = 2.5, 8 -CH); 8 C (70 MHz, CDC13): 18.96, 
22.84, 24.06, 24.22, 25.25, 25.58, 27.92, 31.88, 33.12, 43.81, 77.00 (Boc-C), 79.50 
(Boc-C), 114.70 (Ar-CH), 115.54 (Ar-CH), 124.57 (Ar-C), 126.48 (A-CH), 139.61 
(C=0), 146.42 (C=0); FAB MS m/z 390 (MH+,40%)
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frflHs-2-[(te7*-Butoxycarbonyl)aimno]-3-methoxy-l,l-cIiiiiethyl-l,2,3,4- 
tetrahydro naphthalen-7-yl-terf-butyl carbonate (70)
To a stirred solution of 69 (0.52 g, 1.34 mmol) in MeOH (10 ml) at RT was 
added pyridinium p-toluenesulfonate (0.17 g, 0.68 mmol). The mixture was stirred 
at RT for 15 h under an atmosphere of nitrogen, after which time the solvent was 
evaporated in vacuo. Water (10 ml) and CH2CI2 (30 ml) were added to the residue 
and the layers separated. The aqueous layer was extracted with CH2CI2 ( 2  x  30 ml). 
The combined organic extracts were washed with water (50 ml) and brine (40 ml), 
then dried (MgS0 4 ), filtered and concentrated in vacuo. Column chromatography 
(10% EtOAc: 90% Hexanes) afforded the title product as a light yellow oil (0.45 g, 
80%); Rf (50% EtOAc: 50% Hexanes): 0.59; Vmax (film) 1757 (ester C=0), 1704 
(carb. C=0) cm '1; 8 H (270 MHz, CDC13): 1.12 (3H, s, gem-CH3), 1.32 (3H, s, gem- 
CH3), 1.41 (9H, s, NBoc-(CH3)3), 1.50 (9H, s, OBoc-(CH3)3), 2.78 (1H, dd, J  = 16.3,
8.9, 4-CH), 3.20 (1H, dd, J  = 16.3, 5 .4 ,4-CH), 3.38 (3H, s, 3-OCH3), 3.40-3.48 (1H, 
m, 3-CH), 3.79 (1H, t, J  = 9.6, 2-CH), 4.46 (1H, d, J  = 9.6, N-H), 6.92 (1H, dd, J  =
8.2, 2.2, 6 -CH), 6.99 (1H, d, J  = 8.2, 5-CH), 7.04 (1H, d, /  = 2.2, 8 -CH); 8 C (70 
MHz, CDCI3 ): 15.19, 22.01, 28.70, 29.42, 35.39, 41.00, 57.44, 59.86, 77.00, 77.90 
(Boc-C), 84.32 (Boc-C), 120.21 (Ar-CH), 120.38 (Ar-CH), 130.81 (Ar-C), 130.92 




The procedure used for the preparation of ortho-NO2 compound 59 was 
employed. Aminotetralin 65 (69 mg, 0.31 mmol) was treated with trans- 
cinnamaldehyde (47 pi, 0.37 mmol) and sodium borohydride (47 mg, 1.23 mmol). 
Column chromatography (3% MeOH: 96% CH2CI2 : 1% NH4 OH) afforded the title 
product as a colourless oil ( 8 6  mg, 82%); Rf (10% MeOH: 89% CH2CI2 : 1% 
NH4OH): 0.26; vmax (film) 3327 (O-H) cm '1; SH (270 MHz, CDC13): 1.18 (3H, s, 
gem-CH3), 1.38 (3H, s, gem-CH3), 2.59 (1H, d, /  = 9.9, 2-CH), 2.66 (1H, dd, /  =
15.6, 9 .6 ,4-CH), 3.25 (1H, dd, / =  15.6, 5 .4 ,4-CH), 3.48 (3H, s, 3-OCH3), 3.48-3.58 
(2H, m, 3-CH + NHCH2CH), 3.73 (2H, dd, /  = 13.6, 6.2, NHCH 2CH), 6.33 (1H, dt, 
J  = 15.8, 6.2, CH2CH=CH), 6.54 (1H, d, J  = 15.8, CH=CHPh), 6.61 (1H, dd, J  =
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8.2, 2.5, 6 -ArH), 6.78 (1H, d, /  = 2.5, 8 -ArH), 6.90 (1H, d, J  = 8.2, 5 -ArH), 7.15- 
7.37 (5 H, m, 5  x  Ar-H); 8 C (70 MHz, CDC13): 24.82, 26.61, 33.28, 39.54, 52.43,
55.17, 65.43, 77.00, 111.70 (Ar-CH), 112.17 (Ar-CH), 122.78 (Ar-C), 124.67 (Ar- 
CH), 125.64 (Ar-CH), 126.89 (Ar-CH), 127.61 (Ar-CH), 128.39 (Ar-CH), 129.53 
(Ar-CH), 135.88 (Ar-C), 145.02 (Ar-C), 152.98 (Ar-C); FAB MS m/z 338 (MH+, 
80%); HRMS calc, for C22H28NO2 338.2120, found 338.2119; CHN anal. calc, for 
C22H27NO2.HCLO.5H2O: C 69.0, H 7.63, N 3.66, found: C 6 8 .6 , H 7.71, N 3.96
frYZ7is-2 -[(CycIopropyImethyl)amino]-3 -m ethoxy-l,l-dim ethyl-l,2 ,3 ,4 -tetrahydro 
naphthalen-7-ol (75)
To a stirred solution of 65 (0.24 g, 1.08 mmol) in 4:1 1,2-dichloroethane: 
DMF (15 ml) at RT was added cyclopropanecarboxaldehyde (0.12 ml, 1.63 mmol). 
This was followed immediately by the addition of sodium triacetoxyborohydride 
(0.34 g, 1.63 mmol) in one portion. The reaction was stirred at RT under an 
atmosphere of nitrogen for 16 hours, after which it was quenched by the dropwise 
addition of aq. sat. NaHC03 (10 ml). After the effervescence had subsided, the two- 
phase system was separated and the aqueous layer extracted with CHC13 (2 x  20 ml). 
The combined organic layers were washed with water (30 ml), then dried (MgSCU), 
filtered and concentrated in vacuo. Column chromatography (2-4% MeOH: CH2CI2 : 
1 % NH4 OH) afforded the title product as a yellow oil which solidified on standing 
(70 mg, 23%); Rf (10% MeOH: 89% CH2C12: 1% NH4 OH): 0.30; m.p. 120-122 °C; 
vmax (KBr) 3327 (O-H), 2819 (COCH3) cm '1; 8 H (400 MHz, CDC13): 0.13 (2H, m, 
CH(CH2)2), 0.46 (2 H, m, CH(CH2)2), 1 . 0 1  ( 1 H, m, CH(CH2)2), 1.18 (3H, s, gem- 
CH3), 1.38 (3H, s, gem-CH3), 2.49 (1H, d, J  = 9.6, 2-CH), 2.59-2.66 (2H, m, 
CH 2CH(CH2) 2 + 4-CH), 2.71 ( 1 H, dd, /  = 1 1 .6 , 7.2, CH 2CH(CH2)2), 3.23 ( 1 H, dd, J  
= 16.0, 5.6, 4-CH), 3.44 (3H, s, 3-OCH3), 3.50 (1H, td, J  = 9.6, 5.2, 3-CH), 3.96 
(2H, br-s, NH + OH), 6.61 (1H, dd, J  = 8.4, 2.6, 6 -ArH), 6.77 (1H, d, /  = 2.6, 8 - 
ArH), 6 . 8 8  (1H, d, /  = 8.4, 5-ArH); 8 C (100 MHz, CDC13): 0.00, 0.37, 8.40, 23.20, 
24.99, 31.51, 53.41, 54.31, 64.68, 75.17, 110.04 (Ar-CH), 110.59 (Ar-CH), 120.63 
(Ar-C), 126.72 (Ar-CH), 143.31 (Ar-C), 151.44 (Ar-C); FAB MS m/z 277 (MH+, 
100%); HRMS submitted; CHN calc, for C 17H25NO2 .HCI: C 65.5, H 8.40, N 4.49, 
found: C 65.1, H 8.61, N 4.12
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/ra/is-2-(Allylamino)-3-methoxy-l,l-dimethyl-l,2,3,4-tetrahydroiiaphthalen-7-ol 
(76) and tozjf5-2-(diallylamino)-3-methoxy-l,l-dimethyl-l,2,3,4-tetrahydro 
naphthalen-7-ol (77)
To a stirred solution of 65 (0.29 g, 1.31 mmol) and allyl bromide (0.16 ml,
2.10 mmol) in anhydrous THF (15 ml) at RT was added sodium carbonate (0.25 g, 
3.28 mmol) and tetra-n-butylammonium iodide (97 mg, 0.26 mmol). The reaction 
was heated to reflux under an atmosphere of nitrogen for 24 hours, then allowed to 
cool to RT. The solvent was evaporated in vacuo and the residue partitioned 
between CHCl3 ( 2 0  ml) and water (15 ml). The layers were separated and the 
aqueous layer extracted with CHCI3 (2 x 20ml). The combined organic layers were 
dried (MgSCU), filtered and concentrated in vacuo to yield a yellow oil. Column 
chromatography (0-5% MeOH: CH2CI2 : 1% NH4 OH) afforded firstly dialkylated 
product 57 as a yellow oil which solidified on standing (0.14 g, 35%); Rf (10% 
MeOH: 89% CH2C12: 1% NH4 OH): 0.68; m.p. 127-128 °C; vmax (KBr) 3355 (O-H) 
cm '1; 8 h (400 MHz, CDC13): 1.14 (3H, s, gem-CH3), 1.34 (3H, s, gem-CH3), 2.63 
(1H, dd, J  = 15.2, 10.0, 4-CH), 2.79 (1H, d, J  = 10.4, 2-CH), 3.27 (1H, dd, J  = 15.2,
5.6, 4-CH), 3.31-3.38 (4H, m, 2 x  CH2CH=CH2), 3.43 (3H, s, 3-OCH3), 3.67 (1H, 
td, J  = 10.4, 5.6, 3-CH), 5.03 (2H, d, J  = 9.6, 2 x CH2CH=CH2), 5.16 (2H, br-d, J  =
16.2, 2 x  CH2CH=CH2), 5.86 (1H, ddt, J  = 16.2, 10.4, 6.0, CH2CH=CH2), 6.59 ( 1 H, 
dd, J  = 8.2, 2.4, 6 -ArH), 6.76 (1H, d, /  = 2.4, 8 -ArH), 6.89 (1H, d, J  = 8.2, 5-ArH); 
5C (100 MHz, CDCI3): 27.22, 29.38, 30.96, 35.87, 42.20, 55.79, 67.43, 76.50, 113.32 
(Ar-CH), 115.66 (broad: CH=CH2 + Ar-CH), 124.58 (Ar-C), 129.83 (Ar-CH), 
138.35 (CH=CH2), 147.73 (Ar-C), 153.97 (Ar-C); FAB MS m/z 301 (M+, 100%); 
HRMS submitted; CHN calc, for C 19H27NO2 .HCI.O.2 5 H2O: C 66.7, H 8.39, N 4.09, 
found: C 6 6 .8 , H 8.24, N 4.11
Continued elution afforded monoalkylated product 56 as a yellow oil which 
solidified on standing (0.17 g, 50%); Rf (10% MeOH: 89% CH2C12: 1% NH4 OH): 
0.36; m.p. 105-107 °C; vmax (KBr) 3415 (O-H) c m 1; 5H (400 MHz, CDC13): 1.16 
(3H, s, gem-CH3), 1.36 (3H, s, gem-CH3), 2.54 (1H, d, /  = 9.6, 2-CH), 2.64 (1H, dd, 
J  = 15.6, 9.6, 4-CH), 3.23 (1H, dd, J  = 16.0, 5.6, 4-CH), 3.34 (1H, dd, J  = 14.0, 6.4, 
CH 2CH=CH2), 3.45 (3H, s, 3-OCH3), 3.48 (1H, td, J  = 10.0, 5.6, 3-CH), 3.57 (1H, 
dd, J  = 14.0, 6.4, CH 2CH=CH2), 5.06 (1H, dd, J  = 10.4, 1.4, CH2CH=CH2), 5.20
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( 1 H, dd, J  = 17.6, 1.4, CH2CH=CH2), 5.95 (1H, ddt, J  = 17.4, 10.4, 6.0, 
CH2CH=CH2), 6.60 (1H, dd, J  = 8.2, 2.8, 6 -ArH), 6.77 (1H, d, J  = 2.8, 8 -ArH), 6.89 
(1H, d, J  = 8.2, 5-ArH); 6 C (100 MHz, CDC13): 26.36, 28.14, 34.78, 41.04, 54.56,
56.70, 66.94, 78.46, 113.20 (Ar-CH), 113.64 (Ar-CH), 115.79 (CH=CH2), 124.17 
(Ar-C), 129.96 (Ar-CH), 137.49 (CH=CH2), 146.67 (Ar-C), 154.34 (Ar-C); FAB MS 
m/z 263 (MH+, 100%); HRMS submitted; CHN calc, for Ci6H23NO2.HC1.0.25H2O: C
63.6, H 8.17, N 4.63, found: C 63.5, H 8.05, N 4.66
/raws-3-Methoxy-l,l-Dimethyl-2-(propylamino)-l,2,3,4-tetrahydro 
naphthalen-7-ol (78)
To a stirred solution of 65 (0.19 g, 0.86 mmol) and 1-bromopropane (94 pi,
I.03 mmol) in anhydrous THF (10 ml) at RT was added sodium carbonate (0.23 g,
2.15 mmol) and tetra-n-butylammonium iodide (0.16 g, 0.26 mmol). The reaction 
was heated at reflux under an atmosphere of nitrogen for 44 hours, before the 
addition of further sodium carbonate (0.14 g, 0.86 mmol) and 1-bromopropane (78 
pi, 0.86 mmol). Heating was continued for a further 24 hours, after which the 
reaction was allowed to return to RT. The solvent was removed in vacuo and the 
residue was partitioned between water (20 ml) and CHC13 (30 ml). The layers were 
separated and the aqueous layer was extracted with CHC13 (2 x 30 ml). The 
combined organic layers were washed with brine (20 ml), dried (MgSCU), filtered 
and concentrated in vacuo. Column chromatography (2-3% MeOH: CH2C12: 1% 
NH4 OH) afforded a yellow oil (0.18 g) which was shown by NMR to be a mixture of 
the product and tetra-n-butylammonium iodide. The crude product was subsequently 
redissolved in EtOAc (50 ml) and washed with water (3 x 20 ml) and brine (20 ml). 
The organic layer was dried (MgS0 4 ), filtered and concentrated in vacuo to afford 
the pure title product as a colourless oil which solidified on standing (93 mg, 43%); 
Rf (10% MeOH: 89% CH2C12: 1% NH4 OH): 0.21; m.p. 116-118 °C; (KBr) 3415 
(O-H) c m 1; 8 H (400 MHz, CDC13): 0.92 (3H, t, /  = 7.2, CH2CH2CH3), 1.16 (3H, s, 
gem-CH3) , 1.37 (3H, s, gem-CH3), 1.53 (2H, sext. d, J  = 7.6, 1.6, CH2CH2 CH3), 
2.51 (1H, d,J =  10.0, 2-CH), 2.65 (2H, m, CH 2CH2CH3 + 4-CH), 2.89 (1H, ddd, J  =
II.2 , 8.0, 6.4, CH 2CH2CH3), 3.23 (1H, dd, J  = 16.0, 5.6, 4-CH), 3.44 (3H, s, 3- 
OCH3), 3.50 (1H, td, J  = 9.6, 5.6, 3-CH), 4.11 (2H, br-s, NH + OH), 6.60 (1H, dd, /  
= 8.0, 2.4, 6 -ArH), 6.77 (1H, d, J  = 2.4, 8 -ArH), 6 . 8 8  (1H, d, J  = 8.0, 5-ArH); 8 C
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(100 MHz, CDCI3): 11.78, 23.53, 26.38, 28.27, 34.66, 41.00, 54.33, 56.58, 68.20,
78.14, 113.23 (Ar-CH), 113.80 (Ar-CH), 123.79 (Ar-C), 129.90 (Ar-CH), 146.49 
(Ar-C), 154.66 (Ar-C); FAB MS m/z 265 (MH+, 100%); HRMS submitted; CHN 




To a stirred solution of 65 (0.12 g, 0.54 mmol) and l-bromo-3-phenylpropane 
(0.27 ml, 1.36 mmol) in anhydrous THF (7ml) was added sodium carbonate (0.23 g,
2.17 mmol) and tetra-n-butylammonium iodide (0.10 g, 0.27 mmol). The reaction 
was heated at reflux under an atmosphere of nitrogen for 60 hours then allowed to 
cool to RT. The solvent was evaporated in vacuo and the residue redissolved in 
EtOAc (40 ml). It was then subsequently washed with water (3 x  20 ml), brine (20 
ml), dried (MgSCU), filtered and concentrated in vacuo. Column chromatography 
(2% MeOH: 97% CH2CI2 : 1% NH4 OH) afforded the title product as a yellow oil 
(0.10 g, 54%); vmax (film) 3328 (O-H) cm '1; SH (400 MHz, CDC13): 1.16 (3H, s, gem- 
CH3), 1.36 (3H, s, gem-CH3), 1.84 (2H, quint., 7 = 7.2, CH2CH2CH2), 2.49 (1 H, d, 7 
= 10.0, 2-CH), 2.61-2.71 (3H, m, O ^C H iP h  + 4-CH), 2.74 (1H, dt, 7 = 11.4, 7.2, 
CH 2CH2CH2), 2.97 ( 1 H, d t,7 =  11.4, 7.2, CH 2CH2CH2), 3.22 (1 H, dd ,7  = 16.0, 5.6,
4-CH), 3.45 (3H, s, 3-OCH3), 3.47 (1H, td, 7 = 10.0, 5.6, 3-CH), 6.60 (1H, dd, 7 =
8.4, 2.6, 6 -ArH), 6.77 (1H, d, 7 = 2.6, 8 -ArH), 6.90 (1H, d, 7 = 8.4, 5-ArH), 7.15-
7.20 (3H, m, 2 x  Ar-H[m-CH2CH2] + Ar-H[p-CH2CH2]), 7.27 (2H, m, 2 x  Ar-H[o- 
CH2CH2]); 6 c (100 MHz, CDC13): 26.38, 28.29, 32.39, 33.62, 34.72, 41.09, 51.79, 
56.60, 68.01, 78.29, 113.20 (Ar-CH), 113.64 (Ar-CH), 124.13 (Ar-C), 125.63 (Ar- 
CH), 128.24 (Ar-CH), 128.37 (Ar-CH), 129.93 (Ar-CH), 142.73 (Ar-C), 146.73 (Ar- 
C), 154.37 (Ar-C); FAB MS m/z 340 (MH+, 100%); HRMS submitted; CHN calc, for 
C2 2H29N 0 2 .HC1.H20 : C 67.1, H 8.19, N 3.56, found: C 67.4, H 8.04, N 3.48
terf-Butyl-(lS)-l-({[/ra/fs-7-hydroxy-3-methoxy-l,l-dimethyl-l,2,3,4-tetrahydro 
naphthalen-2 -yl]amino}carbonyl)-2 -methylpropylcarbamate (80)
To a stirred solution of 65 (0.45 g, 2.03 mmol) and Boc-L-valine (0.53 g,
2.44 mmol) in anhydrous THF (70 ml) at RT was added benzotriazol-1-
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yloxytris(dimethylamino)-phosphonium hexafluorophosphate (1.08 g, 2.44 mmol) 
followed by triethylamine (1.43 ml, 10.2 mmol). The reaction was stirred at RT for 
22 hours after which the solvent was evaporated in vacuo. The residue was 
partitioned between CH2CI2 (40 ml) and water (30 ml). The layers were separated 
and the aqueous layer extracted with CH2CI2  (2 x 30 ml). The combined organic 
layers were dried (MgS0 4 ), filtered and concentrated in vacuo to yield a yellow oil. 
Column chromatography (20% EtOAc: 80% Hexanes) afforded the tide product (1:1 
mixture of diastereomers) as a colourless foam (0.46 g, 54%); Rf (50% EtOAc: 50% 
Hexanes): 0.43; vmax (film) 3318 (O-H), 1694 (amide C=0), 1531 (amide N-H) cm '1; 
5h (400 MHz, CDCI3): 0.96 (3H, d, /  = 6 .8 , Val-CH3CHCH3), 1.00 (3H, d, /  = 6.4, 
Val-CH3CHCH3), 1.14 (3H, s, gem-CH3), 1.26 + 1.29 (3H, s, diast. gem-CH3), 1.44 
+ 1.46 (9H, s, diast. Boc-(CH3)3), 2.72 (1H, m, 4-CH), 3.19 (1H, pseudo-quint., J  =
10.0, 4-CH), 3.33 + 3.37 (3H, s, diast. 3-OCH3), 3.50 (1H, pseudo-q, /  = 10.0, 3- 
CH), 3.88 (1H, pseudo-U J  = 8.2, Val-CH3CHCH3), 4.20 (1H, pseudo-1, /  = 10.0, 2- 
CH), 5.35 + 5.40 (1H, d, J  = 8 .8 , Val-COCHNHBoc), 6.28 + 6.46 (1H, d, /  = 8 .8 , 
diast. CHNHCO), 6 . 6 8  (1H, d-pseudo-t, J  = 8.4, 2.0, diast. 5-ArH), 6.81 (1H, 
pseudo-1, J  = 2.4, diast. 8 -ArH), 6.87 (1H, d ,J  = 8 .6 , 6 -ArH); 5C (100 MHz, CDC13): 
17.97 + 18.24 (diast.), 19.18 + 19.53 (diast.), 26.77 + 26.87 (diast.), 27.91 + 28.10 
(diast.), 28.32, 30.28 + 30.42 (diast.), 34.23, 40.06, 56.12, 57.70, 60.93 + 61.15 
(diast.), 75.30 + 75.43 (diast.), 79.98 + 80.21 (diast.), 113.11 + 113.16 (diast. Ar- 
CH), 114.28 + 114.32 (diast. Ar-CH), 122.99 + 123.07 (diast. Ar-C), 130.04 (Ar- 
CH), 144.84 + 144.94 (diast. Ar-C), 155.20 (C=0), 156.21 + 156.29 (diast. Ar-C), 
172.73 + 172.84 (diast. C=0); FAB MS m/z 421 (MH+, 100%); HRMS calc, for 
C23H3 7N20 5 421.2702, found 421.2708
(2S)-2-Amino-A-[/raiis-7-hydroxy-3-methoxy-l,l-dimethyl-l,2,3,4-tetrahydro 
naphthalen-2-yl]-3-methylbutanamide (81)
To a stirred solution of 60 (0.46 g, 1.09 mmol) in CH2C12 (12 ml) at RT was 
added trifluoroacetic acid (0.81 ml, 10.9 mmol) dropwise. The reaction was stirred 
at RT for 3 hours then quenched by the dropwise addition of aq. sat. NaHC0 3 (10 
ml). The pH was adjusted to 9 with conc. NH4OH and CH2C12 (15 ml) was added. 
The two-phase system was separated and the aqueous layer extracted with CH2C12 (2 
x 20 ml). The combined organic layers were dried (MgS0 4 ), filtered and
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concentrated in vacuo. Column chromatography (6 % MeOH: 93% CH2CI2 : 1% 
NH4 OH) afforded the title product as a colourless foam (0.23 g, 6 6 %); Rf (10% 
MeOH: 89% CH2C12: 1% NH4 OH): 0.19; vmax (film) 3307 (O-H), 1652 (amide 
C=0), 1531 (N-H) cm '1; 8 H (400 MHz, CDC13): 0.90 (3H, d, J  = 6 .8 , Val- 
CH3 CHCH3), 1.03 (3H, d, /  = 6 .8 , Val-CH3CHCH3), 1.16 + 1.17 (3H, s, diast. gem- 
CH3), 1.27 (3H, s, gem-CH3), 2.36 ( 1 H, d septet, J  = 6 .8 , 3.6, Val-CH3CHCH3), 2.74 
(1H, dd, /  = 15.6, 9.2, 4-CH), 3.20 (lH ,pseudo-dt, J  = 15.6, 5.2, diast. 4-CH), 3.35 
(1H, m, NHCOCHNH2), 3.38 + 3.40 (3H, s, diast. 3-OCH3), 3.50 + 3.54 (1 H, td, J  =
9.6, 5.6, diast. 3-CH), 4.18 + 4.19 (1H, pseudo-1, /  = 10.0, diast. 2-CH), 6.70 (1H, 
dd, J  = 8.4, 2.4, 6 -ArH), 6.82 (1H, pseudo-1, J  = 2.4, 8 -ArH), 6.87 (1H, d ,J  = 8.4, 5- 
ArH), 7.39 + 7.54 (1H, d, J=  10.4, diast. CHNHCO); 8 C (100 MHz, CDC13): 15.71 + 
16.35 (diast), 19.83 + 19.90 (diast), 26.88 + 26.93 (diast.), 28.15 + 28.30 (diast),
30.82 + 30.92 (diast.), 31.01, 34.20, 40.08, 56.06 + 56.17 (diast), 57.29 + 57.49 
(diast.), 60.24 + 60.54 (diast.), 75.59 + 75.73 (diast), 113.35 (Ar-CH), 114.42 (Ar- 
CH), 122.86 + 122.89 (diast. Ar-C), 129.98 (Ar-CH), 144.83 + 144.85 (diast. Ar-C),
155.46 (Ar-C), 175.29 + 175.48 (diast. C=0); FAB MS m/z 321 (MH+, 100%); 
HRMS calc, for C 18H29N2O3 321.2178, found 321.2174
/raws-2-{[(2S)-2-Amino-3-methylbutyI]amino}-3-methoxy-l,l-dimethyl-l,2,3»4-
tetrahydronaphthalen-7-ol (82) via reduction of amide 61
To a stirred solution of 61 (0.16 g, 0.49 mmol) in anhydrous THF (10 ml) at 
0°C under an atmosphere of nitrogen was added borane.DMS complex (2.0M 
solution in THF, 2.47 ml, 4.93 mmol) dropwise over 10 minutes. The reaction was 
allowed to warm to RT and stirred for 1 hour, after which it was heated to reflux for 
a further 19 hours. The mixture was then cooled to -20°C and quenched by the 
dropwise addition of MeOH (0.5 ml), cautiously at first as vigorous effervescence 
occurred. After stirring at RT for 1 hour, a 1M solution of HC1 in propan-2-ol (0.2 
ml) was added and stirring was continued for a further 30 minutes. The solvent was 
then evaporated in vacuo and the residue adjusted to pH 9 by the addition of aq. sat. 
NaHC03. 4:1 CHC13: EtOH (15 ml) was added and the layers separated. The 
aqueous layer was extracted with 4:1 CHC13: EtOH (4 x 15 ml) and the combined 
organic layers were dried (MgS0 4 ), filtered and concentrated in vacuo. Column 
chromatography (10% MeOH: 89% CH2CI2 : 1% NH4 OH) afforded the title product
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as a colourless oil (0.13 g, 87%); Rf (10% MeOH: 89% CH2C12: 1% NH4OH): 0.15; 
vmax (film) 1610 (N-H) cm '1; 8 H (400 MHz, CDC13): 0.97 (6 H, pseudo-1, /  = 6 .8 , 
diast. Val-CH3 CHCH3), 1.16 (3H, s, gem-CH3), 1.36 (3H, s, gem-CH3), 1.71 (1H, 
oct, J  = 6 .8 , Val-CH3 CHCH3), 2.46 + 2.47 (1H, d, J  = 9.6, diast. 2-CH), 2.65 (2H, 
dd + m, /  = 16.4, 9.6, 4-CH + Val-CH 2CHNH2), 2.80 + 2.93 (1H, d, /  = 12.4, diast. 
Val-CH 2CHNH2), 3.19-3.30 (2H, m, 4-CH + Val-CH2CHNH2), 3.43-3.51 (4H, m, 
diast. 3 -OCH3  + 3-CH), 3.96 (4H, br-s, OH + NH + NH2), 6 . 6 6  (1H, d-pseudo-i, J  =
8.4, 2.4, diast. 6 -ArH), 6.80 (1H, d, J  = 2.4, 8 -ArH), 6.89 (1H, 2 x d, /  = 8.4, diast.
5-ArH); 8 c (100 MHz, CDC13): 18.51 + 18.64 (diast.), 19.24 + 19.34 (diast.), 26.49 +
26.52 (diast.), 28.20 + 28.25 (diast), 31.54 + 31.61 (diast.), 34.89, 41.04 + 41.49 
(diast.), 54.79 + 55.84 (diast.), 56.54 + 56.67 (diast.), 57.29 + 57.33 (diast.), 67.89 +
68.07 (diast), 78.48 + 79.06 (diast.), 113.54 + 113.67 (diast. Ar-CH), 114.13 +
114.19 (diast. Ar-CH), 122.93 + 123.08 (diast. Ar-C), 129.78 + 129.85 (diast. Ar- 
CH), 146.34 (Ar-C), 155.61 + 155.64 (diast. Ar-C); FAB MS m/z 307 (MH+, 100%); 
HRMS calc, for C 18H31N 20 2 307.2386, found 307.2386
trans-2-{ [(2S)-2-Amino-3-methyIbutyl]amino}-3-methoxy-l,l -dimethyl-1,2,3,4- 
tetrahydronaphthalen-7-ol (82) via Boc-deprotection of 91
To a stirred solution of 91 (0.35 g, 0.86 mmol) in CH2C12  (15 ml) at RT was 
added trifluoroacetic acid (0.64 ml, 8.61 mmol) dropwise. The reaction was stirred 
at RT for 24 hours after which time it was neutralised by the cautious addition of sat. 
aq. NaHC03. The pH was adjusted to 9 with conc. NH4 OH and the two-phase 
system was separated. The aqueous layer was extracted with 4:1 CHC13: EtOH (3 x 
2 0  ml) and the combined organic layers were washed with brine ( 2 0  ml) then dried 
(MgS0 4 ), filtered and concentrated in vacuo. Column chromatography (1-5% 
MeOH: CH2C12: 1% NH4 OH) afforded the title product as a colourless oil (0.22 g, 
83%). See above procedure for data.
te/t-Butyl-(3R)-7-hydroxy-3-({[(lS)-l-(hydroxymethyl)-2-methylpropyl]amino} 
carbonyl)-3,4-dihydroisoquinoline-2(l//)-carboxylate (87)
To a stirred solution of L-Valinol (0.16 g, 1.54 mmol), Boc-D-Tic(OH)-OH 
(0.41 g, 1.40 mmol) and triethylamine (0.58 ml, 4.19 mmol) in CH2C12 (30 ml) at RT 
was added benzotriazole-l-yl-oxy-trispyrrolidinophosphonium hexafluorophosphate
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(0.80 g, 1.54 mmol). The reaction was allowed to stir at RT for 16 hours after which 
time water (15 ml) was added. The layers were separated and the aqueous layer was 
extracted with CH2CI2  (2 x 20 ml). The combined organic layers were washed with 
1M HC1 (30 ml), aq. sat. NaHC03 (30 ml) then dried (MgSCU), filtered and 
concentrated in vacuo. Column chromatography (4% MeOH: 95.5% CH2CI2 : 0.5% 
NH4 OH) afforded the title product (0.51 g, 96%). Characterisation was not carried 
out due to poor solubility (see Section 3.3.3).
terf-Butyl-(lS)-l-({[<ra/is-7-hydroxy-3-methoxy-l,l-dimethyl-l,2,3,4-tetrahydro 
naphthalen-2-yl]amino}methyl)-2-methylpropylcarbamate (91)
To a stirred solution of Boc-L-valinol (0.29 g, 1.43 mmol) in CH2CI2 (5 ml) 
at RT was added a solution of Dess-Martin periodinane (0.91 g, 2.14 mmol) in 
CH2CI2 (5 ml) dropwise. The reaction was stirred at RT for 1.5 hours then diluted 
with diethyl ether (10 ml). Sat. aq. NaHC0 3 (20 ml) was added to quench the 
reaction and the mixture was stirred for a further 15 minutes. The resulting two- 
phase system was separated and the aqueous layer extracted with CH 2CI2 ( 2  x 2 0  
ml). The combined organic layers were washed with brine (10 ml), dried (Na2SC>4 ), 
filtered and concentrated in vacuo to yield the crude aldehyde as a colourless oil 
(0.27 g); Rf (50% EtOAc: 50% Hexanes): 0.53. This was then redissolved in 4:1 1,2- 
dichloroethane: DMF (20 ml) and aminotetralin 65 (0.25 g, 1.18 mmol) was added 
with vigorous stirring. When a clear solution had been obtained, sodium 
triacetoxyborohydride (0.45 g, 2.14 mmol) was added portion wise over 10 minutes at 
RT. The reaction was stirred under an atmosphere of nitrogen for 48 hours before 
cautiously quenching with aq. sat. NaHC03 (10 ml). When the effervescence had 
subsided, the layers were separated and the aqueous layer extracted with CHCI3 (2 x 
20 ml). The combined organic layers were dried (Na2 SC>4 ), filtered and concentrated 
in vacuo to give a yellow oil. Column chromatography (1-3% MeOH: CH2CI2 : 1% 
NH4 OH) afforded the title product as a colourless oil (0.37 g, 81%); vmax (film) 3338 
(O-H), 1684 (C=0) cm '1; 6 H (400 MHz, CDC13): 0.90 (6 H, pseudo-1, J  = 6 .8 , Val- 
CH3 CHCH3), 1.09 + 1.10 (3H, s, diast. gem-CH3), 1.32 (3H, s, gem-CH3), 1.45 (9H, 
s, B oc-(C H 3)3), 1.78 (1 H, m, Val-CH3CHCH3), 2.40 (1H, pseudo-1, J  = 9.6, diast. 2- 
CH), 2.60 (1H, dd, J  = 16.0, 10.4, 4-CH), 2.72 (1H, dd, J  = 12.0, 3.6, Val- 
NHCH2CH), 2.97 (1H, dd, J  = 12.0, 6 .8 , Val-NHCH2CH), 3.22 (1H, dd, J  = 15.6,
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5.6, 4-CH), 3.38-3.50 (2H, m, 3-CH + Val-NHCH2CH), 3.43 + 3.44 (3H, s, diast. 3- 
OCH3), 6.63 (1H, dd, J  = 8.4, 2.4, 6 -ArH), 6.80 (1H, pseudo-1, J  = 2.4, diast. 8 - 
ArH), 6.85 (1H, d, J  = 8.4, 5-ArH); 8 C (100 MHz, CDC13): 18.52, 19.01, 26.22 + 
26.29 (diast.), 27.89 + 27.95 (diast.), 28.37, 30.45, 34.86, 41.20, 53.35, 56.17, 56.46 
+ 56.55 (diast.), 67.97, 78.76 + 78.87 (diast.), 79.05, 113.17 + 113.20 (diast. Ar-CH),
113.70 (Ar-CH), 123.20 + 123.37 (diast. Ar-C), 129.73 (Ar-CH), 146.29 + 146.41 




The procedure used for the preparation of 6 8  was followed, although an 
additional equivalent of boron tribromide was employed. Thus a solution of methyl 
ether 129 (0.13 g, 0.33 mmol) in CH2CI2 ( 8  ml) was treated with boron tribromide 
(1.0 ml, 1 .0 M solution in CH2CI2 , 0.99 mmol) at -78°C and worked up as described 
for 6 8 . Column chromatography (2% MeOH: 97% CH2CI2 : 1% NH4 OH) afforded 
the title product as a yellow oil which solidified on standing (0.06 g, 49%); Rf (10% 
MeOH: 89% CH2C12: 1% NH4OH): 0.24; m.p. 126-128 °C; vmax (film) 3415 (O-H) 
cm-1; 5h (270 MHz, CDC13): 1.21 (3H, s, gem-CH3), 1.42 (3H, s, gem-CH3), 1.75 
(4H, m, py-N(CH2)2(CH2)2), 2.53 (2H, d, J  = 10.6, 2-CH), 2.65 (4H, m, py- 
N(CH2 )2 (CH2)2), 2.83 (2H, m, 4-CH2), 3.06 ( 1 H, td, J  = 9.9, 6.4, 3-CH), 3.43 ( 1 H, 
ddd, J  = 13.6, 6.9, 1.0, CH2CH=CH), 3.63 (1H, dd, J  = 13.6, 5.5, CH 2CH=CH), 4.09 
(2H, br-s, OH + NH), 6.31 (1H, ddd, /  = 15.8, 6.7, 5.7, CH2CH=CH), 6.52 (1H, d, J  
= 15.8, CH=CHPh), 6.60 (1H, dd, J  = 8.2, 2.5, 6 -ArH), 6.80 (1H, d, /  = 2.5, 8 -ArH), 
6.90 (1H, d, /  = 8.2, 5-ArH), 7.15-7.35 (5H, m, CH=CHPh); 8 C ( 6 8  MHz, CDC13): 
23.89, 26.17, 26.64, 28.98, 41.60, 47.62, 55.07, 55.72, 66.94, 113.10 (Ar-CH),
113.52 (Ar-CH), 126.06 (Ar-C), 126.35 (Ar-CH), 127.30 (Ar-CH), 128.58 (Ar-CH),
129.19 (Ar-CH), 130.07 (Ar-CH), 130.91 (Ar-CH), 137.39 (Ar-C), 147.30 (Ar-C), 
154.26 (Ar-C); FAB MS submitted; CHN submitted
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Attempted preparation of £ra«s-2-amino-l,l-dimethyl-3-pyrrolidin-l-yI-l,2,3,4- 
tetrahydronaphthalen-7-ol dihydrobromide (96)
To a stirred solution of 98 (0.25 g, 0.47 mmol) in glacial acetic acid (7.5 ml) 
at RT was added aq. 48% hydrobromic acid (7.5 ml). The reaction was stirred at RT 
for 19 hours, then the solvent was evaporated in vacuo to leave the crude HBr salt as 




To a stirred solution of aziridine 6 8  (0.35 g, 1.85 mmol), triethylamine (1.04 
ml, 7.40 mmol) and 4,4-dimethylaminopyridine ( 6 8  mg, 0.55 mmol) in CH2CI2 (20 
ml) at 0°C was added benzyl chloroformate (1.05 ml, 7.40 mmol) dropwise. The 
reaction was subsequently allowed to warm to RT and stirred for 16 hours. Aq. 2M 
HC1 (15 ml) was then added and the two-phase system separated. The aqueous layer 
was extracted with CH2CI2 ( 2  x 15 ml), and the combined organic layers were 
washed with aq. sat. NaHCC>3 (20 ml), dried (MgS0 4 ), filtered and concentrated in 
vacuo to yield a yellow oil. Column chromatography (20% EtOAc: 80% Hexanes) 
afforded the title product as a colourless oil (0.71 g, 84%); Rf (50% EtOAc: 50% 
Hexanes): 0.43; v™* (film) 1761 and 1719 (C=0) cm '1; 8 H (400 MHz, CDC13): 1.25 
(3H, s, gem-CH3), 1.62 (3H, s, gem-CH3), 2.70 (1H, d, J  = 6.4, 2-CH), 3.11 (2H, m,
3-CH + 4-CH), 3.37 (1H, dd, J  = 17.6, 2.0, 4-CH), 5.12 (2H, s, NCO2CH2PI1), 5.29 
(2H, s, OCO2CH 2PI1), 7.01 (1H, dd, J  = 8.4, 2.4, 6 -ArH), 7.08 (1H, d, /  = 8.4, 5- 
ArH), 7.14 (1H, d, J  = 2.4, 8 -ArH), 7.33-7.50 (10H, m, 10 x Cbz-ArH); 8 C (100 
MHz, CDCI3): 26.64, 28.72, 29.25, 35.68, 37.19, 47.55, 68.03, 70.30, 118.22 (Ar- 
CH) , 119.09 (Ar-CH), 128.03 (Ar-CH), 128.22 (Ar-CH), 128.48 (Ar-C), 128.54 (Ar- 
CH), 128.60 (Ar-CH), 128.72 (Ar-CH), 128.78 (Ar-CH), 130.34 (Ar-CH), 134.81 
(Ar-C), 135.91 (Ar-C), 143.36 (Ar-C), 150.21 (Ar-C), 153.69 (C=0), 163.33 (C=0); 





To a stirred solution of protected aziridine 97 (0.71 g, 1.55 mmol) in 
anhydrous THF (20 ml) at RT was added ytterbium (IE) trifluoromethanesulfonate 
(96 mg, 0.15 mmol). The mixture was stirred at RT for 15 minutes before the 
dropwise addition of pyrrolidine (0.64 ml, 7.76 mmol). Stirring was continued for 18 
hours at RT and then the solvent was evaporated in vacuo. The residue was 
partitioned between CH2CI2 (20 ml) and water (15 ml), and the layers were 
separated. The aqueous layer was extracted with CH2CI2 ( 2  x  15 ml) and the 
combined organic layers were washed with water ( 2 0  ml), dried (MgS0 4 ), filtered 
and concentrated in vacuo to give an orange oil. Column chromatography (30% 
EtOAc: 70% Hexanes) afforded the title product as a colourless oil (0.73 g, 89%); Rf 
(50% EtOAc: 50% Hexanes): 0.40; Vmax (film) 1703 and 1675 (C=0) cm '1; 8 h (400 
MHz, CDCI3): 1.23 (3H, s, gem-CH3), 1.61 (3H, s, gem-CH3), 1.90 (4H, m, Py- 
N(CH2)2 (CH2 )2 ), 2.68 (1 H, d, J  = 6.4, 2-CH), 3.03-3.10 (2H, m, 3-CH + 4-CH), 3.30 
(1 H, dd, J  = 17.2, 2.8, 4-CH), 3.39-3.49 (4H, m, Py-N(CH2 )2 (CH2)2), 5.11 (2 H, s, 
NC0 2CH2Ph), 5.18 (2H, s, OCChCH^h), 6 . 6 6  (1H, dd, J  = 8.4, 2.4, 6 -ArH), 6.84 
(1H, d, /  = 2.4, 8 -ArH), 6.92 (1H, d, /  = 8.4, 5-ArH), 7.32-7.43 (10H, m, 10 x Cbz- 
ArH); 8 C (100 MHz, CDC13): 25.00 + 25.76 (2 x Py-CH2), 26.64, 26.69, 28.93, 
35.52, 37.51, 45.87 + 46.30 (2 x Py-CH2), 47.77, 66.72, 67.96, 112.50 (Ar-CH), 
113.72 (Ar-CH), 122.30 (Ar-CH), 127.90 (Ar-CH), 127.93 (Ar-CH), 128.04 (Ar- 
CH), 128.19 (Ar-CH), 128.48 (Ar-CH), 128.52 (Ar-CH), 130.44 (Ar-CH), 135.95 
(Ar-C), 137.06 (Ar-C), 143.17 (Ar-C), 155.02 (Ar-C), 163.58 (Ar-C); FAB MS m/z 
529 (MIT, 45%); HRMS calc, for C32H37N2O5 529.2702, found 529.2684
7-Azabicyclo[4.1.0]heptane (101)
To a stirred solution of sodium azide (8.03 g, 124 mmol) in 1:1 acetone: 
water (70 ml) at RT was added cyclohexene oxide (5.00 ml, 49.4 mmol) dropwise. 
The reaction was heated at reflux for 16 hours then allowed to cool to RT. The 
acetone was removed in vacuo and the resulting emulsion extracted with diethyl 
ether (3 x  40 ml). The combined organic layers were dried (MgS0 4 ), filtered and 
concentrated in vacuo to yield a yellow oil. The crude azido-alcohol was 
subsequently redissolved in THF (60 ml) and triphenylphosphine (13.0 g, 49.4 
mmol) was added in one portion. The mixture was heated to reflux for a further 16 
hours before again allowing to cool to RT. The solvent was evaporated and n-
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pentane (40 ml) added to the residue. Precipitated triphenylphosphine oxide was 
collected by suction filtration and washed with rc-pentane (2 x 30 ml). The filtrate 
was concentrated in vacuo and the residue distilled under reduced pressure using a 
Kugel-Rohr oven (bpt. 95-100°C at 150 mmHg) to afford the title product as a 
colourless liquid (1.66 g, 35%); 8 H (270 MHz, CDC13): 1.18-1.35 (4H, m, ring), 1.79 
(4H, s, ring), 2.19 (2H, s, ring), 3.22 (1H, d, J  = 2.1, ring); 8 C (70 MHz, CDC13):
20.40, 24.82, 29.53
7-(3-Phenylpropyl)-7-azabicyclo[4.1.0]heptane (102)
To a vigorously stirred solution of 101 (0.57 g, 5.83 mmol) and 18-crown-6 
(0.15 g, 0.58 mmol) in acetonitrile (20 ml) at RT was added potassium carbonate 
(3.22 g, 23.3 mmol). l-Bromo-3-phenylpropane (0.89 ml, 5.83 mmol) was then 
added dropwise, followed immediately by lithium iodide (78 mg, 0.58 mmol). The 
reaction was heated at reflux for 40 hours then allowed to cool to RT. The solvent 
was evaporated in vacuo and the residue partitioned between CH2CI2 (30 ml) and 
water (20 ml). The layers were separated and the aqueous layer extracted with 
CH2CI2 (2 x 20 ml). The combined organic layers were washed with water (40 ml), 
dried (MgSCU), filtered and concentrated in vacuo to yield a yellow oil. Column 
chromatography (100% Hexanes to elute residual starting material, then 20% EtOAc: 
80% Hexanes) afforded the title product as a yellow oil (0.56 g, 38%); 8 h (270 MHz, 
CDCI3 ): 1.06-1.37 (4H, m, cyclohexyl), 1.38-1.43 (2H, m, cyclohexyl), 1.68-1.80 
(4H, m, cyclohexyl), 1.86 (2H, quint, J  = 7.4, CH2CHPh), 2.23 (2H, t, J  = 7.7, 
NCH2 (CH2)2Ph), 2.64 (2H, t, 7 =  7.7, (CH2)2CH2Ph), 7.14-7.27 (5H, m, 5 x Ar-H)
A-[/raws-2-Anilinocyclohexyl]-A-(3-phenylpropyl)amine (103)
To a vigorously stirred solution of 102 (0.14 g, 0.65 mmol) in non-anhydrous 
acetonitrile (3 ml) at RT was added tris(pentafluorophenyl)borane (32 mg, 0.07 
mmol), followed immediately by aniline (70 pi, 0.78 mmol). The reaction was 
heated at 70°C for 40 hours then allowed to cool to RT. The solvent was removed in 
vacuo and the residue redissolved in CHCI3 (4 ml). Amberlyst A-21 ion-exchange 
resin (0.6 g) was added and the mixture stirred at RT for 3 hours. The resin was 
separated by suction filtration and washed with CHCI3 ( 2 x 5  ml). The filtrate was 
concentrated in vacuo to yield an orange oil which was subsequently purified by
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column chromatography (100% CHCI3 to elute residual aniline, then 10% MeOH: 
89% CHCI3 : 1% NH4 OH to elute product) to afford the title product as a light brown 
oil (0.21 g, 100%); Rf (10% MeOH: 89% CH2C12: 1% NH4 OH): 0.60; vraax (film) 
3344 and 1602 (N-H) cm '1; 6 H (400 MHz, CDC13): 1.08-1.22 (2H, cyclo CH2), 1.22-
I.46 (2H, cyclo CH2), 1.76-1.92 (4H, m, cyclo CH2  + CH2CH2Ph), 2.15-2.28 (2H, 
cyclo CH2), 2.37 (2H, td, J  = 9.4, 3.6, NHCH2 (CH2)2Ph), 2.58 (1H, ddd, J  = 11.2,
7.6, 6 .8 , CHNH(CH2)3Ph), 2.72 (2H, t, J  = 7.6, (C H ^ C H ^ h ), 2.83 (1H, ddd, J  =
II.2 , 7.6, 6.4, CHNHPh), 6.74-6.82 (3H, m, 3 x Ar-H|> + p-NH]), 7.22-7.37 (7H, m, 
7 x Ar-H); 8 C (100 MHz, CDC13): 24.77, 25.16, 31.43, 31.88, 32.70, 33.66, 46.33, 
57.44, 62.33, 114.18 (Ar-CH), 117.83 (Ar-CH), 125.85 (Ar-CH), 128.40 (Ar-CH),
128.49 (Ar-CH), 129.39 (Ar-CH), 142.10 (Ar-C), 148.26 (Ar-C); FAB MS m/z 309 
(MH+, 100%); HRMS calc, for C2 iH29N2  309.2331, found 309.2326; CHN calc, for 
C2 iH28N2 .2HC1.0.75H2O: C 63.9, H 8.04, N 7.09, found: C 63.9, H 7.79, N 6.74
A-Benzyl-A-methyl-A-{rran5-2-[(3-phenylpropyl)amino]cycIohexyl}amine (104)
The procedure used for the preparation of 103 was followed, although 
different proportions of reagents were employed. Thus aziridine 102 was treated 
with A-benzylmethylamine (0.61 ml, 4.74 mmol) and tris(pentafluorophenyl)borane 
(0.12 g, 0.24 mmol) in acetonitrile (5 ml). After stirring at 70°C for 40 hours, the 
crude product was isolated according as described for 103. Column chromatography 
(0-2% MeOH: CHCI3) afforded the tide product (0.25 g, 63%); Rf (10% MeOH: 89% 
CH2C12: 1% NH4 OH): 0.69; SH (270 MHz, CDC13): 1.06-1.33 (4H, m, cyclohexyl),
1.70 (1H, m, cyclohexyl), 1.79-1.93 (4H, m, CH 2CH2Ph + cyclohexyl), 2.04-2.11 
(1H, m, cyclohexyl), 2.12 (3H, s, NCH3), 2.36-2.52 (3H, m, NHCH 2 CH2 + 
cyclohexyl CH), 2.66 (2H, t, J  = 7.2, C ^ C H ^ h ) , 2.75 (1H, td, /  = 11.6, 6.7, 
cyclohexyl CH), 3.48 (1H, d, J  = 13.3, NCH2Ph), 3.64 (1H, d, J  = 13.1, NCH 2Ph), 
3.96 (1H, br s, N-H), 7.14-7.32 (10H, m, 10 x Ar-H; FAB MS m/z 337 (MH+, 
100%); HRMS calc, for C23H3 2N2 337.2644, found 337.2643
A-Benzyl-A-(cyclopropylmethyl)amine (109)
To a stirred solution of (aminomethyl)cyclopropane (0.60 ml, 7.00 mmol) in 
MeOH (4 ml) was added benzaldehyde (0.59 ml, 5.84 mmol) dropwise. The reaction 
was heated to reflux under an atmosphere of nitrogen for 2  hours before cooling to
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0°C. Sodium borohydride (0.88 g, 23.3 mmol) was added portionwise over 2 hours 
to the imine whilst maintaining the temperature at 0°C. The cloudy mixture was 
allowed to warm to RT and stirred for 40 hours, then cooled back to 0°C. The 
reaction was then quenched by the dropwise addition of aq. 1M HC1 (10 ml). The 
mixture was stirred at RT for 1 hour and the pH subsequently adjusted to 9 by the 
cautious addition of conc. NH4 OH. The two-phase system was separated and the 
aqueous layer extracted with CH2CI2 ( 3 x 1 5  ml). The combined organic layers were 
dried (MgSCU), filtered and concentrated in vacuo. Column chromatography (1% 
MeOH: 98% CHCI3 : 1% NH4 OH) afforded the title product as a colourless liquid 
(0.99 g, 8 8 %); 8 H (270 MHz, CDC13): 0.07 (2 H, pseudo-q, J  = 7.3, CH(CH2)2), ddd, 
J  = 7.9, 5.7, 4.5, CH(CH2)2), 0.90-1.04 ( 1 H, m, CH(CH2)2), 1.56 ( 1 H, br-s, N-H),
2.47 (2H, d, J  = 6.9, NHCH2CH), 3.79 (2H, s, N H CH ^h), 7.24 (1H, m, Ar-H[p- 
CH2NH]), 7.28-7.32 (4H, m, 4 x ArH)
[7V-(4-Nitrophenylsulfonyl)imino]phenyIiodinane (110) 130
To a stirred mixture of 4-nitrobenzenesulfonamide (1.52 g, 7.52 mmol) and 
potassium hydroxide (1.05 g, 18.7 mmol) in MeOH (30 ml) at 0°C was added 
iodobenzene diacetate (2.42 g, 18.7 mmol). The reaction was allowed to warm to RT 
and stirred for 3 hours, during which time a cream precipitate formed. The 
precipitate was collected by suction filtration, washed with water ( 2  x 1 0  ml) and 
dried overnight in a desiccator to afford the title product as a cream solid (1.82 g, 
60%); 8 h (270 MHz, DMSO-d6): 7.45 (2H, m), 7.56 (1H, m), 7.95 (4H, m), 8.22 
(2H, d, J  = 8.9); 8 C ( 6 8  MHz, DMSO-d6): 124.12, 125.02, 127.79, 128.28, 130.55, 
131.26,133.70,137.67
7-[(4-Nitrophenyl)sulfonyl]-7-azabicyclo[4.1.0]heptane (111)
To a stirred solution of cyclohexene (0.30 ml, 2.96 mmol) in anhydrous 
acetonitrile (10 ml) at RT were added 4A molecular sieves (0.6 g) followed by 
copper (II) trifluoromethanesulfonate (0.16 g, 0.44 mmol). To the resulting light 
blue solution was added nitrene donor species 110 (1.83 g, 4.44 mmol) in small 
portions over 4 hours. The reaction was stirred at RT for 18 hours and then the 
solvent was evaporated in vacuo. Column chromatography (10% EtOAc: 90% 
Hexanes) afforded the title product as a white solid (0.84 g, 77%); vmax (KBr) 1541
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(N=0) cm '1; 8 H (270 MHz, CDCI3): 1.10-1.42 (4H, m, (CH2)2 (CH2)2(CH)2N), 1.67-
1.82 (4H, m, (CH2)2(CH2)2 (CH)2N), 3.06 (2H, m, (CH2)4 (CH)2N), 8.08 (2H, d- 
pseudo-t, J  = 8.9, 2.2, 2 x  Ar-H[0 -SO2]), 8.32 (2H, d-pseudo-X, J  = 8.9, 2.2, 2 x Ar- 
H[0 -NO2]); FAB MS m/z 283 (MH+, 100%); HRMS calc, for C 12H 15N2O4 S 
283.0753, found 283.0758
4-Nitro-iV-[<ra/is-2-pyrrolidin-l-ylcyclohexyl]benzenesulfonamide (112)
To a stirred solution of aziridine 111 (0.21 g, 0.73 mmol) in anhydrous THF 
(4 ml) at RT was added ytterbium (HI) trifluoromethanesulfonate (45 mg, 0.07 
mmol). Pyrrolidine (0.18 ml, 2.18 mmol) was added dropwise and the reaction was 
stirred at RT for 15 hours. The solvent was then evaporated in vacuo and the residue 
partitioned between CHCI3 (20 ml) and water (15 ml). The layers were separated 
and the aqueous layer extracted with CHCI3 (3 x 20 ml). The combined organic 
layers were dried (MgS0 4 ), filtered and concentrated in vacuo. Column 
chromatography (6 % MeOH: 93% CHCI3 : 1% NH4 OH) afforded the title product 
(0.23 g, 8 8 %); Rf (10% MeOH: 89% CH2C12: 1% NH4 OH): 0.20; vmax (KBr) 1530 
(N=0), 1350 cm '1; 8 H (270 MHz, CDC13): 0.97-1.21 (4H, m, N(CH2)2(CH2)2), 1.44- 
1.75 (7H, m, 7 x  Cyclohexyl CH), 2.04-2.43 (6 H, m, N(CH2 )2 (CH2 ) 2  + 1 x 
Cyclohexyl CH), 2.67 (1H, m, CHNHS02Ar), 8.00 (2H, d-pseudo-X, J  = 8 .8 , 2.4, 2 x 
Ar-H[o-S02]), 8.29 (2H, d-pseudo-X, J  = 8 .8 , 2.4, 2 x Ar-H[o-N02]); 8 C (100 MHz, 
CDCI3 ): 21.77, 23.55, 24.15, 24.90, 32.61, 46.75, 55.59, 61.50, 124.19 (Ar-CH),
128.44 (Ar-CH), 146.41 (Ar-C), 149.92 (Ar-C); FAB MS m/z 354 (MH+, 100%); 
HRMS calc, for C 16H 24N 3O4 S 354.1488, found 354.1491
4-Nitro-A/-(3-phenylpropyI)-A7-[(lS,2R)-2-pyrrolidin-l-ylcyclohexyl]benzene 
sulfonamide (113)
To a stirred solution of 112 (0.11 g, 0.30 mmol) in DMF (5 ml) at RT was 
added potassium carbonate (0.26 g, 0.75 mmol) followed immediately by l-bromo-3- 
phenylpropane (0.12 ml, 0.33 mmol). The reaction was stirred at RT for 20 hours 
then the solvent was evaporated in vacuo. The residue was partitioned between 
CH2C12  (15 ml) and water ( 1 0  ml). The layers were separated and the aqueous layer 
extracted with CH2C12 ( 2  x 15 ml). The combined organic layers were dried 
(MgSC>4 ), filtered and concentrated in vacuo. Column chromatography (100%
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Hexanes to remove excess bromide then 20% EtOAc: 80% Hexanes) afforded the 
title product (82 mg, 58%); vmax (KBr) 1521 (N=0), 1349 cm '1; 8 h (270 MHz, 
CDC13): 0.90-2.00 (14H, m, 14 x Alkyl CH), 2.30 (4H, m, N(CH2 )2 (CH2)2), 2.51 
(3H, m, CHN(CH2 ) 4 + (CH2)2CH2Ph), 3.10 (2H, t, J  = 7.7, NCH2 (CH2)2Ph), 3.57 
(1H, td, J  = 11.1, 3.7, CH NS0 2Ar), 7.05-7.24 (5H, m, (CH2)3Ph), 7.95 (2H, d- 
pseudo-t, J  = 8.9, 2.0, 2 x Ar-H[o-S02]), 8.17 (2H, d-pseudo-i, J  = 8.9, 2.0, 2 x Ar- 
H [o-N 02]); FAB MS m/z 472 (MH+, 50%)
trans-iV-(3-Phenylpropyl)-2-pyrrolidin-l-ylcyclohexanamine (114)
To a vigorously stirred suspension of potassium carbonate (149 mg, 1.08 
mmol) in anhydrous DMF (1 ml) was added benzenethiol (85 pi, 0.72 mmol). The 
mixture was stirred for 30 minutes before a solution of 113 (85 mg, 0.18 mmol) in 
anhydrous DMF (2 ml) was added dropwise under an atmosphere of nitrogen. The 
reaction was stirred at RT for 18 hours and then the solvent was evaporated in vacuo. 
The residue was partitioned between 4:1 CHCI3 : EtOH (20 ml) and water (10 ml). 
The layers were separated and the aqueous layer was extracted with 4:1 CHCI3 : 
EtOH ( 2 x 1 5  ml). The combined organic layers were washed with aq. sat. NaHC03 
(20 ml), then dried (M gS04), filtered and concentrated in vacuo. Column 
chromatography (1-5% MeOH: CHCI3 : 1% NKjOH) afforded the title product as a 
colourless oil (38 mg, 74%); Rf (10% MeOH: 89% CH2C12: 1% NKjOH): 0.47; 0.90-
1.20 (5H, m, N(CH2)2(CH2 ) 2  + cyclohexyl), 1.54-1.82 (8 H, m, 8  x  Alkyl CH), 1.97 
(1H, m, cyclohexyl), 2.21 (1H, td, 7 =  10.4, 4.2, CHNH(CH2)3Ph), 2.34-2.72 (9H, m, 
N(CH2 ) 2  + cyclohexyl), 7.07-7.23 (5H, m, (CH2)3Ph); FAB MS m/z 287 (MH+, 
100%)
iV'-(2,2-Dimethylcyclohexylidene)-4-nitrobenzenesulfonohydrazide (117)
To a stirred suspension of powdered sodium amide (5.15 g, 132 mmol) in 
diethyl ether (50 ml) at 0°C was added a solution of 2-methylcyclohexanone (8.0 ml, 
66.0 mmol) in diethyl ether (40 ml) dropwise over 1 hour. When the addition was 
complete, the enolate was allowed to warm to RT and stirred for 16 hours. This was 
followed by 2 hours at gentle reflux, after which the mixture was cooled to 0°C. 
Iodomethane (4.5 ml, 72.6 mmol) was added rapidly and the reaction heated to reflux 
for a further 3 hours. After allowing to cool to RT, the reaction was quenched by
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pouring over 100 g of crushed ice. The mixture was subsequently acidified by the 
addition of aq. 2M HC1 (100 ml) and transferred to a separating funnel. The layers 
were separated and the aqueous layer extracted with diethyl ether (2 x 100 ml). The 
combined organic layers were washed with aq. 2M sodium thiosulfate (150 ml), then 
dried (MgS0 4 ), filtered and cautiously evaporated (at 30°C to avoid evaporation of 
product) to give crude 2,2-dimethylcyclohexanone as a yellow oil. The crude ketone 
was redissolved in EtOH (80 ml) and p-toluenesulfonylhydrazide (12.3 g, 66.0 
mmol) added in one portion. The reaction was heated at 60°C for 1.5 hours, before 
allowing to cool to RT. The mixture was then concentrated in vacuo until its volume 
had been reduced to -30  ml. The flask was kept in a freezer for 3 days, after which 
time crystals had been deposited. These were subsequently collected by suction 
filtration, washed with EtOH (3 x 20ml) and dried under vacuum to afford the title 
product as colourless prisms (8.42 g, 43%); Rf (50% EtOAc: 50% Hexanes): 0.28
2,2-Dimethylcyclohexene (118)
Tosylhydrazone 117 (1.63 g, 5.54 mmol) was ground to a fine powder and 
suspended in diethyl ether (10 ml). The mixture was cooled to -78°C and 
methyllithium (8.0 ml of a 1.6 M solution in diethyl ether, 12.7 mmol) was added 
dropwise over 15 minutes under an atmosphere of nitrogen. The reaction was 
subsequently stirred at -78°C for 45 minutes before allowing to slowly warm to RT. 
During this period, the mixture turned from yellow to deep red accompanied by 
vigorous evolution of nitrogen, and finally back to yellow again. When the gas 
evolution had ceased (approximately 2  hours), the reaction was quenched by the 
cautious dropwise addition of water ( 2 0  ml), causing the colour of the reaction to 
change from yellow to white. The mixture was stirred until two distinct layers had 
formed, at which point pentane (20 ml) was added. The layers were separated and 
the aqueous layer further extracted with pentane (2 x 20 ml). Most of the diethyl 
ether was then removed in vacuo and the remaining pentane extracts were dried 
(MgSC>4 ) and suction filtered through a pad of Celite® to remove residual starting 
material. The filter pad was washed with pentane (2 x 15 ml) and the filtrate 
concentrated in vacuo to afford the title product as a colourless liquid (0.51 g, 84 %); 
8 h (270 MHz, CDC13): 0.95 (6 H, s, gem-CH3), 1.42 (2H, m, (CH3)2CH2CH2), 1.60 
(2H, m, CH2CH2 CH2 ), 1.91 (2H, m, CH2CH 2CH=CH), 5.39 (1H, dt, J  = 10.2, 2.0,
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(CH3)2CH=CH), 5.52 (1H, dt, J  = 9.9, 3.7, CH=CHCH2); 8 C (67.8 MHz, CDC13): 
19.55, 25.16, 29.92, 37.30, 124.57 (CH=CH), 137.85 (CH=CH)
2,2-Dimethyl-7-[(4-nitrophenyI)sulfonyl]-7-azabicyclo[4.1.0]heptane (119)
Copper(II) trifluoromethanesulfonate (0.76 g, 2.09 mmol) and 4A molecular 
sieves (1.7 g) were added to a solution of alkene 118 (0.92 g, 8.35 mmol) in 
anhydrous acetonitrile (30 ml). To this resulting green mixture was added nitrene 
donor species 110 (5.10 g, 12.5 mmol) portionwise over 4 hours at RT. The reaction 
was stirred at RT for 16 hours before suction filtering through a pad of Celite®. The 
filter pad was washed with EtOAc (3 x 30 ml) and the filtrate subsequently washed 
with aq. saturated NaHC03 (30 ml), dried (MgS0 4 ), filtered and concentrated in 
vacuo to give a white solid. Column chromatography (15% EtOAc: 85% Hexanes) 
afforded the title product as white crystals (1.47 g, 57%); Rf (50% EtOAc: 50% 
Hexanes): 0.51; vmax (KBr) 1532 (N=0), 1351 cm*1; 8 H (400 MHz, CDC13): 0.78 
(3H, s, gem-CH3), 1.05 (1H, m, (CH3 )2CH2CH2), 1.08 (3H, s, gem-CH3), 1.26 (1H, 
m, (CH3 )2CH 2CH2), 1.38 (2H, m, CH2CH2 CH2), 1.76 (1H, m, CH2CH 2CH), 1.87 
(1H, dq, J  = 14.8, 5.2, CH2CH 2CH), 2.76 (1H, d, J  = 6 .8 , (CH3 )2CHCH), 3.25 (1H, 
ddd, J  = 6 .8 , 5.2, 1.6, CH2CHCH), 8.19 (2H, m, J  = 8 .8 , 2 x Ar-H[d>-S02]), 8.42 (2H, 
m, J  = 8 .8 , 2 x Ar-H[o-N02]); 8 c (100 MHz, CDC13): 16.57, 22.14, 26.70, 27.90, 
28.92, 33.73, 42.14, 50.52, 124.19 (Ar-CH), 129.25 (Ar-CH), 144.60 (Ar-C), 150.47 
(Ar-C); FAB MS m/z 310 (M \ 45%)
A-[£raws-2,2-Dimethyl-6-pyrrolidin-l-ylcycIohexyl]-4-nitrobenzenesulfonamide
(120)
To a stirred solution of 119 (0.35 g, 1.13 mmol) in anhydrous THF (7 ml) 
was added ytterbium(III) trifluoromethanesulfonate (0.07g, 0.11 mmol) at 0°C. The 
resulting mixture was stirred at 0°C for 10 minutes before the dropwise addition of 
pyrrolidine (0.28 ml, 3.38 mmol). The reaction was allowed to warm to RT and then 
stirred for 24 hours, after which the solvent was removed in vacuo. The residue was 
partitioned between CHC13 (20 ml) and water (20 ml). The layers were separated and 
the aqueous layer extracted with CHC13 (2 x 20 ml). The combined organic layers 
were dried (MgSC>4 ), filtered and concentrated in vacuo to give an orange solid. 
Column chromatography (100% CH2C12 then 2% MeOH: 1% NH4 OH: 97% CH2C12)
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afforded the title product as fine yellow prisms (0.40 g, 92%); Rf (10% MeOH: 89% 
CH2C12: 1% NH4 OH): 0.33; (KBr) 1528 (N=0), 1349 cm’1; 5H (270 MHz, 
CDCI3): 0.72 (3H, s, gem-CH3), 0.74 (3H, s, gem-CH3), 1.27 (4H, m, 
(CH3)2CH 2CH2CH2), 1.52 (4H, m, py-N(CH2)2), 1.59 (1H, m, CH2CH 2CH), 1.77 
(1H, br-d, J=  12.1, CH2CH 2CH), 2.47 (4H, m, py-N(CH2)2(CH2)2), 2.60 (1H, dd, 7  =
11.2, 3.5), 3.16 (1H, d, 7 = 11.2), 5.44 (1H, br-s, NH), 8.07 (2H, d, 7 = 8.7, 2 x Ar- 
H [o-S02]), 8.27 (2H, d, 8.7, 2 x Ar-H[<?-N02]); 8 C (67.8 MHz, CDC13): 19.62, 20.51,
22.71, 23.65, 30.98, 36.59, 39.57, 46.95, 57.92, 64.67, 123.87 (Ar-CH), 127.93 (Ar- 
CH), 148.43 (Ar-C), 149.44 (Ar-C); FAB MS m/z 382 (M+, 100%)
A-[£ra/is-2,2-Dimethyl-6-pyrroIidin-l-ylcyclohexyl]-4-nitro-iV-[(Zi)-3- 
phenylprop-2 -enyl]benzenesulfonamide (1 2 1 )
To a stirred solution of 120 (0.29 g, 0.75 mmol) in anhydrous DMF (10 ml) was 
added cesium carbonate (0.49 g, 1.49 mmol), causing the reaction colour to change 
from yellow to deep red as deprotonation of the sulfonamide occurred. Cinnamyl 
bromide (0 . 2 2  g, 1 . 1 2  mmol) was then added in one portion and the reaction stirred 
at RT for 20 hours, during which time the colour became yellow again. The solvent 
was removed in vacuo and the resulting residue partitioned between CH2C12 (20 ml) 
and water (15 ml). The layers were separated and the aqueous layer extracted with 
CH2C12 (2 x 20 ml). The combined organic layers were dried (MgS0 4 ), filtered and 
concentrated in vacuo to afford a yellow solid (0.49 g). Column chromatography 
(100% Hexanes to elute residual cinnamyl bromide then 10% EtOAc: 90% Hexanes) 
gave the title product as a yellow powder (0.34 g, 94%); Rf (50% EtOAc: 50% 
Hexanes): 0.54; m.p. 164-166 °C; vmax (KBr) 1525 (N=0), 1345 cm '1; 8 H (400 MHz, 
CDC13): 1.02 (3H, s, gem-CH3), 1.14 (3H, s, gem-CH3), 1.44 (4H, m, 
(CH3)2CH2 CH2CH2), 1.70 (4H, m, J = 6.4, py-N(CH2)2 (CH2)2), 1.76 (1H, m, 
CH2CH 2CH), 2.58 (2H, m, J  = 8.0, py-N(CH2 )2(CH2)2), 2.79 (2H, m, J  = 8.0, py- 
N(CH2 )2(CH2)2), 2.98 (1H, dd, 7 = 10.8, 7.2, CH2CHCH), 3.92 (1H, ddd, J  = 16.4,
5.6, 1.6, CH 2CH=CH), 4.06 (1H, d, J=  11.6, (CH3)2CHCH), 4.13 (1H, dd, 7 =  16.4,
8.0, CH2CH=CH), 5.85 (1H, ddd, J  = 16.4, 8.0, 5.6, CH2CH=CH), 6.42 (1H, d, J  =
16.4, CH=CHPh), 7.11 (2H, dd, J  = 8.0, 1.6, Ar-H|>-CHCH]), 7.28 (3H, m, Ar- 
H[m,p-CHCH]), 8.02 (2H, d, J  = 8 .8 , 2 x  Ar-H[<?-S02]), 8.07 (2H, d, J  = 8 .8 , 2 x Ar- 
H [o-N02]); 8 c (100 MHz, CDC13): 20.88, 21.96, 23.59, 24.57, 31.96, 42.37, 47.62,
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48.20, 54.95, 68.72, 123.25 (Ar-CH), 126.08 (Ar-CH), 126.73 (Ar-CH), 128.07 (Ar- 
CH), 128.67 (Ar-CH), 130.03 (Ar-CH), 132.58 (Ar-CH), 136.23 (Ar-C), 148.25 (Ar- 
C), 149.07 (Ar-C); FAB MS m/z 498 (M+, 50%)
fra/is-2,2-Dimethyl-A-[(Z?)-3-phenylprop-2-enyl]-6-pyrroIidin-l-ylcyclo 
hexanamine (1 2 2 )
To a stirred solution of 121 (0.27 g, 0.56 mmol) in anhydrous DMF (10 ml) at 
RT was added lithium hydroxide monohydrate (0.12 g, 2.78 mmol) followed by 
mercaptoacetic acid (120 pi, 1.67 mmol). After stirring for several minutes at RT, 
the colour of the reaction was observed to change from yellow to red. TLC analysis 
after 24 hours showed incomplete consumption of 121. The system was 
subsequently heated at 50°C for a further 3 hours, after which time additional lithium 
hydroxide monohydrate (70 mg, 1.67 mmol) and mercaptoacetic acid (78 pi, 1.11 
mmol) was added to the reaction. After heating at 60°C for a further 16 hours, the 
solvent was evaporated in vacuo and the residue partitioned between EtOAc (30 ml) 
and aq. 2M NaOH (15 ml). The layers were separated and the aqueous layer 
extracted with EtOAc (2 x 30 ml). The combined organic layers were dried 
(MgS0 4 ), filtered and concentrated in vacuo to yield a brown oil. Column 
chromatography (1-2% MeOH: CHCI3 : 1% NH4 OH) afforded the title product as a 
colourless oil (92 mg, 53%); Rf (10% MeOH: 89% CH2C12: 1% NH4 OH): 0.20; vmax 
(film) 1612, 1513 cm '1; SH (400 MHz, CDC13): 0.91 (3H, s, gem-CH3), 1.03 (3H, s, 
gem-CH3), 1.09-1.21 (2H, m, cyclohexyl), 1.31-1.35 (1H, m, cyclohexyl), 1.41 (1H, 
tt, J  = 13.2, 3.6, cyclohexyl), 1.61 (1H, dt, J  = 10.0, 3.6, cyclohexyl), 1.63-1.73 (4H, 
m, N(CH2)2 (CH2)2), 1.74-1.80 (1 H, m, cyclohexyl), 2.08 ( 1 H, d, J  = 1 1 .2 , 
C(CH3)2CHCH), 2.50-2.63 (5H, m, N(CH2 ) 2  + CH2CHCH), 3.36 (1H, dd, J  = 13.6,
6 .8 , NHCH2CH=CH), 3.55 (1H, dd, J  = 13.6, 5.6, NHCH2CH=CH), 6.30 (1H, dt, J  =
15.6, 6.4, CH2CH=CH), 6.49 (1H, d, J  = 16.0, CH=CHPh), 7.19 (1H, t, /  = 7.6, Ar- 
H[p-CH=CH]), 7.29 (2H, t, J  = 7.6, 2 x Ar-H[w-CH=CH]), 7.36 (2H, d, J  = 6 .8 , 2 x 
Ar-H[o-CH=CH]); 8 C (100 MHz, CDC13): 19.84, 20.98, 22.56, 23.74, 31.64, 37.00,
40.15, 47.12, 54.83, 58.10, 68.39, 126.18 (2 x Ar-CH), 127.07 (Ar-CH), 128.44 (2 x 




tetrahydronaphthalen-7-yl 7-nitrobenzenesulfonate (124) from 68
To a stirred solution of aziridine 6 8  (0.61 g, 3.21 mmol) and triethylamine 
(1.34 ml, 9.64 mmol) in CH2CI2  (20 ml) at RT was added 2-nitrobenzenesulfonyl 
chloride (2.14 g, 9.64 mmol) in small portions. The reaction was stirred at RT for 16 
hours and then quenched by the cautious addition of water (20 ml). The resulting 
two-phase system was separated and the aqueous layer extracted with CH2CI2  ( 2  x 30 
ml). The combined organic layers were dried (MgSO,*), filtered and concentrated in 
vacuo to yield an orange solid. Column chromatography (30-50% EtOAc: Hexanes) 
afforded 123 as an orange solid (1.56 g, 87%). Aziridine 123 (0.45 g, 0.81 mmol) 
was redissolved in anhydrous dimethylsulfoxide (20 ml) and ytterbium (IE) 
trifluoromethanesulfonate (0.10 g, 0.16 mmol) was added. The mixture was stirred 
for 10 minutes before the dropwise addition of pyrrolidine (0.27 ml, 3.23 mmol). 
The reaction was stirred at RT for 16 hours and then diluted with water (20 ml) and 
ethyl acetate (40 ml). The resulting two-phase system was separated and the aqueous 
layer extracted with ethyl acetate (2 x 40 ml). The combined organic layers were 
washed with water (2 x 50 ml), brine (50 ml), then dried (MgS0 4 ), filtered and 
concentrated in vacuo. Column chromatography (1% MeOH: CHCI3 : 1% NH4 OH) 
afforded the title product as a yellow oil (0.49 g, 95%); Rf (10% MeOH: 89% 
CH2C12: 1% NH4 OH): 0.42; 5h (270 MHz, CDCI3 ): 1.01 (3H, s, gem-CH3), 1.17- 
1.37 (4H, m, Py-N(CH2)2(CH2)2), 1.24 (3H, s, gem-CH3), 2.33 (4H, m, Py- 
N(CH2)2 (CH2)2), 2.75-3.04 (3H, m, 4-CH2  + 3-CH), 3.52 (1H, d, J  = 9.4, 2-CH), 
6.92-7.02 (3H, m, 5-ArH + 6 -ArH + 8 -ArH), 7.62-7.87 (6 H, m, 6  x  ArH), 7.90 (1H, 
m, Ar-H[o-N02]), 8.09 (1H, m, Ar-H[<?-N02])
7-Methoxy-l,l-dimethyl-l-[(4-nitrophenyl)sulfonyl]-l,2,3,4-tetrahydronaphtho 
[2,3-2>]azirene (126)
To a stirred solution of aziridine 67 (0.54 g, 2 . 6 6  mmol) in CH2C12 (30 ml) 
was added triethylamine (1.11 ml, 7.97 mmol) and 4,4-dimethylaminopyridine (30 
mg, 0.27 mmol). The mixture was cooled to 0°C before the dropwise addition of 4- 
nitrobenzenesulfonyl chloride (0.65 g, 2.92 mmol) in CH2C12  (5 ml). The reaction 
was stirred at 0°C for 1 hour then allowed to warm to RT and stirred for a further 18 
hours, after which time the reaction was quenched by the cautious addition of aq.
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saturated NaHCC>3 (20 ml). The layers were separated and the aqueous layer 
extracted with CH2CI2  (2 x 20ml). The combined organic layers were dried 
(Na2 S0 4 ), filtered and concentrated in vacuo. Column chromatography (10-15% 
EtOAc: Hexanes) afforded the title product as a white powder (0.70 g, 6 8 %); Rf 
(50% EtOAc: 50% Hexanes): 0.64; m.p. 140-142 °C; vmax (KBr) 1532 (N=0) c m 1; 
8 h (400 MHz, CDCI3): 1.22 (6 H, s, gem-{CH3)2), 3.07 (1H, d, J  = 7.2, 2-CH), 3.13 
(2H, dd, J  = 6.0, 2.0, 4-CH2), 3.53 (1H, dt, J  = 7.2, 2.0, 3-CH), 3.75 (3H, s, 7- 
OCH3 ), 6.67 (1H, dd, J  = 8.4, 2.8, 6 -ArH), 6.89 (1H, d, J  = 8.4, 5-ArH), 8.06 (2H, d, 
J  = 8 .8 , 2 x  Ar-H[o-S02]), 8.31 (2H, d, J  = 8 .8 , 2 x Ar-H[o-N02]); 8 C (100 MHz, 
CDCI3 ): 26.72, 27.69, 29.11, 34.92, 41.09, 51.14, 55.16, 111.40 (Ar-CH), 111.49 
(Ar-CH), 121.40 (Ar-C), 124.11 (Ar-CH), 129.23 (Ar-CH), 129.96 (Ar-CH), 141.92 
(Ar-C), 144.27 (Ar-C), 150.44 (Ar-C), 158.67 (Ar-C); FAB MS m/z 389 (MH+, 
60%); HRMS submitted
A-[£ra/zs-7-Methoxy-1,1 -dimethyl-3-py rrolidin-1 -yl-1,2,3,4-tetrahy dro 
naphthalen-2-yl]-4-nitrobenzenesulfonamide (127)
To a stirred solution of aziridine 126 (0.31 g, 0.79 mmol) in anhydrous THF 
(7 ml) was added ytterbium(III) trifluoromethanesulfonate (49 mg, 0.08 mmol). The 
mixture was stirred at RT for 5 minutes, before the dropwise addition of pyrrolidine 
(0.20 ml, 2.38 mmol). The reaction was heated at reflux for 42 hours, then allowed 
to return to RT. Water (10 ml) was added and the THF evaporated in vacuo. The 
resulting suspension was extracted with 3:1 CHCI3: MeOH (3 x 20 ml). The 
combined organic layers were dried (MgS0 4 ), filtered and concentrated in vacuo to 
give the crude product. Column chromatography (50% EtOAc: 50% Hexanes to 
elute trace of starting material then 100% EtOAc) afforded the title product as a 
yellow solid (0.34 g, 93%); vmax (KBr) 1530 (N=0) cm '1; 8 H (270 MHz, CDC13):
1.04 (3H, s, gem-CU3), 1.15 (3H, s, gem-CH3), 1.75 (4H, m, py-N(CH2)2 (CH2)2), 
2.58 (2H, m, py-N(CH2 )2 (CH2)2), 2.68 (2H, m, py-N(CH2 )2 (CH2)2), 2.85 (2H, m, 4- 
CH2), 3.04 (1H, td, /  = 10.2, 5.9, 3-CH), 3.66 (1H, d, J  = 10.4, 2-CH), 3.74 (3H, s,
7 -OCH3), 6.68 (1H, dd, J  = 8.2, 2.5, 6-ArH), 6.73 (1H, d, J  = 2.5, 8-ArH), 6.96 (1H, 
d, /  = 8.2, 5-ArH), 8.11 (2H, d, J  = 8.9, Ar-H|>-S02]), 8.35 (2H, d, /  = 8.9, Ar-H[o- 
N 0 2]); 8c (100 MHz, CDC13): 23.59, 25.90, 26.96, 29.72, 41.22,47.37, 55.23, 55.39,
63.41, 111.84 (Ar-CH), 112.53 (Ar-CH), 124.09 (Ar-CH), 125.28 (Ar-C), 128.12
180
(Ar-CH), 130.03 (Ar-CH), 144.98 (Ar-C), 148.02 (Ar-C), 149.66 (Ar-C), 158.22 
(Ar-C); FAB MS submitted
A-[^ra/i5-7-Methoxy-l,l-dimethyl-3-pyrrolidin-l-yl-l,2,3,4-tetrahydro 
naphthalen-2-yl]-4-nitro-A-[(£')-3-phenylprop-2-enyl]benzenesulfonamide (128)
To a vigorously stirred solution of 127 (0.53 g, 1.15 mmol) in anhydrous 
acetonitrile (30 ml) was added freshly powdered potassium carbonate (0.32 g, 2.31 
mmol) and 18-crown-6 (30mg, 0.12 mmol) at RT. The mixture became red as 
deprotonation of the sulfonamide occurred. After stirring for 5 minutes, cinnamyl 
bromide (0.27 g, 1.38 mmol) was added in one portion and the reaction stirred 
vigorously at RT for 30 hours. The solvent was then evaporated in vacuo and the 
residue subsequently partitioned between water (10 ml) and CHCI3 (20 ml). The 
layers were separated and the aqueous layer extracted with CHCI3 (2 x  20 ml). The 
combined organic layers were dried (MgS0 4 ), filtered and concentrated in vacuo. 
Column chromatography (0-15% EtOAc: Hexanes) afforded the title product as a 
yellow powder (0.37 g, 55%); Rf (50% EtOAc: 50% Hexanes): 0.58; m.p. 161-163 
°C; vmax (KBr) 1526 (N=0) cm*1; 5H (400 MHz, CDC13): 1.38 (3H, s, gem-CH 3), 
1.54 (3H, s, gem-CH3), 1.85 (4H, m, py-N(CH2)2(CH2 )2 ), 2.64 (2 H, m, py- 
N(CH2 )2 (CH2)2), 2.77 (1H, dd, J  = 14.4, 6.0, 4-CH), 2.90 (2H, m, py- 
N(CH2 )2(CH2)2), 2.98 (1H, d, J  = 14.8,4-CH), 3.17 (1H, m, 3-CH), 3.36 (1H, dd, /  =
16.4, 3.6, CH 2CH=CH), 3.78 (3H, s, 7-OCH3), 3.97 (1H, dd, J  = 16.4, 8.4, 
CH 2CH=CH), 4.50 (1H, d, J  = 8.0, 2-CH), 5.35 (1H, ddd, J  = 16.0, 8 .8 , 5.2, 
CH2CH=CH), 6.03 (1H, d, J  = 16.0, CH2CH=CH), 6.70 (1H, dd, J  = 8.2, 2.4, 6 - 
ArH), 6.84 (2H, dd, /  = 7.2,4.0, 2 x Ar-H[<?-CH=CH]), 6.89 (1H, d, J  = 2.8, 8 -ArH),
7.04 (1H, d, J  = 8.2, 5-ArH), 7.15 (3H, m, 2 x Ar-H[m-CH=CH] + Ar-H[p- 
CH=CH]), 7.99 (2H, d, J  = 8 .8 , 2 x Ar-H[<?-S02]), 8.28 (2H, d, J  = 8 .8 , 2 x  A r-H |>  
N 0 2]), 5c (100 MHz, CDCI3 ): 24.11, 24.27, 25.43, 30.69, 40.44,47.64, 47.68, 55.19,
60.02, 68.01, 110.50 (Ar-CH), 110.85 (Ar-CH), 123.03 (Ar-CH), 124.48 (Ar-CH), 
125.83 (CH=CH), 127.64 (Ar-C), 128.10 (Ar-CH), 128.47 (Ar-CH), 2 x  129.67 (Ar- 
CH), 133.54 (CH=CH), 135.51 (Ar-C), 145.95 (Ar-C), 149.02 (Ar-C), 149.20 (Ar- 





To a vigorously stirred suspension of potassium carbonate (0.50 g, 3.65 
mmol) in anhydrous DMF (3 ml) was added benzenethiol (0.25 ml, 2.43 mmol) 
dropwise at RT under an atmosphere of nitrogen. The thiolate mixture was stirred 
for 10 minutes, then a solution of 128 (0.35 g, 0.61 mmol) in anhydrous DMF (4 ml) 
was added dropwise over 5 minutes. The reaction was observed to immediately 
change colour from yellow to dark brown. After stirring at RT for 48 hours, the 
solvent was evaporated in vacuo and the residue partitioned between 4:1 CHCI3 : 
EtOH (20 ml) and water (15 ml). The layers were separated and the aqueous layer 
extracted with CHCI3 : EtOH (2 x 20 ml). The combined organic layers were dried 
(MgS0 4 ), filtered and evaporated. Column chromatography ( 1 % NEt3 i 99% CH2CI2) 
afforded the title product as a yellow oil (0.18 g, 76%); Rf (10% MeOH: 89% 
CH2C12: 1% NH4 OH): 0.27; vmax (film) 1504,1494 cm '1; 8 H (400 MHz, CDC13): 1.23 
(3H, s, gem-CH3), 1.45 (3H, s, gem-CU3), 1.75 (4H, m, py-N(CH2)2 (CH2)2), 2.53 
( 1 H, d, / =  10.8, 2 -CH), 2.66 (4H, m, py-N(CH2 )2 (CH2)2), 2.85 (2H, m, 4-CH2), 3.05 
(1H, td, J  = 10.8, 5.6, 3-CH), 3.46 (1H, ddd, J  = 13.6, 6.4, 1.2, CH 2CH=CH), 3.62 
(1H, dd, J  = 13.6, 6.0, CH2CH=CH), 3.79 (3H, s, 7-OCH3), 6.35 (1H, dt, J  = 16.0,
6.0, CH2CH=CH), 6.56 (1H, d, /  = 15.6, CH2CH=CH), 6 . 6 8  (1H, dd, J  = 8.4, 2.4, 6 - 
ArH), 6.89 (1H, d, J  = 2.4, 8 -ArH), 6.98 (1H, d, /  = 8.4, 5-ArH), 7.21 (1H, tt, J  =
7.2, 1.6, Ar-H[p-CH=CH]), 7.30 (2H, t, J  = 7.2, 2 x Ar-H[m-CH=CH]), 7.38 (2H, dt, 
J  = 7.2, 1.6, 2 x Ar-H[o-CH=CH]), 8 C (100 MHz, CDC13): 23.77, 26.08, 26.48, 
28.91, 41.73, 47.45, 55.02, 55.22, 55.48, 66.79, 111.26 (CH=CH), 111.97 (CH=CH),
126.19 (Ar-CH), 126.54 (Ar-C), 127.113 (Ar-CH), 128.46 (Ar-CH), 129.58 (Ar-CH), 
129.80 (Ar-CH), 130.32 (Ar-CH), 137.40 (Ar-C), 147.17 (Ar-C), 157.84 (Ar-C); 
FAB MS m/z 391 (M+, 100%); HRMS submitted
A-{fra«s-3-[(Cyclopropylmethyl)amino]-7-methoxy-l,l-dimethyl-l, 2,3,4- 
tetrahydronaphthalen-2-yl}-4-nitrobenzenesulfonamide (130)
To a stirred solution of aziridine 126 (0.58 g, 1.49 mmol) in anhydrous THF 
(15 ml) was added ytterbium(III) trifluoromethanesulfonate (93 mg, 0.15 mmol) at 
RT. The mixture was stirred for 5 minutes before the dropwise addition of 
(aminomethyl)cyclopropane (0.39 ml, 4.48 mmol), after which the reaction was
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heated to gentle reflux for 5 days. The mixture was allowed to return to RT and the 
THF subsequently removed in vacuo. The resulting residue was partitioned between 
4:1 CHCI3 : EtOH (30 ml) and water (20 ml). The layers were separated and the 
aqueous layer extracted with 4:1 CHCI3 : EtOH (2 x 30 ml). The combined organic 
layers were dried (MgS0 4 ), filtered and concentrated in vacuo. Column 
chromatography (30% EtOAc: 70% Hexanes to elute residual starting material, then 
80% EtOAc: 20% Hexanes) afforded the title product as a yellow solid (0.57 g, 
83%); m.p. 174-176 °C; vmax (KBr) 1609 (N=0), 1531, 1506, 1451 cm '1; 8 H (270 
MHz, CDCI3): -0.05 (2H, m, CH(CH2)2), 0.35 (2H, m, CH(CH2)2), 1.15 (3H, s, gem- 
CH3), 1.33 (3H, s, gem-CH3), 2.26-2.41 (3H, m, CH2 CH(CH2 ) 2 + 4-CH), 2.76 (1H, 
td, J  = 10.4, 4.9, 3-CH), 3.13 (1H, dd, J  = 15.8, 4.9, 4-CH), 3.30 (1H, d, /  = 10.4, 2- 
CH), 3.76 (3H, s, 7-OCH3), 6.67 (1H, dd, J  = 8.4, 2.6, 6 -ArH), 6.80 (1H, d ,J  = 2.6,
8 -ArH), 6.91 (1H, d, J  = 8.4, 5-ArH), 8.09 (2H, d, J  = 9.2, 2 x A r-H [o S 0 2]), 8.32 
(2H, d, J  = 9.2, 2 x  A r-H [oN 02]); 8 C ( 6 8  MHz, CDC13): 3.44, 11.55, 26.46, 28.73,
37.15, 40.97, 52.47, 53.86, 55.38, 65.22, 112.18 (Ar-CH), 112.46 (Ar-CH), 124.18 
(Ar-CH), 124.76 (Ar-C), 128.81 (Ar-CH), 129.82 (Ar-CH), 145.17 (Ar-C), 147.10 
(Ar-C), 149.88 (Ar-C), 158.38 (Ar-C); FAB MS m/z 461 (MH+, 100%); HRMS calc 
for C23H29N3 0 5S 460.1906, found 460.1882
iV-[*raws-7-Methoxy-l,l-dimethyl-3-(methylamino)-l,2,3,4-tetrahydro 
naphthalen-2-yl]-4-nitrobenzenesulfonamide (131)
Nosyl aziridine 126 (0.73 g, 1.88 mmol) was dissolved in methylamine 
solution (14.1 ml, 2.0M in THF, 28.2 mmol) at RT. Ytterbium (HI) 
trifluoromethanesulfonate (0.35 g, 0.56 mmol) was added and the reaction was 
subsequently heated to reflux for 24 hours. After this time, a further 14.1 ml of 
methylamine solution was added and heating continued for another 24 hours. The 
addition was repeated twice more (total volume of methylamine solution added =
56.4 ml, total reaction time = 96 hours), after which the reaction was allowed to cool 
to RT. The solvent and excess methylamine was evaporated in vacuo and the residue 
partitioned between 4:1 CHC13: EtOH (60 ml) and water (40 ml). The layers were 
separated and the aqueous layer was extracted with 4:1 CHC13: EtOH (2 x 60 ml). 
The combined organic layers were washed with brine (30 ml), then dried (MgS0 4 ), 
filtered and concentrated in vacuo to yield a brown oil. Column chromatography
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(100% CH2CI2 to elute residual starting material then 2 % MeOH: 97% CH2CI2 : 1% 
NH4 OH) afforded the title product as a yellow solid (0.29 g, 37%); Rf (10% MeOH: 
89% CH2C12: 1% NH4 OH): 0.34; m.p. 158-161 °C; vmax (KBr) 1528 (N=0), 1348 
cm '1; 5h (400 MHz, CDC13): 1.13 (3H, s, gem-CH3), 1.18 (3H, s, gem-CH3), 2.34 
(3H, s, 3 -NHCH3 ), 2.44 (1H, dd, J  = 15.6, 10.4,4-CH), 2.70 (1H, td, J  = 10.4, 5.2, 3- 
CH), 3.22 (1H, dd, J  = 15.6, 5 .2 ,4-CH), 3.36 (1H, d, J  = 10.4, 2-CH), 3.76 (3H, s, 7- 
OCH3 ), 6.69 (1H, dd, J  = 8.4, 2.4, 6 -ArH), 6.77 (1H, d, /  = 2.4, 8 -ArH), 6.95 (1H, d, 
J  = 8.4, 5-ArH), 8.08 (2H, d-pseudo-t, J  = 8 .8 , 2.4, 2 x Ar-H[o-S02]), 8.34 (2H, d- 
pseudo-1, J  = 8 .8 , 2.4, 2 x Ar-H[o-N02]); 5c (100 MHz, CDC13): 26.29, 28.52, 33.63,
36.00, 40.71, 55.25, 55.56, 65.19, 112.04 (Ar-CH), 112.33 (Ar-CH), 124.03 (Ar- 
CH), 124.66 (Ar-C), 128.53 (Ar-CH), 129.82 (Ar-CH), 144.85 (Ar-C), 147.15 (Ar- 




To a stirred solution of 130 (0.55 g, 1.20 mmol), triethylamine (0.50 ml, 3.59 
mmol) and 4,4-dimethylaminopyridine (30 mg, 0.24 mmol) in CH2CI2  (20 ml) at RT 
was added 4-nitrobenzenesulfonyl chloride (0.32 g, 1.44 mmol) in small portions. 
The reaction was stirred at RT for 18 hours then quenched by the cautious addition of 
water (15 ml). The layers were separated and the aqueous layer extracted with 
CHCI3 (2 x 20 ml). The combined organic layers were dried (MgSC>4 ), filtered and 
concentrated in vacuo. Column chromatography (30% EtOAc: 70% Hexanes) 
afforded the title product as a yellow powder (0.71 g, 92%); Rf (50% EtOAc: 50% 
Hexanes): 0.59; m.p. 212-214 °C; vmax (KBr) 1530 (N=0), 1350 cm '1; 5H (400 MHz, 
CDCI3): 0.17 (1H, m) + 0.53 (3H, m, CH2CH(CH2)2), 0.80 (1H, m, CH2CH(CH2)2),
2.70 ( 1 H, dd, J  = 15.6, 4.4, 4-CH), 3.09-3.19 (2 H, m, CH2CH(CH2)2), 3.35 ( 1 H, dd, 
J  = 15.6, 4 .4 ,4-CH), 3.73 (3H, s, 7-OCH3), 3.85 (1H, dd, J  = 11.2, 9.2, 2-CH), 4.04- 
4.13 (1H, m, 3-CH), 5.72 (1H, d, J  = 9.2, N-H), 6 . 6 6  (1H, dd, J  = 8.4, 2.4, 6 -ArH), 
6.74 (1H, d, /  = 2.4, 8 -ArH), 6.84 (1H, d, /  = 8.4, 5-ArH), 8.11 (4H, overlap br-d, /  
= 8.4, 4 x  Ar-H[0 -SO2]), 8.32 (2H, d-pseudo-t, J  = 8 .8 , 2.0, 2  x Ar-H[o-N02] on 
secondary sulfonamide), 8.35 (2 H, dd, /  = 8 .8 , 2.4, 2  x Ar-H[o-N02] on tertiary 
sulfonamide); 5C (100 MHz, CDC13): 3.47, 7.04, 11.52, 25.87, 28.94, 34.82, 41.97,
184
48.84, 54.63, 55.20, 61.35, 112.33 (Ar-CH), 112.58 (Ar-CH), 123.13 (Ar-C), 124.29 
(Ar-CH), 124.35 (Ar-CH), 128.01 (Ar-CH), 128.13 (Ar-CH), 129.59 (Ar-CH),
144.07 (Ar-C), 147.44 (Ar-C), 147.65 (Ar-C), 149.75 (Ar-C), 149.80 (Ar-C), 159.59 
(Ar-C); El MS submitted
terf-Butyl-cyclopropylmethyl(*ra/is»6-methoxy-4,4-dimethyl-3-{[(4-nitro 
phenyI)sulfonyl]amino}-l,2,3,4-tetrahydronaphthalen-2-yl)carbamate (134)
To a stirred solution of 130 (0.38 g, 0.83 mmol), triethylamine (0.35 ml, 2.48 
mmol) and 4,4-dimethylaminopyridine (10 mg, 0.08 mmol) in CH2CI2  (15 ml) was 
added di-tert-butyl dicarbonate (0.20 g, 0.91 mmol) in one portion at RT. After 
stirring at RT for 24 hours, water (15 ml) was added and the two phase system was 
separated. The aqueous layer was extracted with CH2CI2  ( 2  x 2 0  ml) and the 
combined organic layers were subsequently washed with aq. 1M HC1 (30 ml), dried 
(MgSCU), filtered and concentrated in vacuo. Column chromatography (10-15% 
EtOAc: Hexanes) afforded the title product as a yellow solid (0.28 g, 61%); Rf (50% 
EtOAc: 50% Hexanes): 0.61; m.p. 174-176 °C; Vnu* (KBr) 1695 and 1655 (C=0), 
1533 (N=0) cm '1; 8 H (270 MHz, CDC13): 0.21 ( 1 H, m, CH2CH(CH2)2), 0.48 ( 1 H, m, 
CH2CH(CH2)2), 0.53 (2 H, m, CH2CH(CH2)2), 0.94 (3H, s, gem-CH3), 1 . 0 0  ( 1 H, m, 
CH2CH(CH2)2), 1.14 (3H, s, gem-CH3), 1.54 (9H, s, Boc-(CH3)3), 3.00-3.12 (3H, m, 
CH 2 CH(CH2 ) 2 + 4-CH), 3.24 (1H, dd, J  = 15.3, 7.2, 4-CH), 3.74 (3H, s, 7-OCH3),
4.57 (1H, td, J  = 10.9, 6.7, 3-CH), 5.52 (1H, d, J  = 10.8, 2-CH), 6.69 (2H, m, 6 -ArH 
+ 8 -ArH), 6.97 (1H, d, J  = 8.4, 5-ArH), 8.00 (2H, d, J  = 8.9, 2 x Ar-H[<?-S02]), 8.32 
(2H, d, /  = 8.9, 2 x A r-H [oN 02]); 8 C ( 6 8  MHz, CDC13): 4.76, 12.18, 26.41, 28.63, 
28.83, 34.78, 41.57, 47.93, 51.38, 55.32, 63.98, 81.09, 112.14 (Ar-CH), 112.55 (Ar- 
CH), 124.35 (Ar-CH), 124.73 (Ar-C), 127.95 (Ar-CH), 129.86 (Ar-CH), 144.41 (Ar- 
C), 148.07 (Ar-C), 149.77 (Ar-C), 158.35 (Ar-C), 159.23 (C=0); FAB MS m/z 561 
(MH+, 50%), HRMS submitted
te/t-Butyl-cycIopropylmethyl(*raifs-7-methoxy-l,l-dimethyl-2-{[(Z?)-3- 
phenylprop-2-enyl]amm o}-l,2,3,4-tetrahydronaphthalen-3-yl)carbam ate (135) 
To a vigorously stirred suspension of lithium hydroxide monohydrate (0.15 g,
3.57 mmol) in anhydrous DMF (2 ml) was added mercaptoacetic acid (0.13 ml, 1.79 
mmol) dropwise at RT. The mixture was stirred for 5 minutes before a solution of
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134 (0.25 g, 0.45 mmol) in anhydrous DMF (4 ml) was added dropwise. The reaction 
was heated at 70°C under an atmosphere of nitrogen for 2 hours then allowed to cool 
to RT. The solvent was then evaporated in vacuo and the residue partitioned 
between aq. 1M NaOH (20 ml) and CHCI3 (30 ml). The layers were separated and 
the aqueous layer extracted with CHCI3 (2 x  30 ml). The combined organic layers 
were dried (MgSCU), filtered and concentrated in vacuo to yield the crude amine. 
Column chromatography (20-30% EtOAc: Hexanes) afforded a colourless oil (80 
mg) which NMR showed to be a mixture of the desired product and a slightly more 
polar contaminant. Rf (50% EtOAc: 50% Hexanes): 0.29. The crude amine was 
subsequently redissolved in anhydrous MeOH (4 ml) and frans-cinnamaldehyde (32 
pi, 0.26 mmol) was added. The reaction was stirred under an atmosphere of nitrogen 
for 18 hours at RT then cooled to 0°C. Sodium borohydride (32 mg, 0.85 mmol) was 
added in two portions and the resulting mixture stirred at 0°C for 1 hour, then at RT 
for a further 2 hours. The reaction was quenched by the dropwise addition of aq. sat. 
NaHC0 3  ( 2  ml), followed by water (5 ml). CH2CI2 ( 1 0  ml) was added and the layers 
separated. The aqueous layer was extracted with CH2CI2 ( 2  x  15 ml) and the 
combined organic layers dried (MgS0 4 ), filtered and concentrated in vacuo. Column 
chromatography (15% EtOAc: 85% Hexanes) afforded the title product as a 
colourless oil (75 mg, 34% over two steps). Rf (50% EtOAc: 50% Hexanes): 0.63; 8 h 
(270 MHz, CDCI3 ): 0.15-0.38 (2H, m, CH2CH(CH2)2), 0.52 (2H, d, J  = 8.2, 
CH2CH(CH2)2), 1.04 (1 H, m, CH2CH(CH2)2), 1 . 2 0  (3H, s, gem-CH3), 1.41 (3H, s, 
gem-CH3), 1.46 (3H, s, Boc-CH3), 1.49 (6 H, s, 2 x Boc-CH3), 2.96-3.51 (7H, m, 
alkyl), 3.60 (1H, dd, J  = 13.3, 5.7, 3-CH), 6.26 (1H, dt, J  = 15.8, 5.7, CH2CH=CH),
6.49 (1H, d, J  = 15.6, CH=CHPh), 6.66-6.71 (1H, m, 6 -ArH), 6 . 8 6  (1H, s, 8 -ArH),
6.94 (1H, d, /  = 7.2, 5-ArH), 7.16-7.37 (5H, m, 5 x ArH); 8 C ( 6 8  MHz, CDC13): 
4.50, 11.86, 25.87, 26.00, 27.95, 28.36, 28.68, 42.16, 53.60, 55.33, 64.75, 65.51,
80.04 (Boc-C), 111.58 (Ar-CH), 112.33 (Ar-CH), 112.56 (Ar-CH), 125.86 (Ar-C), 
126.31 (Ar-CH), 127.25 (Ar-CH), 128.58 (Ar-CH), 129.25 (Ar-C), 129.53 (Ar-CH), 
130.09 (Ar-CH), 137.35 (Ar-C), 146.86 (Ar-C), 157.90 (C=0); FAB MS m/z 491 




To a stirred solution of 135 (75 mg, 0.15 mmol) in CHCI3 (7 ml) was added 
trifluoroacetic acid (0.33 ml, 4.58 mmol) dropwise at RT. The reaction was stirred at 
RT for 48 hours, after which the solvent and excess trifluoroacetic acid were 
evaporated in vacuo. The residue was basified to pH 10 with triethylamine before 
partitioning between 4:1 CHCI3 : EtOH (20 ml) and water (10 ml). The layers were 
separated and the aqueous layer extracted with 4:1 CHCI3 : EtOH (2 x 20 ml). The 
combined organic layers were washed with brine ( 2 0  ml), dried (MgS0 4 ), filtered 
and concentrated in vacuo to afford the title product (as an approximately 3:4 
mixture of triethylamine: product) as a beige foam (57mg, 96%); Rf (10% MeOH: 
89% CH2C12: 1% NH4 OH): 0.56; v™* (film) 1613, 1496, 1450 cm '1; SH (400 MHz, 
CDCI3 ): 0.36 ( 1 H, m, CH(CH2)2), 0.42 ( 1 H, m, CH(CH2)2), 0.67 (2 H, m, 
CH(CH2)2), 1.17 (3H, s, gem-CH3), 1.27 (1 H, m, CH2CH(CH2)2), 1.49 (3H, s, gem- 
CH3), 2.74 ( 1 H, dd, J=  13.0, 8 .0 , 4-CH), 3.10-3.19 (3H, m, CH2CH(CH2 ) 2  + 2-CH), 
3.24 (1H, dd, J  = 13.0, 7.2, 4-CH), 3.54 (1H, m, 3-CH), 3.76 (3H, s, 7-OCH3), 3.78 
(2H, m, CH2CH=CH), 6.38 (1H, dt, J  = 16.0, 5.6, CH2CH=CH), 6.59 (1H, d, J  =
16.0, CH=CHPh), 6.69 (1H, dd, J  = 8.0, 2.4, 6 -ArH), 6.80 (1H, d, J  = 2.4, 8 -ArH),
6.95 (1H, d, /  = 8.0, 5-ArH), 7.18-7.32 (3H, m, 2 x Ar-H[m-CH=CH] + Ar-H[p- 
CH=CH]), 7.38 (2H, d, J  = 7.2, 2 x  Ar-H|>-CH=CH]); 8 C (100 MHz, CDC13): 3.96, 
4.67, 7.99, 25.75, 28.43, 31.04, 40.75, 49.58, 53.38, 55.22, 55.64, 63.97, 112.09 (Ar- 
CH), 112.13 (Ar-CH), 126.34 (Ar-CH), 127.44 (Ar-C), 127.61 (Ar-CH), 128.55 (Ar- 
CH), 130.13 (Ar-CH), 131.69 (Ar-CH), 136.62 (Ar-C), 144.84 (Ar-C), 158.44 (Ar- 
C); FAB MS m/z 391 (MH+, 90%); HRMS submitted
(£')-Ar-(4-M ethoxybenzyl)-3-phenyIprop-2-en-l-amine (137)
To a stirred solution of frans-cinnamaldehyde (2.98 ml, 23.7 mmol) in 
CH2C12 (80 ml) at RT was added 4-methoxybenzylamine (3.40 ml, 26.0 mmol) 
dropwise. The reaction was heated to reflux for 1 hour to ensure complete imine 
formation then allowed to cool to RT. The solvent was evaporated in vacuo and the 
residue redissolved in MeOH (60 ml). The mixture was cooled to 0°C and sodium 
borohydride (2.70 g, 71.0 mmol) subsequently added portionwise over 45 minutes. 
The reaction was stirred at 0°C for 2 hours, then at RT for a further 18 hours. Aq. 1M
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HC1 (50 ml) was added dropwise to quench the reaction and the pH adjusted to 10 by 
the cautious addition of conc. NH4 OH. Water (100 ml) and CH2CI2 (100 ml) were 
added and the layers separated. The aqueous layer was extracted with CH2CI2 ( 2  x  80 
ml), and the combined organic layers were washed with water ( 1 2 0  ml), dried 
(MgSC>4 ), filtered and concentrated in vacuo to yield a yellow liquid. The crude 
amine was redissolved in EtOH (30 ml) and aq. 5M HC1 (30 ml) was added, causing 
the HC1 salt to precipitate immediately. The flask was cooled to 0°C for 1 hour to 
ensure maximum precipitation, before the salt was collected by suction filtration. 
Recrystallisation from EtOH gave the hydrochloride as white prisms. The free base 
was obtained by dissolving in aq. 3M NaOH (50 ml) and extracting with CH2CI2 (3 x 
50 ml). Drying (MgS0 4 ), filtering and evaporation of the solvent in vacuo afforded 
the title product as a colourless liquid (3.22 g, 49%); Rf (10% MeOH: 89% CH2CI2 : 
1% NH4 OH): 0.41; vmax (film) 1611, 1512, 1248 c m 1; 8 H (400 MHz, CDC13): 3.46 
(2H, dd, J  = 6.0, 1.2, CH2CH=CH), 3.82 (2H, s, NHCH2Ar), 3.84 (3H, s, OCH3), 
6.36 (1H, dt, J  = 15.6, 6.4, CH2CH=CH), 6.58 (1H, d, J  = 15.6, CH=CHPh), 6.92 
(2H, d-pseudo-t, J  = 8.4, 2.0, 2 x Ar-H[o-OCH3]), 7.24-7.43 (7H, m, 7 x ArH); 8 C 
(100 MHz, CDCI3): 51.12, 52.74, 55.31, 113.86 (Ar-CH), 126.31 (Ar-CH), 127.40 
(C=C), 128.40 (Ar-CH), 128.59 (Ar-CH), 129.48 (Ar-CH), 131.48 (C=C), 132.28 
(Ar-C), 137.16 (Ar-C), 158.71 (Ar-C); FAB MS m/z 255 (MH+, 100%); HRMS calc, 
for C 17H20NO 254.1544, found 254.1549
fra#w-2-{(4-Methoxybenzyl)[(Z£)-3-phenylprop-2-enyl]amino}cyclohexanol 
hydrochloride (138)
To a stirred suspension of 139.HC1 (4.62 g, 15.9 mmol) in 1,2-dichloroethane 
(45 ml) at RT was added frans-cinnamaldehyde (2.21 ml, 17.5 mmol) and 
triethylamine (2.66 ml, 19.1 mmol). Sodium triacetoxyborohydride (5.07 g, 23.9 
mmol) was then added portionwise over 5 minutes and the reaction subsequently 
stirred for 16 hours at RT. Excess hydride was quenched by the cautious addition of 
aq. sat. NaHC(> 3  (20 ml) and the resulting two-phase system was separated. The 
aqueous layer was extracted with CH2CI2 ( 2  x  30 ml) and the combined organic 
layers were dried (MgS0 4 ), filtered and concentrated in vacuo to give a yellow oil. 
The crude amine was treated with 5M HC1 in propan-2-ol (40 ml) and the solvent 
removed to yield the hydrochloride salt. Recystallisation from propan-2-ol/diethyl
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ether afforded the title product as white crystals (5.59 g, 90%); 8 h (400 MHz, 
CDC13): 1.22 (4H, br-pseudo-s, 4 x  cyclo CH), 1.67-1.83 (2H, m, CH2 CHNBn), 1.90 
(1H, m, CH 2CHOH), 2.16 (1H, m, CH 2CHOH), 2.48 (1H, m, CH2CHNBn), 3.13 
(1H, dd, J  = 14.1, 8.4, NCH 2 CH=CH), 3.34 (1H, d, /  = 13.3, NCH2Ar), 3.40-3.54 
(2H, CH2CHOH + NCH 2CH=CH), 3.79 (3H, s, OCH3), 3.87 (1H, d, J  = 13.3, 
NCH 2Ar), 6.10-6.22 (1H, m, CH2CH=CH), 6.50 (1H, d, J  = 16.1, CH=CHAr), 6 . 8 8  
(2H, d, J  = 8 .6 , 2 x  Ar-H[o-OCH3]), 7.24 (2H, d, J  = 8 .6 , 2 x  Ar-H[m-OCH3]), 7.30- 
7.40 (5H, m, 5 x  Ar-H[cinnamyl]); 8 C (70 MHz, CDC13): 22.76, 24.27, 25.68, 33.34, 
52.23, 53.08, 55.32, 65.26, 69.28, 113.97 (Ar-CH), 126.44 (Ar-CH), 127.56 (Ar- 
CH), 128.67 (Ar-CH), 130.13 (Ar-CH), 131.77 (Ar-C), 132.37 (Ar-CH), 137.11 (Ar- 
CH), 158.83 (Ar-CH)
rraws-2-[(4-Methoxybenzyl)amino]cyclohexanol hydrochloride (139)
4-Methoxybenzylamine (3.86 ml, 29.7 mmol) was added dropwise with 
stirring to cyclohexene oxide (3.00 ml, 29.7 mmol) at RT (no solvent). The mixture 
was stirred for 5 minutes, then lithium bistrifluoromethanesulfonimidate (1.70 g, 
5.93 mmol) was added in small portions (warming was observed). The reaction was 
stirred vigorously at RT for 3 days, after which time CH2C12 (40 ml) and aq. sat. 
NaHC03 (15 ml) were added. The layers were separated and the aqueous layer 
extracted with CH2C12 (2 x  40 ml). The combined organic layers were dried 
(MgSCU), filtered and concentrated in vacuo to give a colourless oil. The crude 
amine was redissolved in EtOH (30 ml) and 5M HC1 in propan-2-ol (30 ml) was 
added. The solvent was evaporated in vacuo and the resulting solid recrystallised 
from propan-l-ol to yield the hydrochloride salt as fine colourless prisms (5.35 g, 
6 6 %). The free base was prepared by treating the HC1 salt with aq. 2M NaOH (40 
ml) and extracting the resulting emulsion with CH2C12 (3 x  50 ml). The combined 
organic layers were dried (MgS0 4 ), filtered and concentrated to afford the title 
product as a colourless oil; Rf (10% MeOH: 89% CH2C12: 1% NH4 OH): 0.23; vmax 
(film) 3294 and 3135 (O-H), 1613, 1517 c m 1; 8 h (400 MHz, CDC13): 0.95-1.07 (1H, 
m, cyclo CH), 1.16-1.32 (3H, m, 3 x  cyclo CH), 1.68-1.76 (2H, pseudo-s, 
CH 2 CHNH), 1.94-2.02 (1H, pseudo-s, CH2CHOH), 2.11-2.18 (1H, pseudo-d, J  =
12.8, CH 2CHOH), 2.26-2.34 (1H, CHNHBn), 3.20 (1H, td, J  = 9.6, 3.6, CHOH), 
3.62 (1H, dd, J  = 12.8, 1.6, NHCH 2Ar), 3.80 (3H, s, OCH3), 3.88 (1H, dd, J  = 12.4,
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1.6, NHCH2Ar), 6.87 (2H, dd, J  = 8.4, 1.2, 2 x A r-H |>OCH 3]), 7.26 (2H, d ,J =  8.4, 
2 x  Ar-H[m-OCH3]); 6 C (100 MHz, CDC13): 24.42, 25.05, 30.33, 33.56, 50.20, 
55.26, 62.92, 73.53, 113.83 (Ar-CH), 129.36 (Ar-CH), 132.51 (Ar-C), 158.66 (Ar- 
C); FAB MS m/z 236 (MH+, 50%)
A ttempted preparation of Ar-(4-MethoxybenzyI)-A-[£ra/is-2-(methylamino) 
cyclohexyl]-iV-[(Z£)-3-phenylprop-2-enyI]amme (141)
To a stirred solution of 139 (1.24 g, 3.53 mmol) in anhydrous THF (30 ml) at 
0°C under an atmosphere of nitrogen was added methanesulfonyl chloride (0.54 ml, 
7.06 mmol) dropwise via a syringe. The mixture immediately became cloudy as 
triethylamine hydrochloride precipitated and the reaction was allowed to stir at 0°C 
for 2 hours. TLC analysis (50% EtOAc: 50% Hexanes) showed a prominent spot on 
the baseline by UV, suggesting formation of an aziridinium salt. Triethylamine (1.47 
ml, 10.6 mmol) was added, after which the reaction was allowed to warm to RT. 
Methylamine (8.22 ml, 40% solution in water, 106 mmol) was subsequently added 
and the reaction stirred at RT for 1 hour. TLC analysis indicated the presence of a 
substantial amount of starting material and several polar compounds.
l-Methoxy-4-(4-methylpent-3-enyl)benzene (143)
Magnesium turnings (1.18 g, 48.5 mmol) (which had been previously washed 
with diethyl ether, dried overnight then ground in a pestle and mortar) and a few 
crystals of iodine were placed in an oven dried 250 ml round-bottomed flask and 
covered with anhydrous THF (5 ml) at RT. The flask was fitted with a pressure- 
equalising dropping funnel containing a solution of 4-methoxybenzyl chloride (6.00 
ml, 44.1 mmol) in anhydrous THF (30 ml) and the system flushed with nitrogen. 
Addition of the halide solution was then commenced at such a rate as to maintain 
gentle reflux (20 minutes), after which the reaction was stirred for an additional 15 
minutes to ensure complete consumption of the chloride. The dropping funnel was 
charged with a solution of l-bromo-3-methyl-2-butene (5.69 ml, 44.1 mmol) in 
anhydrous THF (25 ml) and subsequently added dropwise to the Grignard reagent 
over 15 minutes. The reaction was stirred at RT for 1 hour, then quenched by the 
cautious addition of water (70 ml). Hexanes (100 ml) were added and the resulting 
two-phase system separated. The aqueous layer was extracted with hexanes (2 x 100
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ml) and the combined organic layers were washed with water (150 ml), brine ( 1 0 0  
ml), then dried (MgS0 4 ), filtered and concentrated in vacuo to afford the title product 
as a colourless oil (8.05 g, 96%); Rf (50% EtOAc: 50% Hexanes): 0.59; 8 h (400 
MHz, CDC13): 1.56 (3H, s, C(CH3)2), 1-68 (3H, s, C(CH3)2), 2.25 (2H, q, J  = 7.6, 
CH2CH2 CH), 2.57 (2H, t, J  = 7.6, ArCH2CH2), 3.79 (3H, s, OCH3), 5.16 (1H, tt, J  =
7.6, 1.6, CH2CH=C(CH3)2), 6.82 (2H, d, J  = 8.4, 2 x  Ar-H[m-OCH3]), 7.10 (2H, d, J  
= 8.4, 2 x Ar-H[0 -OCH3]); Sc (100 MHz, CDC13): 17.64, 22.65, 30.29, 35.19, 55.22, 
113.60 (Ar-CH), 123.77 (C=CH), 129.28 (Ar-CH), 132.05 (Ar-C), 134.52 (C=CH), 
157.63 (Ar-C); FAB MS m/z 190 (M+, 90%)
2-Chloro-7-methoxy-l,l-dimethyl-l,2,3,4-tetrahydronaphthalene (145)
To a stirred solution of alkene 143 (4.40 g, 23.1 mmol) in 5:1 acetone:water 
(70 ml) at RT was added trichloroisocyanuric acid (2.15 g, 9.25 mmol) in small 
portions over 5 minutes. Warming was observed during the addition and the reaction 
rapidly became cloudy. The system was stirred at RT for 3 hours after which time it 
was filtered under vacuum. The residual solid was washed with acetone ( 2 x 1 0  ml) 
and the filtrate concentrated in vacuo to leave an emulsion which was subsequently 
diluted with water (50 ml) and extracted with CH2C12 (3 x 70 ml). The combined 
organic layers were then washed with aq. 1M sodium metabisulfite (80 ml), dried 
(MgSC>4), filtered and concentrated in vacuo. Column chromatography (0-5% 
EtOAc: Hexanes: 1% Triethylamine) afforded the chlorohydrin as a mixture of 
regioisomers (1.63 g, 29%). 100% Sulfuric acid (0.72 ml, 13.4 mmol) was added to 
a mixture of 5 g of silica gel (which had been kept in an oven overnight then allowed 
to cool to RT) in CH2C12 (30 ml) and the resulting slurry stirred for 5 minutes at RT. 
A solution of chlorohydrin (1.63 g, 6.71 mmol) in CH2C12 (30 ml) was added 
dropwise over 10 minutes, causing a deep red colouration to develop. The reaction 
was allowed to stir at RT for 2 hours before quenching with propan-2-ol (10 ml). 
The silica gel was separated by suction filtration and washed with CHC13 (3 x  20 
ml). Water (60 ml) was added to the filtrate and the layers separated. The aqueous 
layer was extracted with CHC13 (2 x 50 ml) and the combined organic layers were 
washed with brine (50 ml), dried (MgSC>4 ), filtered and concentrated in vacuo. 
Column chromatography (5% EtOAc: 95% Hexanes) afforded the title product as a 
yellow oil (1.17 g, 22% overall yield); Rf (50% EtOAc: 50% Hexanes): 0.67; 8 h (270
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MHz, CDCI3 ): 1.31 (3H, s, gem-CH3), 1.34 (3H, s, gem-CH3), 2.05-2.13 (2H, m, 3- 
CH2), 2.69-2.94 (2H, m, 4-CH2), 3.71 (3H, s, OCH3), 4.12 (1H, dd, J  = 9.0, 2.1, 2- 
CH), 6.63 (1H, dd, J  = 8.4, 2.4, 6 -ArH), 6.79 (1H, d, J  = 2.1, 8 -ArH), 6.90 (1H, d, J  
= 8.4, 5-ArH); 6 C (100 MHz, CDCI3): 26.81, 27.23, 28.86, 29.73, 39.97, 55.23, 
69.18, 111.64 (Ar-CH), 112.19 (Ar-CH), 125.89 (Ar-C), 129.68 (Ar-CH), 144.68 
(Ar-C), 157.96 (Ar-C); FAB MS m/z 224 (M+, 60%)
7-M ethoxy-l,l-dim ethyl-l,2-dihydronaphthalene (146) via KC^Eii-promoted 
rearrangem ent of 141
To a stirred solution of 145 (0.25 g, 1.11 mmol) in anhydrous 
dimethylsulfoxide (5 ml) at RT was added potassium terf-butoxide (0.19 g, 1.67 
mmol) in one portion. The reaction was heated at 60°C for 5 hours then allowed to 
cool to RT. The mixture was quenched by the cautious addition of water (10 ml). 
Pentane (30 ml) was added and the layers were separated. The organic layer was 
washed with water ( 2  x 2 0  ml), dried (MgS0 4 ), filtered and evaporated to afford the 
rearranged alkene (0.18 g); SH (270 MHz, CDC13): 1.24 (3H, s, gem-CH3), 1.25 (3H, 
s, gem-CH3), 2.19 (2H, dd, J  = 4.2, 1.8, CH 2C(CH3)2), 3.80 (3H, s, OCH3), 5.81 (1H, 
dt, J  = 9.6, 5.0, CH=CHCH2), 6.40 (1H, dd, /  = 9.6, 1.7, ArCH=CH), 6 . 6 6  (1H, dd, J  
= 8.4, 2.5, 6 -ArH), 6.87 (1H, d, J  = 2.5, 8 -ArH), 6.97 (1H, d, J  = 8.4, 5-ArH)
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Identification o f a New Scaffold for Opioid Receptor Antagonism  Based on the
2-A m ino-l,l-dim ethyl-7-hydroxytetralin Pharm acophore
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Received March 9, 2004
The £rans-(3,4)-dimethyl-4-(3-hydroxyphenyl)piperidines are a unique class of opioid antagonists 
th a t have recently provided selective antagonists for //-opioid receptors (MOR) and /c-opioid 
receptors (KOR). Molecular modeling indicated a strong structural similarity between the parent 
of this series and 2-amino-1 , 1 -dimethyl-7-hydroxytetralin. In binding and in vitro functional 
assays, the am inotetralin derivatives displayed some overlap in SAR with that previously 
reported for the phenylpiperidine series, providing evidence for a common binding mode for 
the two series a t opioid receptors. Introduction of a methoxy group in the 3-position increased 
potency at MOR and KOR receptors, suggesting that this aminotetralin skeleton can be utilized 
as a new scaffold for the design of selective opioid receptor antagonists.
Introduction
There has been considerable interest over many years 
in the development of selective ligands with which to 
study the function of opioid receptors . 1-2 Significant 
advances have been made with selective agonists and 
antagonists available for each of the three opioid recep­
tors (ju, MOR; 6 , DOR; k, KOR) . 1 3 - 5  Portoghese has 
developed both KOR- and DOR-selective antagonists by 
applying the message—address concept of Schwyzer to 
the opioid antagonist naltrexone (1, Chart 1), which 
itself is slightly MOR-selective. 6 The prototypic KOR- 
antagonist, developed in this way, is norBNI (2) . 7 
Portoghese has since shown that the large bimorphinan 
structure of 2  can be significantly simplified while 
retaining KOR selectivity and antagonist potency. This 
has ultimately led to the development of GNTI (3) . 8
The undoubted success of this approach means a large 
number of KOR and DOR antagonists have been 
synthesized on the basis of the oxymorphone framework.
It is now desirable for the range of scaffolds to be 
increased because this could provide ligands with, for 
example, differing pharmacokinetic and pharmacody­
namic properties or differing receptor subtype selectiv­
ity. In this regard, the provision of KOR antagonists 
that lack the extremely long duration of activity of 2  
and 3 would be of particular value.
Carroll and co-workers have been successful in de­
veloping selective MOR and KOR antagonists based on 
an alternative to the oxymorphone framework, trans- 
(3,4)-dimethyl-4-(3-hydroxyphenyl)piperidines, which pro­
duced a unique class of opioid antagonists, discovered 
by Zimmerman. 9 - 1 1  It was shown that modification of 
the N-substituent provided a means to control both the 
selectivity and potency of the ligands without introduc­
ing efficacy. By this approach, the selective MOR 
antagonist (4a) 10 and the highly selective KOR antago­
nist JDTic (4b)11 were discovered. In these cases the 
phenylpiperidine unit acts as the message while the 
cinnamyl phenyl group and 7-hydroxyterahydroisoquin-
* To whom correspondence should be addressed. Phone: 44-1225- 
383103. Fax: 44-1225-386114. E-mail: s.m.husbands@bath.ac.uk.
Figure 1. O verlay of 4a (green) w ith  9k (red).
oline moieties provide the MOR and KOR address 
components, respectively.
We recognized the structural equivalence of the 14/3- 
amino group in the morphinone series (5)12 and the 
piperidine basic center in the phenylpiperidine series 
(4) in their spatial relationships to the respective 
phenolic binding centers. The 14/3-alkylaminomorphi- 
none series (5a), particularly those members with a side 
chain terminal aryl group, consistently provides potent 
opioid receptor antagonism with only low-level agonist 
activity. This SAR is characteristic also of the phenylpi­
peridine series (4). Though we investigated the 14/3- 
cinnamylaminomorphinone (5a) and showed it to have 
potent noncompetitive MOR antagonist activity , 12 we 
were not immediately attracted to further investigation 
of the 14/3-amino skeleton as a new message scaffold, 
particularly for introducing the address component for 
KOR selectivity because its synthesis from thebaine is 
multistep and very low yielding . 13 We considered the 
simpler but closely related aminobenzomorphan struc­
ture (6 ), but that too failed our criterion of ready 
accessibility. 14
We therefore turned to an even simpler structure, 
2-amino-l,l-dimethyl-7-hydroxytetralin (7). The 2-ami- 
notetralin skeleton has previously been employed in the 
development of opioid analgesics. 1 5 - 1 7  A primary amino 
group was required for good in vivo analgesic activity 
with dezocine (8) the most well characterized example. 18 
Because of their reduced analgesic potency, little atten-
10.1021/jm 040807s CCC: $27.50 © 2004 A m erican Chem ical Society
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I: R1 = cinnamyl, R2 =Me 
d: R1 = R2 = nPr
a Reagents and conditions: (i) RBr, NaHC0 3 , DMF, 80 °C; (ii) cyclopropylcarbonyl chloride, then LiAlH4; (iii) Pd, H 2 ; (iv) formaldehyde 
(1 equiv), NaBfOAchH, CH2CI2 ; (v) formaldehyde or propionaldehyde (2 equiv), NaB(OAc)3H, CH2CI2 .
tion had previously been paid to secondary or tertiary 
amines . 16
The validity of the choice of the aminotetralin (7) as 
a message scaffold for the design of selective antagonist 
ligands for MOR and KOR was confirmed by molecular 
modeling. Figure 1 shows the cinnamylphenylpiperidine 
derivative (4a) and the R  enantiomer of the cinnamyl- 
aminotetralin derivative (9k) with the phenolic rings 
overlaid. In this orientation C3 , C4 , and the C3 methyl 
group of the piperidine (4a) can overlay the reduced ring 
carbons of the tetralin while the latter’s gem-dimethyl 
groups can overlay well with the C4 methyl group and 
C5 ring carbon of the piperidine. Importantly, this also 
allows the hydrogens of the protonated nitrogens to 
assume a common location, and the phenyl rings of the 
cinnamyl moieties are also in proximity to one another.
Our first targets were secondary and tertiary amine 
derivatives of (7) including those with cinnamyl groups.
The secondary cinnamyl derivative (9k) had good MOR 
binding affinity and had moderate MOR and KOR 
antagonist potency. At the completion of this phase of 
the work, Roy et al. reported their work, based on the 
analgesic Dezocine, toward development of the amino­
tetralin pharmacophore for MOR agonist activity . 19 
Their findings showed that a two-atom side chain a  to 
the primary amino function gave optimal agonist po­
tency. We resynthesized the published lead compound 
(13b) and a new cinnamyl derivative (14). The latter 
had high binding affinity particularly for MOR and high 
antagonist potency for MOR and KOR.
Chemistry
As depicted in Scheme 1, the synthesis of the substi­
tuted aminotetralins (9a-m) was accomplished by 
several methods. The tertiary amines (9m j) and the 
secondary amines (9k,h) were prepared by direct alky-
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L13a: R = Boc 13b: R = H
3 Reagents and conditions: (i) NPkOH-HCl, NaOAc, H2O, MeOH; (ii) SMEAH, Bu(Me)NH, toluene; (iii) BBr3 , CH2CI2 ; (iv) B0 C2O, 
DMAP, N Et3 , CH2CI2 ; (v) MeOH, pyridinium p-toluenesulfonate; (vi) TFA, CH 2CI2 ; (vii) PhCH=CHCHO, CH2CI2 , then NaBfh, MeOH.
Table 1. Binding Affinities to Opioid Receptors3
Ki ±  SEM (nM)
compd R1 R2 [3H]DAMGO n [3H]C1-DPDPE d [3H]U69,593 i
9a Me Me 114 ±  31.7 4010 ± 399 333 ±  65.8
9b ”Pr H 491 ±  48.0 >10000 251 ±  55.0
9c ”Pr Me 85.0 ±  14.7 2090 ±  22.8 184 ±  29.4
9d ”Pr "Pr 482 ±61 .1 2720 ±  780 552 ±  42.5
9e CPM H 312 ± 4 5 .0 3830 ±  159 232 ±  4.80
9f CPM Me 104 ±  24.5 601 ±  84.0 146 ±  13.7
9g CPM CPM 422 ±  46.7 5770 ±  591 1830 ± 5 1 7
9h allyl H 202 ±  0.92 5830 ±  682 63.7 ±  6.60
91 allyl Me 1080 ±  142 2220 ±  484 263 ±  5.10
9j allyl allyl 105 ±  0.89 672 ±  127 55.8 ±  18.6
9k cinnamyl H 10.7 ±  2.73 472 ± 108 82.3 ±  18.0
91 cinnamyl Me 39.7 ±  11.7 591 ±  27.3 207 ± 29.6
9m cinnamyl cinnamyl 268 ±  53.4 >10000 1250 ±  143
13b 17.5 ±  5.90 2430 ±  422 149 ±  2.15
14 1.63 ± 0 .5 8 22.4 ±  6.70 7.50 ±  0.84
naltrexone 0.2 ±  0.0 10.8 ±  3.0 0.4 ±  0.1
naltrindole 6.3 ±  2.3 0.2±0.05 10.1 ± 0 .65
nor BN I 21.0 ± 5 .0 5.7 ±  0.9 0.2 ±  0.05
3 D ata provided through NIDA (OTDP).
lation of the known 7-amino-8,8-dimethyl-5,6,7,8-tet- 
rahydronaphthalen-2-ol (7)14 using the appropriate alkyl 
bromide. The most reliable method for synthesis of the 
monopropyl analogue (9b) proved to be hydrogenation 
of the allyl group of 9h. The cyclopropylmethylamines 
(9e,g) were prepared by sequences of acylation with 
cyclopropylcarbonyl chloride and subsequent reduction 
with LLAIH4 . The methylamines (9a,c,f,i,l) and the 
dipropylamine (9d) were synthesized by reductive ami- 
nation using sodium triacetoxyborohydride as the re­
ducing agent.
The synthesis of 13b has been reported previously 
(Scheme 2) . 19 While the use of LLA.IH4 in the presence 
of DEA was reported to give good yields (60%) of 
aziridine (11a) from the oxime (10b), we were unable 
to carry out the reaction in a reproducible manner. An 
alternative method utilizing RedAl with AA-methylbu- 
tylamine gave 11a in lower, but reproducible, 40% yield 
(Scheme 2). Ring opening with MeOH under acid 
catalysis followed by removal of the Boc protecting group 
gave 13b. The cinnamyl group was introduced by 
reaction with cinnamaldehyde and subsequent reduc­
tion with NaBH4 (14).
Results and Discussion
The ligands were evaluated in competition binding 
assays in Chinese hamster ovary (CHO) cells trans­
fected with cloned human opioid receptors (Table l ) . 20  
The displaced radioligands were [3 H]DAMGO (MOR), 
[3 H]C1-DPDPE (DOR), and [3H]U69,593 (KOR). The 
simplest tertiary amino derivative (9a) had modest 
affinity for MOR and KOR but very low affinity for 
DOR. Replacement of one of the methyl groups of 9a 
by n-propyl, allyl, or cyclopropylmethyl (piperidine 
N-substituents that give antagonist activity in the 
epoxymorphinan, morphinan, and benzomorphan series) 
had variable effects on opioid receptor affinity. The 
/7-propyl analogue (9c) had affinity similar to that of 
9a for all opioid receptors. The allyl analogue (9i) had 
KOR and DOR affinity similar to that of 9a but an order 
of magnitude lower affinity for MOR. The cyclopropyl­
methyl (CPM) derivative (9f) had MOR affinity similar 
to that of 9a but somewhat higher KOR affinity and 
substantially higher DOR affinity. The effect of replac­
ing the 7V-methyl group in 9c by a second propyl group 
(9d) was to reduce KOR and MOR affinity. Similar 
replacement of the AAmethyl group in 9f by a second 
CPM group (9g) had an equivalent but more pronounced 
effect having 4-fold lower MOR affinity and an order of 
magnitude lower KOR and DOR affinity. Surprisingly 
the bis-allylamine (9j) had substantially higher affinity 
than the monoallyl tertiary amine (9i) for all opioid 
receptor types but particularly for MOR.
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Table 2. Antagonist Potencies in [35S]GTPyS Assays 
Performed in Cloned Hum an Opioid Receptors3
compd R1 R2
Ke ±  SEM (nM)
vs DAMGO n vs DPDPE 6 vs U69.593 x
9k cinnamyl H 67.7 ± 7.59 NT 42.7 ± 2.75
13b agonist* NT 49.3 ± 4.3
14 2.62 ± 0.40 26.3 ±  3.90 2.12 ±0.11
naltrexone 0.59 ± 0.04 5.44 ±  0.75 1.86 ±0.16
naltrindole 4.26 ± 0.33 0.11 ±  0.005 4.95 ± 0.32
norBNI 18.9 ± 1.80 4.42 ±  0.38 0.039 ±  0.004
3 D ata provided by NIDA (OTDP). b Agonist IC50 =  234 ±  55 
nM, 31.6% stimulation relative to the standard  fi agonist DAMGO.
The propyl and CPM secondary amines (9b,e) had 
lower affinity than the equivalent Af-methyl tertiary 
amines, but the secondary allylamine (9h) had substan­
tially higher affinity for MOR than the tertiary amine 
(9i). The secondary allylamine (9h) and the bisally 1- 
amine (9j) had higher KOR affinity than any of the 
other new ligands. The tertiary cinnamylamine (91) had 
higher MOR affinity than any of the other tertiary 
amines, together with modest selectivity for MOR over 
KOR and substantial selectivity for MOR over DOR. The 
bis-cinnamylamine (9m) had lower affinity than 91, but 
the secondary cinnamylamine (9k) had higher affinity 
than 91, and its MOR affinity (Kj = 10.6 nM) was the 
highest recorded for any opioid receptor by ligands of 
structure 9. It had 8-fold selectivity for MOR over KOR 
and 45-fold selectivity for MOR over DOR. This is 
reminiscent of the findings of Zimmerman who showed 
that a phenyl ring separated by a three-atom chain from 
their phenylpiperidine scaffold was optimal for MOR 
affinity and antagonist activity.9 In the present series, 
in no case was significant affinity seen for the DOR, 
with the highest affinity {Ki = 471 nM) displayed by 
9k
For ligands having K\ values of 200 nM or better in 
the binding assays, opioid agonist and antagonist activ­
ity was determined using the [35S]GTPyS assay in 
cloned human opioid receptors transfected into CHO 
cells.20 Only one of the new ligands of type 9, the 
secondary cinnamylamine (9k), had significant activity 
in this assay (Table 2) with no other ligand displaying 
a Ke, at any receptor, better than 500 nM. 9k was a 
moderately potent antagonist of MOR and KOR with 
no selectivity. Nevertheless, it was of great significance 
that 9k was an antagonist in the in vitro functional 
assays, thus further confirming the relationship of this 
series to the phenylpiperidines. As was to be expected 
there was little similarity in the effect of N-substitution 
between the aminotetralins (9) and the basic N-atom 
in the epoxymorphinan, morphinan, and benzomorphan 
series.21 In these series arylalkyl substitution, particu­
larly phenethyl, enhanced agonist (antinociceptive) 
activity. Though antinociceptive potency was substan­
tially lower for cinnamyl, phenylpropyl, and phenylbutyl 
substitution, there was no evidence of morphine an­
tagonist activity.
The trans-3-methoxy-substituted analogue 14 had 
much higher affinity for all opioid receptor types than 
the lead compound 9k from the aminotetralin series 
(Table 1). MOR affinity for 14 was 6.5-fold higher, KOR 
affinity 11-fold higher, and DOR affinity 21-fold higher 
than for 9k. Compared with the previously reported 
primary amine (13b),19 the cinnamylamino derivative
14 also had much higher affinity, 11-fold for MOR, 20- 
fold for KOR, and 108-fold for DOR. In [35S]GTPyS 
assays 14 showed potent MOR and KOR antagonist 
activity, and in each case potency was ~20-fold greater 
than for 9k. Interestingly, though the primary amine 
was reported to have potent antinociceptive activity,19 
in the GTPyS assay it was a low potency, low efficacy 
MOR partial agonist and a KOR antagonist.
Conclusions
In conclusion, it is clear that the 2-amino-1,1-dimeth­
yl-7-hydroxytetralin skeleton, particularly when incor­
porating an appropriate functional group (e.g., OMe) in 
the 3-position and trans to the C2 amine, offers an 
alternative scaffold for the design of receptor selective 
opioid ligands. The ligands produced were comparable 
to their trans- (3,4) -dimethyl-4- (3-hydroxyphenyl) piperi­
dine analogues in opioid binding affinity and antagonist 
potency. We are currently investigating the use of this 
skeleton in the preparation of KOR selective antago­
nists.
Experimental Section
Colum n chrom atography w as perform ed u n d e r g rav ity  over 
silica gel 60 (3 5 -7 0  //m) purchased  from M erck. P rep ara tiv e  
TLC w as perform ed on p lates m ade w ith Kieselgel 60 P F 254+3 6 6 . 
obtained from M erck. The th ickness of the  silica layer w as 
approxim ately  1 mm. A nalytical TLC w as perform ed using  
alum inum -backed p la tes  coated w ith  Kieselgel 60 F 2 5 4 , from 
Merck. The chrom atogram s w ere v isualized using  e ith e r  UV 
ligh t (UVGL-58, sh o rt w avelength), n inhydrin  (acidic), or 
po tassium  p e rm an g an a te  (basic). M elting po in ts w ere carried  
out using  a R eichert-Jung  T herm o G alen Kopfler block or a 
G allenkam p MFB-595 m elting point ap p ara tu s and  a re  uncor­
rected. High- an d  low -resolution fast atom  bom bardm en t 
(FAB) m ass spec tra  w ere recorded on a Fisons VG AutoSpec 
Q instru m en t, w ith  a m atrix  of m -nitrobenzyl alcohol. Highl­
and  low-resolution electron  im pact (El) m ass sp ec tra  w ere 
recorded using  E l ionization a t 70 eV, on a VG AutoSpec 
instrum ent, equipped w ith a Fisons autosam pler. ‘H NMR and 
13C NMR spectra  were recorded using JE O L  EX 400 (operating 
a t  400 MHz for 'H  an d  101 M Hz for l3C) or JE O L  GX270 
(operating a t 270 MHz for 'H  an d  68 MHz for 13C) spectrom ­
eters. Chem ical sh ifts  (d) a re  m easured  in  ppm  re la tive  to 
TMS. Coupling constan ts (J) a re  expressed in Hz. M icroanaly­
sis w as perform ed w ith  a Perk in -E lm er 240C analyzer. 
Anhydrous THF, DMF, DCM, and MeOH were purchased  from 
Aldrich. All o th er so lvents used  w ere GPR grade, pu rchased  
from M erck or F ish e r Scientific. Chem icals w ere  pu rchased  
from Aldrich, Fluka, L ancaster, and Acros chemical companies.
General Methods. Procedure A. To a so lu tion  of the  
appropria te  am ine (1.0 mmol) in C H 2CI2 (10 mL) w as added 
form aldehyde (75 /iL, 1 mmol, 37 w t %) followed by a sp a tu la  
tip  of M gS0 4  to remove excess w ater. T his m ix tu re  w as then  
trea te d  w ith  solid sodium  triacetoxyborohydride (0.29 g, 1.4 
mmol) and  s tirred  a t  room tem p era tu re  overnight u n d e r an  
a tm osphere  of nitrogen. T he m ix ture  w as quenched by the  
addition  of sa tu ra te d  aqueous N a2C 0 3 solution, an d  the  
product w as ex tracted  into CH 2CI2 . The com bined ex trac ts  
w ere dried (MgSCh) to give th e  crude free base th a t  w as 
purified by th in -lay er chrom atography or flash  ch ro m atogra­
phy followed by crystallization  from m ethanolic  H C l/Et20.
Procedure B. A suspension of 0.19 g (1.0 mmol) of 2-amino-
1,1-d im ethy l-1,2,3,4 -tetrahydronaphthalen-7-o l (7), sodium  
bicarbonate (0.21 g, 2.5 mmol), an d  th e  a p p ro p ria te  alkyl 
brom ide (1.2 mmol) in  10 mL of DM F w as h eated  a t  80 °C for 
16 h. Upon com pletion of th e  reaction, th e  vo latiles w ere 
rem oved in  vacuo and  the  residue  w as purified  by flash 
chrom atography or th in -lay er chrom atography followed by 
cystallization  from m ethanolic  HCl/Et20.
Scaffold for Receptor Antagonism
2-(Di met hy 1 amino) -1,1 -dim ethyl-1,2,3,4-tetrahydro- 
naphthalen-7-ol (9a). 9a w as p repared  from 7 w ith  procedure 
A. u sin g  double the  am o u n t of form aldehyde an d  sodium  
triacetoxyborohydride. Yield: 59%. Mp (hydrochloride): >200 
°C. 7?r(CH 2Cl2/M eOH/NH 4OH. 100:10:1): 0.34. lH NMR (400 
MHz, CDCI3): 6  1.24 (s. 3H), 1.36 (s. 3H). 1.68 (m, 1H), 1.96 
(m, 1H), 2.36 (s. 6 H), 2.50 (dd, J1 1 .9 ,  2.9. 1H). 2 .7 1 -2 .8 9  (m, 
2H), 6.37 (br, 1H), 6.60 (dd. J 8 .2 ,  2.7, 1H), 6.81 (d. J 2.3, 1H), 
6 . 8 8  (d, J 8 .2 ,  1H). 13C NM R (101 MHz, CDC13): d 18.62, 26.67, 
29.21, 30.56, 40.83, 44.55, 69.61, 113.43, 113.97, 127.16, 
129.73, 148.27, 154.07. E IM S (Cl) mlz{%): 219 (100). HRM S 
(C,4H 2 iNO): calcd 219.1623, found 219.1617. Anal. (C,4H 2 i- 
NO HC1) C, H, N.
l,l-Dimethyl-2-propylamino-l,2,3,4-tetrahydronaph- 
thalen-7-ol (9b). A suspension  of 0.25 g (1.08 mmol) of 9h 
and  0.11 g of Pd/C (10%) in  E tO H  (50 mL) w as s tirred  in  a  
hydrogen atm osphere  for 24 h. The cata ly st w as removed by 
filtra tio n  over Celite, an d  th e  crude reaction  m ixture w as 
purified by flash chrom atography (CH2Cl2/Me0 H/NH 4 0 H, 100: 
10:1) to give 0.18 g (77%) of 9b as a  solid. Rr (CH 2Cl2/MeOH/ 
N H 4OH, 100:10:1): 0.40. >H NMR (400 MHz, CDC13): d 0.92 
(t. y 7.4, 3H). 1.19 (s, 3H), 1.32 (s, 3H), 1.54 (sext, J 7 .4 ,  2H),
1.74 (m, 1H), 2.01 (m, 1 H), 2 .5 0 -2 .8 7  (m, 5H), 4.34 (br, 2H),
6.55 (d, J 8 .2 ,  2.3, 1H), 6.77 (d, J 2 .3 ,  1H), 6.85 (d, J 8 .2 ,  1 H). 
13C NMR (101 MHz, CDCI3): <3 12.30 23.42, 24.19, 26.02, 28.12, 
29.47, 39.00, 50.76, 63.76, 113.77, 113.92, 126.55, 129.83, 
146.63, 154.73. EIM S mlz (%): 234 (7). 233 (37), 148 (100). 
HRM S (C15H 2 3NO): calcd 233.1780, found 233.1772. Anal. 
(C15H 2 3N O H C l) C, H, N.
1,1 -Dimethyl-2- (propylmethylamino)-1,2,3,4-tetrahy- 
dronaphthalen-7-ol (9c). 9c w as p rep ared  from 9b w ith  
procedure A. Yield: 46%. Mp (hydrochloride): 192 °C. T?7 (CH2- 
Cl2/M eOH/NH 4OH, 100:10:1): 0.36. ‘H NMR (400 MHz, 
C D C I 3 ) : d 0.88 (t. J  7.4, 3H), 1.18 (s, 3H), 1.35 (s, 3H), 1.53 
(m, 1H), 1.69 (m, 1H), 1.89 (m, 1H). 2.29 (s, 3H), 2.35 (m, 1 H), 
2 .4 9 -2 .5 6  (m, 2H), 2 .6 8 -2 .8 4  (m, 3H), 4.72 (br. 1 H), 6.57 (dd, 
J 8 .2 ,  2.7, 1 H), 6.79 (d, J 2.7, 1H), 6 . 8 6  (d. J 8 .2 ,  1 H). 13C NMR 
(101 MHz, CDCI3): d 12.25, 19.68, 21.60, 26.78, 28.97, 30.91,
40.16, 40.79, 60.00, 68.63, 113.26, 114.04, 127.47, 129.77,
148.72, 153.76. EIM S mlz (%): 247 (59), 148 (100), 42 (99). 
HRMS (Ci6H 25NO): calcd 247.1936, found 247.1934. Anal. 
(C,6H25NO-HCl-0.5H2O-0.25CH3OH) C, H, N.
2- (Dipropylamino)-1,1 -dimethyl-1,2,3,4-tetrahydronaph- 
thalen-7-ol (9d). 9d w as p rep ared  from 7 w ith  procedure A, 
u sing  double the  am oun t of propionaldehyde and  sodium  
triacetoxyborohydride. Yield: 0.18 g (45%). Mp (hydrochlo­
ride): 119 °C. (CH2C l2/M eOH/NH 4OH, 100:10:1): 0 . 3 5 . ^  
NMR (400 MHz, CDCI3): d 0 . 8 6  (t, J 7 .4 ,  6 H), 1.15 (s, 3H), 
1.32 (s, 3H), 1 .36-1 .54  (m, 4H). 1.75 (m, 1H), 1.86 (m, 1H). 
2.40 (t, J  7.4, 4H), 2.54 (dd. J  12.3, 2.5, 1H), 2 .6 8 -2 .8 6  (m, 
2H), 4.3 (br, 1H). 6.57 (dd, J 8.2, 2.7, 1H), 6.81 (d, J 2.7, 1H),
6.87 (d, J 8 .2 ,  1H). 13C NMR (101 MHz, CDC13): d 12.04, 19.81, 
21.87, 26.59, 28.59, 31.01, 40.32, 54.70, 66.57, 112.79, 113.68, 
127.31, 129.51, 148.82, 153.41. EIM S mlz{%): 275 (39), 148 
(52), 43 (100). HRMS (C,8 H 2 9NO): calcd 275.2249, found 
275.2245. Anal. (Ci8H 29N O H C l-0 .25H 20 ) C, H, N.
2- (Cyclopropylmethylamino) -1,1 -dimethyl-1,2,3,4-tet- 
rahydronaphthalen-7-ol (9e). A solution of 7-amino-8,8- 
d im ethyl-5 ,6 ,7 ,8-te trahydronaphthalen-2-ol (7) (0.19 g, 1.0 
mmol) in CH 2C12 (10 mL) w as trea ted  w ith  cyclopropylcarbonyl 
chloride (2.2 mmol) followed by trie th y lam in e  (0.5 mL). The 
resu lting  m ixture w as s tir red  a t  room tem p era tu re  overnight. 
After th is  tim e the  reaction  m ix tu re  w as w ashed  w ith  w a te r  
and  b rine  and  th e  so lvent w as evaporated . T he residue w as 
redissolved in anhydrous TH F (10 mL), and  LiAlH 4 (0.1 g) w as 
added carefully. A fter 3 h, excess LiAlH 4 w as destroyed w ith  
G lauber’s sa lt and the  reaction m ixture w as filtered. The crude 
product w as purified by flash  chrom atography followed by 
cystallization from  m ethanolic  H C l/E t20 .  Yield: 69%. Mp 
(hydrochloride): >200 °C. S igns of decom position: >175 °C. 
Rr (CH2C l2/M e0 H/NH 4 0 H, 100:10:1): 0.37. >H NMR (400 
MHz, CDCI3): d 0.14 (m, 2H), 0.48 (m, 2H), 1.04 (m, 1H). 1.21 
(s. 3H), 1.34 (s, 3H), 1.73 (m, 1 H), 2.01 (m. 1 H), 2.42 (dd, J
12.1, 7.4, 1H), 2.59 (dd, J  10.2, 2.7, 1H), 2 .6 3 -2 .8 2  (m. 3H),
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3.91 (br, 2H), 6.55 (dd, J 8.2, 2.7, 1H), 6.78 (d. J 2 .7 ,  1H), 6.84 
(d, J 8 .2 ,  1H). 13C NMR (101 MHz, CDC13): 6 3 .42 ,3 .89, 11.29, 
23.85, 25.65, 27.72, 29.14, 38.68, 53.63, 63.20, 113.34, 113.52, 
126.36, 129.52, 146.37, 154.23. EIM S mlz (%): 245 (62). 148 
(100). HRM S (C,6H23NO): calcd 245.1780, found 245.1774. 
Anal. (Ci6H 23NO*HC1*0.25CH3OH) C, H, N.
2-(C yclopropylm ethylm ethylam ino)-l, 1-dim ethyl- 
1,2,3,4-tetrahydronaphthalen-7-ol (9f). 9f w as p repared  
from  9e w ith  procedure A. Yield: 57%. Mp (hydrochloride): 
>200 °C. /?HCH2Cl2/M eOH/NH4OH, 100:10:1): 0.37. ‘H NMR 
(400 MHz, CDCI3): d 0.13 (m, 2H), 0.51 (m, 2H), 0.95 (m, 1H),
1.24 (s. 3H), 1.39 (s, 3H). 1.71 (m. 1H), 1.95 m, 1H), 2.42 (dd, 
J  12.9, 6.6, 1H), 2.42 (s, 3H), 2.59 (dd, J1 2 .8 ,  5.9, 1H), 2 .6 1 -  
0.88 (m, 3H), 5.91 (br, 1H), 6.62 (dd, J 8.2, 2.7, 1H), 6.85 (d, J
2.7, 1H), 6.89 (d, J 8 .2 ,  1H). 13C NMR (101 MHz, CDC13) : 6
3.42, 4.81, 9.73, 19.47, 26.46, 28.69, 30.51, 39.80, 40.62, 62.94,
67.45, 113.15, 113.85, 126.90, 129.41, 148.20, 153.58. EIM S 
mlz(%): 260 (10), 259 (51), 204 (34), 148 (89), 55 (100). HRM S 
(Ci7H25NO): calcd 259.1936, found 259.1921. Anal. (Ci7H 25- 
NOHC1-0.25CHC13) C, H, N.
2-(Bis-cyclopropylmethylamino)-1,1 -dimethyl-1,2,3,4- 
tetrahydronaphthalen-7-ol (9g). 9g w as p rep ared  from 9e. 
The sequence for the  form ation of 9e w as repeated. Yield: 64%. 
Mp (hydrochloride): >200 °C ./?r(C H 2Cl2/Me0 H /N H 4 0 H, 100: 
10:1): 0.60. *H NM R (400 MHz, CDC13): <5 0.14 (m, 4H). 0.43 
(m. 2H), 0.57 (m. 2H), 0.94 (m, 2H), 1.23 (s, 3H), 1.42 (s, 3H), 
1.76 m, 1H), 1.93 (m, 1H). 2.42 (m, 2H), 2 .6 9 -2 .9 3  (m, 4H). 
5.11 (br, 1H). 6.62 (dd, J 8 .2 ,  2.7, 1H), 6.85 (d, J 2.7, 1H), 6.90 
(d, J 8 .2 ,  1H). 13C NMR (101 MHz.CDC13): 5 2 .47.5 .74 . 10.11, 
20.23, 26.55, 28.71, 30.95, 40.57, 56.89, 65.63, 112.87, 113.80,
127.28, 129.50, 148.71, 153.33. EIM S mlz (%): 299 (17). 244 
(10), 55 (100). HRMS (C20H 29NO): calcd 299.2249, found 
299.2237. Anal. (C20H 29NO-HCl-0.25CHCl3-0.25H2O) C. H, N.
2-Dially lamino-1,1 -dim ethyl-1,2,3,4-tetrahydronaph- 
thalen-7-ol (9j) and 2-(Allylam ino)-l,l-dim ethyl-l,2,3,4- 
tetrahydronaphthalen-7-ol (9h). 9j and 9h w ere p repared  
from  7 an d  allyl brom ide w ith  procedure B.
Fraction 1 Containing 9j. Yield: 15%. Mp (hydrochlo­
ride): 99 °C. Rr (CH2Cl2/M eOH/NH 4 0 H, 100:10:1): 0.60. *H 
NMR (400 MHz, CDC13): 6 1.16 (s, 3H), 1.33 (s. 3H), 1.73 (m, 
1H), 1.84 (m, 1H), 2 .6 9 -2 .8 4  (m, 3H), 2.99 (dd, J  14.6, 8.0, 
2H), 3.26 (m, 2H). 5.08 (dd, J1 0 .2 ,  1.6, 2H), 5.16 (m, 1.2, 2H), 
5.86 (m. 2H), 6.56 (dd, J 8.2, 2.3, 1H). 6.80 (d, J 2.7, 1H), 6.88 
(d, J  8.2, 1H). l3C NMR (101 MHz, CDC13): 5 20.23, 26.27, 
28.71, 30.63, 40.45, 55.12, 64.32, 112.85, 113.71, 116.20, 
127.25, 129.51, 137.06, 148.41, 153.33. EIMS m/z(%): 271 (23), 
122 (42), 41 (100). HRMS (Ci8H 25NO): calcd 271.1936, found 
271.1933. Anal. (Ci8H 25N 0-H C M ).75H 20 ) C. H, N.
Fraction 2 Containing 9h. Yield: 41%. M p (hydrochlo­
ride): >200 °C ./?r(C H 2Cl2/Me0 H/N H 4 0 H. 100:10:1): 0.36. >H 
NM R (400 M Hz, CDC13): d 1.20 (s. 3H), 1.32 (s, 3H), 1.72 (m, 
1H), 2.02 (m, 1H). 2.62 (dd, 10.5, 2.7, 1H), 2 .6 7 -2 .8 2  (m, 2H),
3.24 (dd, J 1 3 .7 ,  7.0, 1H), 3.51 (dd, J 1 3 .7 ,  5.5, 1H). 4.34 (br, 
2H), 5.11 (d, J  10.2, 1H), 5.20 (dd, J 1 7 .2 ,  1.6, 1H), 5.92 (m, 
1H), 6.55 (dd. J 8.2, 2.3, 1H), 6.76 (d, J 2.7, 1H), 6.85 (d. J 8 .2 ,  
1H). 13C NMR (101 MHz, CDC13): <3 23.87, 26.10, 27.98, 29.58,
39.01, 51.10, 62.67, 113.89, 113.97, 117.47, 126.73, 129.95,
136.45, 146.61, 154.53. EIM S mlz(%): 232 (3), 231 (17), 159 
(27), 148 (94), 41 (100). HRM S (Ci5H 2iNO): calcd 231.1623, 
found 231.161. Anal. (C,5H 2iNOHC1) C, H, N.
2-(Allylmethylamino)-1,1-dimethyl-1,2,3,4-tetrahydro- 
naphthalen-7-ol (9i). 9i w as p repared  from 9h w ith  proce­
dure  A. Yield: 71%. M p (hydrochloride): >200 °C. S igns of 
decom position: > 150 °C. Rr (CH2C l2/M e0 H /N H 4 0 H, 100:10: 
1): 0.39. >H NM R (400 MHz, CDC13): <3 1.21 (s, 3H), 1.36 (s, 
3H), 1.73 (m, 1H), 1.90 (m, 1H), 2.33 (s, 3H), 2.62 (dd. J1 2 .1 .
2.7, 1H), 2 .7 2 -2 .8 8  (m, 2H), 3.02 (dd, J 1 4 .1 ,  7.0, 1H), 3.29 
(dd, J1 4 .1 , 5.5, 1H), 5.10 (dd, J1 0 .9 , 0.8, 1H), 5.19 (dd. J1 7 .0 .
1.8, 1H), 5.35 (br, 1H), 5.85 (m, 1H), 6.59 (dd, J 8 .2 ,  2.7, 1H), 
6.82 (d, J  2.3, 1H), 6.89 (d, J 8 .2 ,  1H). 13C NMR (101 MHz, 
CDCI3): <5 19.37, 26.37, 28.67, 30.43, 40.29, 40.61, 60.18, 67.30,
113.01, 113.75, 116.32, 127.15, 129.47, 136.84, 148.23, 153.37.
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E IM S  mlz  (%): 245 (35), 41 (100). H R M S  (C 16H 23NO ): ca lcd  
245.1780, fo u n d  245.1775. A n a l. (C i6H 23N O H C l- H 20 )  C, H , 
N.
2-{ Bis- [ (£)-3-phenylprop-2-enyl] am ino}-l ,1 -dimethyl-
1,2,3,4-tetrahydronaphthalen-7-ol (9m) and 1,1-Dimeth- 
yl-2-{[(E)-3-phenylprop-2-enyl] am ino}-1,2,3,4-tetrahy- 
dronaphthalen-7-ol (9k). 9m and  9k w ere p rep ared  from 7 
and cinnam yl brom ide w ith  procedure B.
Fraction 1 Containing 9m. Yield: 7%. Mp (hydrochlo­
ride): 148 °C (dec). Rr (EtOAc): 0.89. >H NMR (400 MHz, 
CDC13): d 1.23 (s, 3H), 1.39 (s, 3H), 1.79 (m, 1 H), 1.92 (m, 
1H), 2 .7 1 -2 .8 6  (m, 3H), 3.23 (m. 2H), 3.49 (m, 2H), 4.08 (br, 
1H), 6.29 (ddd, J  16.0, 8.2, 4.7, 2H), 6.53 (d, J  14.8, 2H), 6.54 
(dd, J 8.2, 2.3, 1 H), 6.79 (d, J 2.7, 1H), 6 . 8 6  (d, J 8 .2 ,  1H). 7.20 
(m, 2H), 7.29 (m, 4H), 7.37 (d, J 7.8, 4H). 13C NMR (101 MHz, 
CDCI3): (5 20.45, 26.47, 28.86, 30.68, 40.57, 54.67, 64.68,
112.89, 113.67, 126.12, 127.09, 127.15, 128.43, 128.96, 129.53, 
131.40, 137.22, 148.21, 153.39. EIM S mlz (%) : 423 (4), 307 
(6 6 ), 35 (100). HRMS (C3 0H 3 3NO): calcd 423.2562, found 
423.2573. Anal. (C30H 33N O H C I) C, H. N.
Fraction 2 Containing 9k. Yield: 60%. Mp (hydrochlo­
ride): >200 °C. Signs of decom position: > 175 °C. Rr (EtOAc): 
0.70. »H NMR (400 MHz. C D C I 3 ) :  <5 1.22 (s, 3H), 1.34 (s, 3H),
1.74 (m, 1H), 2.08 (m, 1 H). 2 .6 1 -2 .8 2  (m. 3H), 3.38 (ddd, J
13.7, 7.0, 0.8, 1H), 3.42 (br, 1H), 3.62 (ddd, J  13.7, 5.9, 1.6, 
1H), 6.32 (m, 1H), 6 .5 3 -6 .5 9  (m, 2H), 6.78 (d, J 2.7, 1 H), 6 . 8 8  
(d, J  8.5, 1H), 7 .1 9 -7 .3 7  (m, 5H). 13C NMR (101 MHz, 
C D C I 3 ) :  6  24.10, 26.16, 28.07, 29.68, 39.12, 50.73, 62.79, 
113.98, 114.10, 126.61, 126.89, 127.75, 128.42, 128.82, 130.03,
132.29, 137.19, 146.78, 154.53. EIM S mlz (%): 307 (7), 173 
(19), 148 (17), 117 (29). 82 (100). HRMS (C2 ,H 25NO): calcd 
307.1936, found 307.1927. Anal. (C2 iH 25NOHC1) C, H, N.
1,1 -Dimethyl-2- {methyl- [ (F)3-phenylprop-2-enyl] ami­
no }-l ,2,3,4-tetrahydro-naphthalen-7-ol (91). 91 w as p re ­
pared  from 9k w ith  procedure A. Yield 45%. Mp (hydrochlo­
ride): >200 °C. ^ ( C H 2Cl2/M eOH/NH 4OH, 100:10:1): 0 .8 5 .'H  
NMR (400 MHz, CDC13): 6 1.25 (s, 3H), 1.40 (s, 3H), 1.76 (m, 
1H), 1.93 (m, 1H), 2.38 (s, 3H), 2 .6 3 -2 .8 9  (m, 3H). 3.19 dd,
4.1, 7.4, 1 H). 3.44 (dd, J 1 4 .1 .  5.1, 1H), 6.32 (ddd, J  15.6, 7.0, 
5.5, 1H), 6.52 (d, J  15.6, 1 H), 6.59 (dd, J 8 .2 ,  2.7, 1 H), 6.83 (d, 
J 2.7, 1H), 6.89 (d, J 8.2, 1 H), 7.24 (m, 1 H), 7.32 (t, J 7.6, 2H), 
7.39 (d. J 8 .2 ,  2H). 13C NMR (101 MHz, CDC13): <5 19.80, 26.78, 
29.03, 30.79, 40.80, 41.02, 59.82, 67.70, 113.17, 113.92, 126.44,
127.42, 127.49, 28.73, 129.15, 129.80, 131.58, 137.50, 148.53,
153.73. EIM S mlz (%): 321 (1), 188 (45), 173 (69), 162 (100). 
HRMS (C22H 2 8C1N0): calcd 321.2093, found 321.2090. Anal. 
(C2 2 H 28C 1 N 0 0 .5 H 20 ) C, H, N.
7-M ethoxy-1, 1 -dim ethy I-3,4-dihydronapht halen-2 
one Oxime (10b). To a vigorously stirred  solution of hydroxy 1- 
am ine hydrochloride (3.79 g, 54.5 mmol) an d  sodium  ace ta te  
(4.47 g, 54.5 mmol) in H 20  (30 mL) w as added a solution of 
10a (3.71 g, 18.2 mmol) in  MeOH (30 mL). S tirrin g  w as 
continued for 1 0  m in a t  60 °C an d  th en  for a  fu r th e r  15 h a t 
room tem perature. After th is  tim e th e  solid oxime w as collected 
by suction filtra tio n  an d  w ashed  w ith  ice-cold MeOH ( 2 x 5  
mL), leaving the  title  p roduct a s  a  w hite  solid (2.13 g, 54%). 
Rr (50% EtOAc/50% hexane): 0.59. Mp 1 4 0 -1 4 2  °C. IR, vma* 
(KBr): 1628 (C=N). ‘H NMR (270 MHz, CDC13): d 1.50 (s. 
6 H), 2 .7 9 -2 .9 2  (m, 4H), 3.81 (s. 3H). 6.71 (dd, J 8 .4 ,  2.6, 1H), 
6.94 (d, J  2.6, 1H), 7.06 (d, J  8.4, 1 H). 13C NMR ( 6 8  MHz. 
CDCI3) : d 22.23, 27.05, 27.99, 41.20, 55.41, 111.13, 111.51, 
128.62, 129.22, 145.07, 158.61, 165.10. EIM S m/z(%): 219(65).
7-Methoxy-1,1 -dimethyl-1,2,3,4-tetrahydronaphtho [2,3] - 
azirene (11a). To a s tirred  solution of 10b (1.50 g, 6.85 mmol) 
and A /-m ethylbutylam ine (0.1 mL) in to luene a t  0 °C w as 
added sodium  bis(2-m ethoxyethoxy)alum inum  hydride (70% 
solution in toluene, 10.7 mL, 34.2 mmol) dropwise over 10 min. 
The m ix ture  w as hea ted  to reflux for 15 h and  th en  allowed 
to cool to room tem p era tu re . T he reaction  w as quenched by 
the dropwise addition of 2 M HC1 (50 m L), an d  th e  layers w ere 
separated . The aqueous layer w as w ashed  w ith  C H 2C12 (3 x 
70 mL) and  th en  basified to pH 10 w ith  10 M N H 4OH. The 
free base w as ex tracted  in to  C H 2C12 (3 x 70 mL), and the  
combined organic layers w ere w ashed  w ith  H 20  (2 x 150 mL),
dried  (MgSCh), and  filtered, and  th e  solvent w as evaporated  
in  vacuo to leave a brown oil. Colum n ch rom atography  (5% 
MeOH/94% DCM /1 % N H 4 O H )  afforded th e  title  product a s  a 
yellow oil (0.48 g, 35%). Rr { 10% MeOH/89% DCM :/1 % N H 4- 
OH): 0.51. IR, vmax (film): 3300 (N -H ). 'H  NMR (270 MHz, 
C D C I 3 ) :  6  1.23 (s. 3H), 1.51 (s, 3H), 2.12 (d, J 6 .2 ,  1H), 2.47 
(d, J  5.7, 1 H), 3.14 (s, 2H), 3.78 (s, 3H), 6.69 (dd, J 8 .2 ,  2.5, 
1H), 6.85 (d, J 2.5, 1H), 6.96 (d, J 8.2, 1H). 13C NM R ( 6 8  MHz,
C . D C . I 3 ) :  d 26,90. 29.36, 29.49, 29.54, 35.94. 41.31. 55.09,
111.38, 111.81, 122.58, 130.43, 142.83, 158.64. E IM S m/z(%): 
203 (60).
1,1 -Dimethyl-1,2,3,4-tetrahydronaphtho [2,3] aziren-7 - 
ol (lib ). A solution  of 11a (0.47 g, 2.31 mmol) in  DCM (10 
mL) w as trea te d  w ith  boron tribrom ide (1 M so lu tion  in  DCM, 
4.6 mL, 4.60 mmol) a t  —78 °C. A fter 15 h th e  reac tion  w as 
quenched by dropw ise add ition  of MeOH (5 m L). T he solvent 
w as evaporated, and  th e  residue w as redissolved in  MeOH (10 
m L). A fter the  m ix ture  w as s tirred  for 15 m in, th e  solvent w as 
again  evaporated  an d  th e  residue m ade basic (pH 10) w ith  10 
M NH 4OH. H20  (10 mL) w as added followed by extraction  w ith  
CHCls/EtOH (3:1, 3 x 15 mL). The combined organics w ere 
w ashed  (H20 ), dried  (M gS04), an d  evaporated. Colum n chro­
m atography  (4% MeOH/95% DCM/1% N H 4OH) afforded the  
title  product as a  brown foam (0.32 g, 73%). /?^(10% MeOH/ 
89% DCM/1% N H 4OH): 0.39. IR, vmax (film): 3284 (O -H ). >H 
NMR (270 MHz, CDC13): d 1.21 (s, 3H), 1.45 (s. 3H), 2.16 (d, 
J 6.2, 1H), 2.51 (d, J 6 .0 ,  1H), 3.12 (d, J 7 .9 ,  2H). 5.25 (s, 1H),
6.55 (dd, J 8.2, 2.5, 1 H), 6.71 (d, J 2 .5 ,  1 H), 6.82 (d, J 8.2, 1H). 
13C NMR ( 6 8  MHz, CDC13): d 27.18, 28.87, 29.59, 30.63, 35.84, 
42.09, 113.14, 114.68, 119.93, 130.90, 141.82, 156.92. EIM S 
mlz (%): 189 (20).
ferf-Butyl 7- [ (terf-Butoxycarbonyl)oxy] -1,1 -dimethy 1-
1,2,3,4-tetrahydronaphtho[2,3]azirene-1 -carboxylate (12). 
To a  s tirred  solution of l ib  (0.38 g, 2.01 mmol), 4,4-(dim ethyl- 
am ino)pyridine (0.07 g, 0.57 mmol), and trie th y lam in e  (0.56 
mL, 4.02 mmol) in  DCM ( 8  mL) w as added di-ferf-butyl 
d icarbonate  (0.88 g, 4.02 mmol). The m ix ture  w as allowed to 
s t i r  a t  room tem p era tu re  for 5 h, a fte r w hich th e  solvent w as 
evaporated  in vacuo. The residue w as partitio n ed  betw een 
EtOAc (30 mL) and  1 M HC1 (30 mL). The layers w ere 
separa ted , and  th e  aqueous phase  w as ex tracted  w ith  EtOAc 
(4 x 20 mL). The combined organic layers w ere d ried  (M gS04) 
and  filtered, an d  the  solvent w as removed in  vacuo. Purifica­
tion by colum n chrom atography (20% EtOAc/80% hexane) 
afforded the  title  product a s  a  colorless oil (0.51 g, 65%). Rr 
(50% EtOAc/50% hexane) 0.70. IR, v^  (film): 1757, 1716 (2 
x C = 0 ). *H NMR (270 MHz, CDC13): (5 1.18 (s, 3H), 1.38 (s. 
9H), 1.44 (s, 3H), 1.52 (s, 9H). 2.52 (d, J  6.7, 1H), 2.94 (m, 
1H), 3.02 (m, 1H), 3.27 (d, J  15.6, 1 H), 6.92 (dd, J  8.2, 2.5, 
1H), 6.98 (d, J 8 .2 ,  1H), 7.05 (d, J 2.5, 1H). 13C NM R ( 6 8  MHz, 
CDCI3): 6  18.96. 22.84, 24.06, 24.22, 25.25, 25.58, 27.92, 31.88, 
33.12, 43.81, 77.00, 79.50, 114.70, 115.54, 124.57, 126.48,
139.61, 146.42. FAB MS mlz (%): 390 (40).
2-[(ferf-Butoxy carbonyl) amino] -3-methoxy-1,1 -dimeth- 
yl-l,2,3,4-tetrahydronaphthalen-7-yl ferf-Butylcarbonate 
(13a). To a s tirred  solution of 12 (0.52 g, 1.34 mmol) in MeOH 
(10 mL) w as added pyridinium  p-toluenesulfonate (0.17 g, 0.68 
mm ol). T he m ix ture  w as s tirred  a t  room tem p e ra tu re  for 15 h 
under N2, a fte r which H 20  w as added (20 mL) an d  th e  m ixture 
w as ex tracted  w ith  E t20  (3 x 30 mL). The com bined organic 
ex trac ts  w ere w ashed w ith  H 20  (70 mL) and  b rin e  (50 mL), 
d ried (M gS04), and filtered, and  the  solvent w as evaporated  
in vacuo. Purification by column chrom atography (20% EtOAc/ 
80% hexane) afforded the  title  product a s  a  yellow oil (0.45 g, 
80%). Rr(50% EtOAc/50% hexane) 0.59. IR, (film): 1757, 
1704 (C = 0). *H NMR (270 MHz, CDC13): d 1.12 (s, 3H), 1.32 
(s. 3H), 1.41 (s, 9H), 1.50 (s, 9H), 2.78 (dd, J  16.3, 8.9, 1H), 
3.20 (m, 1H). 3.38 (s, 3H), 3.79 (m, 1H), 4.46 (d, J  10.2, 1H).
6.92 (d, J 2 .2 ,  1H), 6.99 (s, 1H), 7.04 (d, J 2 .2 ,  1H). 13C NMR 
( 6 8  MHz, CDCI3): d 15.19, 22.01, 28.70, 29.42, 35.39, 41.00, 
57.44, 59.86, 61.35, 77.00, 80.21, 84.32, 120.21, 120.38, 130.92,
146.39, 150.76, 152.95, 157.64. FAB MS m/z(%): 422 (35). 322 
(20).
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2 - A m in o -3 -m e th o x y -1,1 - d im e t h y l - 1,2 ,3 ,4 - te t r a h y  d ro -  
n a p h th a le n -7 -o l  (1 3 b ). To a s tirred  so lu tion  of 13a  (0.42 g, 
1.00 mmol) in DCM (5 mL) w as added trifluoroacetic  acid (0.7 
mL, 9.96 mmol) dropw ise. T he m ix tu re  w as allowed to s t i r  for 
15 h before rem oval of th e  solvent in  vacuo in th e  presence of 
to luene (0.5 mL) to form  an  azeotrope w ith  TFA. Purification  
of th e  residue  by colum n chrom atography (8% MeOH/91% 
DCM/1% N H 4OH) afforded th e  title  product as a  colorless oil 
(0.13 g, 59%). Rr (10% M eOH/89% DCM/1% N H 4OH): 0.15. 
IR. (film): 3392, 3350 (N -H ), 3294 (O -H ). *H NMR (270 
MHz, CDCI3): <5 1.15 (s, 3H), 1.38 (s. 3H), 2.56 (dd, J1 5 .4 , 9.9, 
1H), 2.84 (d, J  9.9, 1H), 3.22 (dd. J  15.4, 5.5, 1H), 3.37 (m. 
1H), 3.46 (s, 3H), 6.61 (dd, J 8.2, 2.5, 1H), 6.78 (d, J 2 .5 ,  1H),
6.88 (d, J 8 .2 ,  1H). 13C NM R (68 MHz, CDCI3): <3 25.22, 27.49, 
33.56, 40.00, 56.13, 60.25, 77.00, 112.79, 113.58, 122.82,
129.61, 145.16, 154.56. FAB MS mlz (%): 222 (100). HRMS 
(C13H 20NO 2) calcd 222.1494, found 222.1506. Anal. (C,3H ,9N02- 
H C M .5H 20 ) C, H, N.
3 -M e th o x y -1,1 -d im e th y l-2 -  {[ (£ )  -3 -p h e n y lp r o p -2 -e n y  1] - 
a m in o } -l,2 ,3 .4 - te tr a h y d r o n a p h th a le n -7 -o l (14). To a stirred  
solution of 13b (69 mg, 0.31 mmol) in anhydrous CH 2CI2 (3 
mL) w as added frans-cinnam aldehyde (0.05 mL, 0.37 mmol). 
The reaction m ix ture  w as s tirred  for 15 h  a t  room tem p era tu re  
afte r w hich tim e th e  so lven t w as removed in vacuo. The 
residue w as redissolved in anhydrous MeOH ( 8  mL), and  the  
solution w as cooled to 0 °C. Sodium  borohydride (50 mg, 1.23 
mmol) w as added portionw ise over 1 h, an d  the  resu lting  
m ix ture  w as s tirred  for a  fu r th e r  15 h  a t  room tem pera tu re . 
The reaction  w as quenched  by the  dropwise addition  of 1 M 
HC1 (5 mL), and  th e  so lu tion  w as ad justed  to pH 7 w ith  
sa tu ra ted  aqueous N a H C 0 3. T he m ix ture  w as ex tracted  w ith  
EtOAc (3 x 20 mL), an d  th e  combined ex trac ts  w ere w ashed 
w ith  b rine  (20 mL), d ried  (MgS0 4 ), and  filtered, and  the  
solvent w as evaporated  in  vacuo. Column chrom atography (3% 
MeOH/96% DCM /1 % N H 4OH) afforded the  title  product as a 
colorless oil ( 8 6  mg, 82%). Rr{ 10% MeOH/89% DCM /1 % N H 4- 
OH): 0.26. IR, (film): 3327 (O -H ). >H NMR (270 MHz, 
C D C I 3 ) :  <31.18 (s, 3H), 1.38 (s, 3H), 2 .57 -2 .71  (m, 2H). 3.25 
(m, 1H). 3.48 (s, 3H), 3 .5 0 -3 .5 4  (m, 1H), 3.73 (dd, J 1 3 .6 , 6.2, 
2H), 6.33 (m, 1H), 6.54 (m, 1 H). 6.61 (dd, J 8.2, 2.5, 1H), 6.78 
(d, J 2 .5 ,  1H), 6.90 (d, J 8.2, 1 H), 7.26 (m, 5H). 13C NMR ( 6 8  
MHz, C D C I 3 ) : <312.73, 19.72, 24.82, 26.61, 33.28, 39.54, 52.43,
55.17, 65.43, 77.00, 111.70, 112.17, 122.78, 124.67, 125.64,
126.89, 127.61, 128.39, 129.53, 135.88, 145.02, 152.98. FAB 
MS mlz (%): 338 (80). HRM S (C22 H 2 8N 0 2) calcd 338.2120, 
found 338.2119.
M o le c u la r  M o d e lin g . S tru c tu re s  4 a  and  9 k  w ere d raw n 
using the  B uilder option in  M OE (version 2004.03; Chem ical 
Com puting G roup Inc.) an d  m inim ized using  the  M M FF94x 
force field. The Flexible A lignm ent function w as used for the  
overlay, w ith  th e  R e s tra in ts  com m and en su ring  th a t  the  
phenolic rings rem ained  aligned.
S u p p o r t in g  I n fo r m a t io n  A v a ila b le :  R esults from el­
em ental analysis. T h is m ate ria l is available free of charge via 
the In tern e t a t  h ttp ://pubs.acs.o rg .
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